Genetic control of apoptosis and tumourigenesis in murine models of intestinal neoplasia by Sansom, Owen James














During the course of my PhD, I have been helped by a large number of great people.
In fact I have enjoyed my PhD much more than I thought I would. There really are
too many people to mention (and I don't want to alter my page count!). After my
masters I thought my PhD would only last a few months but I was lucky to live and
work with some really good people. Both the labs in Edinburgh and Cardiff have been
very supportive. In addition I have some friends that I could have a good rant with. I
thank the many people who have had to put up with my near incessant moaning.
Moving during the PhD is quite traumatic, especially when the date of the movement
kept changing. So special thanks to Tim and Est for putting up with me staying for a
'few days' which was actually over 2 months. Also thanks to James for putting me up
at his place for a couple of months, when I realised that I had accidently rented (well I
went round so many places in Cardiff) a house with pschyos in Cardiff. Apart from
that things were surprisingly smoothly with the move, so thanks to all the people who
made me feel really welcome and a pox on those who did not.
I am greatly indebted to my long suffering supervisor Alan who's been brilliant.
Many thanks to my family for their constant support. It's great to go home and forget
all my own worries.
This PhD was supported by the Cancer Research Campaign
3
Abstract
Colorectal cancer is one of the most predominant cancers in the Western World. By
the age of 70, 1 in 2 people will have a colon tumour. The genetic analysis of both
spontaneous and hereditary forms of this disease have greatly added to our
understanding of colorectal cancer, with mutations in a range of genes now strongly
linked to neoplasia. In recent years, several different transgenic models of colorectal
cancer have been generated. Key amongst these are strains mutant for the Ape
(.Adenamatous Polyposis Coli) gene and strains mutant for different members of the
mismatch repair (MMR) gene family, the majority of which show predisposition to
intestinal neoplasia. In this thesis, these transgenic models are used in an attempt to
systematically characterise the nature of the genetic control over a series of end
points. These include the apoptotic response of enterocytes to cytotoxic agents; the
effect of genotype upon clonogenic survival and mutation and ultimately the effect of
genoytype upon the development of intestinal neoplasia.
Previously analyses of enterocyte apoptosis had established roles for p53 and Msh2
following DNA damage of methylation type. This prompted an analysis in mice
deficient for two other members of the MMR family, Mlhl and Pms2. Mlhl and Pms2
deficient mice were seen to have a significantly reduced apoptotic response to
temozolomide, confirming again an association between the MMR family and
apoptosis. However, both Mlhl'" and Pms2~/~ mice were found to possess a normal
apoptotic response to high levels of the alkylating agent NMNU, even though they are
deficient for functional MMR. This unexpected finding dissociates normal mismatch
repair from MMR dependent apoptosis and raises fundamental questions about the
nature of the death signal following damage of methylation type.
Perturbations to the normal apoptotic response would be predicted to impact upon
longer term survival as determined through the microcolony assay. Therefore
clonogenic survival was examined using this approach in Msh2 and p53 null mice.
Despite being necessary for apoptosis for all cytotoxic agents studied, loss ofp53 only
led to an increased in survival following cisplatin treatment and not following NMNU
or Nitrogen Mustard treatment.
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The above data was obtained from morphologically normal tissue. Therefore this
analysis was extended to the apoptotic response within intestinal lesions. This
displayed that there was both lesion type dependent differences and genotype
dependent differences in the apoptotic response. As there were high basal levels of
apoptosis in the smallest lesions whilst virtually no apoptosis in adenomas, this
highlighted that loss of this apoptotic programme may be crucial to tumour
progression.
The interaction between Msh2 and p53 in tumourigenesis was also investigated. Both
homozygosity and hemizygosity for p53 were found to dramatically accelerate
tumourigenesis on a mismatch (Msh2) deficient background. Significantly, the levels
of micro-satellite instability (MSI) were highest in tumours which were additionally
heterozygous for p53. EMSA, Western and immunohistochemisty analysis of these
tumours indicated retention ofp53 function in at least a proportion of these tumours.
Similar data were obtained from primary cultures, with again increased microsatellite
instability and retained p53 functionality in cultures derived from p53 heterozygotes.
Taken together, this data shows that hemizygosity for p53 increases microsatellite
instability and that, at least in a percentage of tumours, complete loss ofp53 is not a
required event. These findings have particular relevance to our understanding of cross
talk between p53 and MMR deficiency in human colorectal disease.
The battery of in vivo analyses used throughout this thesis were applied to a new
candidate tumour suppressor, Mbd4. Mbd4 deficient mice have no overt phenotype,
but fail to mediate normal apoptosis following a wide variety of DNA damage.
Following cisplatin treatment, Mbd4 treatment confers increased clonogenic survival
Surprisingly, Mbd4 mice are not characterised by an in increase in either spontaneous
or induced mutation rate, but when crossed to ApcMm mice they accelerate tumour
development. These studies demonstrate that Mbd4 is a central mediator of the
response to DNA damage and that it functions as an intestinal tumour suppressor in
the mouse.
Finally the ability of aspirin to suppress intestinal neoplasia in murine models of
colorectal cancer was examined. Numerous epidemological and animals studies have
shown that Non-Steroidal Anti-Inflamatory Drugs (NSAIDS) are associated with
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lower risks of colorectal cancer. However studies using aspirin in the ApcMm/+ mouse
have yielded contrasting results. Here it is shown that aspirin does not reduce
tumourigenesis when ApcMl + mice are put on diet containing aspirin post weaning.
However when parents were put on aspirin, a significant suppression of
tumourigenesis was observed in the min offspring. In fact there was incomplete
penetrance of the ApcMm/+ phenotype (40%). To test whether in utero administration
of aspirin could also suppress murine models of HNPCC, Msh2 deficient and
(ApcMm/+, Msh2~/~) deficient mice were examined. In both cases a significant
attenuation of tumourigenesis was observed. Taken together this raises the exciting
prospect of prophylactic treatment of FAP and HNPCC patients and highlight the
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1.1 Colorectal cancer genetics
Cancer is the endpoint of a process whereby normal cells are altered by the
cumulative acquisition of genetic changes which confer proliferative, invasive,
and metastatic properties upon the cell (see figure 1.1 Vogelstein and Kinzler,
1993). This process can be rapidly accelerated by the loss of systems that
safeguard genomic stability resulting in an increased rate of mutagenesis (e.g. loss
of mismatch repair) and chromosomal rearrangements (e.g. loss ofp53) (Hartwell,
1992; Kolodner, 1995). Colorectal cancer is one of the most predominant cancers
in the Western World. It is thought that 1 in 2 people over the age of 70 have a
colorectal tumour (Vogelstein and Kinzler, 1996). The molecular characterisation
of colorectal cancer is the most advanced of all solid malignancies. There are two
well characterised pathways (figure 1.1) of colorectal malignancies which
probably account for approximately 70% of colorectal tumours. The first of these
was proposed by Vogelstein and Kinzler (1996) where there are mutations in
APCIrasI18q and P53, resulting in aneuploid tumours. These account for around
50-60% of colorectal tumours. The second pathway (approximately 20% of
tumours) is characterised by loss of mismatch repair activity which results in
diploid tumours with high levels of microsatellite instabilty (MSI). These tumours
tend to be left sided and have a better prognosis than the aneuploid tumours.
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Figure 1.1 Diagram of colorectal cancer progression (Adapted from Vogelstein
and Kinzler, 1996). ACF stands for aberrant crypt foci, the first identifiable
morphological changes in colorectal neoplasia. Carcinoma refers to invasive
tumours.
APC K-ras DCC p53
Normal Lk Dysplatic -► Early L* Intermediate L> Late u Carcinoma
epithelium ACF Adenoma Adenoma Adenoma
►
MMR Deficiency (Msh2 / Mlhl/ Pms2)
(EPIGENETIC CHANGES, e.g. hypermethylation?)
►
(The genes studied in this thesis are in bold)
This is certainly a simplification of the true situation as many genetic changes
have been associated with colorectal cancer so questioning the absolute
significance of all these changes. Similarly, regarding the process of neoplasia as
a simple series of linear events is likely to be an oversimplification (Ilyas et al.,
1999). Recently, a third as yet poorly characterised pathway has been identified
wherein tumours are diploid (or near diploid) but do not exhibit MSI. This
pathway accounts for up to 30% of all colorectal cancers (Hawkins et al., 2001,
Chan et al., 2001).
This thesis focuses upon the use of transgenic models of intestinal neoplasia to
investigate the consequences of the loss of function of a number of genes in this
pathway {Ape, Msh2, p53) and the implications of this loss for apoptosis,
clonogenic survival mutation and tumourigenesis.
1.2 The relevance of apoptosis to tumourigenesis
Apoptosis is a form of programmed cell death. It was originally characterised
morphologically, with cells showing plasma and nuclear membrane blebbing, cell
shrinkage, chromatin condensation and fragmentation. These changes distinguish
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it from necrosis. Necrosis occurs after physical, chemical or osmotic damage to
the cells disrupting internal and external membranes of cells and organelles. The
cytoplasm of these cells become grossly swollen, and the cell membrane breaks
down. This causes the release of denatured proteins and DNA into the
intracellular space producing a local inflammatory response. This does not occur
after apoptosis where apoptotic fragments are phagocytosed (Kerr et al., 1972,
Wyllie et al., 1980).
Apoptosis occurs in normal development and as a genetically controlled response
to variety of stimuli e.g. injury / DNA damage. It is the genetic control of the
second of these scenarios that this thesis will examine.
There are 2 major areas where apoptosis is hypothesised to play a role in
tumourigenesis:
A) Tumor growth and progression
Tumour growth may be thought of as an imbalance between proliferation and
apoptosis. Increased cellular proliferation through inappropriate expression of
oncogenes (e.g. c-myc) and loss of cell cycle arrest (e.g. loss of checkpoint genes)
would be predicted to lead to an increase in tumour size. However, if this was
accompanied by a comparable increase in the levels of apoptosis then homeostasis
would be maintained. In fact, overexpression of the oncogene c-myc can also
stimulate apoptosis (Evan et al., 1992). Therefore this leads to the prediction that
loss of the apoptotic response would be required for the progression of the tumour.
Several groups have attempted to address this simple hypothesis that loss of the
apoptotic programmes are relevant to progression of neoplasms. Although it is
clear that growth rate of the tumour is not a simple reflection of proliferation
(Wyllie, 1985), this hypothesis has not proved the easiest to test. Bedi et al.,
(1995) showed that during progression of colorectal cancer from normal
epithelium to carcinoma there is a reduction in the levels of apoptosis, suggesting
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that loss of apoptosis is important to such progression. However when Faezli et
al., (1997) investigated the transition from human colonic adenoma to
adenocarcinoma, no difference in basal levels of apoptosis was observed. It is
possible that by this stage of colorectal tumourigenesis, there has already been a
reduction in the levels of apoptosis (see chapter 9). One of the difficulties for
these studies investigating basal levels of apoptosis is that are relatively low (0.5-
1% of cells in the adenomas that Faezli et al., 1997 studied). In addition, in vivo
studies only provide a snapshot of the apoptosis that is occurring. It has previously
been shown that small differences in apoptosis can actually translate into
significant cell loss over an extended period (Vogelstein and Kinzler, 1996).
However such differences may often be too subtle to detect.
Many genes that are lost in tumourigenesis e.g. P53 and MSH2 and which have
been shown to be important in the induction of apoptosis, have also been ascribed
roles in cell cycle arrest and repair. This again makes it difficult to assess the
importance of apoptosis in isolation. Therefore despite it being widely accepted
that loss of apoptosis is important for tumour progression, there is still little direct
evidence for this notion.
B) Apoptosis and Chemoresistance
Loss of the apoptotic programme may also be related to gain of resistance to
chemotherapy in tumours. Many of the agents used to treat tumours have been
shown to induce apoptosis e.g. gamma irradiation, 5-Flurouracil (5-FU),
doxorubicin, cisplatin. (Clarke et al., 1997, Bearss et al., 2000). Trying to
ascertain the significance of this apoptosis is again difficult. A large number of
these cytotoxic agents produce p53 dependent apoptosis, thus loss ofp53 in a high
percentage of tumours correlates well with a model where loss of apoptosis
produces resistance to therapy (Lowe et al., 1993). However p53 deficiency is
also associated with loss of cell cycle arrest and senescence and so
chemoresistance may not necessarily arise due to loss of the apoptotic response.
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Probably the best study linking apoptosis to chemoresistance was performed in
murine primary lymphoma in vivo. Schmitt et al., (2000) demonstrated that
overexpression ofBcl-2 (a potent suppressor of apoptosis though not thought to be
involved in arrest) resulted in multi-drug resistance. Interestingly Bcl-2 had no
effect on long term clonogenic survival when these tumours were then cultured in
vitro. This highlights the difficulties of translating in vivo responses in vitro.
In fact it is much easier to find instances where there is no link between apoptosis
and chemoresistance, than those proving such a link. Bearss et al., (2000) showed
that in trangenic MMTV-myc and MMTV-ras/ myc mammary and salivary
tumours, apoptosis was not important in the response to paciltaxel and
doxorubicin. Normally these agents induce apoptosis, however in the tumours
there was no induction of apoptosis (prior to selection for resistance). Instead the
drugs induced cell cycle arrest. However they did show that the tumours with
higher basal levels of apoptosis (from biopsy), were more likely to undergo
regression.
This thesis investigates both of these questions (the significance of apoptosis and
the genetic control of apoptosis post-cytotoxic agents) using murine models of
intestinal neoplasia.
1.3 Hereditary colorectal cancer and murine models of intestinal neoplasia
The understanding of the genetic basis of colorectal cancer has been greatly aided
by the study of hereditary early onset colorectal cancer. These are thought to
account for approximately 15% of all colorectal cancers (Houltson et al., 1992).
The two most common of these are FAP (Familial Adenomatous Polyposis) and
HNPCC (Hereditary Non-Polyposis Colorectal Cancer).
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1.3.1 Familial adenamatous polyposis (FAP)
FAP is an autosomal dominant disease that afflicts approximately 1 in 7000
people (Vogelstein and Kinzler, 1996). The disease is characterised by the
development of 100's of adenomatous polyps in the colorectum. This normally
occurs during the teenage years and by the age of 25, 80% of patients will have
developed cancer. It is thought that these invasive adenocarcinomas arise from
the adenomatous polyps. Other intestinal lesions that can be developed by FAP
patients include gastric fundic gland polyposis (50%), duodenal adenomas and
gastric, pancreatic, bilary or distal small intestinal lesions (Damjanov et al., 1996).
Lesions are not confined to the intestine, other tumours incude ostemoas, desmoid
tumours and exostoses of long bones.
Patients with FAP have a germline mutation in one copy of the APC
(adenamatous polyposis coli) gene (Groden et al., 1991, Kinzler et al., 1991). In
most cases a further somatic mutation of the remaining allele then occurs leading
to the development of adenomas. APC is also mutated in the majority of sporadic
colorectal cancers (60-80% of tumours) (Rowen et al., 1999, Ilyas et al., 2000).
Up to 20 % of sporadic cancers are thought to have lost APC function through
hypermethylation of its promoter (Toyota et al., 2000). Due to the high frequency
of mutations in the APC gene in colorectal cancer, it is thought to be a very early
change to occur in colorectal neoplasia acting as a cellular "gatekeeper"
(Vogelstein and Kinzler, 1996).
APC is a very large protein of 2483 amino acids which interacts with a large
number of proteins including: (3-catenin, GSK3-(3, E-Cadheran, EB1, HDLG
(human homologue to disc large gene in drosophila) protein, Protein Phosphatase
2A and axin. Thus for some time its precise mode of action as a tumour
suppressor protein has remained unclear (for a recent reviews see Beinz 1999,
Polakis 2000). However recently its prime postulated role for tumour suppression
is through its involvement in Wnt Signalling (discussed in more detail later)
(Morin et al., 1997).
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1.3.2 The Min mouse
The ApcMm/+ (Multiple intestinal neoplasia) mouse was generated through random
germline mutagenesis following exposure to ENU (ethylnitrosourea) (Moser et
al., 1990, Su et al., 1992). Mice were identified as they had anaemia (displayed
by their white feet) and when dissected were found to be moribund with intestinal
polyps. Hence the name Multiple Intestinal Neoplasia. It was later discovered the
reason why the mice developed polyps was due to inactivating mutations at the
Ape locus. The ApcMm/+ mouse is heterozygous for a nonsense allele at codon 850
of the Ape gene (Su et al., 1992). Like FAP, intestinal neoplasia was inherited in a
dominant manner. Unlike FAP, the majority of tumours were in the small
intestine. However by changing the diet to a more westernised one and by
altering the genetic background of the mice, larger numbers of colorectal polyps
occur (Bilger et al., 1996). In fact, genetic background can radically alter the
ApcMin/+ phenotype. One of the most resistant backgrounds is the AKR strain of
mice. A C57BL/6 ApcM,n/+ mouse develops approximately 30 adenomas at death,
compared to only 6 in a mixed AKR x C57BL/6 strain (Dietrich et al., 1993).
Using these strain differences, one of the most powerful modifiers ofApcMm/+ was
mapped between D4Mit54 and D4Mit284. This is called MomlR (Modifier of
Min) and the most likely candidate gene in this region is secretory phospholipase
2 group 2 plag2a, which is expressed mainly in intestinal crypts (Gould et ah,
1996).
When polyps from ApcMm/+ mice on a C57BL/6 background were examined for
loss of the remaining copy ofApc+ all tumours showed loss (Luonga et al., 1994,
Levy et al., 1995). However once again there is a background specific effect on
loss of heterozygosity (LOH), for example in tumours from AKR mice only 63%
showed LOH (Shoemaker et al., 1998).
In contrast to FAP, a small percent ofApcMm/+ mice develop mammary adenomas
(akanthomas) (Moser et al., 1994). Recently Japanese studies have shown a
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number of sporadic mammary tumours have mutations in the Ape gene (Furuuchi
et al., 2000).
Mice homozygous for the ApcM,n/M,n mutation die in utero (Moser et al., 1990).
Other mutations in the Ape gene have been made, for example Fodde et al., (1994)
generated an truncation in the Ape gene at amino acid 716. This again resulted in
intestinal neoplasia in the heterozygote and embryonic lethality at day 8 in the
homozygote.
To overcome the problem of embryonic lethality conditional mutants for Ape have
been made using the cre-lox P system. Shibata et al., (1997) made an Ape mutant,
which lost a region of exon 14 of the Ape gene and induced a frameshift mutation
in Ape upon infection of a Cre recombinase expressing adenovirus. This mutation
was also shown to predispose to intestinal neoplasia, as within 4 weeks mice of
infection of the colorectal region, adenomas developed.
Therefore given some species variation in phenotype, the ApcMin/+ mice do appear
a good model of human FAP.
1.3.3: Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
Hereditary Non-Polyposis Colorectal Cancer is an autosomal dominant disease
(HNPCC) that accounts for approximately 3% of all colorectal cancers. Patients
have an early onset of colorectal and uterine cancers. They also have increased
numbers of gastric, upper urinary tract and ovarian malignancies. Patients are
designated as HNPCC patients if they conform to the Amsterdam critea (Vasen et
al., 1992).
1. Three or more relatives with histologically provable colorectal cancer, one of
whom is a first degree relative.
2. At least 2 successive generations affected.
3. FAP excluded
4. One ofmore of the cancers must have developed before 50 years of age.
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Although HNPCC has been recognised for many years, the molecular basis has
only recently been characterised. Previously two major critea had been used to
define it: linkage of the disease to 2pl6 or 3ql5 and microsatellite instability
(MSI) (Lynch et al, 1991,1993).
2pl6 or 3ql5 are now known to be the mismatch repair genes MSH2 and MLH1
indicating that the HNPCC is caused primarily by a defect in mismatch repair
(MMR) (Lui et al., 1996). This also explains why HNPCC tumours exhibit
Microsatellite Instability (MSI)/Replication Error (RER+) as MMR is important in
repairing microsatellite instability. Microsatellites are small repeats ofDNA of 1-
5 base pairs that are repeated from 15-35 times. When these are replicated by
DNA polymerase often a few of these repeats can be inserted or deleted. These
produce insertion/deletion loops (IDL's) that are recognised and corrected by the
MMR machinery. Therefore when MMR is lost, MSI ensues (Modrich and
Lauhe, 1996). A more detailed overview ofMMR will be given later.
Mutations in 5 MMR genes have been associated with colorectal cancer MSH2,
MLH1, PMS1, PMS2 and MSH6. Mutations in MSH6, PMS1 and PMS2 are very
rare in HNPCC (Wheeler et al., 2000). MSH6 deficient tumours do not exhibit
MSI and were often overlooked for scoring as HNPCC (Akiyama et al., 1999).
13-15% of other sporadic colorectal cancer exhibit MSI. Many of these tumours
have been characterised as having either MSH2 or MLH1 mutations. For
example in a Scottish cohort A/1 sporadic colorectal cancers had a MSH2
mutation (Bubb et al 1996/ However a large number of sporadic colorectal
cancer despite showing MSI, had no identifiable MMR mutation. Recently, it
has been shown that in up to 70% of these sporadic colorectal cancer there is
indeed no mutation, yet there is hypermethylation of the MLH1 promoter (Veigl
et al., 1998, Herman et al., 1998). Biallelic methylation of the MLH1 promoter
blocks transcription and therefore no MLH1 protein is produced. Further
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discussion of the relevance of methylation to colorectal cancer will be given
later.
There are also slightly lower levels ofAPC mutations in MSI Colorectal Cancer
(CRC) than microsatellite stable colorectal cancers. However there are higher
levels of the (3-Catenin oncogenic activating mutation (CTNNbl) in MSI CRC
indicating that inappropriate Wnt signalling is still necessary for all of these
colorectal cancers (Polakis, 2000).
1.3.4 Murine Models of loss of the MMR genes
At present six MMR deficient murine strains have been produced: Msh2 (MutS
homolgue 2), Msh3, Msh6, Mlhl (Mut L homologue), Pmsl (post-meoitic
separation) and Pms2 (for a review see Buermeyer et al., 1999a). Of all these
mutants strains, only Msh3'f' and Pmsl''' mice do not have a spontaneous tumour
predisposition (Prolla et al., 1998). However Msh3 deficiency accelerates
tumourigenesis on a Msh6''~ background (De wind et al., 1999, Edelmann et al.,
1996, 2000). In fact (Msh3"~, Msh6'!~) mice appear equivalent to the single Msh2~/~
mice.
The spectrum of tumours developed in the MMR deficient mice differs from the
ApcMxnl+ mouse. MMR deficient mice predominantly present with tumours of
lymphoid origin (De Wind et al., 1995, Prolla et al., 1998). This difference
between HNPCC patients and MMR deficient mice is thought to reflect a species
specific difference in spontaneous tumour predisposition: lymphoid tumours occur
relatively frequently whilst epithelial tumours are relatively rare in mice (Bradley
1996).
However in both Msh2~'~ and MlhP1' mice (though not Pms2~'~ mice), intestinal
neoplasia is observed (Reitmair et al., 1996a, Prolla et al., 1998).
Approximately one half of Mlhl'1' mice develop intestinal adenocarcinoma
whilst 70% of Msh2''' mice that survive past 6 months (20% of total) develop
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intestinal neoplasia. These older Msh2~'~ mice also develop extra-intestinal
tumours (such as skin neoplasia and uterine tumours) of a comparable spectrum
to HNPCC patients (Bradley, 1996). To overcome the strong lymphoma
predisposition of the Msh2~'~ mice, immune compromised (Tapl", Msh2~'~) mice
were produced. These mice all died from HNPCC-like tumours (De Wind et al
1998). Therefore arguing that MMR deficient mice reasonably model human
HNPCC. Intestinal neoplasia in the MMR deficient mice is also associated with
loss of Ape, again arguing the importance of inappropriate Wnt signalling for
colorectal cancer, with MMR accelerating loss of the Ape locus (Reitmair et al.,
1996a, Prolla et al., 1998).
One of the powers of transgenics is that by inter-crossing knockouts, one gains
insights into pathways and mechanisms e.g. the doubly mutant {Msh3~'~, Msh6'/')
mice are equivalent to the single Msh2'/' mice. Thus far, Msh2~/~, Mlhl" and
Pms2~/~ mice have been crossed onto ApcMm/+ background. All of these mice
show accelerated intestinal neoplasia, even the Pms2~'~ mice. (Reitmair et al.,
1996b, Baker et al., 1998, Shoemaker et al., 2000). Adenomas were shown to
have lost expression of Ape although the frequency of LOH (loss of
heterozygosity) was significantly reduced (Approximately 20% in the Min Mlhl
-/- tumours). This is consistent with Ape being lost in a mismatch repair
dependent manner. Taken together these studies indicate that the rate-limiting
step for intestinal neoplasia in a MMR deficient background is loss ofApe.
In MMR deficient mice, two hits at the Ape locus are required for adenoma
formation. As MMR deficient mice are prone to lymphoma, it is possible that
many mice die of lymphoma prior to development of gut tumours. On an
ApcM,n/+ background only one hit is needed, thus animals develop intestinal
neoplasia prior development of lymphoma.
In summary, MMR deficient mice model HNPCC neoplasia relatively
accurately. HNPCC patients are germline heterozgotes for the MMR mutations.
However in the mouse both Msh2 and Mlhl hemizygotes do not develop
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intestinal neoplasia (De Wind et al., 1998). In fact when survival data were
compared between heterozygotes and wild type mice, there was no difference in
survival. However the Msh2 heterozygotes have more tumours than wild mice
although there were no intestinal neoplasia. Only 1/71 tumours showed loss of
heterozygosity at the Msh2 locus in a Msh2 specific assay PCR. Obviously this
could miss many possible mutations, however the only tumour to show MSI was
the one that showed LOH at the Msh2 locus (De Wind et al., 1998). This
indicates that Msh2 heterozygosity could alone predispose to tumourigenesis
(this will be discussed in more detail later).
However heterozygosity for Msh2 did not accelerate intestinal neoplasia on an
ApcM,n/+ background (De wind et al., 1998). Thus despite the possibility of a
gene dosage effect of Msh2 (see chapter 7), in terms of modelling HNPCC, mice
completely deficient in MMR appear a closer representation.
1.4 Molecular basis of colorectal cancer
Colorectal cancer is one of the most clearly understood cancers in terms of
molecular changes. For some time, several different patterns of genetic linkages
have been established for colorectal cancer and recently this has led to the
identification of genes mutated in colorectal cancer (Vogelstein and Kinzler 1996,
Lengauer et al., 1997).
1.4.1 Ape and Wnt Signalling
The Wnt signalling pathway was first discovered in Drosophila, where it mediates
anteroposterior patterning in the segments of the fly embryo (Wieschaus and
Riggleman, 1987, Nusse, 1997). In vertebrates the Wnt pathway is important for
the induction of the dorsoventral and the anteroposterior embryonic axes. In fact
the discovery of Wntl as a proto-oncogene predated the discovery of wingless in
Drosophila (Nusse, and Varmus, 1982). However it was the elucidation of this
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Figure 1.2: Wn/ signalling pahtway adapted from Beinz 1999.
This diagram gives a simplified picture of Wnt Signalling. In the absence of a
Wnt Signal, P-catenin is phosphorylated targeting it for degradation by the
proteasome pathway (Orford et al., 1997). In these circumstances Lef/Tcf
transcription is repressed via interactions with Groucho co-repressors.
Following a Wnt signal, Dishevelled is activated by Frizzled. Dishevelled then
binds the axin-Apc-GSK3p-P-catenin complex inhibiting the phosphorylation of
p-catenin. This prevents its being targeted for degradation. P-catenin then
translocates to the nucleus where its binds Tcf4, stimulating transcription from
Wnt target genes. When Ape is mutated, P-catenin cannot be phosphorylated and
therefore transloactes to the nucleus and stimulates transcription.
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The Drosophila wingless pathways forms the basis of our understanding of the
vertebrate Wnt signalling. The pathway seems highly conserved between the
Drosophila and vertebrates. As expected vertebrate Wnt signalling is more
complex with a plethora of Wnt ligands (at least 16) and a large number of
Frizzled receptors (at least 11) (Polakis, 2000). In response to a Wnt signal in
vertebrates, frizzled is activated and transduces this signal to Dsh. Dsh through
its interaction with axin disrupts the quaternary axin, Ape, Glycogen Synthetase
kinase 3p (GSK-3P) and P-catenin complex. This prevents GSK-3P from
phosphorylating P-catenin and targeting it for degradation, thus free p-catenin
translocates to the nucleus where its stimulates Lef-Tcf transcription (Hart et al.,
1998, Beinz, 1999, Polakis, 2000). The Drosophila homologues of Dsh, GSK-3/3,
P-catenin are dishevelled, zeste-white 3 kinase and armadillo respectively.
The significance for tumourigenesis is that inappropriate Wnt signalling (such as
that caused by a loss of function Ape mutation or dominant phosophorylation
resistance /3-catenin mutation) will cause activation of this Lef-Tcf transcription.
An ever increasing number of target genes for Wnt signalling have recently been
discovered. These include the oncogenes: c-myc, AP-1, Cyclin Dl, Wispl(He et
al., 1998, Mann et al., 1999, Testu and McCormick, 1999, Shtutman et al., 1999,
Xu et al., 2000). Therefore this leads to the very attractive hypothesis that
following inappropriate Wnt signalling (e.g. loss of Ape), transcription of these
oncogenes would then cause dysregulated cell proliferation. Thus explaining, the
role of Ape as a 'gatekeeper' protecting against this dysregulated growth
(Vogelstein and Kinzler, 1996).
Other genes stimulated by fi-catenin include Tcf4 and Tcfl, which are both
involved in Tcf/Lef transcription. Tcfl is a negative regulator of Tcf/Lef
transcription through its interaction with groucho co-repressors (Roose et al.,
1998). This role as a negative regulator was proved in vivo through crossing the
Tcfl'1' mice to ApcM,n/+ mice. Here (ApcMin/+, Tcfl'1") mice showed a 10 fold
increase in the number of intestinal neoplasms. Thus when Tcfl is lost, this
additional check on Wnt signalling is lost and tumourigenesis is more rapid
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(Roose et al., 1999). This experiment also highlights that probably the key role
for Ape and p-catenin in tumourigeneis is through their role in Wnt signalling.
However both Ape and P-catenin are large proteins with a number of other
functions and interactions which could also play a role in tumourigenesis.
1.4.2 Other Interactions of Ape and P-catenin
1.4.2.1 Ape
Figure 1.3 Structure of Ape (adapted from Polakis 1999) (not to scale). The Ape
protein has a number of binding sites in addition to those involved those protein
involved in Wnt signalling (P-catenin and axin).
p-Catenin Microtubule binding EB1 binding
Oligomerisation Mutation Cluster p -Catenin degradation
Domain region sites
As can been seen from the structure of Ape, in addition to its ability to bind p-
catenin, there are also sites for binding microtubules and the proteins EB1 and
DLG (Drosophila disc large). The mutation cluster region (MCR) is within the
central portion of the protein. Mutations in this region produce truncated proteins
that still have the P-catenin binding sites though they would have lost the P-
catenin degradation/regulatory sites and the axin binding sites, preventing the
formation of the quaternary complex (Polakis, 2000). In addition, microtubule
binding, EB1 binding and DLG1 binding would also be lost. Therefore this argues
that loss ofAPC could have additional affects independent ofWnt signalling.
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Both in vivo and in vitro studies have indicated that Ape may also interact with the
cellular cytoskeleton. In both ApcMm/+ and Apc716/+ mice migration of intestinal
enterocytes up the crypt axis is affected. There is approximately 25% less
enterocyte migration up the crypt-villus axis in ApcMin/+ mice (Oshima et al.,
1995,1997, Mahmoud et al., 1997). Likewise overexpression of APC leads
dysregulated migration (Wong et al., 1996). Ape also interacts with microtubules,
again highlighting a possible role in the cytoskeleton. Ape in fixed epithelial cells
localises to clusters at the end ofmicrotubules (Nathke et al., 1996).
Another potential function of Ape comes from its interaction with EB1. A yeast
homologue of EB1 has also been shown to a function at cytokinesis, a cell cycle
checkpoint (Mihua et al., 1998). Loss of yeast EB1 abolishes this checkpoint
which normally delays cytokinesis until the spindle is properly positioned. EB1 is
normally located on the microtubules of the mitotic spindle so may act as a sensor
for their allignment. Given the ability of Ape to bind microtubules and EB1, it
may also be involved in detecting whether the spindle is correctly alligned in
vertebrate cells.
Further evidence of a role for Ape in mitosis comes from its localisation to
external faces of kinetochores where microtubules attach to chromosome (Kaplan
et al., 2001, Fodde et al., 2001). Therefore Ape may facilitate the attachment of
the microtubules to the kinetochores in mitosis. When Ape mutants were made
lacking the C-terminus microtubule binding domains, cells exhibited errors in
chromosomal segregation and a propensity to develop aneuploidy. Furthermore,
Ishidate et al., (2000) showed that the interaction between APC-hDLG (human
discs large) protein negatively regulates cell cycle progression.
Consistent with all these studies (although most of the mutations in FAP patients
occur in the MCR region), several patients have mutations very close to the C-
terminus indicating that these potential roles in mitosis and cell cycle checkpoints
could also be important in the role of Ape in tumour suppression (Pedemente et
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al., 1998). Although it cannot be discounted that these mutations could affect
protein folding and so be the equivalent to inactivating mutations.
In summary, loss of Ape could affect a range of cell cycle checkpoints
independently of dysregulated Wnt signalling, but it remains unclear how
important these functions are to tumour suppression.
1.4.2.2 p -Catenin
Figure 1.4 Structure of p-catenin. Adapted from Wiltert and Nusse (1998). In
addition to binding of Ape and Tcf, P-catenin has binding sites for a- catenin, E-
Cadherin and fascin.
Putative Phosphorylation
Sites a- catenin Ape E-cadherin and fascin
Ubiquitination sites
p-catenin is a protein of 1300 amino acids containing 12 armadillo repeats of
approximately 42 amino acids. As can been seen from the figure, Ape, Tcf and E-
cadherin bind P-catenin at these arm repeats whilst a-catenin binds at the N-
terminus. (Wiltert and Nusse, 1998). In addition to its role in Wnt signalling, P-
catenin is also important in cellular adhesion through its interactions with a-
catenin and E-cadherin. As these proteins bind to the arm repeats of p-catenin in a
mutually exclusive manner with Ape, it indicates that the cellular adhesion
function is disparate from Wnt signalling (Hulsken et al., 1994). In epithelial cells,
cell-cell adhesion is mediated primarily through epithelial (E) cadherin, a 120 kDa
transmembrane glycoprotein localised at adherin junctions (Takeichi, 1991).
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P-catenin can bind both a-catenin and E-cadherin at once, thus linking the
adherens junction to the cytoskeletal polymer actin. This is essential for the
adhesion function of cadherins at the zonula adherens junction. The binding of
cadherin-catenin complexes to transmembrane tyrosine kinases and phosphatases
allows cells to respond to extracellular signals with rapid and local changes in
adhesion.
The independence of the cell mobility and Wnt Signalling has been shown by
producing mutants of p-catenin. Mutants in the a-catenin binding site can still
activate Wnt signalling whilst mutants in the transactivation domain remain
efficient in cell adhesion (Orsulic and Peifer, 1996). From the role it mediates in
cell adhesion, it is clear that mutations of P-catenin will also lead to altered cell
mobility.
In summary, as those colorectal tumours that lack an APC mutation, often have a
dominant P-catenin mutation, this indicates that inappropriate Wnt signalling is
the prime mechanism underlying tumourigenesis (Akiyama et ah, 2000, Polakis
2000). However both APC and p-catenin have a number of other potential roles
in cell cycle control (e.g. APC with hDLG/spindle control) and cellular adhesion
(.B-Catenin). These other interactions could have quite different implications for
the evolution of tumour in terms of both tumour progression and therapy.
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1.4.3 Mismatch repair
Originally, most of our knowledge on the basic biology of mismatch repair was
derived from unicellular organisms: first E.coli and more recently Sacchromyces
cerevisiae (Modrich, 1994). The conservation of this pathway highlights the
importance of mismatch repair to all organisms and not just tumour suppression.
The fundamental role of mismatch repair is to correct mispairs produced by DNA
polymerase during DNA replication (Modrich and Lauhe, 1996). If these mispairs
were left uncorrected it would produce a mutation in the next round of replication
(see figure 1.5).
Figure 1.5: The consequence of an unrepaired mismatch (adapted from
Modrich 1994).
GT MISPAIR GC PAIR
T
C
CG PAIR AT MUTATION
The best characterised system of mismatch repair is the MutHLS system in E.coli
(Modrich, 1994, Kolodner, 1995). MutS is the only protein that specifically binds
to mismatches of the 10 proteins known to be involved in this mismatch repair
pathway (Modrich, 1991). It recognises all mispairs apart from C-C. Out of the
10 proteins only MutS, MutH and MutL are specifically associated with MMR,
7R
the other proteins are more general replication and recombination proteins: Mut U
(DNA Helicase ll/UvrD), Single Stranded Binding Protein (SSBP), RecJ
exonuclease, exonuclease I, exonuclease VI, DNA polymerase III and DNA ligase
I (Modrich, 1991).
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Figure 1.6 Recognition and removal of mismatches by the MutHLS system of
























Excision (either RecJ exonuclease, exonuclease I, VI, X )
and then resynthesis ofDNA (SSBP, DNA helicase II,
DNA polymerase III and DNA ligase)
The binding of MutS to the mispair in the presence of ATP allows the binding of
MutL to MutS at the mismatch and allows MutH to bind the nearest GATC site to
the mismatch (Modrich, 1991). The ATPase activity of MutS promotes the
formation of the a shaped loop of the DNA, allowing the interaction of the
proteins at the mismatch with MutH.
MutH alone has a very weak endonuclease activity however in the presence of
mismatch, MutS, MutL and ATP, this is activated to produce a single stranded
nick in the newly synthesised strand (Welsh et al., 1987). This strand specificity
is attained due to the restriction system in E.coli (Modrich, 1991). Here the G of
the GATC site is methylated by DAM methylase, a hemi-methylase, after
replication (Lauhe et al., 1989). Immediately after replication the G of the
template strand will be methylated whilst the G of the newly synthesised strand
will be unmethylated. Thus MutH nicks the newly synthesised unmethylated
strand. MutU is then loaded onto the MutH nick in a MutL dependent manner,
unwinding the DNA facillitating exonuclease removal of the nascent strand. 4
exonucleases are involved in MMR : exonuclease I, VII, X and recJ. They
apparently work relatively redundantly as it is only when all 4 are knocked out,
that MMR is lost (Buermeyer et al., 1999a). The DNA is then resynthesised
(Lauhe and Modrich, 1996). This process is bidirectional and depending on the
specific exonuclease, DNA can be excised in either a 5' to 3' or 3' to 5' manner
from the GATC site. Exonuclease I has a 3' to 5' exonuclease activity whilst
exonuclease VII and RecJ has a 5' to 3' activity. (Modrich, 1991).
Although many questions still remain on this MutHLS pathway in E.coli: the
precise role of MutL, the redundancy of the exonucleases exoVII and RecJ, the
specific stopping of the exonucleases when they have removed the mismatch etc.,
it is still better characterised than the mismatch repair pathway in eukaryotes
(Jirincy, 1994, Fischel and Wilson, 1997).
31
1.4.3.1 Mismatch Repair in Eukaryotes
Studies ofMMR in eukaryotes have been aided by the conservation of the system
between single cell eukaryotes and multicellular eukaryotes. Thus parallel work
has been undertaken in yeast, murine models and human cancer cell lines to
investigate MMR. The ease of manipulation of the genetics of the yeast
Sacchromyces cerevisiae has allowed the genetic characterisation of many
members of the mammalian MMR pathway (Fishel and Wilson, 1996).
Unsurprisingly, the MMR pathway in eukaryotes appears to be more complex
than in E.coli. Thus far 6 MutS homologues (MSH1-6) have been discovered in
yeast and 5 in mammalian cells (MSH2-MSH6) (Fishel and Wilson, 1997).
MSH1 has only been shown to be expressed in yeast. Interestingly, it is involved
in mitochondrial mismatch repair, raising questions upon possible mechanisms (if
any) ofmitochondrial MMR in mammals (Chi and Kolodner, 1994).
In both yeast and mammalian cells only three of these MutS homologues have
been shown to be involved in mismatch repair: MSH2 (Muts Homologue 2),
MSH3 and MSH6 (or GTBP 160) (Modrich and Lauhe, 1996). Much more is
known about the action of these proteins than the MutL homologues. The MutL
homologues that are thought to be important in MMR are: MLH1 (MutL
homologue 1), yeast PMS1 / mammalian PMS2 and possibly yeast
PMS2/mammalian Pmsl (Post-meiotic segregration 1 and 2 ) (Fischel and
Wilson, 1997, Prolla et al., 1998). This confusion in the nomenculature is because
PMS1 in yeast has the greatest identity to PMS2 in mammalian cells and PMS2 in
yeast has the greatest identity to PMS1 in mammals. As most of thesis is
concerned with murine models of these genes when I discuss PMS1 and PMS2
this will refer to mammalian PMS1 and PMS2, yPMSl and yPMS2 refer to the
yeast genes. Recently 2 other MutL proteins have been shown to exist in both
yeast and mammalian cells : MLH2 and MLH3 however their role in MMR like
PMS1 remain obscure (Wang et al., 1999, Lipkin et al., 2000). So far no MutH
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homologues have been found in eukaryotes nor a mechanism for strand
specificity.
Figure 1.7 Proposed model of mismatch recognition in eukaryotes (adapted from











MSH2 acts as a heterodimer with MSH3 or MSH6 in mismatch recognition. At
first it was proposed that MSH2 worked alone as a homodimer which recognised
mismatches (Jirinchy, 1994). However in vitro it recognised mismatches quite
weakly compared to the mismatch binding activity of MUTSa that was isolated
from yeast (Iccarino et al., 1996). When this complex was isolated first in yeast
and then in human cells, it was shown to be a heterodimer ofMSH2 and a 160kda
protein: MSH6/GTBP 160 (Habraken et al., 1996, Drummond et al., 1995). This
extract was shown to then restore MMR in MMR deficient human colorectal
cancer cell lines HCT-115 and LoVo (Drummond 1995).
The HCT-115 cell line was shown to have a functional MSH2 gene and a mutated
MSH6 gene. As expected this cell line shows an inability to bind single
mismatches producing an increased mutation rate (mutator phenotype). It also
showed instability in its mononucleotide tracts. However microsatellite instability
at dinucleotide and trinucleotide tracts; common in yeast and colorectal cancer
cell lines with the MSH2 mutation was not evident (Papadopoulous et al., 1995,
Johnson et al., 1996). This indicated that there was likely to be another protein
involved in preventing this microsatellite instability. It was shown eloquently in
S.cerevisaie that this other protein involved in MMR was the other cloned MutS
homologue MSH3 (Johnson et al., 1996, Marischky et al., 1996). In S.cerevisiae
the msh3 mutation alone has a very weak mutator phenotype, which is almost
indistinguishable from wild type, though its MSI is 40 fold higher. Although
msh6 has a strong mutator phenotype this is still lower than msh2 mutant and there
is no MSI. However the msh3 msh6 double mutant has a mutation rate and
spectrum that is indistinguishable from the msh2 mutant, indicating that MSH3
and MSH6 interact in a partially redundant manner with MSH2 (Johnson et al.,
1996, Marischky et al., 1996).
More recently this interaction has been confirmed in mammalian cells using
transgenic mouse knockouts. The combined (.Msh3MshS1") mouse gave a
comparable phenotype to the single Msh2~/~ mice (De wind et al., 1999,
Edelmann et al., 2000).
The interaction between MSH2 and MSH3 was confirmed in vitro when the
MSH2-MSH3 heterodimer was purified (MUTSp complex) (Habraken et al.,
1996). As predicted this complex was shown to have a low affinity for single
GT mismatches and a high affinity to bind larger insertion/deletion mismatch
loops. This produces the model shown above where MSH2 in a heterodimer
with MSH6 or MSH3 recognises single mismatches and insertion/deletion loops
(IDLs)
Mutations in Mlhl and Pms2 produce a mutator phenotype both in vitro and in
vivo (Prolla et al., 1998, Glaab and Tindell 1997). Therefore it is known that
Mlhl and Pms2 are essential for MMR although like the situation in E.coli, their
precise function is not known. However again it is postulated to act as a
'molecular matchmaker' coupling mismatch recognition to downstream removal
of the mismatch. The MLH1-PMS2 in humans and the MLH1-PMS1
heterodimers in yeast have been purified (Li and Modrich, 1995, Habriken et al.,
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1997). Although this heterodimer is unable to recognise mismatches (as expected
from E.coli), the heterodimer promoted the binding of MSH2-MSH3 and MSH2-
MSH6 to mismatches (Habriken et al, 1997). Another MutL heterodimer MLH1-
PMS1 heterodimer has been isolated in human epithelial cells though its function
is unclear. (Raschle et al., 1999).
After mismatch recognition, ATP hydrolysis appears to be required in the
following steps of the MMR pathway though the actual details of these are still
unknown (Alani et al., 1996,1997). Recently, Fishel (1998, 1999) proposed that
the MSH (Muts S Homologues) proteins act as a ADP-ATP molecular switch.
Thus, on recognition of the mismatch there is ADP to ATP exchange which
induces a conformational change of the MSH proteins meaning that they can act
as a sliding DNA clamp, which then directly interacts with the downstream MMR
machinery (Gradia et al., 1998, Fishel, 1998, 1999). One potential 'effector'of
MMR is PCNA (Proliferating Cell Nuclear Antigen). PCNA can bind both the
Mutsa (via MSH6) and Mutsp (via MSH3) as well as MLH1 (Buermeyer et al.,
1999a, Flores-Rozas et al., 2000). Flores-Rozas et al., (2000) showed that PCNA
is involved in the mispair recognition complex. This interaction with PCNA may
provide the basis for strand specificity in mammalian cells. As was said earlier
there is no MutH homologue nor restriction system in mammalian cells so
questions have remained on strand discrimination. An interaction with PCNA
could tether the MMR machinery to the replication proteins during DNA
replication, allowing rapid repair of mispairs. Alternatively PCNA binding on
DNA post replication could then allow loading of the MMR proteins onto the new
synthesised strand allowing it to recognise mispairs. Fishel's 'molecular switch'
model proposes that the MMR sliding clamp interacts with PCNA, which is also a
sliding clamp causing the polymerase to switch from a forward processivity to a
reverse processivity steered by it 3' to 5' exonuclease domain (Fishel, 1998,
1999, Gradia et al., 2000). However this model is still highly speculative. Thus
far all that has been shown is the ADP to ATP switch.
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Bellacosa et al., (1999) argued that a MLH1 interacting protein MBD4/MED1
could act as functional homologue of MutH for strand discrimination. It is a
member of the methyl binding domain (MBD) family of proteins and has been
shown to interact with methylated DNA, MLH1 and cause MSI when
overexpressed. When examined more carefully Mbd4 appears to be a mismatch
specific thymine glycolase. Thus it was able to remove Thymine or Uracil
mispaired with Guanine. However it could only bind to symmetrically methylated
sequence or a mismatch in the context of a MeCpG (5 methylcytosine: guanine)
(Hendrich and Bird 1998, Heindrich et al., 1999). Given that MeCpG makes up
only a very small percentage of the genome, it would be highly unlikely that
Mbd4 could act as a general MutH homologue. (Mbd4 is discussed at length in
chapter 8).
1.4.3.2 Mismatch Repair and Apoptosis: Methylation Resistance.
MMR is thought to be involved in the clearance of lesions in the DNA produced
by methylating agents and cisplatin (Modrich and Lauhe 1996, Fischel and Wilson
1997). Thus the loss of MMR genes could be important in acquiring
chemoresistance to these agents. The evidence for this includes both biochemical
and genetic evidence.
Duckett et al., (1996) showed that human MUTSa specifically bound DNA
containing O6 methylguanine (06meG), O4 methylthymine (04meT) and cisplatin
induced 1,2 intrastrand crosslinks. Ceccotti et al (1996) showed a similar
phenomenon in human colorectal cancer cell lines where methylated plasmids
(methylated by NMNU producing 06meG adducts) introduced into cells caused
repair synthesis to occur in MMR proficient cells. However in MMR negative
cells (e.g. LoVo MSH2'") no repair synthesis was shown to occur.
Originally the majority of the genetic evidence focussed upon human tumour cell
lines lacking MMR enzymes (normally MSH2 or MLH1) and exposing them to
methylating agents e.g. MNNG, NMNU or temozolomide or other agents such as
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cisplatin. NMNU (N-methyl-N-nitrosourea), MNNG (N-methyl-N'nitro-N-
nitrosoguanidine) and temozolomide all produce 06meG adducts (Pegg 1990,
Newlands et al., 1997). These MMR deficient tumours cell lines showed increase
resistance and clonogenic survival (Fink et al., 1997).
One of the difficulties of using in vitro tumour cell lines is proving that the reason
for this resistance is loss of MMR rather than another genetic alteration in the
tumour cell line (Fink et al. 1997). For example many of the tumour cell lines
which lack MMR (e.g. LoVo, HCT-15 and DCD1) have increased levels of ATase
(O6 alkylguanine transferase), an enzyme reponsible for removing O6 meG adduct
in vivo (Pegg, 1990). Thus this could be the cause of the methylation resistance.
However, Branch et al., (1995) showed that the SW48 colorectal cancer cell line
lacking MSH2 exhibits methylation resistance despite having low levels of Atase,
although this still did not provide a conclusive link between MMR and apoptosis.
The relationship between loss ofMMR and methylation resistance was established
by complementation studies where the mutant cell line had the wild type
chromosome (which contained the MMR gene) added back to the cell line. In this
instance when the original tumour cell line was compared to the complemented
one, most of the methylation resistance was lost (Hawn et al., 1995). Hawn et al.,
(1995) also showed that complimented cells now entered a G2 arrest, implicating
MMR in producing a G2 arrest.
Probably the best evidence of the loss of MMR leading to methylation resistance
was from studies using the MMR deficient mice. Msh2~'~, Mlhl'1' and Msh6~'~
embryonic stem (ES) cells and primary embryonic fibroblasts derived from MMR
mice, all show methylation resistance (De Wind et al., 1995,1999, Buermeyer et
al., 1999b, Toft et al., 1999). Such primary lines carry the considerable advantage
that they will not have been selected for additional genetic change in culture, and
so should parallel the genotype of the mutant strain.
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Figure 1.8: Replicative Cycling model of MMR dependent apoptosis (adapted
from Karran and Bignami, (1991)
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The mechanism by which the MMR pathway is invoked in clearance of the
damage caused by methylating agents is still quite speculative. Studies on Msh2
deficient mice and cells have shown that there are reduced levels of apoptosis
compared to wild type cells following treatment with methylating agents (Modrich
and Lauhe, 1996, Toft et al 1999).
The alkylating agents MNNG, temozolomide and MNNG all produce a similar
spectrum of lesions (see appendix). However, the lesion that is thought to be
important for MMR recognition and apoptosis is the cytoxic lesion 06meG
(methylguanine lesion). The reason for this is that 06meG causes a
misincorporation of a T opposite the G. Thus the MMR machinery will recognise
this as a mismatch, excising the newly synthesised T. The replicative cycling
hypothesis of MMR dependent apoptosis then suggests that, as the newly
synthesised T is removed and not the O6 meG lesion, another T will be re-inserted
again which will be recognised again by the MMR machinery. This produces
cycles of removal and re-synthesis. It is proposed that this continual cycling of the
repair machinery causes a signal to induce apoptosis either due to energy
depletion or long term presence of single strand breaks (Karran and Bignami,
1991, Fishel and Wilson, 1997, Fink et al., 1997).
However the precise nature of this apoptotic signal is still under debate. Fishel's
(1999) molecular switch model argued against this futile cycling and instead a
more direct signalling from the MMR complex to the apoptotic machinery (Gradia
et al., 2000).
For apoptosis to be basis of the methylation tolerance, this short term decrease in
apoptosis needs to translate into longer term (clonogenic) survival. Furthermore,
MMR deficiency may translate into an increased mutation rate (compared to wild
types) due to long term perpetuation of cells bearing a higher level of DNA
damage. Although increased survival and mutation seem two very obvious
consequences of failure to engage gene dependent apoptosis, it should be noted
that in many instances this is not the case, as has been shown for p53 (see chapter
6).
Several studies appear to confirm these two predictions for MMR and methylation
resistance. Toft et al., (1999) showed that Msh2 null mice had a reduced level of
apoptosis when they were treated with MNNG or temozolomide and that Msh2~/~
ES cells have increased clonogenic survival when treated with temozolomide.
Two studies have reported that Msh2~/~ mice have an increased mutation
frequencies in vivo in response to these cytotoxic drugs. Andrew et al., (1998)
showed this using a lacl reporter system (this is described in more detail in
1.4.5.2). After injection with NMNU, Msh2'/~ mice had significantly higher
frequencies than wild type animals. This was significantly higher than differences
between untreated Msh2~/~ mice and wild type animals (Andrew et al., 1998).
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One other study has examined the impact of second methylating agent
temozolomide on in vivo mutation frequency (Toft et al., 1999). This study used
the Dlb-lb mutation assay (described in more detail in 1.4.5.2 and in Winton et
al., 1988). Again the basal mutation frequency was higher (XI0) in untreated
Msh2~/~ mice when compared to heterozygotes and wild type animals.
Heterozygotes and wild type animals had similar levels ofmutation.
When temozolomide was administered a significant increase in mutation rate was
observed between Msh2~' mice and wild type and heterozygous mice. These two
studies provide clear evidence that Msh2 is involved in clearance of lesions
produced by the methylating agents NMNU and temozolomide. Thus, this
increase in survival and mutation correlates well with the loss of the apoptotic
response.
As mentioned earlier, MMR deficient cell lines and primary fibroblasts, also lose
the G2 arrest in response to these methylating agents (Hawn et al., 1995,
Buermeyer et al., 1999b). Thus failure of the cell to arrest could also explain the
increased survival and increased mutation. One potential method of obviating the
arrest that could be MMR dependent is through replicative bypass around the
lesion (Moreland et al., 1999). The basis behind this is that MMR is also
involved in preventing illegimate 'homeologous' recombination (De wind et al.,
1995, Dudenhoffer et al., 1998). MMR binds to the mispaired recombination
intermediates so preventing recombination to occur. The theory of replicative
bypass of the lesion is that replication complex becomes stalled at a lesion,
producing a G2 arrest. However illegimate recombination around the lesion
occurs in cells that lack MMR, causing loss of G2 arrest and permitting
proliferation to occur. The best evidence for this comes from studies with
cisplatin (see 1.4.3.3). In the case of methylation damage, as MMR both binds the
06meG lesion and signals apoptosis from it, this appears to be a direct role in
damage recognition rather than replicative bypass of the 06meG lesion (Moreland
et al., 1999, Buermeyer et al., 1999a).
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1.4.3.3 Mismatch repair and cisplatin resistance
Duckett et al., (1996) showed that human MUTSa bound DNA and cisplatin
induced 1,2 G-G intrastrand crosslinks. Unlike the 06meG lesion which produces
the GT mispair, the basis of how MMR recognises this lesion is unclear. However
the evidence that MMR deficiency plays a subtle role in contributing to cisplatin
resistance is clear.
Cisplatin is often used as a chemotherapeutic in ovarian carcinoma, however drug
resistance often follows initial regression of the tumour (Aebi et al., 1997).
Strathdee et al., (1999) showed that approximately 12.5% of these tumours
demonstrated loss of function of MLH1 through promoter hypermethylation.
When the MMR complemented ovarian cell line A2780 was examined in respect
to cisplatin tolerance, a series of tumour cell lines had around a 2 fold higher
tolerance to cisplatin than the MMR complemented cells (Fink et al., 1996,1997).
Carboplatin showed similar MMR dependent resistance although other platinated
compounds such as oxaliplatin exhibit no such differences in resistance (Fink et
al., 1996,1997).
Due to this relatively low increase in resistance, further experiments were carried
out to examine the significance of this phenomenon. Fink et al., (1997) did this
by selecting resistance to cisplatin both in vivo and in vitro. This was done in
vitro by taking HCT116 MMR deficient cells, which expressed gfp {green
fluorescence protein) and culturing these with HCT116 MMR proficient cells that
did not. 5% of the cells at the start of the experiment were MMR deficient but 5
days later following a one-hour exposure to cisplatin there were 53% more MMR
deficient cells than in the untreated controls.
In vivo selection experiments were performed by implanting wild type and Msh2
null ES (embryonic Stem) cells subcutaneously into nude mice. The mice were
then treated with cisplatin. The wild type tumours shrank in size over the first ten
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days. In the Msh2 null tumours, no shrinkage of tumours was observed, instead
there was a growth delay for 4 days. 18 days after the implantation the Msh2 null
tumours had a significantly higher volume (Fink et al., 1997).
One of the most eloquent studies showing that MMR is important in cisplatin
resistance was shown using ovarian tumour xenografts lacking MLH1 due to
promoter hypermethylation. After addition of 2'-deoxy-5-azacytidine (DAC), a
methylation inhibitor, MLH1 was re-expressed. Coincident with MLH1 re-
expression, the xenografts were re-sensitised to cisplatin (Plumb et al., 2000).
However this appears to be a rather subtle affect as loss ofMMR only confers a 2
fold increase in resistance compared to a 50-100 fold increase in resistance to
alkylating agents (Branch et al., 2000). When apoptosis was examined in Msh2'/'
mice, there was only a small decrease in the level of apoptosis compared to
complete loss of apoptosis in p53~'~ mice at the same timepoint (Toft et al., 1999).
Branch et al., (2000) showed, in ovarian tumour cell lines, that MMR deficiency
was relatively minor when compared to p53 deficiency.
As stated above, MMR may initiate a G2 arrest following cisplatin treatment by
preventing replicative bypass of the cisplatin lesion. The best evidence for this
was shown using yeast mutants for MMR and DNA recombination. Durant et al.,
(1999) showed that inactivation of mlhl and msh2 caused resistance to cisplatin.
However when they were crossed to recombination deficient rad52 or radl
mutants, the resistance was lost. This indicates that MMR resistance was through
a recombination mediated pathway. In a similar study in ovarian cell lines the
DNA polymerase inhibitor Aphidicolin was used to inhibit the replicative bypass
(Moreland et al., 1999). In vitro studies have shown that DNA polymerase 8 and
s are able to bypass 1, 2 crosslinks induced by CDDP at replication forks
(Hoffmann et al., 1996). The addition of aphidicolin to MMR deficient cells
caused re-sensitisation to cisplatin (Moreland et al., 1999).
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This replicative bypass model could account for the recent proliferation of DNA
damage responses that MMR is associated with. MMR deficiency has been
associated with ionising radiation, 6-thioguanine (6-TG), doxorubicin, 5-
flurouracil (5-FU), oxidative damage, etoposide and chloroethylating agents (Fink
et al., 1997, Durant et al., 1999, Davies et al., 1998, De Reese et al., 1998,
Hickman and Samson, 1999). Out of these only 6 -TG would produce a substrate
the MMR machinery would recognise directly i.e. a mismatch. Thus it could be
that replicative bypass could account for MMR's minor role in resistance to these
types of damage.
Another explanation for the growing number of roles of the MMR proteins could
be that they are members of a much larger 'repairosome' complex. Recently in
HeLa cells a large complex called BASC (BRCA1-associated genome
Surveillance complex) containing BRCA-1, MSH2, MSH6, MLH1, ATM, BLM,
and the RAD50-MRE11-NBS1 protein complex was isolated (Wang et al., 2000).
As MMR has been shown to be important for apoptosis and cell cycle arrest this
has recently led to a debate about what is the primary reason for selection of loss
ofMMR in colorectal cancer. The previously accepted theory was that a mutator
phenotype is required for tumourigenesis, thus loss of MMR provides this (Loeb
et al., 1991,1993). However more recently this view has been challenged.
Tumours from lacl and lacZ transgenic mice from both p53 and Msh2 null
tumours do not always show an increased mutational burden compared to wild
type tissues (Sands et al., 1996, Andrew et al., 2000). Bodmer and Tomlinson
(1999) have argued that the selection benefit for the cell of a mutator phenotype
would not take effect immediately so that there would not be no positive selection
for it. Instead they argue that selection for loss of MMR is for loss of apoptosis
or arrest which would give an immediate selective advantage. However a
secondary effect would be to produce a mutator phenotype (Ilyas et al., 1999). As
yet the models of somatic evolution of tumours are not yet sufficiently advanced
to answer these questions. One problem with this theory is that thus far MMR-
dependent apoptosis and arrest has only been displayed after a high level of a
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specific drug/ DNA damaging agent. Whether this is relevant in an untreated
tumour has not been shown. One study that argues against this is Plumb et al.,
(2000) which was described earlier. After treatment with DAC, there is re¬
activation of MLH1 which causes sensitisation to cisplatin treatment. However,
when MLH1 was re-expressed in untreated tumours there was no effect on cell
growth. Thus if loss of MLH1 equated to loss of apoptosis or cell cycle arrest,
one would expect some decrease in cell growth in these untreated tumours after
re-expression ofMLH1.
1.4.3.4 Other MMR functions
This sections provides a very brief overview of other roles that have been ascribed
to the MMR proteins.
1. Meiosis:
The MMR proteins: Mlhl, Pmsl, Pms2 and Msh4 have been shown to be
important in meiosis. In fact all Mlhlmice and male Pms2~/~ mice are sterile
(Edelmann et al., 1996, Bakker et al., 1995.)
2. Somatic Hypermutation.
The MMR proteins Msh2, Mlhl and Pms2 also play a role in somatic
hypermutation. Somatic hypermutation is the process of immunoglobulin (Ig)
gene somatic mutation to introduce specific nucleotide changes into the variable
region of the Ig during the immune response (Reynauld et al., 2000). Surprisingly
loss of MMR causes reduction in hypermutation. In addition the spectrum of
mutations in the different MMR mutants also differ. (Reynauld et al., 2000)
3.Transcription Coupled Repair (TCR) and Nucleotide Excision Repair
(NER).
Functional overlap between MMR and Nucleotide Excision Repair (NER) has
been shown on many occasions. Many types of DNA damage e.g. cisplatin
lesions are thought to be recognised by both NER and MMR proteins (Reed 1998,
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Jordan and Carmo-Fonseca, 2000). NER has also been shown to supress
'homeologous' recombination and be involved in repair of certain mismatches
(Sugwara et al., 1997). One type of mismatch that NER recognises is the C-C
mismatch not recognised by MMR (Fleck et al., 1999). Some types of repair
require both MMR and NER. Kirkpatrick and Petes, (1997) showed that Msh2
and Radl were both required to repair 26bp DNA loops in S. cerevisaie.
Probably the best evidence for an interaction between the MMR and NER genes
occurs in Transcription Coupled Repair (TCR). In E.coli, MutS and MutL mutants
selectively abolish rapid repair in the transcribed strand and render the cells
moderately sensitive to UV irradiation (Mellon and Champe, 1996). MSH2 has
been shown to physically interact with NER genes RAD2, RADIO, RAD14 and
RAD25 in yeast (Bertrand et al., 1998). Post UV damage, mutations in MSH2
increases the UV sensitivity of NER deficient yeast mutants. Tumour cells lines
deficient in MMR have also been shown to be deficient in TCR (Mellon et al.,
1996). Leadon and Avrutskaya, (1997) showed that MSH2~/~ tumour cell lines
were deficient in TCR of adducts of UV and oxidative damage (Leadon and
Avrutskaya, 1997). Surprisingly MLH1 mutants were only defective in TCR of
UV and not oxidative damage.
However recently it has been shown that, in Msh2v~ mice, the levels of TCR
following UV damage was normal so questioning the significance of this in vivo
(Sonneveld et al., 2001).
1.4.4. p53 and colorectal cancer
Any search on P53 soon yields a staggering number of publications (in 1998 alone
there were 3744 publications), highlighting that this is probably the most studied
protein in scientific world. This statistic reflects the fact that P53 mutations are
amongst the commonest molecular events in neoplasia: it is mutated in
approximately 50% of human cancers and is possibly inactivated in all tumours
through loss or upregulation of other genes in the P53 pathway e.g. P14ARF and
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MDM2 (Harris, 1996, Haupt et al., 1997). P53 is thought to be lost at a relatively
late stage in colorectal cancer (Vogelstein and Kinzler, 1996). It is thought to be
lost in up to 70% of colorectal cancers, marking the transition from benign colonic
adenoma to adenocarcinoma (Vogelstein and Kinzler, 1996, Fazeli et al., 1997).
The precise reason for this loss at this stage is still unclear. However its role as a
general mediator of the DNA damage response is thought to be important.
For many years it has been known that P53 is a critical cellular mediator of the
response to genotoxic damage in vivo and in vitro (Wyllie et al., 1994). P53 has
been shown to induce apoptosis in response to a wide variety of insults and shown
in vitro to also induce G1 and G2 cell cycle arrest via transcriptional activation of
p21/WAF (Agarwal et al., 1995). Recently, a series of significant advances have
been made in the in vitro characterisation of the P53 pathway. These include the
identification of ever increasing types of cellular stress that upregulate P53; the
identification of post-translational modifications in response to such stress; and
the characterisation of proteins that interact with or are transactivated by P53 (see
figure 1.10)(for a recent review see Prives and Hall, 1999). One obvious goal of
these studies is to link stimuli such as ionising radiation to a particular set of
events which determine biological fate such as the engagement of apoptosis or cell
cycle arrest. However, whether the system will be as straightforward as this
remains to be seen. It has also been demonstrated in vitro that P53 may have a
direct role in maintaining genome integrity by preventing homeologous
recombination, recognising and removing mismatches and participating in
Nucleotide Excision Repair (Lee et al., 1995, Janus et al., 1999).
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Figure 1.9: Postulated P53 pathway, (adapted from Prives and Hall, 1999).
Following a range of stresses, the P53 protein is modified. Thus far the proteins
identified to modify P53 are mainly kinases: DNA-PK, ATM and ATR.
Although as yet unproven, such modifications are postulated to render Mdm2
unable to bind P53 thus causing accumulation of P53. Depending on the specific
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One obvious reason for loss of P53 in colorectal cancer is due to loss of the
apoptotic response. A large number of studies have shown that basal levels of
apoptosis in the murine intestine and adenomas are unaffected by p53 status
(Merrit et al, 1994, Clarke et al., 1994). However, post DNA damaging agents
(e.g. gamma irradiation, 5-Flurouracil (5-FU), cisplatin) p53 is necessary for the
normal apoptotic response (Clarke et al., 1994, 1997 Pritchard et al., 1999). Thus
chemotherapy treatment of a tumour may have selected for loss of P53, possibly
explaining the association of P53 loss with the later stage of tumourigenesis.
However, if loss ofP53 is independent of treatment, then many tumours may have
already lost P53 prior to treatment. This raises clear doubts over the efficacy of
treatments that are thought to work through P53 dependent apoptosis. If they are
seen to be effective this raises questions upon role of P53 dependent apoptosis in
chemoresistance.
Another potential reason for the loss ofP53 in colorectal tumourigenesis, is due to
its role in governing apoptosis in response to hypoxia (Graeber et al., 1996). This
is of particular relevance to late tumour development, as regions of low oxygen
and necrosis are common features of solid tumours. Loss of this apoptotic
pathway has therefore been proposed as a key feature in tumour development and
in the selection within tumours ofmore aggressive clones.
As yet, the relevance of DNA damage induced apoptosis to spontaneous
malignancy is still unclear and difficult to investigate. Therefore assigning which
out of p53 plethora of functions is crucial to tumourigenesis remains difficult.
1.4.5 The phenotype of the /i55-deficient mice
Prior to the generation of mice deficient for p53, a number of different in vitro
studies had suggested key roles for p53 in initiating both apoptosis and cell cycle
arrest. These predicted a severe phenotype for p53 deficiency and it was therefore
of some surprise that p53 deficiency did not result in embryonic lethality as had
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been reported for other cell cycle genes such as Retinoblastoma (Rb) (Harrison et
al., 1995). This led to the suggestion that p53's true role was as a "guardian of the
genome", with a primary function of protecting against genotoxic damage (Lane,
1992). Any role for p53 in development was therefore initially discounted,
however several lines of evidence have now made it clear that p53 does indeed
play a role in normal embryonic development. Data has been obtained in support
of a role in embryogenesis from the careful analysis of p53 breeding data. This
indicated an apparent deficiency in the number of live born p53~' female mice
(Armstrong et al., 1995, Sah et al., 1995). When embryos were examined in utero
and at the point of parturition, 23% of female null embryos were found to have
neural tube defects, which presented as exencephaly from approximately day 12
of development, ultimately resulting in anencephaly at birth. Further support of
the concept that p53 might suppress germline mutations comes from the
observation that a significant increase (60%) in exencephaly is seen in p53"
female progeny derived from males irradiated prior to mating. Again this suggests
that p53 plays an important role in protection of the embryo against genotoxic
stress. The reason why this manifests itself predominantly within females remains
unclear, but this does reflect a similar sex bias seen in some human neural tube
defects. These studies have demonstrated at least partial dependency upon p53 for
normal development. Our understanding of this role has now been extended by
experiments using mice null for Mdm2 which have shown that abnormal
regulation of p53 is also incompatible with normal development (Jones et al.,
1995, Luna et al., 1995). On its own, Mdm2 deficiency results in lethality, yet this
is rescued in the absence ofp53. The basis of this rescue is assumed to lie in the
ability of Mdm2 to target p53 for degradation. Thus, in the absence of functional
Mdm2, p53 is overexpressed resulting in lethality (see figure 1.10). Similar
evidence for interaction between these two genes has been obtained using a
transgenic approach to overexpress a Mdm2 transgene and so cause loss of p53
(Jones et al., 1998).
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Therefore although p53 does appear to have a significant role in development, the
fact that the majority of mice were viable allowed the testing of its role as a
guardian of the genome in vivo (Lane, 1992)
1.4.5.1 Tumourigenesis in p53' " mice
Three different strategies were employed to generate the first p53 knockout mice
in the early 1990's (Donehower et ah, 1992, Purdie et al., 1994, Jacks et al.,
1994). All gave similar phenotypes with the majority of the p53~'~ mice dying
from lymphoma at around 6 months. This gave definitive proof that p53 was a
tumour suppressor gene, which previous clinical data and in vitro work had
suggested (Harris and Holstein, 1993). However none of the p53''' mice develop
colorectal lesions.
Li-Fraumeni patients are germline heterozygotes for P53. Mice heterozygous for
p53 can be viewed as a relatively accurate model of the Li-Fraumeni Syndrome,
as they develop tumours of a similar spectrum as those seen in Li-Fraumeni
patients (Oestosarcomas, lymphomas and soft tissue sarcomas) (Malkin et al.,
1990, Srivastava et al., 1990). However there are two notable exceptions to this,
namely the high incidence of lymphoma in the mice and the absence of breast
tumours (for recent reviews of mouse data see Loazona and Lui, (1999), Attardi
and Jacks, (1999). P53 heterozygotes develop symptoms of disease later than
their p53 null counterparts, with approximately 50% of mice succumbing to
tumours by 18 months. As wiid type mice live for up to 36 months, this age of
death of the heterozygotes is often compared to Li-Fraumeni patients where
affected individual have a 50% chance of developing cancer by the age of 30
(Donehower et al., 1996). However, great care should be taken in making direct
comparisons between the consequences of p53 deficiency in man and mouse as
many species specific differences exist, perhaps most notably in the strong
predisposition to lymphoma observed in the mouse.
Within the mouse, strain dependent differences in phenotypes have readily been
observed (Donehower et al., 1995, Donehower et al., 1996). For example, pure
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bred 129SV p53''' mice die from tumours much earlier than those crossed onto a
C57B16 background. Furthermore, 50% of p53~'~ males in 129SV develop
testicular teratomas which are only observed rarely in other backgrounds. This
latter observation probably reflects that p53 deficiency accentuates any natural
tumour predisposition, as wild type 129SV mice show a spontaneous
predisposition to testicular teratomas compared to other strains (VanMeyel et al.,
1998, Stevens and Little, 1954, Harvey et al., 1995).
This strong predisposition for lymphoma in the mouse, may have masked a more
subtle intestinal phenotype. To overcome this problem (as with the mismatch
repair deficient mice), p53~'~ mice was crossed to the ApcM""+ mice. The original
studies suggested that there was no accelerated intestinal tumourigenesis in the
(ApcMin/+, p53~ ') mice (Clarke et al., 1995, Fazeli et al., 1998). However there
was an increase in pancreatic tumours and desmoid fibromas. Two caveats to this
lack of this effect in the mouse was that ApcMm/+ mice rarely develop carcinoma,
probably due to their high burden of adenomas causing mortality. Thus if p53
plays a role in the adenoma-carcinoma transition then this may not produce a
phenotype in the mouse. Also (unlike the situation of (ApcM,n/+, Msh2~'~) mice),
(ApcM'n/+, p53") mice still die of lymphoma which could mean that a subtle
intestinal phenotype could be missed. By crossing the (ApcMm/+, p53'/~) mice onto
a uniform C57BL/6 background with known Moml resistance alleles (resistance
and sensitive), Hallberg et al., (2000) showed that there was increased intestinal
tumour multiplicity and invasiveness in (ApcMnv+, p53~'~) mice compared to the
ApcM,,l/+ mice at 90 days. This effect was quite subtle: on a resistance background
the number of tumours increased from an average 5 to 13 whilst on the sensitive
background they increased form 32 to 45. Again the increase in invasive
phenotype was also relatively minor : 2/42 (ApcMm/+, p53~'~) tumours were
invasive compared to 0/78 in ApcM,n/+ tumours and (ApcM'"/+, p53+/~) tumours.
Therefore, p53 plays a relatively small role in intestinal tumourigenesis in the
mouse. Probably the best way to further analyse this phenomenon would be to
use an intestinal specific p53 knockout (e.g an intestinal specific ere mouse
crossed to ap53 floxed mouse).
p53 has been shown that to be involved in a myriad of functions, such that
working out the significance of each of these is difficult. Recently the production
of specific knockouts has help elucidate p53 function. Probably the most crucial
function ofp53 is its role as a transcription factor. Jiminez et al., (2000) made a
p53 transactivation deficient mouse which showed defects in apoptosis and cell
cycle arrest. Like p53~/~ mice they also developed lymphomas and sarcomas.
Thus it appears transactivation is a central component ofp53 tumour suppression.
Choa et al., (2000) also showed that p53 transactivation deficient ES cells do not
undergo apoptosis following UV damage. Targets of p53 transactivation post
genotoxic damage include p21, Box, Gadd45a, Mdm2, cyclin Gl, a large number
of PIG genes (p53 Inducible Genes) and possibly Msh2 (Bates and Vousden,
1996, Polyak et al., 1997). Of these, Bax is a potent inducer of apoptosis, p21
mediates cell cycle arrest and Gadd45a is important in protecting against genomic
instability (Hollander et al., 1999). Murine knockouts have been made of these
genes. Interestingly there was no obvious phenotypes to the Bax and p21
knockout mice (Deng et al., 1995). In fact p53 dependent apoptosis still occurred
in the murine small intestine post DNA damage in the Bax'1' mice (Pritchard et al.,
1999b). Although there was no obvious phenotype in the mouse, p21'/' murine
embryonic fibroblasts (MEFs) had a defect in the Gl arrest response (Deng et al.,
1995). Furthermore it has now been shown that p21" mice are in fact tumour
prone although this only becomes apparent in mice over 16 months (Martin-
Caballero et al., 2001). Gadd45a'/' mice exhibit many similar symptoms to p53'''
mice. MEFs from Gadd45a" mice show genomic instability e.g aneuploidy,
chromosome aberrations, gene and centrosome amplification. They also exhibit
increased radiation carcinogenesis, exencephaly and an impaired G2 arrest to UV
and alkylation damage (Hollander et al., 1999,Wang et al., 1999). However they
do not show a deficiency in apoptosis. This similarity in phenotype to the p53~'~
mice again highlights the importance ofp53 transactivation to its overall function.
In summary, from these studies it appears that transactivaton domain of p53 is
crucial to p53 function. As the transactivation domain is crucial to p53's ability to
induce apoptosis and arrest this argues that these phenomena are also important
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for p53's role in tumour suppression. However despite being crucial for the
induction of apoptosis after DNA damage, a role for p53 in tumour suppression in
the murine intestine is still unclear showing that care should be taken in
extrapolating a role for apoptosis to a role in tumourigenesis.
Through the interaction of Msh2 and p53, this thesis will also examine other
functions of p53 that are possibly not dependent on its role as a transcription
factor (Chapter 6).
1.4.5.2 p53 and spontaneous mutation in vivo
The fact that the majority of p53~'~ mice (and Msh2''~ mice) are viable has allowed
questions to be posed addressing the importance of loss of gene function for
phenotypically normal cells in vivo, when previously these questions had been
restricted to (usually immortalised) cell lines in vitro. Although studies on such
lines have produced invaluable data and will continue to do so, nearly all of these
lines carry multiple genetic alterations. This makes the task of dissecting out the
effect of individual genes very difficult.
The advent of knockout technology has not only produced a range of new in vivo
systems, but it has also permitted the production of a new series of in vitro
models. An obligatory step in the production of the knockout mice is the
generation of targeted Embryonic Stem (ES) cells. If so desired, these can be
rendered homozygous by either a second round of targeting or by the use of high
levels of the appropriate antibiotic, which can select for conversion of the wild
type allele. The availability of mutant cell lines are not however restricted to ES
cells, as primary lines such as embryonic fibroblasts can relatively easily be
derived from mutant strains. Such primary lines carry the considerable advantage
that they will not have been selected for additional genetic change in culture, and
so should parallel the genotype of the mutant strain
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In each of these systems attempts have been made to determine the effect of
genotype upon mutation rate. In reality these assays measure mutation
frequencies, and broadly fit into two categories. First, those that that focus on a
phenotypic change due to inactivation or overexpression of a somatic gene which
is either autosomal or X-linked. These include changes resulting in loss of
function at the Dlb-lb (Clarke et al., 1997) and HPRT loci (Corbet et al., 1999),
overexpression of metallothinein (Jasani et al., 1999) and ouabain resistance
(Turker 1998). The second category includes those approaches which measure
mutation frequency from exogenous transgenes, including lacl (Big Blue™, lacZ
(Muta™) and supF (tRNA suppressor gene) (Turker, 1998).
The most commonly used in vivo assays in the mouse are the Dlbl assay, and
assays using the lacl and lacZ transgenes (Winton et ah, 1988, Nishino et al.,
1995). The HPRT (Hypoxanthine phosphoribostltransferase) is the most
commonly used assay for in vitro estimates (Corbet et al., 1999). All of these
techniques have drawbacks associated with them, however it is encouraging that
many of the in vivo tests yield relatively similar frequencies (see Cosentino and
Heddle, 1999).
In this thesis mutation frequency will be investigated at the Dlb-lb locus. The
Dlb-1 locus encodes for 2 lectin binding proteins. Dlb-la is constitutively
expressed on vascular endothelium. The Dlb-lb allele specifies binding of the
Dolichos biflorus agglutinin to intestinal epithelium. Thus, in mice heterozygous
for these alleles a single inactivating mutation at the Dlb-lb will abrogate the
ability to bind this lectin in the intestinal epithelium. After cell proliferation and
clonal expansion, mutations that occurred in the stem cell population will form
clones that fail to bind a peroxidase conjugate of Dolichos biflorus agglutinin.
These mutant clones can easily be visualised and scored to give an estimate of the
mutation frequency.
As with the other approaches, the Dlb-1 assay does suffer from some
shortcomings. One drawback of this approach is that it is limited to the analysis of
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intestinal mutation rates, as specific Dlbl-lb expression is restricted to the
intestine and thus mutation frequency can only be estimated in this tissue. A
further difficulty is that the locus has not yet been cloned and so questions relating
to mutational spectra cannot be addressed (Buettner et al., 1997). The assay does
however possess a number of unique advantages over other approaches. Key
amongst these is its ability to specifically score mutation within the stem cell
population and to permit visualisation of the mutant clones in situ (Winton et al.,
1988). Furthermore, because the Dlb-1 locus is an endogenous allele, there are
few concerns over the in vivo relevance of results, as have been raised following
the use of an exogenous transgene.
When mutation frequencies are compared between the Dlbl assay and the
transgenic mice Big Blue™ and MutA™, the transgenic models generally appear
a little less sensitive (Cosentino and Heddle, 1999). You et al., (1998) showed that
one of the reasons for this was the presence of a large number of CpG sites in the
lacl gene which are methylated in vivo. The lacl transgene usually consists of
multiple concatemers (around 40) of the lacl gene within a lambda-like shuttle
vector. This can be harvested from the mouse genome and packaged within the
lamda phage. Bacteria are then infected on XGAL containing plates. After lysis
those phages which contained a mutated copy of the lacl will produce clear
plaques whilst those with a functional copy will produce blue plaques. The
number of blue plaques therefore provides an estimate of mutation frequency
(Nishino et al., 1995, Buettner et al., 1997, You et al., 1998). Likewise the
transgene used in the MutA ™ system is lacZ, which encodes the (3-galactosidase
gene. Here the numbers of mutants are counted by growing the phages on PGAL
(Sigma) containing substrate, which prevents wild type lacZ plaques from
growing (Gossen et al., 1992).
One feature of the transgenic assays is that they allow the precise nature of the
mutation to be determined. This can therefore be used to generate mutation
spectra, the detail of which can often be used to rationalise apparently
contradictory results. For example, one unexpected finding was that mutation
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frequency in the lad transgene did not increase significantly following treatment
with X-rays, whilst a marked increase was observed at the Dlb-1 locus (Tao and
Heddle, 1994). The probable explanation for this is that X-Rays predominantly
cause gross deletions, which may result in deletion of the entire shuttle vector. In
such circumstances these events will be under-represented in the lad assay but not
the Dlb-1 assay.
One potential difficulty with assays using endogenous loci is that there may be in
vivo selection against mutants. For example, it has been shown that there is
selection against HPRT deficient T lymphocytes cells in mice. Also, large
deletions encompassing the FIPRT locus can be selected against as a result of the
deletion of flanking loci (Duebel et al., 1996). Notably, these difficulties have not
been reported for the Dlb-1 assay. Some of these considerations may also hold
true for the transgene based assays, as the site of transgene integration is thought
to influence assay readout (Nishino et al., 1996).
Despite the individual limitations of each approach, the assays described above
have been shown to yield broadly consistent results, and to be capable of
identifying increases in mutation following most types of DNA damage. These
assays have now been applied to murine strains mutant for genes implicated in
DNA repair. Such analyses have proven particularly powerful where use has been
made of both the transgenic and endogenous gene-based assays. For example, an
increase in mutation frequency in vivo in the Msh2~'~ mouse has been reported
using both the Big Blue™ mouse and Dlbl assay (Andrew et al., 1998, Toft et al.,
1999). The Big Blue mouse showed an increase in all the three tissues studied:
small intestine, thymus and heart. Comparison of the data generated by the two
assays shows remarkable similarity: an approximate 10 fold increase was scored
in the Big Blue mouse (3.1 x 10"5 in wild type intestine rising to 34 x 10"5 in the
Msh2~/~ intestine). A similar 7 fold increase was scored at the Dlb-lb locus (4
mutants per 10000 villi for wild type intestine rising to 28 mutants per 10000 villi
in the Msh2~'~ nulls intestine). Furthermore, both assays concurred in that
heterozygosity for Msh2 did not impact upon mutation frequency.
56
The proposed role for p53 as a 'guardian of the genome' predicts that p53
deficiency should lead to an increase in mutation frequency. Surprisingly, this has
not been substantiated experimentally (Clarke et ah, 1997, Nishino et ah, 1995,
Buettner et ah, 1997, Sands et ah, 1995). The initial report showed no increase in
the spontaneous mutation frequency in the liver, spleen or brain of the Big Blue™
mouse when bred onto a p53~'~ background (Nishino et ah, 1995). Subsequent
sequencing of the entire lacl gene confirmed that there was no increase in either
mutation frequency or spectra (Buettner et ah, 1997). One possibility was that p53
deficiency only influenced the mutation rate in some tissue types. The most likely
candidate tissue for such an effect was the thymus, as this is heavily predisposed
to malignancy in the p53~'~ background. However a similar study to those above
extended the essentially negative finding to this tissue (Buettner et ah, 1996).
When spontaneous mutation frequency in the small intestine was examined at the
Dlb-lb locus, again this yielded no significant /?55-dependent increase. Likewise
when Corbet et ah, (1999), examined mutation frequency at the HPRT locus in ES
cells, p53" ES cells again failed to show a significant elevation in mutation
frequency.
Five potential explanations may be advanced to explain the observed lack ofp53-
dependency. First, these experiments were performed with 6-10 week old mice
and it could be argued that insufficient time had elapsed for mutations to
accumulate (Nishino et ah, 1995). Certainly this is possible, ifp53 is considered
to be responding to DNA damage which will accumulate with age. However,
since the majority of cells will have undergone many rounds of replication by 6-
10 weeks of age, it seems unlikely that they will not have been exposed to
substantial DNA damage (Nishino et ah, 1995). Second, the spectrum of
mutations identified by these assays may be inappropriate for the type of
instability produced by lack of p53. However, this possibility seems extremely
unlikely given the concordance between the different types of assay.
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A third possibility arises from the fact that a large proportion ofp53 mutations in
human tumours are dominant negative, implying that the nullizygous state may be
an inappropriate model for the study of p53 as a tumour suppressor (Harris and
Holstein, 1993). However, the vast majority of studies strongly argue that loss of
function of p53 is functionally equivalent, whether through the acquisition of a
dominant negative mutation or through a homozygous null genotype. Although
this difference is an important caveat to remember when considering the p53~'~
mouse as a model for p53 mediated tumourigenesis, it is extremely unlikely to
bear any significance on the role played by p53 in protecting against mutation in
normal cells.
A fourth possibility is that p53 is only relevant in guarding against increased
mutation within abnormal or malignant cells. However, this also seems unlikely,
as when Buettner et al., (1996) analysed thymic lymphomas from p53 null mice
only 1 out of four tumours had an increased mutation frequency compared to
normal thymus. In 4 tumours examined by Sands et al., (1995), none were found
to have an increased mutation frequency. This in itself is a fascinating
observation, questioning the mutator hypothesis of cancer which attempts to
explain why tumours acquire so many somatic mutations (far above the postulated
mutation rate for somatic tissues) (see Loeb, 1998).
Finally, it may be that p53 cannot be shown to play a role because it is essentially
redundant. Recently, several p53 homologues have been identified that could
theoretically substitute for p53 in the p53~'~ mice. For example, the homologue p73
has been implicated in p53 independent apoptosis following both cisplatin
treatment and ionising radiation (Gong et al., 1999, Yuan et al., 1999). Obviously,
this cannot reflect complete redundancy, otherwise no exclusively /?53-dependent
phenomena (such as /?55-dependent apoptosis) would be observed. However,
given that mutation frequency is almost certainly determined by a number of
interacting factors, redundancy remains a tenable explanation.
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Given the current state of the field, it is not yet possible to discriminate between
these possibilities. However, the fundamental observation that deficiency of p53
fails to influence spontaneous mutation rate has challenged the view that p53
plays a direct role that in DNA repair. It has also questioned the in vivo
significance ofp53 dependent apoptosis and cell cycle arrest.
1.4.5.3 P53 and apoptosis, clonogenic survival and mutation frequency in
vivo
The preceding discussion has addressed the consequences of loss of gene function
at spontaneous levels ofDNA damage. These studies are clearly limited to the low
levels of environmental insult that may exist in a normal laboratory animal house
setting, and will therefore not address the consequences of exposure to defined
types of DNA damage. Analysis using spontaneous levels of DNA damage also
precludes the determination of a series of endpoints. Thus, apoptotic dependency
can only be scored in circumstances that induce apoptosis. Similarly, clonogenic
survival can only be scored when the majority of cells are lethally damaged. This
is a particularly crucial endpoint to study as the emergence of malignant clones
must be absolutely dependent upon the long term survival of the founder cell. For
these reasons mice mutant for p53 and Msh2 have been studied following
exposure to defined types ofDNA damage.
Amongst the first studies performed using the p53 knockout mice were those
investigating the p5J-dependency of apoptosis following genotoxic insult
(normally ionising radiation). Initially Clarke et al., (1993) and Lowe et al.,
(1993) showed that unlike wild type thymocytes, which rapidly undergo apoptosis
following treatment with ionising radiation and etoposide, p53~'~ thymocytes were
resistant. Heterozygotes were found to have an intermediate phenotype. However,
p53~'~ thymocytes were not resistant to the glucocorticoid methylprednisoline, nor
to apoptosis induced following treatment with a calcium ionophore. These
experiments showed that /;53-dependence was restricted to certain types of stress,
usually clastogenic damage. These observations gave rise to the notion that the
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failure to engage apoptosis may be the critical predisposing factor to
tumorigenesis in a p53~'~ environment. Thus, cells exposed to DNA damage would
not be deleted in the absence of p53, but would persist with a higher mutation
burden and therefore a greater predisposition to malignancy.
Many different groups have attempted to directly test this hypothesis in vivo. As
discussed above, p53 deficiency apparently failed to influence the spontaneous
mutation frequency. In order to analyse the effects of p53 deficiency post DNA
damage, Griffiths et al., (1997) analysed short term primary cultures of IL7-
dependent B cell precursors following exposure to X-rays. Here, they showed that
p53~'~ cells were resistant to apoptosis and that there was no gross difference in
DNA repair as scored by the COMET assay. Clonogenic survival was measured
and the p53~'' cells were found to have significantly enhanced survival. Mutation
frequency was scored amongst the surviving cells, yielding an intriguing result.
The frequency of mutants arising in the p53~'~ cells was found to be equivalent to
that previously scored for wild type cells. However, the total mutation burden
(number of mutant clones) was considerably higher than predicted for wild type
cells as a direct consequence of the difference in clonogenic survival. Taken
together, these findings strongly argue for a /GJ-dependent increase in mutation
burden occurring through increased clonality. These results are therefore
essentially supportive of the central hypothesis that p53 is the guardian of the
genome (Wyllie et al., 1994, Griffiths et al., 1997).
The in vivo /?5J-dcpendency of apoptosis has also been investigated in the small
intestine and in splenocytes. Analysis of both these tissue types again identified a
wave of /?53-dependent apoptosis peaking at 4-6 hours. However, a delayed p53-
independent wave of cell death was also identified which was specific to the
intestine and occurred at 48-72 hours (Clarke et al., 1994, 1997, Merrit et al.,
1994,1997). These results highlight clear tissue specific differences in the
dependence upon p53 for the induction of apoptosis. When this p53 independent
wave was examined further, it was noted that the apoptotic bodies were much
larger, suggesting that cells had entered apoptosis from a G2 block (Potten, 1990).
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The precise significance of /?53-independent death remains to be established,
however it seems likely that it is effective in removing many of those cells survive
by virtue of p53 deficiency. This may well reflect p73 activity, as has been
reported in other systems (Gong et al., 1999).
The tissue specific differences in /?JJ-independent death may also explain two
basic observations made in the p53~'~ mice. First, the failure to see a /GJ-dependent
difference in spontaneous mutation frequency in the intestine, as here there is an
efficient alternative to /?5J-mediated death. Second, the strong predisposition to T-
cell lymphoma in p53~' mice, as this tissue relies exclusively on p53 to mediate
cell death.
1.4.5.4 Mutation and Clonogenic survival following DNA damage in the
intestine
The small intestine provides an extremely well characterised system in which to
study cellular proliferation, apoptosis and differentiation (for a review see Potten,
1997, Potten et al., 1997). It is proposed that at the base of the crypt, there are
approximately 4-6 stem cells. These are thought to be exquisitely sensitive to
damage and undergo apoptosis under low levels of radiation (lGy). However once
these are destroyed other clonogenic cells can then substitute for the original stem
cells. Following exposures of up to 9 Gy, there are thought to be an additional 6
clonogenic cells. Beyond this level of damage it is thought that up to 16-24 cells
can then act as clonogenic cells (approximately a 1/3 of the crypt) (Roberts et al.,
1995).
The significance of the above is that clonogenicity can be investigated in vivo via
an analysis of crypt survival (the micro-colony assay see Roberts and Potten 1994)
and this data can subsequently be related to the ability to engage apoptosis. One
problem with this assay is that relatively high levels ofDNA damage must be used
to deliver scorable crypt death. However, this assay circumvents one of the major
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problems of in vitro assays in that it scores clonogenicity in a normal cellular
setting.
Mutation frequency has also been investigated following exposure to DNA
damage using those approaches discussed above. Again, the prediction from the
central hypothesis is that p53 deficiency will result in a significant increase in
mutation frequency following treatment. Both clonogenicity and mutation
frequency experiments have generated similar data. Hendry et al., (1997) showed
that there was essentially no increase in survival in p53~'~ mice in the small
intestine after gamma irradiation. In the large intestine, this study even indicated
that p53~'~ mice were more sensitive than wild type counterparts. Clarke et al.,
(1997) examined mutation frequency at the Dlbl-b locus. At 200 and 400 rads,
there was no significant difference between p53'f' and wild type mice. However a
/?5J-dependent difference was observed at the higher dose of 600 rads. Notably,
this increase was not seen to be p53 gene-dose dependent, despite the fact that
heterozygotes have an intermediate apoptotic phenotype.
One possible explanation for these results is that /?J5-independent apoptosis may
be sufficient to remove cells harbouring DNA damage cells following exposure to
low doses of ionising radiation, but that this mechanism is incapable of dealing
with the damage inflicted at high doses. Such an explanation does not however
rest easily with the failure to see a ^55-dependent difference in clonogenic
survival, as this predicts a difference at the high levels of DNA damage used in
the reported assays.
In summary, the available data examining the relationship between apoptosis,
clonogenic survival and mutation frequency in vivo is at the least inconsistent with
the simple hypothesis originally proposed. Indeed, the clearest published
demonstration of p53 dependency in intestinal epithelial cell survival appears to
disassociate apoptosis and survival (Pritchard et al., 1998). Here both low
(40mg/kg) and high (400mg/kg) doses of the drug 5 FU were used. Both induced
similar levels of apoptosis, which was p53 dependent at the 24 hour peak
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(although in the wild types the levels of apoptosis returned back to basal levels
sooner in the animals treated at 40mg/kg). However it was only the mice treated at
the higher dose which showed increased /GJ-dependent intestinal epithelial cell
survival. Pritchard et al., (1998) suggested that this was due to changes in cellular
proliferation as mitotic cell indices and thymidine incoroparation fell to a much
lower level in the mice treated at the higher dose. Thus, the presence or absence of
a p53 dependent growth arrest is suggested as the crucial factor governing
clonogenic survival. These results again strongly suggest that simple correlations
cannot readily be drawn between loss of apoptosis, increased clonogenic survival
and mutation frequency.
This thesis will further investigate the significance of loss of apoptosis to long
term clonogenic survival and mutation in both p53"~ and Msh2~/~ mice (chapter 5).
1.4.6 DNA methylation and tumourigenesis.
Over the last few years, there has been a proliferation of publications noting that
many genes are lost from tumours not through mutation but through
hypermethylation of their promoters e.g P16, MLH1, BRCA-1, P73, ATASE, E-
Cadherin (Baylin and Herman, 2000, Issa, 2000, Toyata et al, 1999).
This methylation only occurs at cytosines which are 5' to a guanine (CpG
dinucleotide). These CpG dinucleotides appear at about 10% of their expected
frequency in the genome as 5-methyl cytosine can undergo spontaneous
hydrolytic deamination to uracil/thymine. The majority of the remaining CpG
dinucleotides are heavily methylated throughout the human genome
(approximately 70%) (Bird, 1987,1992). However there are small streches of
DNA called CpG islands of around 500-2000bp that are located around the
transcriptional start site of around 40000 genes (approximately half of all genes).
In virtually all cases these promoter CpG sites are unmethylated. It is these
islands which have been shown to be hypermethylated in cancer.
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As was mentioned earlier MLH1 is often lost in sporadic colorectal and ovarian
cancer through methylation (Herman et al., 1998, Strathdee et al., 1999). In these
sporadic colorectal tumours, it was not just MLH1 that was hypermethylated but a
host of other promoters e.g PI6 and ER (oestrogen receptor) (Toyota et al., 1999,
Pao et al., 2000). These were described as CIMP (CpG Island methylator
phenotype) positive. Originally, Lengauer et al., (1997b) proposed that these
CIMP (+) lines were always MMR deficient, however this now seems not the case
as both Toyota et al., (1999) and Pao et al., (2000) have shown CIMP positive,
MMR proficient tumours and CIMP negative, MMR deficient tumours. However
the majority of the CIMP+ lines do have MLH1 hypermutation.
The precise reason for the CIMP phenotype is still unknown, however it leads to
tumours that have inactivation of a specific subset of genes that have promoters
susceptible to hypermethylation.
One of the most exciting potential therapeutic aspects of epigenetic changes like
methylation is that they are potentially reversible (unlike mutation). As was
described earlier, MLH1 was re-activated by DAC in human xenograft tumours so
raising possibilities for chemotherapy (Plumb et al., 2000). .
However it is not just hypermethylation that has been correlated to
tumourigenesis, hypomethylation has also been shown to occur outside these CpG
islands. Global hypomethylation has been shown to occur in many different
tumours (Breivik and Gaudernack, 1999). However its role in tumourigenesis is
less well understood. Experimental hypomethylation through inactivation of 5-
cytosine DNA methyltransferase (DNMT1) (the enzyme which maintain
methylation through cell divisions) has shown that cells with hypomethylation
have an increased mutation rate and induce apoptosis via a p53 dependent
pathway (Chen et al., 1998, Jackson-Grusby et al., 2001). Interestingly enhanced
genomic instability was characterised by increased mitotic recombination,
chromosomal loss and duplication in the DnmntlES cells, all phenotypes of
p53~ ' cells as well. One hypothesis explaining the function of this methylation is
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that it might repress transcription of repeated sequence such as Alu and
transposons thus preventing genomic instability produced by transposition.
Methylation may also cause chromatin changes to keep most of the genome late
replicating thus possibly preventing rearrangement at replication (Baylin and
Herman, 2000). However questions on the significance of global
hypomethylation remain. Using the Apcmm/+ mouse model, it was shown that
hypomethylation caused a reduction in the number of tumours in the ApcMm/+
mouse. As the Dnmtl'1' mutation is lethal in mice, this was performed using
(Ape"" +, Dnmtl+/~) mice injected with low levels of DAC (which causes loss of
methylation). When the Dnmtl+/~ mice were crossed to Apcmm/+ mice with the
strongest Mom resistance allele almost no tumours were found (Cormier and
Dove, 2000). Interestingly this was independent of p53. One possible
explanation for this is that recently the Ape promoter has been shown to be
hypermethylated in approximately 18% of colorectal cancers. Thus, as the AKR
tumours show relative low levels of LOH at the Apc+ locus compared to mice with
other Moml sensitive alleles, it is possible that here loss of Ape occurs through
hypermethylation. This would then be suppressed in the Dnmtl+/~ mice (Esteller
etal., 2000).
The importance of global hypomethylation to tumourigenesis is still unclear.
However, specific hypomethylation does have a role in disease and
tumourigenesis. The best example of this is in human cancer where 24% of
mutations in p53 are G to A transitions at methylated CpG sites (Waters and
Swan, 2000).
This thesis will investigate the impact that MBD4 (a methyl binding domain)
protein (which is a mismatch specific thymine glycolase) has upon apoptosis,
mutation and Apcmm/+ tumourigenesis. The MBD (methyl binding domain)
proteins in more detail in chapter 8
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In summary, this thesis aims to investigate the following principle questions:
First, what is the gene dependency of apoptosis in the small intestine to a range of
DNA damage in respect to Msh2, p53 and Mbd4?
Second, what is the significance of this gene dependent apoptosis in terms of long
term survival and mutation accumulation?
Third, is the gene dependency of the apoptotic response retained in tumours?
Fourth, can therapies be tailored to the genetic background of the tumour?
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2.0 Methods
2.1 Generation and Maintenance of Mice colonies
All mice were maintained under non-barrier conditions and given a standard diet
(Harlan) (except those on aspirin diet) and water ad libitum.
The knockout mice used in this thesis are as follows: Msh2~/~ mice (provided by Hien
te Riele, see De Wind et al., 1996), p53~'~ mice (provided by C. Purdie see Purdie et
al., 1994), Mlhl''' and Pms2'/~ (provided by M. Liskay, see Prolla et al., 1997), Ape
Mm/+
(provided by W. Dove see Su et al., 1992) and Mbd4'f mice (made by Jacky Guy
from the Adrain Bird laboratory).
2.2 Genotyping of mice
2.2.1 DNA Extraction from tails
DNA was extracted from tails using the PUREGENE DNA EXTRACTION kit. Tails
were lysed overnight in 500pl of cell lysis solution (Puregene) and 10pl of proteinase
K (20mg/ml, Sigma), shaken at 37°C. Tails were left to cool at room temperature,
200pl of protein preciptation solution (Puregene) was added to each tube. These were
vortexed and centrifuged at top speed for 5 minutes in a microfuge.
The supernatant was removed into a clean tube containing 500pl of isopropanol,
vortexed and centrifuged at top speed for 5 minutes. The supernatant was poured and
off and the DNA pellet was left to dry overnight. DNA was resuspended in 500pl
DNA hydration solution (Puregene).
2.2.2. Genotyping ofMice via PCR
All genotyping ofmice was done by genomic PCR (Polymerase Chain Reaction) from
DNA extracted from tails (2.2.1). All PCR were done in 50pl volumes using 2pl of
the tail DNA preparation.
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2.2.2.1 Mslt2 PCR
The Msh2 specific PCR reaction was designed by Toft et al., (1999). The protocol for
a 50pl reaction was as follows. The 50pl reaction mix contained 5pl PCR Buffer
(Gibco), 2.5(0.1 of 1% W1 detergent (Gibco), lpl of each primer (lOpmoles per pi)
(OSWEL see below), lpl of each DNTP (40mM) (Gibco), 2pl of MgCh (50mM)
(Gibco), 30pl of Autoclaved DDW (deionised distilled water), lpl Taq polymerase
(Gibco) and 2pl of template DNA (approximately 200ng). Reaction conditions were
as follows: 94°C 5 minutes, then 30 cycles 94°C 1 minute (denaturation), 60°C 2
minutes (annealing) and 72°C 2 minutes (extension) and 10 minutes of 72°C. All PCR
reactions were carried out using OmniGene Hybaid PCR machines.
18pl of PCR product was analysed on 4% TBE (Anachem) agarose gel stained with
ethidium bromide (lOmg/ml) (Sigma) and viewed under UV light. The Msh2






The p5i specific PCR reaction was designed by Purdie et al., (1994). The protocol
for a 50pl reaction was as follows. The 50pl reaction mix contained 5pl PCR Buffer
(Gibco), 2.5pl of 1% W1 detergent (Gibco), lpl of each primer (lOpmoles per pi)
(OSWEL see below), lpl of each DNTP (40mM) (Gibco), 2pl of MgCh (50mM)
(Gibco), 2 pi DMSO (Sigma), 28 pi of autoclaved DDW, lpl Taq polymerase (Gibco)
and 2pl of template DNA (approximately 200ng). Reaction conditions were as
follows: 94°C 5 minutes, then 30 cycles 94°C 1 minute (denaturation), 62°C 1 minute
(annealing) and 72°C 1 minute (extension) and 10 minutes of 72°C. All PCR reactions
were carried upon OmniGene Hybaid PCR machines.
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18f.il of PCR product was analysed on 2% TBE agarose gel. The p53 knockout allele





ApcM' + genotyping was determined by digestion of PCR product by Hindlll (Gibco)
as described Luonga et al., (1994). The protocol for a 50pl reaction was as follows.
The 50pl reaction mix contained 5pl PCR Buffer (Gibco), lpl of each primer
(lOpmoles per pi) (OSWEL see below), lpl of each DNTP (40mM) (Gibco), 2.5 pi of
MgCb (50mM) (Gibco), 33.5 pi of autoclaved DDW, lpl Taq polymerase (Gibco)
and 2pl of template DNA (approximately 200ng). Reaction conditions were as
follows: 94°C 5 minutes, then 30 cycles 94°C 1 minute (denaturation), 60°C 1 minute
(annealing) and 72°C 1 minute (extension) and 10 minutes of 72°C. All PCR reaction
were carried on OmniGene Elybaid PCR machines.
16 pi of product was digested by Hindlll (Gibco) for 2 hours at 37°C and products
analysed on a 4% TBE agarose gel. The digested wild type fragment generated a
111 bp band whilst the digested Min fragment produced a 123bp band.
Primer 1: TCTCGTTCTGAGAAAGACAGAAGCT
Primer 2: 5' TGATACTTCTTCCAAAGCTTTGGCTAT
2.2.2.4. Mlhi PCR
The Mlhl specific PCR reaction was designed by Edelmann et al., (1995). The
protocol for a 50pl reaction was as follows. The 50pl reaction mix contained 5pl PCR
Buffer (Gibco), 2.5pl of 1% W1 detergent (Gibco), lpl of each primer (lOpmoles per
pi) (OSWEL see below), lpl of each DNTP (40mM) (Gibco), 2pl ofMgCf (50mM)
(Gibco), 30pl of autoclaved DDW, lpl Taq polymerase (Gibco) and 2pl of template
DNA (approximately 200ng). Reaction conditions were as follows: 94°C 5 minutes,
then 30 cycles 94°C 1 minute (denaturation), 60°C 1 minute (annealing) and 72°C 1
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minute (extension) and 10 minutes of 72°C. All PCR reactions were carried out using
OmniGene Hybaid PCR machines.
Products were analysed on a 2.5% TBE gel. The wild allele generated a 258bp band





The Pms2 specific PCR reactions was designed by Baker et al., (1995). As there is
competition between the primers 2 separate reactions are done: 1 for the knockout
allele and one for the wild type allele. Both protocols use the same reaction mix. The
protocol for a 50pl reaction was as follows. The 50pl reaction mix contained 5pl PCR
Buffer (Gibco), 2.5(4,1 of 1% W1 detergent (Gibco), lpl of each primer (lOpmoles per
pi) (OSWEL see below), 1 pi of each DNTP (40mM) (Gibco), 2pl of MgCf (50mM)
(Gibco), 30pl of autoclaved DDW, lpl Taq polymerase (Gibco) and 2pi of template
DNA (approximately 200ng). Reaction conditions for the wild type allele was as
follows: 94°C 5 minutes, then 30 cycles 94°C 1 minute (denaturation), 48°C 1 minute
(annealing) and 72°C 1 minute (extension) and 10 minutes of 72°C. Reaction
conditions for the targeted allele was as follows: 94°C 5 minutes, then 30 cycles 94°C
1 minute (denaturation), 60°C 1 minute (annealing) and 72°C 1 minute (extension)
and 10 minutes of 72°C. All PCR reactions were carried out using a OmniGene
Hybaid PCR machines.
Products were analysed on a 2.5% TBE gel.
Primer 1 (used in both reactions): TTCGGTGACAGATTTGTAAATG
Primer 2 (Mutant): TTTACGGAGCCCTGGC
Primer 3 (Wild type): TCACCATAAAAATAGTTTCCCG
2.2.2.6. Mb(14 PCR
The Mbd4 specific PCR reaction was designed by Jacky Guy (unpublished). The
protocol for a 50pl reaction was as follows. The 50pl reaction mix contained 5pi PCR
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Buffer (Gibco), lpl of each primer (lOpmoles per pi) (OSWEL see below), lpl of
each DNTP (40mM) (Gibco), 2.5pl of MgCh (50mM) (Gibco), 30pl of autoclaved
DDW, lpl Taq polymerase (Gibco) and 2pl of template DNA (approximately 200ng).
Reaction conditions were as follows: 94°C 5 minutes, then 30 cycles 94°C 1 minute
(denaturation), 65°C 1 minute (annealing) and 72°C 1 minute (extension) and 10
minutes of 72°C. All PGR reactions were performed on a OmniGene Hybaid PCR
machines.
Products were analysed on a 2.5% TBE gel. The wild allele generates a 322bp band







2.3 Apoptosis- inducing agents, quantification of apoptosis, clonogenic survival
and mutation frequency.
2.3.1 Reagents and administration
For apoptosis studies 8-12 week old mice were given intraperitoneal (i.p.) injections
of either Temozolomide (Gift from Malcolm Stevens), N-Methyl-Nitrosourea
(NMNU) (sigma isopac), MNNG (sigma), Nitrogen Mustard (Sigma), Cisplatin
(Faulding Pharmaceutical/ David Bull), or 5-FU (5-Flourouracil) (Faulding
Pharmaceutical/ David Bull).
Temozolomide was prepared fresh and first dissolved in DMSO (10% v/v) and made
to a final concentration with Phosphate Buffer Saline (PBS) (Gibco). MNNG was
prepared fresh and first dissolved in DMSO (10% v/v) and made to a final
concentration with corn oil (sigma). NMNU was bought as an isopac and dissolved to
appropriate concentration with PBS with 0.05% Glacial Acetic Acid. Nitrogen
Mustard was dissolved to the appropiate concentration with DDW. Both Cisplatin
and 5FU were bought as solution (lOmg/ml).
Mice were exposed to y-irradiation using a 137Cs source at 0.27Gy min"1 for 15 min,
so that each animal received a dose of 5,10 and 15 Gy.
2.3.2 Quantification of apoptosis
At each indicated time point following injection, a minimum of three animals were
killed and the small intestine removed, flushed with water and fixed overnight in
methacarn (4 parts methanol, 2 parts chloroform, 1 part acetic acid). Samples were
wound into 'swiss rolls' and stored in 70% ethanol prior to staining.
Haematoxylin and Eosin (H&E) stained sections were made and apoptosis scored
through the use of the Highly Optimised Microscopic Environment (FIOME)
microscope (Clarke et al., 1994).
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Apoptosis was identified through its morphological appearance. Apoptosis is
recognisable in the intestine through the appearance of smooth membrane bound
apoptotic bodies. Cell shrink to produce a halo around the apoptotic bodies with clear
chromatin condensation within the nuclei. The nuclei also stains a much redder
colour (see Kerr et al., 1972, Wyllie et al., 1980).
A separate individual assigned each slide a reference number and thus data scored
blind. Running Means values were generated prior to counting which showed that 50
half crypts produced a robust running mean when scoring apoptosis in normal
intestine. When apoptosis was scored in lesions, all cells were scored in type I and
type II lesions and a random field of 500 cells in adenomas (Kongkantuutn et al.,
1999). Running mean values were generated for each lesion type which showed that
10 single crypts lesion, 10 complex lesions and 4 adenomas produced robust running
means.
To address the possibility of intra-observer error sample slides were scored on 3
separate occasions. These counts did not significantly differ from each other (the
degree of error was always below 10%). To check for inter-observer error, slides were
counted by an independent observer. This process was facilitated by the HOME
microscope as individual assessment of apoptosis could be checked by another
observer.
All experiments were initiated at the same time of day (10 hours am) in order to
control for the effects of diurnal changes in susceptibility to apoptosis since a clear
circadian rhythm has been shown to exist for the induction of apoptosis in the murine
small intestine. A minimum of fifty half crypts were scored per animal.
2.3.3 Assessment of Clonogenic Survival: Micro-colony assay of clonogenic
survival.
The micro-colony assay was performed as described by Potten, (1990), Hendry et al.,
(1997). Briefly, 72 hours after injection with cytotoxic agents, murine small
intestines were removed, and divided into three sections: top, middle and bottom.
Each section was cut into small pieces and bound into a bundle with 3M surgical tape.
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These were fixed in 10% formalin and embedded. Histological cross sections were
made and the numbers of surviving crypts were then counted around the
circumference of the intestines. As all mice were harvested at the same time and
comparison between genotypes are being made, there was no rationale for applying
any correction factor (see Hendry and Potten ,1985). Crypts were designated as alive
if they had more than 5 consecutive live epithelial cells in the crypt (see Hendry et
al.,. 1997). Again running means were generated and 10 circumferences per slide
produced a robust running mean of numbers of live crypts. Doses of 10 - 20mg/kg
were used for cisplatin and l-10mg/kg of Nitrogen Mustard according to Ijiri and
Potten (1983,1987).
2.3.4 Mutation frequency at the Dlb-lb locus
The Dlb-1 assay is a specific locus assay in which somatic mutations are detected that
inactivate the polymorphic genetic locus Dlb-lb which encodes a lectin binding site
(see Winton et al., 1988). The assay is autosomal with the Dlb-1 locus located on the
mouse chromosome 11. The Dlbl-lb allele specifies the binding of the Dolichos
biflorus agglutinin to intestinal epithelium. The Dlbl-la allele specifies the binding of
the Dolichos biflorus agglutinin to vascular epithelium. In mice Dlbl-b/Dlbl-a any
inactivating mutation of the Dlbl-b gene leads to loss of the ability to bind the lectin
in the intestine. After cell proliferation and clonal expansion, mutations that occurred
in the stem cell population of the intestine result in the formation of a clone that does
not bind a peroxidase conjugate of Dolichos biflorus agglutinin (EY Laboratories).
These unstained clones are easy to score in the wholemounts of the small intestine.
For this assay, experimental cohorts were derived by crossing mutant mice (in this
thesis the mutation experiment were performed in mice singly mutant for either
Msh2~/~, Mllil''', Pms2~/~ or Mbd4") to two different C57B1/6 strains, one ofwhich was
homozygous for the Dlb-1a allele and one of which was homozygous for the Dlb-1b
allele. Mice were subsequently intercrossed from these two lines to generate mice
heterozygous at the Dlb-1 locus and segregating for all possible mutant genotype.
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2.3.5 Wholemount Method for scoring mutation frequency at the Dlbl-b locus.
For spontaneous mutation frequencies mice were taken at the appropriate age (as
noted in text). This was done at a range of ages for wild type, Msh2+/~ mice, Msh2"
mice, Mlhr'~ mice, Pms2~ ~ mice and Mbd4~' mice.
For assessing induced mutation frequency following DNA damage, 8-12 week old
mice were exposed to cytotoxic agent 3 weeks prior to harvesting. This gives time for
clonal expansion as described above.
The method was as follows. After killing the mouse, the small intestine was removed
and flushed with ice cold PBS. The second fifth of the intestine was removed and one
end tied off. This was flushed with 5% formalin/PBS (Sigma) to expand intestine.
The tied end was cut off and the intestine was again flushed with ice cold PBS.
The piece of intestine was pinned down at one end with pins (Watson and Doncaster)
and the mesentry removed. The other end of the intestine was then stretched and
pinned. The intestine was then cut open and pinned flat.
Intestines were fixed for one hour in 10% formalin (Sigma). They were washed with
PBS and incubated with demucifying solution (see below) for 30 minutes .The plate
was the flooded with PBS and mucus pipetted off.
The plate was then incubated in 0.5% BSA (Bovine Serum Albulmin) (Sigma) / PBS
for 10 mins. The intestines were then incubated in the Dlbl peroxidaes conjugate (EY
Laboratories) overnight in 1:200 concentration in 0.5% BSA/PBS.
The plates were washed and developed using Diaminobenzidine (DAB) (Sigma).
Two 20mg tablet of DAB was dissolved in 40mls of DAB buffer (see below). 80pl of
1 % H2O2 was then added and the DAB solution poured onto the guts for 5 minutes.
After development, plates were stored in 70% ethanol until they are scored. Mutation
frequency was scored per 10000 villi. This was done through scoring the number of
non-staining villi in 50 fields of 200 villi.
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Demucifying solution : 1:1:2:6 (Glycerol: 0.1M Tris: 100% ethanol: Saline)
For 100ml:
10 ml Glycerol (Sigma)
10ml 0.1M Tris (pH 8.2) (Fisher)
20ml 100% Ethanol (Fisher)
60ml Saline (Fisher)
340mg Dithiothreitol (DTT) (Sigma)
DAB Buffer: 100 ml pH 7.6
24ml 0.2M Tris
38ml 0.1M HC1 (Fisher)
38ml DDW
0.068 lmg Imidazole (Sigma)
2.4 Monitoring of cohorts
2.4.1 Msh2 and p53_/" mice
Mice were checked daily for symptoms of disease. The predominant cause of death in
Msh2~p53'' and multiply mutant mice in these two genes is lymphoma. Mice with
thymic lymphomas have a hunched, puffing appearance whilst mice with lymphoma
of the spleen (splenomegally) have a swollen, hunched appearance. Other tumours in
these mice are sarcomas and akanthomas which are can be seen on the mice. When
mice were ill, they were culled and dissected. Organs and tumours were removed into
10% formalin for histology and gut 'roll' performed as above.
For microsatellite analysis the tumour and a piece of tail were removed and snap
frozen in liquid Nitrogen and stored at -80°C. DNA was then extracted from them as
above and Microsatellite analysis performed by Lucy Curtis.
For EMSA (Electrophoreic Mobility Shift Assay) and Western analysis for p53
functionality (see below) mice were irradiated with 5GY of irradiation 6 hours prior
to culling.
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2.4.2 ApcMin/+ and (ApcM'"~/+ MbdS') cohort
Mice were monitored daily for signs of disease. ApcM,n/+ and (ApcMm/+, Mbd4';') mice
develop intestinal neoplasia (Su et al., 1992). The timing of intestinal neoplasia in
ApcMin/+ mice has been shown be highly dependent of the Moml locus (Modifier of
Min) (Cormier et al., 2001). Thus all death cohorts were performed on a congenic
background for Min, the C57BL6 Mom allele. The symptoms of intestinal neoplasa
in the ApcMiny+ mice is rapid weight loss, anaemia, blood in faeces and a hunched
appearance. ApcMin/' mice also rarely developed mammary akanthoma.
After culling, tissues were removed, fixed in 10% neutral buffered formalin,
embedded in paraffin, sectioned at lOpM and stained with haematoxylin and eosin
prior to microscopic analysis. Scoring of intestinal lesion was achieved by removing
the entire intestine at necropsy and flushing with Phosphate Buffered Saline and
mounting en face. These preparations were then fixed in methacarn (4:2:1 methanol,
chloroform and glacial acetic acid). Lesions were then scored macroscopically.
Intestine were then wound into a "swiss" roll which were subsequently embedded in
paraffin and then sectioned as above
2.4.3. Aspirin Cohort.
2.4.3.1 Administration of dietary aspirin at weaning
C57BL/6 mice wild type and heterozygous for the ApcMm mutation were placed on
diet containing either 0, 200, or 400mg/kg of aspirin (Harlan/Tekad). These levels of
exposure are comparable with the highest doses used in previous studies (Mahmoud et
al., 1998, Barnes and Lee, 1998, Williamson et al., 1999, Chiu et al., 2000) Mice were
monitored everyday for signs of disease: generally manifesting itself as anaemia, loss
of weight and a hunched appearance.
Two experiments were performed: one where mice were killed at 150 days of age and
one where mice were killed where they showed signs of disease (see 2.4.2).
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2.4.3.2 Permanent administration of aspirin
Matings segregating for progeny which were ApcMm/+, Msh2~/~ or (ApcMm/+, Msh2~'~)
were placed on aspirin diet containing either 0 or 400mg/kg of aspirin prior to
conception and throughout pregnancy and lactation. Progeny were weaned onto
appropriate diets. Mice were killed when they showed signs of disease, generally
intestinal neoplasia or lymphoma (see 2.4.1 and 2.4.2).
2.5 Primary Culture
2.5.1 Primary Murine Embryonic Fibroblast (MEFS).
Msh2'/~, (Msh2~/~, p53+/~) and (Msh2~/~, p53~'~) MEFS were generated from crosses of
(.Msh2~/~, p53+') mice. Upon mating male mice produce a sperm plug in the female
vagina which can easily be seen by eye. Primary MEFs were made from day 13-14
embryos, with day Zi being the day when the plug was first observed.
On day 13 V2 the female was culled and the embryos removed. The embryos were
killed via cutting off of the head. They were dipped into 70% ethanol to make them
sterile and then chopped up using a sterile scapel. At this point a small piece of the
embryo was frozen for making DNA for genotyping (see 2.2).
After the embryo was finely chopped, 5ml of 2.5 % trypsin in PBS (Gibco) was added
and the embryo was left for 5 minutes at 37°C. After trypsination, 10 ml of fibroblast
media (see below) was added and cells were centrifuged at 1000 rpm for 5 mins. The
supernatant was then removed and the pellet was resuspended in 10ml of media and
plated on 10cm2 tissue culture dishes (NUNC). MEFs are grown at 37°C , 5% CO2.
Cells were confluent within 2 days.
Fibroblast Media:
500ml BHK21 Glasgow MEM media (Gibco)
50ml Foetal Calf Serum (Gibco)
5 ml Penicillin/ Streptomycin (100X Gibco)
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2.5.2 MEF Clones.
From confluent plates of day 2 MEFs, fibroblasts were plated to grow clones for MSI
and p53 functionality analysis. Unlike ES cells which produce rounded discrete clones
(see Corbet el al., 1999), fibroblast clones can be rather dispersed. Therefore a range
of different cloning densities were plated. Confluent plates were trypsinised with
5ml of 1 x Trypsin/EDTA (Gibco) which was neutralised with 10ml of media.
Centrifugation of cells at this stage is surprisingly incompatible with the formation of
clones. Thus from the 15ml typsin and media mix lpl, 5pi, 10pl, 20pl,50pl, lOOpl
9 •
and lml were plated on 10cm tissue culture plates 10ml of media. Cells were re-fed
the next day and then left for 2 weeks.
For immunohistochemistical analysis of p53 in clones, MEFs were grown on chamber
slides.
For Western analysis, clones were pooled from plates and protein extracted (see
2.6.2).
For MSI analysis, clones were visualised by staining with Giesma (sigma). Clones
were then picked and DNA made from them as in 2.5.1.
2.6 Protein analysis
2.6.1. Immunohistochemistry
2.6.1.1 p53 immunohistochemistry from fibroblast clones
Unlike formalin or methacarn fixed mouse tissues, no antigen retrieval steps are
required for the p53 immunohistochemistry on fibroblasts clones. To induce p53 in
the clones, cells were irradiated with 50J/M of UV-C and left for 6 hours. The cells
were then washed with PBS to remove any traces of serum and fixed in pre-cooled (in
the freezer) acetone/methanol for 5 minutes. The slides were then frozen at -70°C
until usage.
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After thawing at rooming temperature, slides were washed with Tris Buffered Saline
(sigma) with 0.1% Tween 20 (Sigma) (TBST). To block endogenous peroxidases,
cell were blocked in 0.5% H2O2 (Sigma) in Methanol (Fisher Scientific) for 15
minutes. Cells were then washed in running tap water, then 5 lots of 2 minutes washes
in TBST were performed.
To block any non-specific antibody binding, cells were blocked with 20% Normal
Swine Serum (Dako) in TBST for 15 minutes. Cells were then blocked in Avidin D
and Biotin (Dako) for 15 minutes. After washing 3 times in TBST, cells were
incubated for 2 hours with the primary CM5 p53 antibody (Novacastra) at a
concentration of 1 in 250 at room temperature.
Cells were washed 3 times with TBST and incubated in secondary antibody:
biotinylated Swine anti-rabbit (Dako) at a concentration of 1:400.
After washing 5 times with TBST, cells were incubated in the Avidin biotin complex
(ABComplex)/ HorseRadish peroxidase (HRP) (Vector laboratories) for 30 minutes
and developed using DAB after a further 5 washes in TBST.
Slides were washed in running water and counterstained with haemoxytoxin (2
minutes). They were mounted in aquamount (Sigma) and sealed with nail varnish.
2.6.1.2 Brdll immunohistochemistry.
Mice were injected with 0.25ml of BrdU (bromodeoxyuridine) (Amersham) for 2
hours prior to harvesting.
The staining was done on paraffin embedded, methacarn fixed intestines. 3pM
sections of intestines were cut onto Poly-L-lysine slides (Sigma). Sectioned were
dewaxed by placing into xylene for 20 minutes. They were rehydrated through
graded ethanol solutions (absolute alcohol, 74 % ethanol and 64% ethanol).
After a quick wash in water, slides were shaken at 60°C for 10 minutes in 1M HC1 for
antigen retrieval. They were washed in PBS and then blocked for 20 minutes in 1.5%
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H2O2. Slides were incubated in 1% BSA/PBS for 20 minutes and then incubated in
BrdU conjugate (Roche) at a concentration of linlOO. Slides were washed in PBS
and then developed in DAB.
They were then stained with haemotoxylin for 2 minutes. Slides were then
dehydrated in graded ethanol solutions (64%, 74%, absolute alcohol) and cleared in
xylene. They were then mounted using DPX mounting medium (Sigma).
2.6.1.3 p-Catenin immunohistochemistry
Slides were cut and rehydrated as in 2.6.1.2. Antigen Retrieval was performed by
microwaving slides 3 times for 15 minutes in Dako Antigen Retrieval solution. Slides
were washed in TBS and blocked in the same way as 2.6.1.2. Cells were incubated in
normal rabbit serum (Dako) for 20 minutes.
Slides were incubated in primary p-Catenin antibody (CI9220, Signal Tranduction
labs) for 1 hour at room temperature at a concentration of 1 in 50. After 3 washes in
TBST, slides were incubated for 30 minutes with a rabbit anti-mouse biotynalated
secondary (Dako) at a concentration of 1 in 200. Slides were washed and incubated in
the ABComplex-HRP for 30 minutes. Slides were then developed with DAB,
rehydrated and mounted as in 2.6.1.2.
2.6.1.4. Cyclin D1 immunohistochemistry
Slides were heated to 60°C for 3 hours. They were then rehydrated as in 2.6.1.2. and
placed into high pH Antigen Retrieval Solution (Dako) at 99°C for three hours. Slides
were cooled to room temperature for 20 minutes and then rinsed in TBS.
Immunohistochemisitry was then performed according to the catalogue of the DAKO
Envision Plus System kit (Dako cat K4006). Briefly, slides were blocked in
peroxidase block for 5 minutes and washed with TBS. Slides were incubated with
primary Cyclin D1 antibody (DCS-6, Novacastra) overnight at 4°C at a concentration
of 1 in 100. Slides were washed in TBS and the HRP secondary (Dako kit) was added
for 30 minutes at a concentration of 1 in 400. Slides were the washed, developed with
DAB and mounted as described in 2.6.1.2.
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2.6.2 Immunoblotting of proteins
2.6.2.1 Protein extraction
2.6.2.1.1 Extraction from pooled fibroblast Clones
Fibroblasts were washed with ice cold PBS and then scraped off into 5ml of PBS and
transferred to a 20ml universal. The flask was then washed with a further 5 ml of
PBS, which was also transferred to the universal. Cells were centrifuged at 1000 rpm
(revs per minute) for 5 minutes and supernatant removed.
Cell pellets were resuspended in 200pl of RIPA buffer (see below) and vortexed until
the pellet had dispersed.
Cells were then sheared through a green needle (21G) and transferred to an eppendorf
and centrifuged at 10000 rpm at 4°C.
The supernatant was then removed, aliquoted and snap frozen into liquid Nitrogen
and stored at -70°C until use.
2.6.2.1.2 Extraction from murine tissues.
Tissues were removed from sick animals and snap frozen at -70°C until extraction. A
small piece of frozen tumour was then crushed using a mortar and pellet in liquid
Nitrogen until it was a fine powder.
Using liquid nitrogen, this powder was then poured into a universal and the liquid
nitrogen was left to evaporate off.
400pl of RIPA buffer was then added and tissue was sheared, centrifuged and
aliquoted as described in 2.6.2.1.1.
RIPA buffer:
50mM Tris HC1 pH7.5 (Fisher)
15OmM NaC 1 (Fi sher)
l%Nonidetp40 (Sigma)
0.5% sodium deoxycholate (Sigma)
0.1% SDS (Fisher)
To 10ml of RIPA buffer, 1 mini-cocktail tablet (Roche) of protease inhibitors was
added
82
2.6.2.2 Determination of protein concentration
For estimation of protein concentration a microscale variant of Bradford's dye of
binding method was using used (Bradford 1976). 5-10pI of protein sample was added
to lml of Bradford reagent (BioRad), mixed and allowed to stand for 10 minutes
before measurement of A595. In each case absorbance measurements were performed
against blanks containing an equal volume of the Bradford reagent.
These absorbance measurements were then correlated with freshly generated
calibration curve (0-25pg of bovine serum albumin in lml of bovine serum albumin in
lml Bradford Reagent) to estimate the protein concentration of the unknown sample.
2.6.2.3 Western Analysis
For Western analysis, proteins are run on denaturing polyacrylamide gels (10% gels
for p53 westerns and 15% gels for p21 Westerns).
Protein samples were equalised with RIPA buffer so that all samples were 20pg and
of equal volume (20pl). They were then boiled for 5 minutes in 4 x Loading Buffer
containing (3-mercaptoethanol, quenched on ice, centrifuged and loaded onto the gel.
Gels were run for 2 hours at 125V in running buffer or until the protein markers
(Gibco) had separated.
Gels were then blotted on PDVF membrane (Millipore) in transfer buffer overnight at
15 mA. Prior to transfer PDVF membrane was soaked in methanol (Fisher) for 30
minutes.
After transfer, blots were blocked in TBS/0.1% Tween/10% Marvel (TTM) for one
hour. Blots were incubated with primary antibodies were incubated for one hour at
room temperature. The p53 antibody (rabbit polyclonal) CM5 (novacastra) was used
at a concentration of 1 in 200 whilst the p21 antibody (goat polyclonal) SC-672G
(Santa Cruz) was used at a concentration of 1 in 100. Blots were washed 3 times in
TTM and incubated in secondary antibody (Santa Cruz): anti-rabbit-HRP (p53) and
anti-goat-HRP (p21) at a concentration of 1 in 2000.
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Blots were then washed in TBS and visualised using ECL plus (Amersham) on ECL
film (Amersham). To confirm equal loading after blotting, blots were then stained
with Ponso Red (Sigma).
Reagents




9.37ml 1M Tris HCL pH 8.8
250pl of 10% SDS (Fisher)
72pl of 25% APS (Fisher)




9.37ml 1M Tris HCL pH 8.8
250pl of 10% SDS





0.62ml 1M Tris HCL pH6.8
50pl of 10% SDS
33pl of 25% APS
3.6pl of Temed
4x Loading Buffer





lOx Running Buffer: For 1 L
30.2g Tris
188g Glycine (Fisher)






2.6.3. Electrophoretic Mobility Shift Assay (EMSA)
2.6.3.1 Protein extraction
EMSA were used to test whether the DNA binding activity of p53 was still intact.
Thus unlike Western analysis where a whole cell extract was prepared, a nuclear
extract is required for EMSAs. This was done using a high salt concentration in the
Nuclear Extraction buffer.
For cell extractions, cells were scraped from plates in cell lysis buffer (2.5 x 107
nuclei per ml). Cells were pelleted via centrifugation at 2000 rpm at 4°C and
resuspended in nuclear extraction buffer (2.5 x 107 nuclei per ml). The nuclei were
then rocked for 1 hours at 4°C and centrifuged at 10,000 rpm for 10 minutes at 4°C.
The supernatant was then removed and frozen in liquid nitrogen and kept at -70°C
until use.
For protein extractions from animal tissues, tissues were crushed into a fine powder as
in 2.6.2.1.2. and protein extracted as above except that 400pl of cell lysis solution and
nuclear extraction buffer was used. Protein concentrations were determined as in
2.6.2.2.
Cell Lysis Buffer:












The same as cell lysis buffer apart from 500mM NaCl.
2.6.3.2 EMSA protocol
p53 consensus and mutant oligonucleotide (from Santa Cruz) were end labelled with
y-ATP (ICN) using T4 polynucleotide kinase (Gibco). They were filtered using a
Biogel p-4 gel (Biorad).
lOpl of nuclear extract (25pg of protein from p53 wild type cells/tissues or 50pg of
protein from p53 heterozygous cells/tissues) was mixed with an equal volume of
binding buffer containing 0.1-0.3ng of 32P labelled probe. These were incubated for
30 minutes at room temperature. For antibody supershift analysis 2pl of anti-p53
antibody was added (AB-1 Oncogene Science/ Santa Cruz) for an additional 20
minutes before electrophoresis. 0.05% bromophenol blue/xylene blue (sigma) was
added to each sample and loaded onto a 5% non-denaturing acrylamide gel (made up
in TBE, Sigma). The gel was ran at 150V in TBE for 2-3 hours.
Gels were dried on a vacuum dryer (Biorad) and exposed overnight to BIOMAX MS-








1 pg of Salmon sperm DNA (Stratagene)
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Chapter 3: O -Alkylguanine-DNA-alkyltransferase (ATase) does not affect
apoptosis following alkylating agents in the murine small intestine
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3.0 Introduction
A central focus of this thesis is the gene dependency of apoptosis following
alkylating agents. The murine small intestine offers an ideal experimental system
to allow the study of both apoptosis and mutation frequency in response to DNA
damaging agents such as DNA alkylating agents (Clarke et al., 1997; Merritt et
al., 1997 Potten et al., 1997).
The DNA repair protein 06-alkylguanine-DNA-alkyltransferase (ATase) is
expressed in the murine small intestine and is known to be up-regulated in a p53-
dependent manner in response to DNA strand breaks following ionising
irradiation (Rafferty et al., 1996). ATase functions by recognising and removing
specific alkyl lesions from DNA (Pegg & Byers, 1992). Substrates include O6-
methylguanine which is believed to be the major pre-mutagenic lesion induced by
alkylating agents. ATase mediated repair occurs via the transfer of the alkyl group
to a cysteine residue in the ATase protein, a process which is stoichiometric and
autoinactivating (Pegg, 1990). ATase therefore confers protection against the
mutagenic effects of alkylating agents, many of which are of clinical importance
as anti-tumour agents such as Temozolomide and Dacarbazine (von Hofe &
Kennedy, 1992; Dumenco et al., 1993; Liu et al., 1996b; Sanderson & Shield,
1996). Failure of ATase to repair (96-methylguanine results in O6-
methylguanine:thymine mispairs following DNA replication and it is postulated
that these mediate cell death via mismatch repair (Karran & Bignami, 1994). The
DNA mismatch repair enzyme MSH2 is known to bind to and recognise Ob-
methylguanine:thymine mispairs and is also essential for a large proportion of
apoptosis observed in the murine small intestine following exposure to alkylating
agents (Duckett et al., 1996; Toft, et al. 1999). In fact, in many tumours ATase
activity is often lost through promoter hypermethylation (Wheeler et al., 2000)
Therefore prior to characterising the importance of mismatch repair proteins in
mediating the apoptotic response following alkylation damage, the significance of
ATase to apoptosis in the murine small intestine was investigated. This was done
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by comparing the induction of apoptosis in untreated wild type mice and in mice
that had ATase chemically inactivated through administration of BeG (O6-
Benzylguanine).
BeG is a competitive and irreversible inhibitor of ATase which acts by binding to
the -CH3 cysteine acceptor site of ATase forming S-Benzylcysteine (Dolan et al.,
1990: Pegg et al., 1993). BeG bound ATase is inactive and is subsequently
degraded. Cellular ATase activity can be restored only by de novo protein
synthesis (Pegg & Byers, 1992) and its depletion by BeG has been proposed as a
useful adjuvant to methylating and chloroethylating treatment of tumours in the
clinic (Wedge & Newlands, 1996). Adjuvant therapy of BeG combined with an
alkylating agent offers the potential to use lower, and hence less toxic doses of
chemotherapeutic drug, and may also be of benefit in overcoming tumour
resistance associated with an up-regulation of ATase (Dolan et al., 1993).
Administration of 60mg/kg BeG functionally depletes ATase activity in the small




Figure 3.1 Small intestinal ciypt showing cells undergoing
apoptosis and mitosis. The cell underoing apoptosis shows
chromatin condensation, nuclear membrane blebbing and a halo.
Most apoptosis occurs in the stem cell region of the crypt (position
4-6) whilst mitosis generally occurs at positions higher up the




3.1.1 Apoptosis in the murine small intestine following exposure to alkylating
agents is not affected by BeG treatment.
The peak induction of apoptosis in the murine small intestine following alkylating
agents is approximately 6 hours (for timecourse see Toft et al., 1999). Therefore
apoptosis was scored in 50 half crypts 6 hours post 50mg/kg NMNU. Two cohorts
of mice were used, either untreated or injected with 60mg/kg BeG two hours prior
to injection with NMNU. To ensure that BeG treatment did not induce apoptosis,
mice were injected with BeG alone and compared to mock treated mice.
Figure 3.2 BeG does not affect apoptosis per se or following NMNU.
Apoptosis was scored per 50 Vi crypts in intestinal enterocytes. Addition of
60mg/kg BeG did not alter either basal levels of apoptosis or apoptosis induced
following lOOmg/kg NMNU.
250
Untreated 60mg/kg BEG 100mg/kg NMNU 100mg NMNU +
60mg/kg BEG
Following exposure to BeG alone, levels of apoptosis were not elevated above
background levels. This conclusion is further consolidated by Toft et al.,
(1999,2000) who showed that apoptosis was not affected over 72 hour timecourse
following BeG treatment. There was also no difference between levels of
apoptosis induced by NMNU and NMNU + BeG (Mann Whitney, P=0.38).
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Therefore BeG treatment does not appear to affect levels of apoptosis induced by
the alkylating agent NMNU.
3.1.2 Low levels of alkylating agents inactivate ATase in the murine small
intestine
Toft et al., (1999, 2000) had previously shown that BeG treatment also did not
affect apoptosis following temozolomide treatment (from 2 to lOOmg/kg). One
possible explanation for the failure to observe a difference in apoptosis following
BeG treatment is that injection of alkylating agent alone is sufficient to inactivate
ATase by depleting cellular pools of active ATase and therefore rendering BeG
treatment irrelevant (even at very low doses). To investigate this further (in
collaboration with the Geoffrey Margison laboratory) levels of Atase was
measured in temozolomide and mock treated mice, 6 hours post exposure.
Samples of small intestine and liver (for a comparision) were harvested and snap
frozen in liquid nitrogen. ATase activity was assayed from these tissues by
Michelle Wood.
92
Figure 3.3 The effect of temozolomide on ATase activity. ATase activity was
measured in fmol/mg protein in the liver (A) and in the small intestine (B)
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As can be seen, the resting levels of ATase in the murine small intestine
(approximately 40fmol/mg) were much lower than that in the liver (150fmol/mg).
Importantly even low levels 2-16mg/kg of temozolomide are enough to inactivate
ATase in the small intestine, with no activity being found at lOOmg/kg. The liver
however showed only a small decrease in levels of ATase from 2-16mg/kg though
at lOOmg/kg a large reduction in ATase activity (lOfmol/mg +/-6) is evident.
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3.2 Discussion
No induction of apoptosis was associated with BeG treatment. This excluded the
possibility that either BeG itself or depletion of ATase could induce apoptosis in
the murine small intestine. In the absence of detectable ATase activity, exposure
to NMNU induced apoptosis. The levels of apoptosis were similar to those
observed in BeG untreated controls. Thus, BeG treatment neither reduced nor
augmented the prevalence of apoptosis in the intestine following alkylation
damage.
Such failure to modify phenotype may have occurred because in vivo exposure to
methylating agents ablates cellular ATase activity by depleting pools of
unmethylated ATase, so rendering BeG treatment irrelevant (Pegg & Byers, 1992;
Lacal et al, 1996). To address this possibility, temozolomide was administered at
decreasing doses in the presence and absence of BeG. Similar levels of apoptosis
were scored in both BeG treated and untreated mice, suggesting that either
ablation of ATase was occurring following exposure to very low levels of
temozolomide, or that BeG mediated inactivation of ATase is irrelevant to the
induction of apoptosis following methylation damage.
Ablation of the ATase activity might be predicted to lead to an increase in
mutation frequency scored in this manner. Toft et al., (2000) examined mutation
frequency at the Dlb-lb locus following increasing doses of NMNU in both the
presence and absence of BeG. However, pre-treatment of mice with BeG failed to
elevate the mutation rate following NMNU treatment. As with the effect of BeG
treatment upon the induction of apoptosis, the observed failure to modify the
mutation rate in the murine small intestine may be interpreted in two ways. First,
ATase activity may not be relevant to protection against mutation in this tissue.
Second, exposure to the methylating agent alone may be sufficient to inactivate
ATase activity irrespective of BeG activity. Although it is not possible to
absolutely differentiate between these two possibilities, it is clear that BeG
pretreatment does not alter either the apoptotic response or mutation frequency.
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There is increasing interest in the possible use of BeG clinically as an adjuvant to
alkylating agent chemotherapy to overcome tumour resistance mediated by ATase
and also to potentiate the cytotoxic effects of the chemotherapy (Wedge &
Newlands, 1996; Kurpad et al., 1997). For a number of reasons the potential
clinical benefits of BeG may be overestimated. First, alkylating agents themselves
are capable of inactivating ATase activity by depleting cellular pools (Pegg &
Byers, 1992). Second, the addition of BeG to cells treated with MNNG or
Temozolomide is known to increase mutation rates and chromosome aberrations
within cells, although there is a proportional increase in apoptosis (Lukash et al.,
1991; Bean et al., 1994; Chinnasamy et al., 1997). Third, from the data presented
in this thesis, it is clear that in the murine small intestine ATase depletion does not
elevate in vivo apoptotic levels following methylating DNA damage. Furthermore,
Toft et al., (2000) showed that BeG can alter the metabolism of drugs or
carcinogens, e.g. Dacarbazine, and may therefore be a cause of unexpected
adverse drug reactions if used clinically.
In conclusion, these results in conjuction with Toft et al., (2000) have shown that
BeG treatment does not affect basal levels of apoptosis per se or apoptosis
induced by the alkylating agents temozolomide, MNNG or NMNU in the murine
small intestine. Toft et al., (1999) also showed that there are no differences in the
levels of ATase between Msh2 and wild type mice. Taken together with the very
low levels of ATase in the small intestine which are rapidly inactivated, this
argues that ATase levels will not affect experiments in the murine small intestine.
Therefore any differences observed will instead reflect true gene dependency in
the knockout mice
96
Chapter 4: The role of Mlhl and Pms2 in apoptosis induction
following the alkylating agents: NMNU and Temozolomide
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4.0 Introduction
This chapter investigates the importance of the MutL homologues Mlhl and Pms2
in the induction of the normal apoptotic response following exposure to the
alkylating agents temozolomide and NMNU. Previously it has been shown that
Msh2 can bind the 06meG lesion and loss of Msh2 causes a reduced apoptotic
response following temozolomide and MNNG in vivo (Toft et al., 1999). Andrew
et al., (1998) and Toft et al., (1999) showed that this ability to engage apoptosis is
an important indicator for mutation as Msh2" mice injected with NMNU (N-
methyl-nitrosourea) and temozolomide have much higher levels of mutation than
wild type mice. Taken together, these studies suggested in vivo that Msh2
deficiency may predispose to malignancy not only through failed repair of
mismatch DNA lesions, but also through the failure to engage apoptosis.
The replicative cycling model (shown in figure 1.8.) argues that functional MMR
is required to signal apoptosis following alkylation damage (Karran and Bignami,
1991). Although the precise role of the MutL homologues Pms2 and Mlhl have
not been completely characterised, they are both essential for MMR. MLH1 and
PMS2 have been shown to be mutated in HNPCC, though MLH1 is mutated much
more frequently (MLH1 is lost in approximately 60% of HNPCC whilst PMS2 is
lost in less than 1 % of families (Yogelstein and Kinzler, 1996). Therefore if the
model of replicative cycling is correct the prediction is that the apoptotic response
following the alkylating agents: temozolomide and NMNU should be reduced to
the same levels as those observed in the Msh2~/~ mice.
Previous in vitro studies have suggested that this should be the case. Unike wild
type immortalised MEFS,Mlhl" MEFS do not undergo a G2 arrest in response to
NMNU exposure (Buermeyer et al., 1999b). A similar failure to undergo a G2
arrest is observed in immortalised Mlhl'1' following cisplatin, 5-FU, 6-TG and
gamma irradiation (Fink et al., 1997b, Davis et al., 1998, Meyers et al., 2001). In
each of these experiments no differences in the levels of apoptosis were observed,
though this is thought to represent that in vitro these agents preferentially induce
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arrest rather than apoptosis (at the doses used in these studies). Thus far the only
in vitro study highlighting a role for Mlhl in apoptosis rather than arrest was
following H202 treatment which elicited Mlh 1 -dependent apoptosis (Hardman et
al, 2001)
Immortalised Pmsl' MEFS have been shown to have a compromised apoptotic
response to ionising radiation (albeit a at very high dose of gamma irradiation)
(Zeng et al., 2000). Pms2~/~ mice have also been shown to have significantly
higher levels of mutation in reporter transgenes in skin following gamma
irradiation than wild type mice (Xu et al., 2001). However whether this was due to
failed apoptosis cannot be ascertained as there was no investigation of levels of
apoptosis in the skin.
Fishel's (1998,1999) model of direct signalling again proposes that functional
MMR is required for signalling apoptosis. However unlike replicative cycling
(which is a more passive process), Fishel argues that the MMR can sense very
high lesional loads and thus signal death instead of repair. As yet all the
experiments on the molecular switch hypothesis has focussed on the MSH
homologues, thus it still theoretically possible that this direct signalling could
occur in the absence of the MLH homologues.
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4.1. Results
4.1.1 Normal apoptotic response following 50mg/kg NMNU treatment
In order to investigate whether Mlhl and Pms2 were important for induction of
apoptosis following alkylation damage, the apoptotic response following 50mg/kg
NMNU was investigated. This was the same dose that Andrew et al., (1998) used
to show that Msh2 was important for suppressing mutation following NMNU
treatment.
Figure 4.1 Apoptosis following NMNU treatment. Apoptosis was scored 6
hours following treatment with NMNU. Black bar, wild type mice; Open bar,
Msh2'f' mice; Grey bar, Mlhl''' mice; blue bar, Mlhl+/~ mice; Yellow bar, Pms2"
mice, Green bar, Pms2+/' mice and pink bar, p53" mice. At least three mice were
used for each timepoint and error bars represent SD.
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Apoptosis was scored six hours following treatment with 50mg/kg NMNU. As
expected there was a reduced level of apoptosis in the Msh2~' mice (p=0.04, Mann
Whitney) and an abrogated response in the p53''~ mice (p=0.04, Mann Whitney)
compared to wild types. This is consistent with the gene dependency of apoptosis
after the alkylating agents seen in Msh2" and p53" mice following MNNG and
temozolomide treatment. However surprisingly both Mlhland Pms2~/~ mice had
a normal apoptotic response to NMNU compared to wild type mice (Mann
Whitney, Mlhl'/' mice (n=5) compared to wild type mice (n=5), p=0.77, Pms2
compared (n=4) to wild type mice, p=0.18). No gene dose dependency was
observed in either Mlhl+/~ and Pms2+/~ mice.
4.1.2 Reduced apoptotic response following lOOmg/kg temozolomide
To determine if this represented a generic difference in the gene dependency of
the apoptotic response to alkylating agents, this study was extended to
temozolomide which produces a similar spectrum of lesions to NMNU (Denny et
al., (1994), see appendix 13.1)
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Figure 4.2: Apoptosis at 6 hours following lOOmg/kg temozolomide.
Apoptosis was scored 6 hours following treatment with NMNU. Black bar, wild
type mice; Open bar, Msh2~/~ mice; Grey bar, Mlhlmice; blue bar, Mlhl+/~ mice;
Yellow bar, Pms2~/~ mice, Green bar, Pms2+/~ mice At least three mice were used
for each timepoint and error bars represent SD.
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In contrast to results with NMNU, a significantly reduced apoptotic response at
six hours following temozolomide treatment was seen in both the Mlhl" and
Pms2~/~ mice compared to wild type mice (Mann Whitney, Mlhl'mice (n=10)
compared to wild type mice (n=10), p=0.002, Pms2 compared (n=8) to wild type
mice, p<0.001). The peak induction of apoptosis in the murine small intestine
following alkylating agents is from 4 to 6 hours (Toft et al., 1999). However the
apoptotic response extends over a 72 hours period, therefore to investigate the
precise kinetics of the apoptotic response apoptosis was scored over this period.
in?
Figure 4.3. Apoptosis scored at 4, 6, 12, 24, 36 and 72 hours following
lOOmg/kg temozolomide. Black line, wild type mice; Dotted line, Msh2~/~, Pink
line, Mlhl'1' mice. At least 3 mice were used for each timepoint and error bars
represent SD.
hours
From the 72 hour timecourse, it was clear that Mlhl deficiency produces a marked
reduction in the apoptotic response following temozolomide. At each of the six
timepoints there was a significant reduction (Mann Whitney, p=<0.05) in the level
of apoptosis compared to wild type mice.
4.1.3 Apoptosis following lOmg/kg of NMNU isMlhl dependent.
The observed differences in the gene dependency of the apoptotic response was
hard to reconcile with the hypothesis that both temozolomide and NMNU elicit
apoptosis through the same mechanism, namely the production of the 06meG
lesion (Tentori et al., 1997, Bignami et ah, 2000). Even the spectrum of lesions
they produce are very similar, although NMNU has been shown to produce a
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higher percentage of 06meG lesions (Pieper 1995, Eisenbrand et al., (1994),
Goldmacher et al., (1986) and Denny et al., (1994) and see appendix 13.1 for
lesion profile of temozolomide and NMNU). This, in conjunction with the
slightly higher levels of apoptosis elicited by NMNU raised the possibility that the
gene dependency of the MLH proteins at this level of DNA damage was
sufficiently saturating to render undetectable any deficiency associated with
Mlhl" deficiency. Thus the apoptotic response to a lower dose (lOmg/kg) of
NMNU was investigated.
Figure 4.4. Reduced apoptotic response in Mlhl" mice. Apoptosis was scored
in 50 V2 crypts six hours following lOmg/kg NMNU treatment. Black bars, wild
type mice; grey bars, Mlhl'" mice. At least 3 mice were used for each timepoints






After treatment with lOmg/kg NMMU, there was a significant reduction in the
apoptotic response in Mlhlmice (Mann Whitney, p=0.04). This argues very
strongly that at the higher levels ofNMNU apoptosis, the Mlhl dependence of this
pathway is swamped, with apoptosis occuring in a Mlhl independent fashion.
Whilst at low levels of apoptosis Mlhl is required for the normal apoptotic
response.
4.1.4. No reduction in BrdU incorporation following temozolomide.
The replicative cycling hypothesis invokes futile cycles of repair. Therefore this
leads to the prediction that as a consequence of these cycles of repair one would
expect perturbation of cell cycle kinetics especially within S Phase. Agents such
as gamma irradiation and 5-FU have been shown to produce a G1 arrest in vivo
(Clarke et al., 1995, Merrit et al., 1995, Pritchard et al., 1998). One approach to
examine cell cycle kinetics in vivo is to investigate the level of BrdU
incorporation during S Phase by exposing mice to BrdU in vivo. Cohorts of mice
were therefore injected for two hours with BrdU before harvest. BrdU
incorporation was then scored per 50 half crypts. Results represent the percent of
live cells within the crypt labelled with BrdU.
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Figure 4.5: Intestinal crypts stained with BrdU. Brown staining cells represent
Brdu positive nuclei.
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Figure 4.6. No reduction in BrdU incorporation over at 36 hour timecourse.
Mice were mock injected or injected for 6, 12, 24, 36 hours with lOOmg/kg of
temozolomide and injected with BrdU at 4, 10, 22 and 34 hours respectively.
Black line, wild type mice; Pink line, Mlhl'' mice. At least 3 mice were used at
each timepoint and errors bars represent SD. No significant differences were seen
at any of the timepoints compared to mock treated mice (Mann Whitney, p<0.20).
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Unlike the scenarios reported for gamma irradiation and 5-FU (Clarke et al., 1995,
Pritchard et al., 1998), there was not a significant reduction in BrdU labelling over
the 36 hour timecourse in either wild type orMlhl'' mice.
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4.1.5 Increased mutation following lOOmgkg temozolomide inMlhJ'' mice
Given that Msh2"~ deficiency produces a large increase in mutation frequency
compared to wild type mice following temozolomide treatment (Toft et al., 1999),
the effect ofMlhl deficiency on mutation frequency at the Dlb-lb locus was then
determined. This was of particular interest given there was a marked reduction in
the apoptotic response in the Mlhl'1' nulls, yet no obvious perturbation of the cell
cycle (as measured by BrdU incoropartion). Therefore this provided an excellent
opportunity for examining the impact of the loss of an apoptotic pathway on long
term mutation induction.
Figure 4.7. Intestinal wholemounts from (Dlb-la, Dlb-lb) stained with Dlbl
peroxidase conjugate. Inset intestinal villus with white mutant clone dissected
out from the intestinal wholemounts (large picture). The white mutant clones
represent a loss of function mutation within the intestinal stem cell compartment
of the Dlb-lb allele. Therefore as Dlb-la is not expressed in the intestine a white
mutant ribbon grows out.
ins
Figure 4.8 Increased mutation frequency at the Dlb-lb locus in Mllil'1' mice
compared to wild type mice. 8 week old male mice were injected with lOOmg/kg
of temozolomide for three weeks prior to harvest. Mutation frequency at the Dlb-
lb locus was scored per 10000 villi. Black bars, wild type mice; Grey bars,
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As expected Mlhr'~ mice (n=4) had significantly higher basal levels of mutation
than wild (n=3) type mice (Mann Whitney, p=0.03). After treatment with
lOOmg/kg temozolomide there was a significant increase in mutation frequency in
the treated Mlhl" mice (n=4) compared to treated wild type (n=8) (Mann
Whitney, p=<0.001). Importantly this was not simply a reflection of the higher
basal rates of mutation in untreated Mlhlmice as the increase was much greater.
On average the mock treated Mlhlmice had 16 more mutations per 10000 villi
than mock treated wild type mice, whilst temozolomide treated Mlhl" mice had
101 more mutations per 10000 villi than temozolomide treated wild type mice.
109
4.2. Discussion
Msh2, Mlhl and Pms2 are all essential for MMR. Therefore it was assumed that
they would all be essential for MMR-dependent apoptosis. However it has been
shown here that for apoptosis following high levels of alkylation damage, they are
not functionally equivalent. This has implications for the models of MMR-
dependent apoptosis after alkylation damage.
The data produces two scenarios, one where there are relatively low levels of
alkylation damage where functional MMR is required to elicit apoptosis and
another where there are very high levels of alkylation damage where functional
Msh2 is required for apoptosis though not functional MMR (e.g. independent of
Mlhl and Pms2). Consistent with this is that Msh2 binds the methylation damage
and thus is required for both damage recognition and apoptotic signalling.
Recently, dissociation of the roles that the MMR proteins play post alkylation
damage was suggested by analyses of both the intracellular localisation and levels
of Msh2 and Mlhl prior to and following alkylation damage. Christmann and
Kaina (2000) showed that following damage, levels ofMsh2 increase dramatically
in the nucleus through translocation of Msh2-Msh6 from the cytoplasm.
However there was not a comparable increase in levels of Mlhl. Therefore one
could envisage a situation where under normal circumstances Mlhl and Msh2 are
at relatively equal levels in the nucleus to facilitate functional MMR. However
post damage there is a huge induction of Msh2-Msh6 (though not Mlhl) and thus
Msh2-Msh6 can signal death independently of Mlhl when there are high levels of
damage. This Msh2-Msh6 signal is p53 dependent at six hours as there is
virtually no apoptosis in the p53'A mice.
This non-equivalence of the MMR proteins has been shown in other systems. For
example MMR proteins are important in inducing somatic hypermutation,
however when mutation spectra are examined in Msh2, Mlhl and Pms2 nulls they
are not the same (Reynauld et al., 2000). The MutL homologues Mlhl and Pms2
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function in meiosis whilst Msh2 does not. This produces radically different
phenotypes in the knockout mice as Msh2 nulls are fertile, Pms2 null females are
fertile and all Mlhl nulls are sterile (Prolla et al., 1997). Even in terms of MMR,
Mlhl and Pms2 null mice have different mutational spectra and frequency
(Buermeyer et al., 1999a). This is highlighted by the tumour predisposition of the
Pms2 nulls as none succumb to intestinal neoplasia unlike Mlhl and Msh2 null
mice (Prolla et al., 1997).
One of the models of to explain how 06meG lesions elicit apoptosis is the
replicative cycling model (described in 1.4.3) (Karran and Bignami, 1992).
Briefly, this proposes cycles of futile repair that are dependent on MMR. It is
these cycles of repair which are then thought to trigger apoptosis, possibly due to
energy depletion or the persistence of strand breaks. However, at high levels of
NMNU, it is shown here that there are normal levels apoptosis in both Mlhl and
Pms2 null mice. As the Mlhl and Pms2 nulls are inefficient in MMR, it is highly
unlikely that such futile cycling could occur, arguing against this model following
high levels of alkylation damage.
Fishel, (1998, 1999) proposed that the MSH (Muts S Homologues) proteins act as
an ADP-ATP switch (see 1.4.3). Recently Berardini et al., (2000) showed that the
Msh2-Msh6 heterodimer recognises 06meG lesions and stimulates the ADP-ATP
switch. They speculated that if there were high lesional loads there may be a
pathway that signals directly to apoptosis whilst a separate pathway signals for
repair at lower levels of damage. Therefore it is possible (and indeed the data here
implies) that this very high lesional pathway could be independent ofMlhl.
Another question raised here which relates to the replicative eyeing model of
apoptosis is the failure to observe altered cell cycle kinetics (as measured by BrdU
incorporation). Although not totally implicit in the replicative cyclig hypothesis,
one would presume that these cycles of futile repair would lead to perturbations of
the cell cycle. Therefore as no perturbations were discovered against this raises
doubts on the replicative cycling model.
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The finding that there is a significant Mlhl dependent increase in mutation
frequency following lOOmg/kg temozolomide treatment when there is significant
Mlhl dependent apoptosis (in the absence of an arrest), is one of the clearest
correlations between the failure to engage apoptosis and long term-term
perpetuation ofmutant cells in vivo. The next chapter will discuss how rarely the
failure to engage apoptosis in vivo correlates with increased clonogenic survival
and mutation . Therefore given that methylation damage is present in human
gastrointestinal DNA (Hall et al., 1991), this finding predicts that MMR
deficiency will not only predispose to malignancy through failure to repair DNA
but also through failure to engage apoptosis and delete damaged cells in the
replicative and stem cell compartments of the intestinal crypts.
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Chapter 5: Failure to engage apoptosis does not predict long-term
survival in p53 and Msh2 deficient mice
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5.0 Introduction
The previous two chapters have investigated the apoptotic response in the murine
small intestine. This chapter examines the long term significance of this apoptosis
using Msh2" and p53'' mice.
It is widely considered that chemotherapy functions through the induction of
apoptosis and that resistance is gained through loss of this apoptotic response (Lowe
et al., 1993,1994, Symonds et al., 1994). The paradigm for this is the gene p53,
which has been shown to be vital for the apoptotic response both in vitro and in vivo
following a range of cytotoxic agents. P53 is frequently lost during tumourigenesis,
indeed the frequency of inactivation of P53 may be much greater than first thought as
a consequence of mutations in other genes in the P53 pathway, as for example both
upregulation ofMDM2 or loss ofARF affects P53 expression (Prives and Hall, 1999).
The seminal studies on the link between p53, apoptosis and chemotherapy were
performed by Lowe et al., (1993,1994) and Symonds et al., (1994). They showed that
a wide variety of anticancer drugs induced apoptosis in a p53 dependent manner and
that p53 was important in suppressing tumour growth in vivo. Taking these findings
together they argued that p53 dependent apoptosis is vital for chemotherapy in vivo.
However these studies did not prove a definitive link between loss ofp53 dependent
apoptosis and chemotherapy, merely a correlation. Thus, Lowe et al., (1993,1994)
also showed there was a p53 dependent arrest in response to many of these drugs, loss
of which was also correlated with increased tumour volume in the p53~'~ mice.
Furthermore these studies made use of fibroblasts immortalised with either ElA or T
antigen which differ from primary fibroblasts by their high sensitivity to apoptosis
(Brown and Wouters 1999).
The generic relevance of these findings to spontaneous neoplasias is not yet clear. For
example, in human colorectal cancer P53 is frequently lost at the adenoma to
adenocarcinoma transition (Vogelstein and Kinzler, 1996), yet in contrast to
predictions from the Lowe and Symonds studies there are no differences in the levels
of apoptosis between these stages of tumourigenesis (Fazelli et al., 1997).
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Correlations do not always exist between apoptosis and chemoresistance. In fact it is
much easier to find instances where there is no link between apoptosis and
chemotherapy. For example, Bearss et al., (2000) showed that in mammary and
salivary tumours arising in transgenic MMTV-myc and MMTV-ras/ myc transgenic
mice, apoptosis was not important for the response to paciltaxel and doxorubicin.
Normally these agents induce apoptosis, however in these tumours there was no
induction of apoptosis but an induction of cell cycle arrest.
In order to determine the relevance of apoptosis to chemotherapeutic outcome, it is
necessary to examine long term measures of survival. This can be done both in vivo
and in vitro using clonogenic assays. Loss of p53 has been shown on several
occasions to be vital for the apoptotic response following gamma irradiation (Lowe et
al., 1993, Clarke et al., 1993). However, outside of hematological systems where
correlations between loss of apoptosis and increased survival do occur (Schmitt et al.,
2000, Griffiths et al., 1997), loss of p53 dependent apoptosis does not appear to
correlate with increased survival. Brown and Wouters (1999) reviewed 10 different
studies using P53 deficient non-hematological tumour cell lines treated with gamma
irradiation. Of these, 3 showed increased survival, 3 showed no difference whilst 4
reported increased sensitivity. Similarly, using the murine micro-colony assay of
intestinal crypt survival in vivo, Hendry et al., (1997) showed that p53 deficiency
caused complete abrogation of the immediate apoptotic response, yet this did not
translate into an increase in long term survival.
Given the aim to tailor chemotherapy to the genetic profile of the tumour (Vogelstein
et al., 2000), it is of utmost importance that we truly understand the links between
apoptosis and chemotherapeutic response. Clearly we are not yet in this position; as
perhaps best exemplified by the debate that still continues over whether P53 status is
a good prognostic indicator of therapeutic outcome in colorectal cancer (Bosari and
Yiale 1995). Generally it appears that loss of P53 is an indicator of poor
responsiveness to therapy in colorectal cancer (e.g. Hamelin et al., 1994, Hamada et
al., 1996, Benhattar et al., 1996), however other studies have shown that loss of P53
has a weak or even a beneficial effect upon therapy depending on tumour stage and
location (e.g. Elsaleh et al., 1999, Soong et al., 1997, 1999, Poller et al., 1997,
Petersen et al., 2001). If induction of apoptosis and chemotherapeutic success were
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mutually dependent, one would have predicted a very clear correlation between P53
status and prognosis.
In this study, the impact of loss of apoptosis (due to both p53 and Msh2 deficiency)
upon long term crypt clonogenic survival in vivo is investigated with 3 different
cytotoxic agents: Cisplatin, nitrogen mustard and N-Methyl-N-Nitrosourea (NMNU),
each of which is briefly discussed below.
Cisplatin is a particularly effective chemotherapeutic against testicular and ovarian
cancer. In ovarian cancer, resistance to cisplatin has been correlated with loss of the
mismatch repair gene MLH1 through promoter hypermethylation (Strathdee et al.,
1999). The putative cytotoxic lesion produced by cisplatin is a GG intrastrand
crosslink which both Msh2 and p53 have been shown to bind (Duckett et al., 1997,
Karsparkova et al., 2001). Cisplatin has been shown to be a potent inducer of both
Msh2 and p53 dependent apoptosis in the murine small intestine in vivo (Toft et al.,
1999, Sansom et al., 2001). Previous studies on clonogenic survival in vitro have
produced contrasting results. Using the ovarian cell line A2760, loss of mismatch
repair is associated with a small increase in resistance (1.5-3x) whereas P53
deficiency was associated with a much larger increase (Brown et al., 1997, Branch et
al., 2000). When Branch et al., (2000) characterised a panel of MMR deficient and
proficient colorectal cancer cell lines for resistance to cisplatin, MMR status did not
influence survival. In contrast, Lin et al., (2001) used isogenic HCT116 cell lines to
show that MSH2 deficiency caused an increase in survival whilst P53 status made no
difference to long term survival. In fact P53 deficiency in the HCT116 cells failed to
increase survival to a range of different agents including 6-thioguanine and etopside
(see also Bunz et al., 1999). We have previously analysed the response to cisplatin in
vivo in the murine intestinal epithelium. In this context, p53 deficiency causes
complete abrogation of the immediate wave of apoptosis directly predicting an
increase in clonogenic survival. Similar analysis showed Msh2~'~ deficiency to weakly
reduce the apoptotic response, predicting a more modest increase in survival.
Nitrogen mustard is one of the oldest chemotherpeutics still in clinical use (Hemminki
1994). It produces crosslinks in the DNA and is a potent inducer of apoptosis,
implicating a p53 dependent apoptotic response in the small intestine. However, Fan
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et al., (1997) showed that P53 deficient HCT116 cells treated with either nitrogen
mustard or cisplatin were more sensitive than wild type isogenic HCT116 controls.
The alkylating agents MNNG, NMNU and temozolomide are thought to induce
apoptosis through the production of the cytotoxic 0-6 methyl guanine (0-6meG)
lesion (Karran and Bignami, 1991). Duckett et al., (1997) have shown that Msh2-
Msh6 complex (MutS alpha) can bind this lesion. The alkylating agents
temozolomide and MNNG have been shown to induce MMR dependent apoptosis in
the murine intestine (Toft et al., 1999). The last chapter discussed the importance of
MMR following alkylation damage. The role ofp53 is much more debatable. Toft et
al., (1999) showed that p53 deficiency caused abrogation of the immediate wave of
apoptosis following the alkylating agents MNNG and temozolomide. As with
irradiation, temozolomide also induced a delayed, reduced wave of p53 independent
apoptosis. In this case this was shown to be Msh2 dependent. Duckett et al., (1999)
have also showed that Muts alpha was required for phosphorylation of P53 post
alkylation damage again suggesting a role for P53 in signalling from alkylation
damage. However the p53 dependency for apoptosis following alkylation does
appear to be cell type specific. For example, Hickman and Samson (1999) showed
that apoptosis was only partially dependent on P53 in the human lymphoblastoid TK
line but totally dependent upon MutS alpha. Similarly Ochs and Kaina (2000)
showed apoptosis following MNNG was p53 independent in CHO cells.
In order to further examine the relationship between apoptosis and chemotherapeutic
outcome, and to define the roles of Msh2 and p53 in these processes, the apoptotic
responses in Msh2~/~ and p53~/~ mice were investigated and compared to long term
survival in vivo following exposure to cisplatin, nitrogen mustard and NMNU.
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5.1 Results
5.1.1 Apoptosis following cisplatin damage
The apoptotic response to cisplatin at lOmg/kg, 15mg/kg and 20mg/kg of cisplatin at
6 hours following exposure was characterised (Figure 5.1). A dose dependent
increase in apoptosis was seen in wild type intestinal enterocytes in response to
cisplatin. Msh2 deficiency caused a slight yet significant reduction in the apoptotic
response and again there was a dose dependent increase. P53 deficiency caused a
complete abrogation of the apoptotic response at all 3 doses.
Figure 5.1: Apoptosis at scored 6 hours following lOmg/kg, 15mg/kg and
20mg/kg of cisplatin. Black bars, wild type mice; open bars, Msh2~' mice; grey bars,
p53~;~ mice. At least 3 mice were used for every time point and error bars represent
SD. Deficiency of p53 led to loss of the apoptotic response at 6 hours at all doses
compared to wild type mice (Mann Whitney, p=0.04) whilst Msh2 deficiency caused
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In order to investigate whether there was a delayed apoptotic response in the p53 "
and (Msh2'/~, p53 mice, the apoptotic response was scored over a 72 hour period
following cisplatin treatment. As has been reported with y-irradiation (Clarke et al.,
1997, Merrit et al., 1997) and temozolomide (Toft et al., 1999) there was a delayed
wave of p53 independent apoptosis which peaked at 24 hours following cisplatin
treatment. Previous reports by Gong et al., (1999) argued that functional mismatch
repair (MMR) was required to upregulate of P73 and so mediate apoptosis in the
absence ofp53 following cisplatin treatment. However after cisplatin treatment there
was a delayed wave of apoptosis in the (Msh2~/~, p53 v~) mice indistinguishable from
p53~'' mice (figure 5.2).
Figure 5.2: Apoptosis scored over a 72 hour timecourse following 15mg/kg of
cisplatin. Black line, wild type; pink line, Msh2~/~ mice; orange line, p53v' mice;
green line, (Msh2~/~, p53~/~) mice. In both p53~'~ and (Msh2~/~, p53~'~) mice there was a
delayed wave ofp53 independent apoptosis.
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5.1.2.Clonogenic survival following cisplatin damage
In order to determine the effect ofp53 and Msh2 deficiency on micro-colony survival,
mice mutant for both genes were exposed to 15mg/kg of cisplatin (lOmg/kg of
cisplatin does not result in detactable crypt killing) Both p53~/~ and (Msh2~'~, p53 "/")




































































Figure 5.4 Clonogenic survival at 15mg/kg of cisplatin as scored by the
microcolony assay (Potten et al., 1997). Striped bars, untreated mice; black bars,
wild type mice; open bars, Msh2~'~ mice; grey bars, p53~'~\ Blue bars, (Msh2'/~, p53~'~)
mice. Both p53~/~ and (Msh2~/~, p53~/~) mice showed increased clonogenic survival
compared to wild type and Msh2''~mice (Mann Whitney, p=<0.04).
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At the higher dose of 20mg/kg the extent of killing by cisplatin was increased with
nearly total crypt death in the wild type and Msh2~/~ mice. P53 deficiency led to a
marked increase in survival (Figure 5.4).
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Figure 5.5 Microcolony survival at 20mg/kg of cisplatin. Black bars, wild type
mice; open bars, Msh2~/~ mice; grey bars, p53~'~ mice. Again p53v~ mice showed








5.1.3. Apoptosis following Nitrogen Mustard.
Apoptosis was scored at 6 hours in wild type, Msh2~'~ and p53v' mice following three
different doses of Nitrogen Mustard. At the levels of Nitrogen mustard used, no dose
dependency was observed in the apoptotic response (Figure 5.5). A small, significant
reduction in apoptosis in Msh2~'~ mice was seen at lmg/kg and 5 mg/kg (p=0.04,
Mann Whitney). No induction of apoptosis, above basal levels, was observed in the
p53~/~ mice
Figure 5.6: Apoptosis scored at 6 hours following 1 mg/kg, 5mg/kg and lOmg/kg
ofNitrogen Mustard. Black bars, wild type mice; open bars, Msh2~/~ mice; grey bars,
p53" mice. At least 3 mice were used for every time point and error bars represent
SD. P53 deficiency led to loss of the apoptotic response at 6 hours to all dose (Mann
Whitney, p=0.04) compared to wild types whilst Msh2 deficiency caused a small yet
significant reduction at lmg/kg and 5mg/kg though not lOmg/kg.
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In order to investigate whether there was a delayed apoptotic response in the p53 ~/"
and mice, the apoptotic response was scored over a 72 hour period following Nitrogen
Mustard treatment (Figure 2B). Once again there was a small delayed wave of p53
independent apoptosis, which was highest at 24 hours following Nitrogen Mustard
treatment.
Figure 5.7:Apoptosis scored over a 72 hour timecourse following 5mg/kg of
Nitrogen Mustard. Solid black line with square points, wild type; hashed line with
circular points, Msh2~/~ mice; hashed line with triangular points ,p53~'~ mice. In the
p53~'~ mice there is a delayed wave ofp53 independent apoptosis peaking at 24 hours
Hours
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5.1.4.CIonogenic survival following Nitrogen Mustard.
Figure 5.8 shows the clonogenic survival as determined by the micro-colony assay
following 1,5 and lOmg/kg Nitrogen Mustard. Despite the clear gene dependency of
the apoptotic response no gene dependency was observed in crypt survival for either
Msh2~/~ or p53''~ mice.
Figure 5.8. Microcolony survival at 1, 5 and lOmg/kg of Nitrogen Mustard.
Black bars, wild type mice; open bars, Msh2~;~ mice; grey bars, p53~/'. There were no
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5.1.5.Apoptosis following N-methyl-N-Nitrosourea (NMNU)
Apoptosis was scored at 6 hours following NMNU treatment. As with cisplatin, a
dose dependency was observed in both wild type and Msh2~' mice (figure 3A). Msh2~
'
mice showed a significant reduction in the level of apoptosis at each dose. The
extent of this reduction was much greater than that observed for both cisplatin and
Nitrogen Mustard. Once again loss ofp53 causes abrogation of the apoptotic response
at 6 hours.
Figure 5.9: Apoptosis scored at 6 hours following 50 mg/kg, lOOmg/kg and
150mg/kg of NMNU. Black bars, wild type mice; open bars, Msh2~' mice, grey bars,
p53~'~ mice. At least 3 mice were used for every time point and error bars represent
SD. P53 deficiency led to loss of the apoptotic response at 6 hours to all dose (Mann
Whitney, p<0.04) compared to wild type mice whilst Msh2 deficiency caused a
significant reduction at all doses (Mann Whitney, p<0.04).
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Apoptosis was scored at 72 hours to determine if there was a delayed apoptotic
response (figure 5.9). At 72 hours, the apoptotic response was greatly reduced.
However the p53" mice showed significantly higher levels of apoptosis (p=0.02
Mann Whitney), demonstrating a wave of />5J-independent apoptosis. No evidence
was seen for a delayed Ms7?2-independent wave of apoptosis.
Figure 5.10: Apoptosis scores at 6 and 72 hours following 150mg/kg NMNU
treatment. Open bars, 6 hours; Closed bars, 72 hours. In only the p53'A mice there is
a significant increase in apoptosis at 72 hours (Mann Whitney, p=0.04),
corresponding to a delayed wave ofp53 independent apoptosis.
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5.1.6.Clonogenic survival with NMNU
Previously NMNU has not been characterised with respect to crypt survival using the
micro-colony assay. Therefore an escalating dose of NMNU was used in order to
determine its impact upon crypt survival (figure 5.10). A dose of 150mg/kg ofNMNU
results in a high level of crypt death in wild type mice. In the absence of Msh2 there
was an increase in survival at this dose, but this was not observed in the absence of
p53.
Figure 5.11: Clonogenic survival at 50, 100 and 150mg/kg of NMNU. Black bars,
wild type mice; open bars, Msh2'' mice, grey bars, p53~Doses of 50 and lOOmg/kg
do not produce high levels of crypt killing. 150mg/kg kills approximately 50% of
crypts in wild type and p53~/~ mice. Msh2 deficiency causes a significant increase in
crypt survival (Mann Whitney, p=0.02).
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The table below summarises all apoptosis and survival data..
Table 5.12: Summary of apoptosis and clonogenic data. For apoptosis: single
arrow pointing up, normal apoptotic response; single arrow pointing down, slight
(though significant) reduction; 2 arrows down, large reduction in the apoptotic
response, 3 arrows, virtually no apoptotic response. For clonogenic data: one arrow
pointing down, normal survival, one arrow point up, increased survival.
Apoptosis Clonogenic survival
WT Msh2 pS3 Wt Msh2 p53
Cisplatin 1 1 hi 1 1 t
Nitrogen Mustard t 1 hi 1 1 1
NMNU t h hi 1 t 1
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5.2.Discussion
The murine small intestine provides an excellent model for investigating the genetic
dependency of apoptosis, longer term survival and mutation following DNA damage.
Results from these assays contradict the simple model whereby loss of apoptosis is
predicted to cause cells to persist long term and so increase the burden of mutation
and predisposition to malignancy (reviewed in Sansom and Clarke 2000). For
example, despite the well documented p53 dependent apoptotic response of murine
enterocytes, p53'' mice do not have higher basal levels of mutation and only show
increased levels of mutation following very high levels of gamma irradiation (Sands
et al, 1997, Clarke et al., 1997). P53~/~ mice also do not show increased clonogenic
survival following gamma irradiation (Hendry et al., 1997).
5.2.1.Genetic control of apoptosis
Following each of the three agents used there was complete abrogation of the
immediate wave of apoptosis in the absence ofp53. This highlights the role ofp53 as
the central mediator of the apoptotic response in the murine small intestine to DNA
damaging agents (Clarke et al., 1994). Each of the three agents also induced a
smaller, delayed wave of p53 independent apoptosis. As the micro-colony assay is
performed at 72 hours, it would be unlikely that this delayed apoptosis would account
for crypt death. Therefore this predicts that loss of the apoptotic response in p53~/~
mice should cause an increase in clonogenic survival following all three of the agents.
After treatment with NMNU, Msh2 deficiency leads to a reduction in the apoptotic
response. This is consistent with previous studies using temozolomide and MNNG,
highlighting the role of MMR in signalling apoptosis from O6 methylguanine lesions
(Toft et al., 1999). Msh2 deficiency also led to a reduction in the apoptotic response
to both cisplatin and nitrogen mustard. In the case of nitrogen mustard, this reduction
in apoptosis is unexpected as there is no existing evidence that MMR recognises this
type of damage. This could reflect a compromised generic apoptotic response in the
MMR deficient mice, consistent with studies that have shown MMR to be important
after a range of DNA damage including oxidative damage, ionising radiation,
alkyaltion damage, cisplatin, and 6 thio-guanine (De Weese et al., 1998, Fink et al.,
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1998). Another explanation for the reduction of apoptosis in Msh2~/~ mice is that p53
upregulation and phosphorylation is partially dependent on functional MMR (as has
been shown for both cisplatin and MNNG)(Lin et ah, 2001, Duckett et al., 1999),
such that absence of MMR could lead to a reduction in the p53 dependent wave of
apoptosis.
Gong et ah, (1999) have previously shown that following cisplatin treatment of
HCT116 cells, the /?5J-independent apoptotic response was mediated by p73 and
furthermore that this was MMR dependent. This leads to the prediction that (.Msh2~/~,
p53~') mice should lose their p53 independent apoptotic wave in response to cisplatin,
a phenomenon demonstrated by Toft et ah, (1999) following temozolomide treatment.
However, it was shown here that following cisplatin treatment the (Msh2~p53~')
mice had an identical apoptotic response to p53~'~ mice. This raises two possibilities,
first, that p73 is still induced in the (Msh2~'~, p53~/~) mice independently of MMR or,
second, that p73 is not necessary for this delayed wave of apoptosis.
5.2.2. Genetic control of clonogenic survival
The results presented here clearly show that the ability to engage apoptosis does not
directly predict long term survival. Two very different scenarios are reported:
1)Where abrogation or reduction of the immediate apoptotic response correlates with
increased long-term survival
Following cisplatin treatment, p53 deficiency resulted in diminished apoptosis and
increased crypt survival. Previously Pritchard et ah, (1998) have shown increased
cellular survival within p53~' intestinal crypts surviving 4 days post treatment with
400mg/kg 5-FU. However this did not correspond with loss of apoptosis as no
increase was observed in the levels of apoptosis in wild type intestinal enterocytes
between crypt killing and non-killing doses.
Therefore the data presented here is the first demonstration in vivo of increased crypt
survival correlating with loss of a /?55-dependent apoptotic response. The data is
supported by the studies of Branch et ah, (2000) in ovarian cell lines where P53 is a
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major component of cisplatin resistance. These results predict that cisplatin would kill
most effectively in a P53+/+ environment. In this respect it is interesting that the
ONYX 015 adenovirus, which replicates specifically in and kills P53'A cells, has been
shown to work well in combination with both 5FU and cisplatin. This suggests that
ONYX 015 targets the P53'/~ cells whilst the cytotoxic drugs targets the P53 cells
(Khuri et al., 2000). It is also relevant that testicular cancers are very sensitive to
cisplatin treatment and very rarely show P53 mutations (Fleischaker et al., 1994,
Lutzkar and Levine 1996). Indeed testicular cancers have been shown to display very
high levels of wild type P53 following chemotherapy (Lutzkar and Levine, 1996) and
the rare cases of resistance to cisplatin have been associated with loss of P53
(Houldsworth et al., 1998, Eid et al., 1997).
Similar results were obtained following NMNU treatment of Msh2~'~ mice, where
there was also a reduced apoptotic response and increased clonogenic survival. This is
consistent with previous data where loss of mismatch repair caused increased survival
in vitro in ES cells following temozolomide and increased mutational burden in vivo
following temolozomide, MNNG and NMNU (Andrew et al., 1998, Toft et al., 1999,
Sansom et al., 2001). This data therefore supports the paradigm of failed apoptosis
leading to an increase in survival and therefore a higher burden of mutation burden.
Therefore it has been shown that loss ofp53 or Msh2 can confer resistance in vivo. In
the case of cisplatin, this would directly predict that p53 status would be critical to
therapy.
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2) Where Reduced or abrograted of the apoptosis does not correlate with increased
survival
In only 2 / 6 of experiments performed here did loss of apoptosis correlate with
survival. Msh2 deficiency did not lead to increased survival following either Nitrogen
Mustard or cisplatin, despite a small reduction in the apoptotic response. Previous
reports have strongly associated loss of MMR with cisplatin resistance in ovarian
tumours. One explanation for our failure to observe increased survival (consistent
with the previous chapter) may be that saturating levels of DNA damage may have
been used, which could have obscured the impact of MMR deficiency. This is
unlikely as it has previously shown that Msh2 deficiency does not cause increases in
mutation following low levels of cisplatin exposure (Sansom et al., 2001).
Furthermore it has shown here that the apoptotic response was not saturated at
15mg/kg, the high dosage used for the micro-colony assay.
The studies reported here have been performed in normal intestinal enterocytes. It
remains possible that the reliance upon functional MMR markedly differs between
normal and neoplastic cells. Pertinently, Strathdee et al., (2001) have shown that
mouse embryonic fibroblasts deficient for Msh2 still undergo a G2 arrest following
cisplatin treatment in marked contrast to MMR deficient tumour cell lines which lose
this checkpoint (Brown et al., 1997).
In fact, clonogenic survival appears to be very cell line and context dependent, as Lin
et al., (2001) show that P53 does not affect survival in colorectal cell lines following
cisplatin treatment in contrast to the study here and by that of Branch et al., (2000).
Probably the best study highlighting the importance of cellular context for apoptosis
and survival was performed by Schmitt et al., (2000). Flere, using primary
lymphomas, apoptosis and Bcl-2 status was shown to be important for multidrug
resistance and long term survival, however when these lymphomas were cultured in
vitro, Bcl-2 status was no longer important for clonogenic survival.
Deficiency for p53 did not lead to increased survival following either Nitrogen
Mustard or NMNU. Thus it is clear that those cells that escape the immediate wave of
apoptosis do not survive long-term. This may help explain the apparent confusion
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over the role ofp53 following alkylating agents, as although p53 is important for the
immediate wave of apoptosis this does not translate into long term survival. Thus, in
terms of final outcome (survival) the results here concur with those of Hickman and
Samson (1999), despite their failure to observe P53 dependent apoptosis.
The findings also concur with previous studies of the effect of p53 deficiency
following y-irradiation, where there was no increase in survival; and after 5FU
damage, where increased survival was independent of apoptosis. Overall (including
the 3 agents here) loss of p53 dependent apoptosis can only potentially explain
increased survival in 1/5 agents used in vivo (Pritchard et ah, 1999, Potten 1997).
One remaining question relates to the fate of those cells which do not engage
apoptosis but do not survive over the long term. Four possibilities arise:
The first is delayed apoptosis. Delayed, p53 independent apoptosis does occur but at
greatly reduced levels compared to the immediate (6 hours) apoptotic response. The
crypt replenishes itself from stem cells over a 72 hour period. Thus if all the stem
cells and clonogenic cells die, three days later the crypt will be dead (reviewed in
Potten 1990 and Potten et ah, 1997). However as the micro-colony assay is taken 72
hours after cytotoxic agent, delayed death occurring at 24-48 hours would not result in
crypt death by the cessation of the assay. Although delayed apoptosis could affect
survival at later times, it cannot be used to explain the death of crypts at 72 hours.
Delayed apoptosis has been associated with large apoptotic bodies derived from cells
dying out of G2/M of the cell cycle (Merrit et ah, 1997). Similar large apoptotic
bodies were observed, coinciding with the onset of delayed p53 apoptosis (24 hours
and later). However these were not restricted to the p53 deficient animals with all
wild type and mismatch repair deficient mice also exhibiting these large apoptotic
bodies
The second possibility is permanent arrest or senescence. This mechanism was
invoked by Pritchard et al., (1999) to explain the increased survival in the p53"
animals after 5 FU treatment. If there is permanent arrest of stem cells and clonogenic
cells after damage, the crypt would not become repopulated with cells and be killed
72 hours after insult. One of the difficulties with evaluating this mechanism is the
lack of good markers for stem and clonogenic cells, which makes it impossible to
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accurately determine the nature of these cells that are in permanent arrest (for a
review see Potten 1998). Therefore, it is currently not possible to determine the
contribution made by this mechanism to the loss of clonogenic potential.
The third possibility is necrosis. However no evidence of necrosis was observed
during these studies nor was any sign of inflammation that would be associated with
it.
The final possibility is deletion of otherwise viable crypt cells occurs as a
consequence of loss of endothelial cells, which has been reported to occur following
high levels of y-irradiation (Paris et al., 2001). The majority of the data presented here
supports this argument that failure to engage apoptosis in the intestinal enterocytes is
not a reliable indicator of survival. However the observation reported here that loss of
gene dependent apoptosis (e.g. p53 deficiency and cisplatin) in the intestinal crypts
can correlate with survival, argues that the importance of endothelial apoptosis may
be agent type specific.
Whatever the mechanism of the loss of these cells, these studies highlight that our
assumptions concerning apoptosis and survival need to be re-addressed. Several
studies have suggested that in colorectal cancer loss of apoptosis is important for
tumour progression (Bedi et al., 1995) with tumours showing lower rates of apoptosis
compared to the normal epithelium. Furthermore studies using (ApcMm+/~,p53~/~) mice
with intestinal adenomas show there is very little induction of apoptosis following
radiation compared to (ApcMm+/', p53+/+) adenomas (Fazelli et al., 1998). If the
simple hypothesis (that loss of apoptosis directly results in increased survival) is
accepted then the prediction of these studies is that irradiation would be ineffective in
treating P53 deficient colorectal cancer. However y-irradiation remains one of most
clinically effective treatment for colorectal cancer, a scenario which is far more
consistent with the data presented here on clonogenic survival which argues that p53
status can be irrelevant to long term survival.
Taken together, our findings show that apoptosis cannot be used to directly predict
long-term survival. Other studies have shown survival can vary from cell line to cell
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line and from in vitro to in vivo (Brown and Woulters 1999, Schmitt et al., 2000). In
fact, predicting survival on the basis of gene dependent apoptosis in vivo appears to be
virtually impossible, highlighting the difficulties in extrapolating system based
responses from individual cellular responses. Interpreting these relationships
represents a major challenge for our understanding of systems physiology. This has
particularly important implications for the potential of gene based therapies which
aim to restore apoptotic activity and furthermore argues that screens which score
survival rather than the ability to induce apoptosis or arrest may be much better
markers of prognostic success.
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Given that the acquisition of genomic instability in colorectal cancers has been associated with two
separate pathways: a MSI MMR pathway and an aneuploid p53 pathway (see below), Msh2~'~ and
p53~'~ mice were intercrossed to characterise whether there was an acceleration of neoplasia in these
mice. (Cottu et al., 1996; Lengauer et al., 1997).
The first of these two pathways is characterised by defects in components of the DNA mismatch
repair pathway, for example by Msh2 deficiency. The primary manifestation of such loss is an
increase in MSI (Liu et al., 1995), presumed to arise as a direct consequence of failed DNA repair.
The observation of a mismatch repair-dependent G2 cell cycle checkpoint (Hawn et al., 1995) is
consistent with such a role. However, mismatch repair proteins may also exert a protective effect by
mediating the deletion of cells which bear DNA damage, as functional Msh2 has been shown to
confer sensitivity to alkylating agents both in vitro (De Wind et al., 1995) and in vivo (as shown in
chapter 4 and 5, Toft et al., 1999).
The majority of colorectal cancers show no evidence of MSI. However, these cancers frequently
show gross genomic instability (Reichmann et al., 1981). Several lines of evidence suggest that
defects in p53 are associated with this form of instability. First, alterations in p53 are correlated with
the divergence of aneuploid sub-clones in colorectal cancers (Carder et al., 1993). Second, cells
become permissive for DNA amplification when p53 is lost (Yin et al., 1992). Third, cells derived
from p53 null mice display elevated levels of chromosomal instability (e.g. Harvey et al., 1993).
The role of p53 is however not limited to preventing chromosomal instability, as p53
transcriptionally regulates a number of genes associated with cell cycle arrest, apoptosis and DNA
repair. Furthermore, the p53 protein has been shown to directly interact with DNA, both through a
3'5' exonuclease activity (Mummenbrauer et al., 1996) and through direct binding of the C-terminal
domain to DNA mismatches (Lee et al., 1995, Dudenhoffer et al., 1998, Degtyareva et al., 2001).
P53 has therefore been characterised to mediate a number of functions which may have direct
tumour suppressor activity. Some of these activities have been shown to be p53 gene dose
dependent (Clarke et al., 1993, 1994 Rafferty et al., 1996). It is therefore perhaps not surprising that
evidence has been produced which suggests heterozygosity for p53 may predispose to neoplasia
(Venkatachalam et al., 1998).
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Recently evidence has emerged of a close relationship between p53 and Msh2 following DNA
damage, most notably that MMR-mediated apoptosis is mediated through p53 (Toft et al., 1999)
and that p53 becomes phosphorylated in an MMR-dependent fashion after alkylation damage
(Duckett et al., 1998). To study the effects of p53 and Msh2 deficiency upon neoplasia, several
murine strains have been produced which bear mutant alleles of Msh2 (De Wind et al., 1995;
Reitmair et al., 1995 and 1996a) and p53 (Donehower et al., 1992; Clarke et al., 1993; Lowe et al.,
1993). Mice null for p53 are viable, although a significant proportion of female p53" mice die
during embryogenesis (Sah et al., 1995; Armstrong et al., 1995). Surviving animals rapidly develop
tumours, predominantly thymic lymphomas with a smaller proportion succumbing to sarcomas
(Donehower et al., 1992; Purdie et al., 1994). p53+/~ heterozygote mice develop both lymphomas
and sarcomas in approximately equal ratios, but with a longer latency period when compared to
homozygote mice (Purdie et al., 1994). Mice null for Msh2 develop lymphomas with a peak
incidence at 2-3 months of age (De Wind et al., 1995; Reitmair et al., 1995 and 1996). Of those
animals surviving past 6 months of age, 70% develop intestinal neoplasms (Reitmair et al., 1996)
and 7% develop skin neoplasms analogous to those of the Muir-Torre syndrome (Reitmair et al.,
1996).
To examine any possible synergism between Msh2 and p53 in neoplasia, Cranston et al., (1997)
generated (Msh2'/~, p53w~) mice. Combined deficiency of Msh2 and p53 resulted in developmental
arrest of all female embryos at 9.5 days (Cranston et al., 1997). In contrast, male (Msh2'/~, p53~;~)
mice were viable but succumbed to lymphoma more rapidly than either Msh2~'~ or p53~' alone,
demonstrating co-operativity between the two genes. Such co-operativity did not appear to arise as a
consequence of increased MSI, as tumours arising in (Msh2p53") mice did not show
significantly increased levels ofMSI compared to tumours from Msh2~'~ mice. Mice bearing mutant
p53 and Msh2 alleles mice were intercrossed, and confirm here the phenotype of (Msh2~/~, p53~/~)
mice shown by Cranston et al., (1997). The effect of heterozygosity at each locus was additionally
characterised with respect to murine survival and tumour development. Furthermore, the influence
of genotype upon the pattern of genetic instability within tumours was investigated. Taken together,
these studies demonstrate a novel dose sensitive role for p53 in suppressing MSI.
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6.1 Results
6.1.1 Survival cohort of mice segregating for Ms/i2~a and p53~/~
Msh2" mice (De Wind et al., 1995) were crossed to p53w~ mice (Clarke et al., 1993) to generate a
cohort of animals segregating for mutant alleles. This cross was initiated by Neil Toft. Mice with
the following genotypes were studied: (Msh2'/\ p53+/+), (Msh2+/+, p53'/~), (Msh2~/~, p53+/~), (Msh2+/,
p53~/~) and (Msh2~/~, p53'A). Viable animals were obtained for each genotype, and both males and
females in all five genotype groups were fertile beyond six weeks of age. In contrast to the findings
of Cranston et al., (1997) we did not observe increased rates of female embryonic lethality in (
Msh2~'~, p53'A) mice (Toft et al., 1998).
Cohorts of mice were studied to investigate survival rates and tumourigenesis. Colonies were
monitored for a period of 240 days, and mice were killed when they appeared visibly ill by at first
Neil Toft and then myself. Kaplan-Meier survival plots were generated for all genotypes (Fig. 1).
Survival data for Msh2+/+ p53+/~ mice was generated from historical controls (Purdie et al., 1994).
(.Msh2~/~, p53~/~) mice became ill significantly earlier than either Msh2~l~ or p53~'' mice alone (P<
0.0006, log rank test). Heterozygosity for Msh2 on a p53" background did not significantly alter
survival from p53 deficiency alone (P>0.09, log rank test). In contrast, Msh2 deficiency on a p53
heterozygote background reduced survival compared with both (Msh2+ +, p53+') mice (P0.00001,
log rank test) and (.Msh2~'~, p53+,+) mice (P<0.00001 log rank test).
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Figure 6.1.1: Kaplan Meier plot of survival
Age of animals is given in days. Survival ofp53+/~ mice was reproduced from historical data (Purdie
et al., 1994). All cohorts of mice are labelled accordingly. Cohort sizes were as follows: (Msh2~'~,
p53~'~) n= 20; (.Msh2+I\p53_/") n=18; {Msh2''\ p53+l') n= 47; MshT'' n= 28; p53~'~ n= 57.
Msh2 +/- or p53 +/-
Days
Histological examination showed that all Msh2~'~ mice were characterised by lymphoma, with 20%
additionally developing intestinal neoplasia. 88% of p53~'~ mice developed lymphoma and 12%
developed poorly differentiated sarcomas. The tumour spectrum of (Msh2~'~ p53+/~) mice paralleled
that of Msh2~'~ mice (95% lymphoma, 11% intestinal neoplasia). The tumour spectrum of (Msh2+/~
p53~'~) mice paralleled that of p53v~ mice (83% Lymphoma, 22% sarcoma), although 2 of the 4
sarcomas occurring in the (Msh2+'~ p53~'~) mice were identifiable as leiomyosarcomas of the caecal
wall, a tumour type not observed in the p53~'~ cohort.
Figure 6.1.2 Tumour histology. Panels A-D display different types of lymphoma from the mice. Over
90% of the mice from all the cohorts died from lymphomas. Panel A shows a thymic lymphoma (x
400), the predominant form of lymphoma. Panel B shows lymphoma infiltration of the kidney (black
cells)(xl00). Panel C shows lymphoma infiltration of liver (xlOO). Panel D displays splenomegally







6.1.2 DNA content of tumours
Neil Toft analysed the DNA content of tumour cells by flow cytometry (Table 6.2.1). The DNA
content was classified as aneuploid if an additional Gi or G2 peak with a different DNA index was
present. Lymphomas from Msh2~/~, (Msh2'A p53+/~) and {Msh2~'~ p53v~) mice all displayed a diploid
karyotype. In contrast, 2 out of 7 (29%) of the lymphomas arising in p53~' mice showed evidence of
aneuploidy. Flow cytometric analysis permits a relatively crude assessment of chromosomal
instability.
Table 6.2.1 Analysis of thymic lymphomas in MSH2 / p53 intercrossed mice by flow cytometry
Flow cytometric analyses of thymic lymphomas from MSH2'/' p53+/+, MSH2+/+ p53v~, MSH2~/~
p53+/~, MSH2" p53~/~ mice. Tumours were classified as either diploid or as aneuploid. Aneuploidy
was identified by the presence of an additional Gi or G2 peak within the cellular DNA content.
Thymic Total number of tumours Diploid Aneuploid
Lymphoma
MSH2"7" 7 7 0
P53~'~ 7 5 2
MSH2 -/\p53+/- 7 7 0
MSH2"7", 7 7 0
Therefore Lucy Curtis analysed stability using Comparative Genomic Hybridisation (CGH). CGH
was performed on a minimum of four to eight metaphase spreads per tumour and an average
green/red profile was generated for each chromosome. A green/red ratio outside the limits of 1.2 or
0.8 was scored as an increase or decrease in DNA content for a single chromosome. Tumours
arising in Msh2~/~, (Msh2~/~ p53 ''~), (.Msh2+/~ p53~'~) and, perhaps most significantly, (Msh2'/~ p53~/~)
mice displayed stable genomes with few chromosomal gains or losses identified (Table 6.2.2). In
contrast, tumours arising in p53~/~ mice showed a number of amplified or deleted chromosomal
regions
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Table 6.2.2 Analysis of thymic lymphomas in MSH2 / p53 intercrossed mice by CGH
Comparative genomic hybridisation (CGH) analyses of murine thymic lymphomas arising in mice
of varying MSH2 and p53 genotypes. CGH was performed on a minimum of five metaphase spreads
per tumour and an average green / red profile generated for each of the 19 mouse autosomes.
Tumours were scored as aneuploid if one or more chromosomes displayed a green / red ratio outside
of 1.2 or 0.8.
Thymic Total number of tumours Diploid Aneuploid
Lymphoma
MSH2~A 6 5 1
P53v- 10 4 6
MSH2"/",pdi+/" 13 12 1
MSH2+A,/?5JA 6 5 1
MSH2-a,/?53"a 7 6 1
6.1.3 Microsatellite instability in tumours
To investigate whether the accelerated development of tumours in (Msh2~''~, p53~/~) mice was
associated with a /?53-dependent increase in MSI, tumours were assessed for instability at four
separate microsatellite loci. Tumour and tail were harvested by myself and DNA made and sent to
Lucy Curtis for MSI analysis. Data is summarised in table 6.3.1. Compared to tumours arising in
Msh2~'~ mice, MSI was more frequently observed in tumours arising in (.Msh2~/~, p53+/~) mice
(T=0.008 Fisher exact test). In the smaller cohort of (Msh2~/~, p53~'~) tumours analysed a similar
trend was observed, but this difference was not significant (P=0.38 Fisher exact test). These
findings indicate that heterozygosity for p53 increases genomic instability at the nucleotide level on
an Msh2 null background.
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Table 6.3.1:MSI in thymic lymphomas from MSH2 / p53 intercrossed mice
Replication Error (RER) status of thymic lymphomas arising in MSH2 / p53 mutant mice. MSI was
determined by analysing four different loci and determining whether the loci were stable or
unstable. Tumours with one or more unstable loci were deemed to show MSI and hence RER
positivity.
Genotype Total number of Mierosatellite % RER+ve
tumours instability
MSH2V" 16 8 50%
p53''- 3 0 0%
MSH2"A/?53+A 11 11 100%
MSH2+/>5Ja 7 0 0%
MSH2"/>53'a 8 7 87.5%
In the above study an increase in MSI was not demonstrated in the complete absence ofp53 (i.e. in
tumours arising on a (Msh2~/~, p53~'~) background), possibly because the sample size analysed was
too small. Therefore the analysis was extended to primary fibroblast clones representative of each
genotype combination. Primary fibroblast cultures were derived from E14 embryos and cells plated
at cloning density by myself. Two weeks later clones were picked and instability scored as before in
each clone by Lucy Curtis (table 6.3.2). As predicted, the level of instability was low in wild type
clones and higher in Msh2 null clones. In agreement with the analysis of the tumour samples,
heterozygosity for p53 significantly increased the level of instability (P=0.0005, Yates' corrected
chi-squared test). Remarkably, however although the same trend was observed in the double null
samples, the increase in the level of instability was only significant at the 10% level .
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Figure 6.3.2 Geisma stained fibroblasts clones. After staining clones were picked
and DNA made from them (which can be seen as scratches in the clones).
Table 6.3.3.MSI in embryonic fibroblast clones from MSH2/p53 intercrossed
mice.
Genotype Number of shifted clones
- 3 sites
Number of shifted clones
- 4 sites
Msh21 p53+,+ 11/88(12.5%) 14/86(16.3%)
Msh2~'~p53''~ 14/57 (24.6%) 14/47 (29.8%)
Mshl'" P53+/~ 15/45 (33%) 15/31 (48.4%)
Statistics-Yates' corrected chi-square
3 sites 4 sites
Msh2~'~ vs Msh2~'~ p53~'~ P=0.0983 P=0.1086
Msh2~'~ vs Msh2~'~ p53+/~ P=0.0084* P=0.0005*
Mshl1' p53~'~ vs Msh2'''
p53+/'
P=0.45 P=0.1544
MSI in primary cultures derived from mice of varying MSH2 and p53 genotypes. MSI
was assessed at either 3 loci (D7Mitl7, D10Mit2 and D14Mitl5) or at 4 loci (DlMit4
in addition).
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6.1.4 p53 status of tumours from (Msli2~/~, p53+/~) mice and clones
These results raised the possibility that heterozygosity for p53 was sufficient to increase the levels
of microsatellite instability, and indeed that a reduction in p53 levels has a more dramatic affect
than the complete absence ofp53. This was of particular interest as heterozygosity for p53 has been
demonstrated to predispose to malignancy (Yenkatachalam et al., 1998). Therefore the status of the
wild-type p53 allele in tumours arising in (Msh2~'~, p53+/~) mice was assessed. Loss of
heterozygosity was not observed in any of the eighteen thymic lymphomas examined by PCR,
demonstrating that gross chromosomal deletion of the remaining wild-type p53 allele had not
occurred. Three tumours were analysed by sequencing by Neil Toft and a single G—>A transition
was observed at codon 234 in one of these tumours, predicted to give an amino acid change from
methionine to isoleucine. This suggested that a percentage of tumours may have retained functional
p53. To determine if this were the case p53 activity was assessed by analysing the levels of p53 and
p21 by Western analysis six hours following exposure to 5 Gy gamma-irradiation (figures 6.4.1 and
6.4.2). In wild type tissue p53 became stabilised and p21 levels were increased. No p53 was
detectable in tumours arising on a p53 null background, nor was induction of p21 observed.
However, induction of p21 was observed in 4 out of 18 tumours arising in mice heterozygous for
p53, all of which showed stabilisation of p53. One further tumour showed stabilisation of p53 but
no transactivation of p21, suggesting mutation of p53 consistent with our sequencing data. To
confirm that this reflected retention of p53 activity we performed Electrophoretic Mobility Shift
Assay (EMSA) analysis upon the same material, and established that p53 specific DNA binding
does occur within tumours arising on a heterozygous background (figure 3B). Taken together, these
results strongly argue for retained p53 function in a significant subset of tumours arising on an Msh2
null,p53 heterozygous background.
Similar approaches were used to determine if p53 function had been retained in the primary
fibroblast cultures obtained from p53 heterozygous, Msh2 mutant embryos. I used
immunohistochemical and Western analysis to determine p53 functionality in mass cultures of
primary fibroblasts. These were maintained at low density for two weeks prior to harvest such that
they had undergone a similar number of divisions to those cells analysed as single clones for MSI.
Six hours following exposure to DNA damage (10J UVB irradiation for immunohistochemistry, 5
Gy for Western analysis) p53 null cultures did not show upregulation of p21. In contrast, wild type
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and p53 heterozygous cultures showed p53 stabilisation (figure 6.4.1) and upregulation of p21
(figure 6.4.2). Furthermore, individual immunohistochemical analysis of individual heterozygous
clones showed that p53 was upregulated following DNA damage in p53+/~, Msh2" cultures (figure
6.4.1A). Taken together these data argue very strongly that p53 functionality was retained in p53
heterozygous cells over the period of cloning, and therefore that the increase in microsattelite





A) p53 immunohistochemistry of fibroblast clones. Top panel, MSH2-/- p53+/- clones . 6 hours
following 10J UV irradiation. Middle panel, mock treated MSH2-/- p53+/- fibroblast clones. Bottom
panel, Msh2-/- p53-/-+/- clones 6 hours following 10J UV irradiation.
B) EMSA analysis ofp53 DNA binding activity in a tumour sample which showed p53 stabilisation
and p21 induction following DNA damage. Lanes 1-3, wild type ES cells following 10J UV damage.
Lanes 4-6, Msh2-/- p53+/- tumour sample following 5Gy gamma irradiation. Lanes 7-9, p53 null
tumour following 5Gy gamma irradiation. Lanes 1,2,4,5,7 and 8 reflect incubation with a p53 specific
DNA oligonucleotide which resulted in /?55-DNA complex formation in lanes 2 and 5. Lanes 3, 6 and
9 reflect incubation with a DNA oligonucleotide to which p53 does not bind. Lanes 1,4,7 reflect
additional incubation with a p53 antibody which resulted in supershifts in lanes 1 and 4.
C) p53 Western Analysis 6 hours following 5Gy gamma irradiation. Lanes 1,3,4 and 5, irradiated
(Msh2-/-,p53+/-) tumours; lane 2, mock treated (Msh2-/-,p53+/-) tumour; lane 6 irradiated p53-/-
tumour. Lane 7, irradiated (Msh2-/- p53+/-) pooled fibroblast clones. Lane 8, mock treated pooled
fibroblast clones. In total 5 tumours showed p53 stabilisation following DNA damage, 3 of which are




Analysis of p21 status. Western Analysis 6 hours following irradiation with 5Gy gamma irradiation.
Top panel; lanes 1 and 3-8 irradiated Msh2-/- p53+/- tumours. Lane 9, mock treated Msh2-/- p53+/-
tumour. Lane 2, irradiated Msh2-/- p53-/- tumour. Bottom panel. Lane 1, mock treated pooled Msh2-/-
p53+/- fibroblast clones. Lanes 2-3, pooled Msh2-/- p53+/- irradiated fibroblast clones. Lanes 4-5,
irradiated spleen and thymus from a wild type mouse. Lane 6, irradiated p53 null tumour. Lanes 7,
irradiated spleen and tumour from a Msh2-/- p53+/- mouse. Lane 8, irradiated tumour from a Msh2-/-
p53+/- mouse. Lane 9 is a positive control obtained from Kim2 cells overexpressing p21.
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6.2 Discussion
Cranston et al., (1997) have previously described the phenotype of mice functionally null for both
p53 and Msh2. They found that females died in utero, but that males developed normally to birth,
although they subsequently succumbed to lymphoma earlier than either p53 or Msh2 singly null
mice (Cranston et al., 1997). A similar intercross was generated here, using different null alleles
(Clarke et al., 1993, De Wind et al., 1995). As have been previously reported, there was no
increased rates of female embryonic lethality in (Msh2~/~, p53~'~) mice in these strains (Toft et al.,
1998). This difference probably arises from differences in genetic background, as has recently been
strongly argued by Cranston and Fishel (1999). Data summarising survival and tumour spectrum in
all the genotype groups agree well with previously published work (De Wind et al., 1995; Reitmair
et al., 1995 and 1996a; Purdie et al., 1994; Cranston et al., 1997). This suggests that no fundamental
differences exist between the targeted alleles used in this study and those used by Cranston et al.,
(1997).
6.2.1 Accelerated tumourigenesis in (Msh2~/~, p53+/) mice:
Heterozygosity for p53 reduced survival on an Msh2~'~ background, the most obvious mechanism for
this is through inactivation of the remaining wild type p53 allele. However there was no evidence
for this by PCR and furthermore sequencing of the 'mutation hotspot' (Vogelstein and Kinzler,
1992) failed to identify mutations in 2 out of 3 tumours. These observations raised the possibility
that p53 function had been retained in at least a subset of tumours as has previously been reported
(Venkatachalam et al., 1998) and therefore it was tested if p21 could still be transcriptionally
activated following DNA damage. This is a particularly potent test ofp53 activity as upregulation of
p21 in these circumstances is absolutely dependent upon p53 and because it has recently been
confirmed that the transcriptional activity of p53 is essential for many p5i-dependent process
including apoptosis, cell cycle arrest and tumour suppression (Jimenez et al., 2000, Choa et al.,
2000). Western analysis of both p53 and p21 within the samples confirmed retention ofp53 activity
in a proportion (25%) of tumours, demonstrating that a reduction in p53 gene dosage can be
sufficient to accelerate tumourigenesis.
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6.2.2 Tumourigenesis is not accelerated in (Msh2+/~, p53v~) mice
Heterozygosity for Msh2 in a p53 null environment did not accelerate spontaneous tumourigenesis.
This is perhaps not surprising since Msh2+/~ cells do not show MSI (De Wind et al., 1995;
Kolodner, 1995). However, this finding also suggests that the remaining wild-type Msh2 allele does
not act as a target for mutation even though p53 deficiency has been shown to cause genomic
instability (Bouffler et al., 1995) and DNA amplification (Yin et al., 1992). These observations can
perhaps be reconciled by the fact that p53 deficiency does not necessarily lead to an increase in the
in vivo spontaneous mutation frequency (Clarke et al., 1997). In chapter 7, it will be shown that
Msh2 heterozygotes have increased mutation at old age. As there is no increase in tumourigenesis
in the {Msh2~/~, p53~') mice, this again argues that p53 deficiency is driving tumourigenesis in a
MMR-independent manner in the (Msh2", p53") mice. Heterozygosity for Msh2 did weakly
influence the site of sarcoma development. This must reflect complex tissue specific gene
dependency in the prevention of neoplasia, a feature previously reported in several different
intercrosses (e.g. Clarke et al., 1995, Sansom and Clarke 2000).
Taken together, the survival studies indicate that heterozygosity for p53 has a profound effect upon
Msh2 dependent tumorigenesis, but that the inverse is not true. This directly suggests that p53 may
be involved in modulation the levels of MSI within an MMR deficient background; a hypothesis
that was tested by analysing levels ofMSI in tumour samples.
6.2.3 Increased MSI conferred by heterozygosity for p53
Colorectal cancers exhibit two distinct forms of genomic instability, which have been classified by
Lengaurter et al., (1997) as: MIN (microsatelitte instability, MSI), predicted to be associated with
mutations in the MMR genes; and CIN (chromosomal instability), predicted to associated with loss
ofp53 and the development of aneuploidy. The data presented here directly contradicts this view as
it is demonstrated that, in the absence of Msh2, p53 can function to suppress MSI and that a
reduction inp53 gene dosage decreases tumour latency specifically through increasing MSI.
Suppression ofMSI in the absence of Msh2 appears to be a general function ofp53, as it occurs not
only within tumour derived samples, but also within primary fibroblasts derived from the mutant
strains. The results apparently contradict previous data obtained by Cranston et al., (1997).
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However, their study did not include mice heterozygous for p53, for which the clearest phenotype
was observed. Furthermore, where both studies compared Msh2~'~ and {Msh2" p53~'~) mice a similar
trend to increased instability was observed in the absence ofp53, although in neither study did this
attain significance at the 5% level.
Two possible explanations may account for the p53 dependent increase in MSI. First, deficiency of
p53 may reduce genomic instability at the nucleotide level by mediating repair, either directly or
indirectly. This is supported by the observation that p53 is capable of binding insertion/deletion
loops, the DNA lesion associated with MSI (Lee et al., 1995). A second possibility is that p53 may
normally function by clearing (through apoptosis) cells characterised by instability. Both p53 and
Msh2 have well-characterised pro-apoptotic roles following damage of mismatch type (Clarke et al.,
1993; Lowe et al., 1993, Toft et al., 1999, Sansom and Clarke 2000), and again the ability ofp53 to
bind insertion/deletion loops supports a direct role for p53 in lesion recognition.
Currently it is not possible to discriminate between these possibilities, but it is clear from these
results that p53 status only becomes relevant to MSI in the absence of Msh2, as singly mutant p53
deficient mice are not characterised by increased MSI. This strongly suggests that p53 is redundant
to the normal monitoring and clearance of MSI associated lesions, but that following loss of Msh2
the presence of normal levels ofp53 becomes essential to this process.
These findings characterise an interaction between Msh2 and p53 mutations in increasing MSI and
tumour development. Remarkably the largest increase in MSI occurs in p53 heterozygotes,
suggesting that complete ablation of p53 leads to the upregulation of relatively efficient
compensatory mechanisms, perhaps mediated by one of the growing family ofp53 homologues. In
A
human colorectal cancer coincident mutations in both Msh2 and p53 have rarely been reported
(Cottu et al., 1996), although examples of combined microsatellite and chromosomal instability do
exist (Lengauer et al., 1997). One simple explanation for the absence of combined mutation is that
retained heterozygosity for p53 is difficult to establish and is not routinely screened for. Indeed, the
results presented above do not predict combined microsatellite and chromosomal instability, as
double mutants are characterised by enhanced MSI and diminished aneuploidy.
In conclusion, these results demonstrate a novel pathway to tumorigenesis by establishing a role for
p53 in maintaining integrity at the nucleotide level and they also raise the strong possibility that
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combined mutation of both p53 and the DNA mismatch repair proteins are currently under reported
in human colorectal tumourigenesis.
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The majority of HNPCC patients are germline heterozygotes for either MLH1 or
MSH2. Thus far this thesis has examined the phenotypes of mice homozygous for
these mutations. Therefore this chapter investigates whether heterozygosity for Msh2
affects gene dependent apoptosis or mutation accumulation.
Mice heterozygous for Msh2 and Mlhl do not show reduced survival compared to
wild type controls, nor are they predisposed to increased intestinal neoplasia (De
Wind et al. 1998, and chapter 6). Heterozygosity for Msh2 (unlike homozygosity)
also did not accelerate intestinal neoplasia on an ApcMm/+ background (De Wind et al.,
1998). Mice heterozygous for Msh2 are however characterised by increased
tumorigenesis. Surprisingly when these tumours were examined for Loss of
Heterozygosity (LOH) only 1 out of 71 had lost the remaining copy of Msh2 and this
was the only tumour to exhibit microsatellite instability (MI), indicating that the
majority of tumours truly were hemizygous for Msh2 (De Wind et al., 1998). These
results are therefore consistent with a hemizygous effect of Msh2.
In this thesis two possible biological mechanisms underlying the relationship between
MMR deficiency and neoplasia have frequently been discussed. First, that failed
recognition and repair of mismatch lesions leads directly to an increase in mutation
frequency and thereby to malignancy. Second that failure to engage MMR dependent
apoptosis may also predispose to malignancy. Consistent with this second theory is
that it has been shown (both in vitro and in vivo) that Msh2 deficiency is associated
with increased long term survival following alkylating agents (Toft et al., 1999,
chapter 5). In addition Msh2 deficiency leads to an elevation in mutation frequencies
following exposure to DNA damage (Andrew et al., 1998; Toft et al., 1999).
However in chapter 5, the failure to engage an apoptotic response was shown to be a
poor predictor of survival. Likewise, the precise relationship between the ability to
engage apoptosis and mutation surveillance remains relatively poorly defined.
To investigate the in vivo consequences of hemizygosity at the Msh2 locus and to
further explore the relationship between apoptosis and mutation surveillance the gene
dependency of these two endpoints have been examined in the small intestine of mice
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wild type, heterozygous and nullizygous for Msh2. These studies were performed
both at spontaneous levels of damage and following exposure to the DNA damaging
agents MNNG and cisplatin.
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7.1 Results
7.1.1 Mutation frequency is increased in Msh2 heterozygous mice over 1 year old
Mutation frequency was scored at the Dlb-bl locus at spontaneous levels of DNA
damage over a 13 month time course (figure 7.2.1). Msh2~/~ mice exhibited a higher
mutation frequency than wild type controls and Msh2 hemizygous mice. Msh2~/~\ mice
showed a marked increase in mutation frequency from 4 to 8 weeks: a period where
there is a significant increase in the number of crypts (Shoemaker et al., 1995).
However after this period there was not a significant increase in the mutation
frequency in the Msh2~/~ mice.
The most intriguing result was that there was a significant increase in mutation
frequency in the heterozygotes aged over 12 months (n=10) compared to wild types
(n=10) (p=0.04, Mann Whitney).
Figure 7.1. Increased mutation frequency in the aged Msh2 heterozygotes.
Mutation frequency per 10000 villi was scored at the dlb-lb. At least 3 mice were
used for each timepoint. Dashed line with circular points, wild type mice; solid line





7.1.2 Intact apoptotic response in the heterozygotes
The above observations prompted analysis of the apoptotic response, to determine if
this response was also Msh2 gene dose sensitive. Apoptosis of enterocytes within the
crypts of Lieberkuhn was examined at 6 hours after drug exposure (figure 7.2.)
Figure 7.2: The in vivo apoptotic response at 6 hours following drug exposure. For
each animal 50 half crypts were analysed; the total number of apoptotic bodies scored
in all crypts analysed is plotted on the vertical axis. A) Following 50mg/kg of MNNG,
B) Following lOmg/kg of cisplatin. Closed bars, wild type mice; grey bars,
hemizygous mice and open bars, Msh2 null mice. Columns represent mean, errors bar






It had previously been established that this time point coincides with the peak
induction of apoptosis within this structure (see Toft et al., 1999, Sansom and Clarke
2000). Consistent with previous results Msh2" deficient mice showed a reduced
apoptotic response following exposure to MNNG whilst there was a normal apoptotic
response in wild type and Msh2+' mice (p=0.38). Following exposure to cisplatin, no
difference was observed between hemizygotes and wild type mice (p=0.20, Mann
Whitney)
7.1.3 No increase in induced mutation frequency in Msh2 heterozygous mice
Despite the presence of a normal, intact apoptotic response in Msh2 heterozygotes it
remained possible that there could be a gene dosage effect in mutation induction
following these agents. Previously Shcherbakova and Kunkel (1999) have
demonstrated significant increases in mutation frequency in yeast heterozygous for
Mlhl following exposure to either bleomycin or UV irradiation. These phenomena
were assumed to arise from damage enhanced LOH. Furthermore, studies using Mlhl
heterozygous mice following NMNU (N-methyl-N-nitrosourea) exposure have
revealed increased rates of tumourigenesis compared to wild type controls (Kawate et
al., 2000). Therefore mutation frequency was investigated at the Dlb-lb locus in
young (8-12 weeks old) wild type and Msh2 mutant mice following treatment with
either MNNG or cisplatin.
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Figure 7.3: Induced in vivo mutation frequency at the Dlb-lb locus. Mutation
frequencies were determined from intestinal wholemounts 21 days after ip drug
injection: Columns represent mean mutation frequency at the Dlb-lb locus at the drug
dosage shown. At least 3 mice were used per each column. Error bars represent SD.
A) Mutation frequency following MNNG. Open bars, mock treatment; light grey
bars, lOmg/kg; dark grey bars, 25mg/kg; closed bars, 50mg/kg. At 50 mg/kg Msh2
nulls have a significantly higher mutation frequency than wild type and heterozygous




B Mutation frequency following cisplatin. Open bars, mock treatment, light grey bars,
0.5 mg/kg; dark grey bars, 1 mg/kg; closed bars, 5mg/kg.
Wld-type Heterozygote Homozygote
Genotype of mouse
Mutation was scored three weeks post intra-peritoneal injection. Following exposure
to 50mg/kg MNNG a significant increase in mutation frequency in Msh2~'~ mice
compared to controls was observed (p=0.04, Mann Whitney), but not in
heterozygotes (p=0.17, Mann Whitney). These results parallel those obtained
following exposure to the alkylating agent Temozolomide (Toft et al., 1999 and
chapter 4), confirming that Msh2 normally suppresses mutation following damage of
alkylation, but also showing that this response is not Msh2 gene-dose sensitive.
Following cisplatin exposure Msh2~/~mice showed increased mutation frequencies
relative to controls and heterozygous mice, however these increases could entirely be
accounted for by the increase in spontaneous mutation frequency.
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7.2 Discussion
7.2.1 Spontaneous Mutation frequency
Previously Msh2'/' mice have been shown to have increased mutation frequency at the
Dlb-lb locus compared to wild type mice (Toft et al., 1999). Here it is shown that
there is a very large increase in mutation frequency from 4 to 8 weeks of age which
coincides with a period where there is a significant increase in the numbers of crypts
in the murine intestine (Shoemaker et al., 1995). Surprisingly, beyond this time point
there was no further increase in mutation frequency. This may reflect selection for
mice with a reduced predisposition to neoplasia (and potentially reduced mutation
frequencies) at the later time points as the peak incidence of neoplasia occurs at 3-4
months.
The most remarkable result was that there was a significant increase in aged Msh2
heterozygous mice. Similar results have been shown using very sensitive mutation
screens in Msh2 and Mlhl heterozygous diploid yeast (Shcherbakova and Kunkel
1999, Drotschmann et al., 1999,2000). The authors of these studies argued that this
increased mutation frequency occurred due to loss of heterozygosity in a small
population of the heterozygote cells. However, although LOH at the Msh2 locus
cannot be formally ruled out as the mechanism underlying the increase in the aged
hemizygotes, this appears unlikely as this requires two mutations (inactivation of the
remaining Msh2 allele and subsequent inactivation of Dlb-lb) to occur sequentially
within the same stem cell. Wild type cells accumulate on average 1 additional
mutation per 10000 crypts each month (Winton et al., 1988). If it is assumed a null
hypothesis and that heterozygosity for Msh2 plays no direct role in suppressing
mutation, and furthermore that Msh2 is inactivated at a similar rate to Dlb-lb, then
after 13 months there would be approximately 13 Msh2 null clones per 10000 crypts.
This analysis shows Msh2 deficiency increases the mutation frequency to, at
maximum, less than 10 times that found in wild type cells (the highest fold difference
of 9.6 was observed at one month). This indicates that the additional mutation burden
from the Msh2 null clones would be less than 1 mutation per 10000 villi. This
increase is clearly insufficient to account for the actual observed increase, strongly
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implying that the elevation in mutation frequency is occurring as a direct consequence
ofMsh2 heterozygosity.
The data presented here parallels other studies which have suggested gene dose
sensitivity for Msh2 dependent responses. These include analyses of the level of DNA
lesion and the apoptotic response following exposure to low level radiation treatment
(De Weese et al., 1998), and also by studies which have shown very low rates of
LOH at the Msh2 locus in tumours arising in Msh2 hemizygotes (De wind et al.,
1998).
7.2.2 Induced apoptosis and mutation frequency
There are 2 possible explanations for the increase in mutation rate in the heterozygous
mice which would have ramifications for the experiments examining the effect of
gene dosage on apoptosis and mutation.
First, that there is a subtle defect in repair throughout the lives of the heterozygous
mice that only becomes significant when the mice reach old age.
Second, that old heterozygous mice and not young heterozygous mice are defective in
repair. If only aged mice are defective in repair, apoptosis and induced mutation
should be studied in aged mice as well. Mice are currently being aged to examine
this. The most obvious reason for old mice and not young being defective in repair
would be that there is loss of the remaining wild type allele. Analysis of the predicted
increase in mutation following such LOH argues against this as a mechanism.
As has been shown by Toft et al., (1999) Msh2 deficiency causes a reduced apoptotic
response to alkylation damage. However Msh2 heterozygosity did not cause a
reduction in the apoptotic response.
Msh2 heterozygous mice also had a normal apoptotic response to cisplatin, a result
which is perhaps not unexpected as Msh2~/~ mice show only a marginal reduction in
the apoptotic response compared to wild type controls (Toft et al., 1999, chapter 5).
The failure to observe high levels of MMR-dependent cell death following cisplatin
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exposure contradicts the scenario reported for ovarian cancer cells, where resistance
to cisplatin is associated with loss of MMR function and restoration of MMR causes
re-sensitisation. This must either be a reflection of the rather subtle changes in the
ability to engage apoptosis, or must implicate non-apoptotic MMR-dependent
mechanisms in long term cell survival.
Again Msh2 heterozygosity had no effect on mutation induction following MNNG or
cisplatin. Msh2 deficiency did induce a significant increase following exposure to
MNNG. This confirms early studies with the alkylating agents NMNU and
temozolomide that Msh2 in important in recognition of 06 methyl guanine adducts.
However the results fail to demonstrate a role for Msh2 in mutation surveillance
following cisplatin treatment and question the significance of mismatch repair in the
clearance of cisplatin-induced DNA damage in normal cells. This failure to observe
MMR dependent increase in mutation in response to cisplatin concords with the
clonogenic survival data presented in chapter 5 where Msh2 deficiency (unlike p53
deficiency) does not cause an increase in long term crypt survival following cisplatin
treatment. The findings presented here compliment recent studies by Branch et al.,
(2000), who demonstrated that loss ofMMR was only a minor contributor to cisplatin
resistance in ovarian tumour cell lines.
The studies reported here have been performed in normal intestinal enterocytes. It
remains possible that the reliance upon functional MMR for mutation surveillance
markedly differs between normal and neoplastic cells. Pertinently, Strathdee et al.,
(2001) have shown that mouse embryonic fibroblasts deficient for Msh2 still undergo
a G2 arrest following cisplatin treatment in marked contrast to MMR deficient tumour
cell lines which lose this checkpoint (Brown et al., 1997, Strathdee et al., 2001).
In summary, an extremely complex reliance upon Msh2 in mutation surveillance has
been demonstrated. Msh2 is critical in monitoring spontaneous levels of DNA
damage, such that even a 50% reduction in Msh2 gene dosage can elevate mutation
frequency. This reliance upon Msh2 in response to spontaneous levels of DNA
damage is not directly reflected by gene dependencies in either the apoptotic response
or mutation burden following acute DNA damage. Msh2 deficiency leads to an
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increase in the in vivo mutation frequency following MNNG treatment, but
remarkably this is not the case following exposure to cisplatin. Taken in the context of
the recent proliferation of data relating to MMR-dependent DNA damage responses,
these observations show that reliance upon functional MMR is highly lesion type
dependent. They also challenge our understanding of MMR-dependent suppression of
mutation, perhaps partly because MMR dependent responses are usually interpreted in
an experimental setting following high, non physiological levels of DNA damage.
Clearly, although such scenarios may directly relate to the response to
chemotherapeutics in a clinical setting, they may not accurately reflect the reliance
upon MMR in normal tissues exposed to low levels of spontaneous damage.
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Chapter 8: Mbd4 is a mediator of the cellular response to DNA
damage and suppresses intestinal tumorigenesis.
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8.0 Introduction
Mbd4 (Medl) was originally identified in a database search for proteins with a
methyl binding domain. This search pulled out 4 novel proteins Mbdl, Mbd2,
Mbd3 and Mbd4 (Hendrich and Bird 1998). Previously it had been shown that
there were 2 methyl binding activities in the cell MeCPl (Methyl CpG binding
protein 1) and MeCP2 (Meehan et al., 1989, Lewis et al., 1992).
As was mentioned in 1.4.6 the majority of CpGs in the genome are methylated as
5 methyl cytosine (appox 85%) apart from large CpG islands in the promoters of
genes which are unmethylated. It is that thought methylation is important for
tissue specific control of transcription as methylation of promoters causes
transcriptional silencing (Tweedie et al., 1997, Razin 1998). The best example of
this is the dense methylation of CpG promoters on the inactivated X
chromosome and the Xist gene on the active X chromosome (Hendrich and Bird
2000).
Methylation is essential for development and mutations in the enzyme responsible
for maintaining methylation DNA (cytosine 5) methyltransferase (DNMT1)
results in embryonic lethality. Embryos show a developmental delay at E 9.5
days and then fail to develop past E12.5 (Li et al., 1992). DNMT1 is a
maintanance methylase and is not a very efficient de novo methylase (Laird
2000). More recently 2 further mammalian methyl transferases have been
discovered DNMT3a and DNMT3P again through sequence identity to DNMT1
(Okano et al., 1998). Okano et al., (1999) showed that DNMT3a and DNMT3J3
were essential for de novo methylation and for normal mouse development.
Methylation also appears to be important for maintaining genomic stability. DNA
hypomethylation has been associated with ICF (Immunodeficiency, centromeric
instability and facial abnormalities) and more recently mutations in DNMT3|3
have been found in ICF pateints (Hansen et al., 1999). ES cells nullizygous for
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DNMT1 show increased mutation frequencies at both the Hprt (hypoxanthine
phosphribosyltransferase) and the tk (thymidine kinase) locus (Chen et al., 1998).
When the spectrum of mutations at these loci were investigated, it was show that
gene deletions were caused through mitotic recombination or chromosomal loss
accompanied by gene duplications. Other evidence supporting the role of
methylation in protecting against genomic instability comes from studies using
DNMT1 nullizygous fibroblasts. Using cre-mediated deletion of DNMT1 in
fibroblasts, Jackson-Grusby et al., (2001) showed that demethylation of
fibroblasts induced apoptosis. This apoptosis was p53 dependent, indicative that
apoptosis was induced through some type of DNA damage or genomic instability.
Therefore it is quite possible that loss of proteins that are important in binding and
maintaining methylation could be important for a number of diseases and cancers.
The methyl binding domain was first characterised from MeCP2 and this was
used to search the databases. MeCP2 has 2 functional domains within the protein,
the MBD domain and a transcriptional repression domain that recruits histone
deacetylase to cause transcriptional silencing. MeCP2 can bind a single CpG pair
and is localised to methyl CpG rich heterochromatin regions in mouse cells (Nan
et al., 1996). Germline mutations in MeCP2 have been found in patients with
Rett Syndrome. This is a neurodevelopmental disorder that affects 1 in 10000
females. MeCP2 deficient mice also develop a neurological phenotype similar to
Rett Syndrome at around 6-10 weeks (Chen et al., 2001, Guy et al., 2001).
Mice have been made that are deficient for the proteins Mbd2, Mbd3 and Mbd4
(Hendrich et al., 2001). The Mbd2 protein is a component of the MeCPl protein
complex and has been shown to bind to methylated DNA and repress
transcription. MeCPl is a large protein complex of 400-800 Kda which binds 12
or more methylated CpG repeats (Boyes and Bird 1992). This is thought to reflect
large methylated CpG islands. Unexpectedly Mbd2 knockout mice have no
obvious phenotype apart from Mbd2 null females producing smaller litters
(Hendrich et al., 2001). However fibroblast tail lines from these mice show a
25% reduction in transcriptional repression (Guy et al., 2001, Hendrich et al.,
170
2001). Surprisingly there is no additive phenotype when the Mbd2 deficient mice
are crossed to MeCP2 deficient mice (Guy et al., 2001). Mbd2 has remarkable
sequence identity to Mbd2 (75%) though it is the only MBD protein that does not
bind methylated DNA (Hendrich and Bird 1998) Mbd3 is part of the NuRD
corepressor complex which has been shown to silence a wide varitey of genes in
many different organisms (Ahringer et al., 2000). Deficiency in Mbd3 (unlike
Mbdl) produces embryonic lethality by day 9. Due to the sequence similarity of
the proteins it was predicted that there may be some genetic interaction between
Mbd2 and Mbd3. This was shown through careful analysis of breeding data as
there is a deficiency of (Mbd2'/' , Mbd3+") mutants compared to (Mbd2+ +,
Mbd3+ ') mice (Hendrich et al., 2001). However the precise basis for this remains
unclear.
Mbdl has also been shown to be involved in transcriptonal repression of
methylated genes (Ng et al., 2000). This protein can bind single methylated CpG
and is not in the MeCPl complex.
This chapter will focus on Mbd4 deficient mice. Mbd4 had been shown to be
capable of binding single methylated CpG in vitro (Hendrich and Bird 1998).
Unlike the other MBD proteins it is not involved in transcriptional repression.
Two different activities have been attributed to Mbd4\ a thymine glycolase
activity and an endonuclease (Hendrich et al., 1999, Bellacosa et al., 1999).
These have led to the proposals that Mbd4 functions:
1. Thymine Glycolase that removes deamination
2. A mismatch repair endonuclease.
As was discussed in 1.4.6, 5-methylcytosine is prone to undergoing deamination
to thymine (Hendrich et al., 1999). This has led to 5 methyl-CpG being
underepresented in the genome (Hendrich and Bird 2000). In the normal scenario
cytosine deaminates to uracil and is removed by uracil glycolyase. However if
cytosine deaminates to thymine this will not be corrected by this enzyme and will
instead produce a GT mismatch.
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Figure 8.1 Mbd4 binding to a deaminated 5 methyl cytosine.
MBD4
The red T shows the product of 5 methyl-cytosine deaminated to Thymine.
Although Mbd4 has been shown to bind single methylated CpGs as well as GT
mismatches, it was shown to preferentially bind the structure presented in figure
8.1 (Hendrich et al., 1999). It was also shown to be able to bind GU mismatches.
After binding the mismatch, Mbd4 then removes the deaminated thymine using its
C-terminal thymine glycolase domain. As this GT lesion would be produced post
replication, it is difficult to predict whether it could be recognised by the MMR
machinery. More poignantly it is doubtful whether MMR proteins would remove
the incorrect T or the G as there would not be a newly synthesised strand.
MBD4 was also identified through its interaction with MLH1 in a yeast two
hybrid screen. Bellacosa et al, (1999) identified a weak endonuclease activity in
this MLH1 interacting protein and thus called MBD4, MED1 (methyl-CpG-
binding endonuclease). Bellacosa et al., (1999) then proposed that due to this
interaction with the MMR protein, its ability to bind methylated DNA and its
endonuclease activity this made it a potential homologue of the E.coli MMR
protein MutH. One outstanding question concerning mammalian MMR is how
strand specificity is attained. In E.coli this is achieved through GATC restriction
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sites in the DNA. The parental strand is methylated at these sites and thus MutH
endonuclease nicks the newly synthesised unmethylated strand (Modrich 1991).
Although this is an attractive proposal, it is highly unlikely. Mbd4 preferentially
binds to the M5CpG.TpG mismatches rather than a general 5mCpG sites, thus it is
involved in the repair of the mismatches rather than any general strand specific
role. Given that 5mCpG is also under-represented in the genome due to this
deamination and many promoters have large methylation free CpG islands, it is
hard to envisage that MBD4 is a functional Mut H homologue. In addition, the
weak endonuclease activity discovered by Bellacosa et al., (1999), was not found
in the study of Hendrich et al., (1999). This indicates that this may not be of
prime importance to the protein. Indeed, Drummond and Bellacosa (2001)
recently showed that in HeLa cells MMR works independently of CpG
methylation. However its ability to bind to Mlhl and these GT mismatches, does
implicate that it may play a role in MMR. Another potential scenario is that Mbd4
interacts with the MMR proteins to stop them binding at these mismatches to
prevent incorrect removal of the guanine.
MBD4 has also been implicated as a tumour suppressor gene in the intestine.
MBD4 has been shown to be mutated in human colorectal cancers characterised
with microsatellite instabilty (Riccio et al., 1999, Bader et al., 1999, 2000). Bader
et al., (2000) suggested that up to 89% of sporadic colorectal cancers with MSI
had a Mbd4 mutation. However the significance of this is uncertain as nearly all
of the mutations are in the poly A10 tract in the human Mbd4 gene (Riccio et al.,
1999, Bader et al., 1999, 2000). Therefore this could just be a marker of
mismatch repair deficiency and MSI.
To investigate the significance of Mbd4 in vivo, Mbd4 deficient mice were
generated by Jacky Guy of the Adrian Bird laboratory. These mice were viable
and had no obvious tumour predisposition. To address the possibility that Mbd4
may function as a MMR protein, the Mbd4~f~ mice were therefore characterised in
vivo for mutation frequency, apoptosis and accelerated ApchUn + neoplasia.
173
The results obtained show that the activity of Mbd4 cannot be explained through
its interaction with MMR proteins and instead establish a fundamental role for
Mbd4 in the cellular response to DNA damage and in suppression of intestinal
neoplasia.
8.1 Results
Previous studies have demonstrated an interaction between Mbd4 and the
mismatch repair gene Mlhl, an interaction which suggests a potential role for
Mbd4 in recognising mismatch type damage. To determine if this interaction was
specific to Mlhl or could be generalised to other DNA damage associated proteins
Catherine Millar performed a series of immunoprecipitations using Hela cell
extracts. These confirmed an interaction with Mlhl, but also show an interaction
with Msh2 though not Pms2 and Msh6. This argues against Mbd4 being part of
the functional MMR complex. Notably these interactions occur through the C-
terminal domain ofMbd4, rather than through the methyl binding domain (MBD)
To determine the functional significance of Mbd4 deficiency Jacky Guy
generated mice bearing a null Mbd4 allele. Mice heterozygous for this allele were
intercrossed and homozygotes generated. Mice homozygous for the mutation were
detected at the expected Mendelian ratio, demonstrating that deficiency for Mbd4
was compatible with viability. Functional inactivation of Mbd4 was confirmed in
the homozygotes using both Quantitativive PCR and western analysis. The null
mice show no overt phenotype and are not prone to the development of
spontaneous malignancy, at least up the age of 18 months.
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8.1.1 Spontaneous mutation frequency in Mbd4 deficient mice
As was mentioned in 8.1, three different lines of evidence suggest that Mbd4 may
modulate the mutation frequency in vivo. First, that Mbd4 functions as a thymine
glycosylase at CpG sites and therefore deficiency of Mbd4 may increase the rate
of spontaneous deamination. Second, that Mbd4 directly interacts with the MMR
proteins Mlhl and, as we show here, Msh2. Third, it has been suggested by
Bellacosa et al., (1999) that Mbd4 is an endonuclease and as such it has been
proposed as a potential candidate for the eukayotic homologue of the MutH
endonuclease. Taken together, these findings predict that loss of Mbd4 would
result in elevated mutation, and that Mbd4 deficiency may parallel the mutator
phenotype of MMR deficiency. Therefore mutation frequency was scored in the
intestinal epithelium using the Dlb-lb assay in both normal and Mbd4~' mice.
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Figure 8.2: No increased mutation in Mbd4 deficient mice. Mutation frequency at
the Dlbl-b locus per 10000 villi. Black bars, wild type mice; open bars, Mbd4~A
mice; Grey bars, Msh2~/~ mice. By 8 months nearly all Msh2'A mice are dead thus
mutation was not scored in these mice
Using this assay, which reports mutation in vivo within the stem cell compartment
of the crypts of Lieberkuhn, no increase in spontaneous mutation frequency in
Mbd4 null mice was found. This result argues that Mbd4 is not essential for
MMR in vivo.
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8.1.2. Reduced levels of apoptosis in Mbd4"A mice
The mismatch repair proteins Mlhl and Msh2 have also both been shown to
influence the apoptotic response to DNA damage. Therefore influence of Mbd4
status upon the apoptotic response of intestinal enterocytes was analysed at both 6
hours and 72 hours following exposure to DNA damage.
Figure 8.3: Apoptosis per 50 Vi crypts in wild type and Mbd4 deficient
following a range of DNA damaging agents. Black bars, wild type mice; open
bars, Mbd4~/' mice and pink bars,p53w' mice. Error bars represent SD.
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|
Mice null for Mbd4 show a normal apoptotic response following exposure to the
pyrimidine antimetabolite 5-fluorouracil (5FU) at either 6 or 24 hours (p=0.32 and
p=0.10, Mann Whitney), but a markedly reduced apoptotic response following
exposure to ionising radiation (p=0.001, Mann Whitney), cisplatin (p=0.04, Mann
177
Whitney) and the alkylating agent Temzolomide (p=0.04, Mann Whitney) (figure
8.2). These data imply that Mbd4 is specifically required for signalling apoptosis
from DNA damage, as 5FU has been shown to mediate apoptosis through changes
in RNA metabolism rather than by DNA damage (Pritchard et al 1997,1998). The
failure of 5FU to elicit Mbd4 dependent death is also notable in the light of reports
that Mbd4 can bind and remove 5-FU damage (Petronzelli et al., 2000). These
results demonstrate a wide ranging role for Mbd4 in mediating cell death.
To test if the apoptotic phenotype was generic to all proteins containing a methyl
binding domain, the apoptotic phenotype of mice deficient for Mbd2 following
ionising radiation was analysed and found them not to differ from controls was
also analysed.
Figure 8.4: Normal Apoptotic response following gamma irradiation in
Mbd2~/~ mice. Apoptotic response per 50 'A crypts following 5 GY of irradiation.




8.1.3 Clonogenic survival and induced mutation frequency in Mbd4~~ mice
The observed reduction in the apoptotic response of Mbd4 mutant mice implies
that cells fail to be appropriately deleted in the absence of Mbd4. This in turn
argues that clonogenic survival and induced mutation frequency at the Dlbl-lb
locus would be increased in the Mbd4 null mice following these agents.
Figure 8.5: Clonogenic survival in wild type and Mbdf" mice following
gamma irradiation and cisplatin. Average number of surviving (live) crypts per
circumference of small intestine. Black bars, wild type mice; open bars, Mbd4~'
mice.
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Mbd4 deficiency does not lead to increased clonogenic survival following
exposure to exposure to gamma radiation (p=0.4, Mann Whitney), but does but
does cause increased survival following exposure to cisplatin (p=0.01, Mann
Whitney). Due to this increase in survival following cisplatin, mutation frequency
was then scored (figure 8.6).




Wt5Gy Mbd4 5Gy Wt CDDP MBD4CDDP
Despite the damage specific nature of the clonogenic response, no Mbd4-
dependent increase in mutation frequency was found following exposure to either
agent (p=0.4 (Ionising radiation) and p=0.65, Mann Whitney (Cisplatin)). These
results again parallel data obtained from p53 deficient animals, which show that
although p53 functions as a robust tumour suppressor gene and is essential for the
normal induction of apoptosis, deficiency of p53 does not necessarily lead to a
marked increase in mutation frequency or clonogenic survival.
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8.1.4. Mbd4 deficiency accelerates intestinal neoplasia on an ApcM,n/+
background
Mbd4 has previously been implicated as a putative tumour suppressor in the
intestine (Bader et al., 1999, 2000, Riccio et al., 1999). To directly test if Mbd4
deficiency can alter the predisposition to malignancy mice deficient for Mbd4
were crossed onto an ApcMm heterozygous background. This background
predisposes to the development of spontaneous neoplasia within the intestine.
Littermates were divided into two cohorts, either {Mbd4~'~, ApcMin/+) (n=36) or
(Mbd+/", ApcMin/+) (n=17). These cohorts were closely monitored and animals
killed when they became overtly ill.
Min/+
Figure 8.7: Kaplan Meier survival plot of (Mbdf'~, ApcMin/+) and (Mbd4+/",





















Comparison of the survival curves showed that deficiency of Mbd4 markedly
reduced survival (p=0.001 Log Rank). Tumour incidence within the large and
small intestine was scored at necropsy, with (Mbd4~'~, ApcMm/+) (having higher
number of tumours (p=0.02) (figure 8.9). Histological analysis showed no
difference in the morphological appearance of lesions between the cohorts.





Figure 8.9: Median Tumour burden.
Small Intestine Large Intestine Total
(Mbd4+/~, ApcMin/+) 3 11 14
(Mbd4~'~, ApcMm/+) 11 17 28
These findings indicate that tumour development was accelerated in the absence
ofMbd4, but that Mbd4 deficiency did not alter the phenotype of lesions arising.
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8.2 Discussion
This comprehensive analysis of the in vivo consequences of loss of function of
Mbd4 has shown that it interacts with a series of MMR proteins, that it modifies
the apoptotic response and that deficiency ofMbd4 accelerates tumorigenesis in a
murine model of human FAP.
The significance of the interaction with MMR genes however is still unclear.
Bellacosa et al., (1999) showed that over-expressing a mutant MBD4 protein
caused increased MSI. However this mutant still contained its MLH1-binding
domain, thus it could cause this mutator phenotype by binding to MLH1 and
preventing it function in MMR. In fact over-expression ofMLH1 has been shown
to cause a mutator phenotype in yeast (Schberberkova and Kunkel 1999) probably
by inappropriate formation of MLH1 homodimers. Underlining the fact that one
should be wary of over-interpreting of over-expression studies.
The failure to see a mutator phenotype in the Mbd4 deficient mice argues strongly
against it being involved in MMR. We have shown that loss ofMlhl, Msh2 and
Pms2 all produce an increased spontaneous mutation frequency at the Dlb-lb
locus. With respect to the role of Mbd4 in repair of deamination at 5-
methylcytosine sites, the level of mutation resulting from these events may also be
below the threshold of detection by our assays. Alternatively, mouse cells possess
at least one other T-G glycosylase activity, TdG (Neddermann, 1996), which may
in theory compensate for loss ofMbd4.
The interaction with the MMR proteins cannot explain the apoptotic phenotype
seen in the Mbd4 deficient mice as the deficiency in apoptosis in the Mbd4'/" mice
are more marked and wide ranging that the MMR mice. As was shown in chapter
5 there was only a small reduction in the apoptotic response to cisplatin in Msh2
mice. Currently there is no data showing that Msh2 plays a role in mediating the
apoptotic response to y-irradiation.
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One interesting hypothesis is that the interaction between MMR and Mbd4 is a
negative one. The basis for this is that, if MMR bound the M5CpG.TpG
mismatches there would be no indicator for strand specificity, as this is a
deamination event rather than a replication error. Thus it is likely that 50% of the
repair by MMR would result in a mutation (Bellacosa et al., 1999).
As the Mbd4 dependent apoptosis cannot be explained through the interaction
with the MMR proteins, this leaves the mechanism of Mbd4 mediated apoptosis
rather unclear. Although, Catherine Millar was unable to pull down any other
proteins with MBD4 in the HeLa cells, this was experiment was performed using
untreated cells so it will be interesting to see what MBD4 interacts with post DNA
damage.
As Mbd4 responds to such a wide range of damaging agents it is clearly of
fundmental importance in signalling death. The 5-FU experiment indicates at
Mbd4 is important for signalling apoptosis from DNA damage rather than all
types of apoptotic stimuli.
Mbd4 has been shown to bind the structure in fig 8.1, mismatches and methlylated
CpG, thus apart from possibly binding 06meG lesion produced by temozolomide,
it is unlikely that it would be able to bind damage from all these types of lesion.
Therefore it appears that it is involved in signalling apoptosis rather than damage
recognition.
Fishel (pers comm) have shown using GST tagged MBD4 interacts with a range
of DNA repair proteins: BRCA1, BRCA2, MRE11, RAD51 and RAD52. These
proteins have all been shown to be important for signalling the presence of double
strand breaks. In fact these are part of the BASC (BRCA1 associated super
complex) isolated from HeLa cells which was shown to be upregulated after a
range of DNA damaging agents (Wang et al., 2000). As cisplatin, gamma
irradiation and temozolomide all induce strand breaks this produces a model
where Mbd4 is part of a much larger complex which signals apoptosis. Loss of
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Mbd4 could therefore make this complex less efficient at signalling death.
Another model would be that Mbd4 interacts with this complex to signal death.
Catherine Millar was unable to show these interactions in Hela cells, however as
was mentioned this was using untreated HeLa cells. Therefore further work is
required to characterise the mechanism of Mbd4 dependent apoptosis. At present
an Mbd4 antibody is being generated for mouse, therefore the kinetics of the
Mbd4 response following DNA damage can be investigated. For example, it will
be possible to determine whether Mbd4 is induced following DNA damage. This
would also allow an examination of which proteins Mbd4 interacts with in the
murine intestine through co-immunoprecipations with Mbd4 following DNA
damage.
As was shown in chapter 5 and many times in the literature, this reduction in the
apoptotic response does not necessarily lead to increased survival and mutation
(Brown and Woulters 1999). In fact, the increased clonogenic survival following
cisplatin treatment is one of the rare instances where a reduced apoptotic response
correlates with increased survival. In this thesis, both Mbd4 and p53 deficiency
causes increased survival following cisplatin damage. Mbd4 deficiency only
produces increased survival at 15mg/kg of cisplatin, whilst p53 deficient animals
showed increased survival at both 15mg/kg and 20mg/kg. Care should be taken
against over-interpreting the direct comparison of these results as the Mbd4~/~
animals were maintained on a C57B1/6 background and the p53~'~ mice were
maintained on an outbred background. It has previously been reported that levels
of crypt killing is dependent on background and this is confirmed here as there are
very different levels of death in the C57B1/6 wild type mice used in the Mbd4~/~
experiment and the outbred wild types used in the p53 experiment (Potten, 1990).
As with p53 deficiency, there was no increase in survival in Mbd4~f~ mice
following gamma irradiation. One possible explanation is that the very high
levels of damage that is needed to kill crypts in the microcolony assay could
saturate out any gene dependent difference. However when lower levels of
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damage are used for the mutation induction experiment, there was no increase in
mutation at the Dlb-lb locus in the Mbd4 nulls above wild type levels after either
gamma irradiation or surprisingly cisplatin. Therefore this once again this
dissociates loss of apoptosis from mutation induction.
Clarke et al., (1997) have previously shown that mutation frequency in p53~'~ mice
was not significantly higher than wild types levels after 5GY of irradiation
although there was a significant increase after 7.5GY. However there was no
difference in the levels of apoptosis induced by these two doses of gamma
irradiation. It would be interesting to see whether there is an increase in mutation
frequency following 7.5Gy irradiation in the Mbd4~/~ mice.
As Mbd4 has been shown to signal apoptosis it is currently being examined
whether it also signals cell cycle arrest (via BRDU incorporation) following DNA
damage in the small intestine. A more detailed study of cell cycle checkpoint
analysis will then be performed in primary fibroblasts and and compared to
colorectal cell lines. Bader et al., (1999,2000) have shown that there are a number
of colorectal cell lines available that have lost MBD4 thus these could be used.
MBD4 has been described by Riccio et al (1999) as a tumour suppressor, due to its
loss in many mismatch repair deficient tumours. However this could easily be a
reflection of MSI in the MMR tumours as most of the mutations in the Mbd4 gene
are at the A(10) tract in its coding sequence (Bader et al 1999, 2000). Here we
show Mbd4 deficiency per se does not lead to a spontaneous tumour
predisposition. However it does accelerate intestinal neoplasia in the ApcMm/+
mouse, a murine model of FAP. Therefore this confirms the role of Mbd4 as a
tumour suppressor. We have shown that there is no obvious increase in mutation.
Therefore, whilst the possibility remains that Mbd4 is involved in both damage
signalling and repair of the genome, the data presented here implicate the
apoptotic signalling role ofMbd4 in tumour suppression.
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As yet no mutations have been found in MBD4 in FAP nor sporadic colorectal
cancer without MSI (Bader et al., 2000). There are two potential reasons for this,
first that MBD4 has not been screened thoroughly for mutation and second, that
unlike the A10 tract there is not a putative mutation hotspot. In tumours without
MSI, SSCP (Single Stranded Conformation polymorphism) which could
potentially miss some of the mutations in MBD4 (Bader et al., 1999). However the
most plausible explanation is that Mbd4 is not loss in these tumours.
Therefore despite loss accelerating the murine model of FAP, there is no evidence
yet that MBD4 is lost in FAP. This could reflect species specific difference
between human colorectal neoplasia and murine intestinal neoplasia. However the
fact MBD4 is lost in the majority of microsatellite unstable tumours does imply it
plays a role in intestinal malignancy in humans. It is worth remembering that
Msh2 and Mlhl both rapidly accelerate murine models of FAP though they are not
lost in FAP.
At present, Mbd4 deficient mice are being crossed to MMR deficient mice to see
whether intestinal malignancy is accelerated in this background. This should
provide definitive evidence of whether loss of Mbd4 is selected for in a MMR
deficient background or is simply a reflection ofMSI.
Taken together these results argue that Mbd4 is a modifier of intestinal
tumourigenesis which when lost accelerates tumourigenesis. The chance of this
loss is greatly increased in colorectal cancers with defects in its MMR due to the
presence of an unstable A10 tract and has implications for chemotherapy. Given
the similarities between the consequences of loss of Mbd4 and p53 for the
apoptotic response following DNA damage, it is interesting to note that MMR
deficient colorectal cancers very rarely have P53 mutations. It was argued in
chapter 6 that this could be due to under reporting of P53 mutations, another
possible interpretation is that loss of MBD4 in these tumours circumvents the
requirement of a P53 mutation.
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Chapter 9: Characterisation of p-catenin expression and apoptosis
in murine models of intestinal neoplasia.
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9.0 Introduction.
In the previous chapters, this thesis has examined the apoptotic response in normal
intestinal epithelium. This chapter investigates whether apoptosis in adenomas
exhibits the same gene dependency as the apoptosis that occurs in normal mucosa.
This was done by crossing Msh2~;~ deficient mice to ApcMm/+ mice, and analysing
the apoptotic response in these lesions.
Germline mutations in the adenomatous polyposis coli gene (APC) gene at 5q21
characterise an inherited disorder known as familial adenomatous polyposis coli
(FAP) (Nishino et al., 1991).
The precise nature of how loss of function of Ape predisposes to malignancy
remains unclear, however disruption of the normal function of P-catenin has been
implicated in this process (Rubinfeld et al., 1993, Su et al., 1993).
As mentioned in 1.4.1, levels of P-catenin are modulated by APC through the
mammalian Wnt signaling pathway, where APC interacts with axin, GSK3P and
P-catenin. The central portion of APC contains sites at which it can be
phosphorylated by glycogen synthase kinase 3p (GSK3P) and also through which
it complexes with P-catenin. Phosphorylation by GSK3P increases the stability of
the APC/p-catenin complex and is thereby thought to increase the rate of p-
catenin degradation (Rubinfeld et al., 1996) (see figure 1.2 for Wnt signalling).
Immunohistochemical analysis of both human and murine intestinal tumours has
shown that both adenomas and well differentiated carcinomas are characterised by
high levels of p-catenin (Inomata et al.,, 1996, Takayama et al, 1996). However,
both p-catenin and E-cadherin are reported to be expressed at significantly lower
levels in more aggressive malignancies, strongly suggesting that over-expression
of P-catenin is only crucial in early tumour development (Takayama et al., 1996).
In order to further characterise the association between tumourigenesis and
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dysregulation of (3-catenin, levels of p-catenin expression in normal and
neoplastic tissue derived from mice mutant for the tumour suppressor genes
Ape ' + and Msh2 were analysed in this chapter.
Dysregulated Wnt signalling is thought to drive transcription of a plethora of
genes, many of which are oncogenes e.g API, c-myc, cyclin D1 and have been
shown to drive both apoptosis and proliferation depending on cellular context
(Evan et al., 1992). Previous studies have shown that levels of apoptosis in normal
human colorectal epithelium are much higher than in adenomas and carcinomas
(Bedi et al., 1995). This indicates that loss of apoptosis may be important to
tumour progression. This loss of apoptosis may be a relatively early event, as
when Fazeli et al., (1997) compared levels of apoptosis from adenomas to
adenocarcinomas (see figure 1.1), they found no differences in the levels of
apoptosis. This also suggests that the early reduction in the apoptotic is
independent of P53 status as loss of P53 is most frequently reported at the
adenoma-carcinoma transition (Vogelstein and Kinzler, 1996).
Both the ApcMw/+ and the (ApcMm/+, Msh2~/~) models of intestinal neoplasia possess
the great advantage of developing multiple lesion types within the same mouse.
Thus, a spectrum of lesions can be seen from single dysplatic lesions to (very
rarely) large adenocarcinomas within the same animal (Clarke et al., 1995).
Therefore the stage where apoptosis is lost can be accurately characterised
One future aim of chemotherapy is tailoring of the genetic profde of the tumour to
therapy: i.e. if a certain gene is lost, a certain therapy will or will not work. In
chapter 4, reduced levels of apoptosis were shown in Msh2" mice following
temozolomide treatment (also Toft et al., 1999). Therefore whether this gene
dependency is retained in tumours will be assessed by comparing tumours from
(ApcMin/+, Msh2 +/+) to (ApcMin/+, Msh2 v") mice.
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9.1 Results
9.1.1 Expression of p-catenin in intestinal tumours.
The pattern of P-catenin expression in intestinal lesions developing within
4pcMin/+ mice was investigated. Mice were harvested when they had intestinal
neoplasia and the p-catenin staining was performed by R. Kongkanuntn. In
morphologically normal epithelium, P-catenin was localised at the cell periphery
or in the nucleus. Nuclear localisation was also observed in some cells: these were
always located at the crypt base (figure 9.1) The expression of p-catenin was
significantly more intense in dysplastic crypts and small adenomas. To control for
staining variability between sections, changes in the intensity of expression were
always scored relative to normal epithelium within the same section. The lesions
were subclassified as in Clarke et al., (1995): (I) single dysplastic crypts, showing
nuclear pleomorphism and stratification; (II) complex lesions, comprising several
architecturally distorted crypts in the lamina propria with virtually normal
overlying surface epithelium; (III) small adenomas, identified by the overall
disturbance of architecture including the surface and distinguished from the
previous category on the basis of increased size and surface involvement; (IV)
large adenomas, and (V) invasive adenocarcinoma.).
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Figure 9. 1. P-catenin expression patterns within intestinal lesions. Percentage
of each lesion type showing either 100% upregulation of p-catenin (+ve); a
mosaic or heterogeneous pattern of upregulation as defined in the text (M); or no
upregulation (-ve). N indicates the number of lesions scored.
Lesion Type
I II III IV V
+ve M -ve +ve M -ve +ve M -ve +ve M -ve +ve M -ve
Ape +/-;
56 44 0 58 42 0 58 42 0 55 45 0 60 40 0
N=41 N=96 N=36 N=20 N=10
Ape +/-:
Msh2 -/-
70 27 3 68 27 5 50 47 3 60 40 0 50 50 0
N=187 N=12() N=30 N=5 N=4
Msh2 -/-
20 20 60 17 17 66 56 33 11 50 50 0 0 0 0
N=5 N=6 N=9 N=8 N=0
The pattern of p-catenin staining is summarised in figure 9.1. A substantial
proportion of all lesion types showed heterogeneous expression of P-catenin
expression, even where only single crypts were involved (type I lesions, fig
9.2b,9.2e). The term 'heterogeneous' is used here to describe lesions in which
only a proportion of cells were characterised by increased expression. Although
heterogeneous P-catenin was observed in all lesions types, the proportion of cells
overexpressing P-catenin were at their highest in type I, II and III lesions, even
where the level of histological atypia was slight (fig 9.2c-d). Type IV-V lesions
showed a lower proportion of cells staining positive for P-catenin (fig 9.2f), with
large areas of reduced staining observed in some lesions (fig 9.2g).
In all categories of lesion the pattern of p-catenin staining was predominantly
nuclear. Strong nuclear localisation was observed within some lesions as has been
previously reported (Sheng et al., 1998). This pattern of localisation of p-catenin
should be taken with some caution, as it has been observed that there can be a
fixation dependent alteration in the apparent intracellular location of P-catenin
(Kongkanuntn et al., 1999). Although a similar approach did not show fixation
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dependent differences in intestinal material, it remains possible that an element of
the cytoplasmic staining observed here arises as a consequences of either fixation
or processing protocols.
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9.1.2 Expression of P catenin in intestinal tumours from Msh2'A and (ApcM,n+/,
Msh2v") mice
The pattern of P-catenin expression in Msh2~'~ and (ApcM,n/+, Msh2~'~) animals is
summarised in 9.1). Previous studies have shown that the Msh2 mutation
predisposes to intestinal tumorigenesis and also accelerates neoplasia in ApcM,n/+
mice (Reitmair et al., 1996A., De Wind et al., 1995, De Wind et al., 1998). In
Msh2~'' animals there were type I, II and type III lesions which showed normal P-
catenin expression (fig 9.3b), a phenomenon that was not observed in
ApcM'"/+micQ (fig 9.3a). However, the majority of type I and II lesions and all
type III adenomas were characterised by increased levels of P-catenin expression.
In (ApcMm/+, Msh2~'~) mice there was a significant increase in the frequency of
adenomas, as has been previously reported (Reitmair et al., 1996A). The majority
of these lesions stained strongly for P-catenin (fig 9.3c), however there were again
a small number of type I and II lesions (<5%) with the wild type pattern of P-
catenin expression (fig 9.3d). Only 1/35 type III lesions showed normal P-catenin
expression.
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Figure 9.3 The pattern of P-catenin expression in Msh2~'~ mice (A-B) and
(ApcMi"'\Mshf) mice (C-D). All scale bars represent lOuM A) Increased p-catenin
staining in a type I lesion. B) Normal P-catenin expression in a type 11 lesion., with P-
catenin strongly localised to the lateral borders. C) Increased P-catenin expression in a
type II lesion.. D) Normal P-catenin expression in a type II lesion, with retained
localisation to the lateral borders. A type I lesion showing P-catenin dysregulation is
indicated for comparison (arrow).
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9.1.3. Expression of Cyclin D1 in the intestinal neoplasia
Due to the increased levels of p-catenin in the intestinal lesions of the ApcM'"/+
mice, one prediction was that targets of P-catenin TCF/LEF transcription should
also be over-expressed. One potential target of Wnt signalling is cyclin D1 which
was identified as by overexpressing mutant P-catenin (non-regulatable) in
colorectal cell lines and showing that levels of cyclin D1 increased (Tetsu and
McCormick 1999). Notably, these colorectal cells lines would have already had
mutations in the Ape gene so it is quite surprising that they were not already over-
expressing P-catenin and thus cyclin D1.
Here we show that the in all of the ApcM,n+ lesions in vivo Cyclin D1 (like P-
catenin) is over-expressed (figure 9.4). Although this is indicative of P-catenin
driving transcription of cyclin D1 its is not definitive proof (see discussion).
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9.1.4 Spontaneous apoptosis in ApcMin+/~ and (ApcMin+/~, Msh2'A) lesions
In the ApcMm/+ mouse, the incidence of adenocarcinoma (type V) was very rare as
were large adenomas (type IV) which were predominantly located in the large
intestine. This situation is exacerbated in the (ApcM'n/+, Msh2v~) mice which
develops many small lesions (over a 100) (Reitmair et al., 1996A). These
probably cause ill-health and anaemia in the mouse before lesions can progress to
type (IV) and (V) lesions. Therefore apoptosis was scored in the small intestine in
the type I (single lesions) to type III (adenomas) lesions.
Figure 9.5. Apoptosis in lesions from ApcMin/+and (ApcM,n/+, Msh2~/~) mice.
Percentage of cells undergoing apoptosis in mock treated mice. Each bar
represents at least 3 mice and error bars represent SD. For each mouse at least 50
normal /4 crypts were scored, 10 type I (single crypt) lesions, 10 type II lesions


















































Figure 9.5 shows there is a reduction in apoptosis during intestinal neoplasia in
both the ApcMin/+and (ApcMin/+, Msh2~/~) mice. However it appears to be much
1QQ
more complex than a simple reduction in apoptosis with progression of
tumourigensis which was reported in human colorectal neoplasia (Bedi et al.,
1995). Compared to normal epithelium, there was a large increase in the levels of
apoptosis within the smallest type I lesion for lesions arising in both ApcMm/+and
(ApcM,n/+, Msh2'A) mice (Mann Whitney p=0.04). The type II complex lesions had
intermediate levels of apoptosis between the type I lesions and the type III
adenomas. The type III adenomas had the lowest levels of apoptosis.
The {ApcMm/+, Msh2~/~) mice have lower levels of apoptosis than the ApcM"l/+ mice
in the single lesions (p=0.04 Mann Whitney). When the distribution of apoptosis
was examined in the (ApcM,n/+, Msh2~") mice on a per lesion basis there was the
occasional type I lesion with a low level of apoptosis (Figure 9.6). It is possible
that these lesions with the low levels of apoptosis are the ones that give rise to the
larger type II and III lesions, with the lower levels of apoptosis
Figure 9.6. Profile of Apoptosis in the untreated type I lesions from
(ApcMin/+, Mslt2'A) mice. Percent of cells undergoing apoptosis in all type I lesions




9.1.5 Proliferation in lesions from the ApcMin/+ mice.
Previously Oshima et al., (1997) have shown that there were no obvious
difference in cellular proliferation between adenomas and normal epithelium in
ApCM,n/+ mice. As there were clear differences in the level of apoptosis between
lesion types, the levels of proliferation were also investigated. This was done by
injecting Bromodeoxyuridine (BrdU) into the mice two hours prior to culling.
BrdU incorporates into the DNA at S Phase and thus gives an estimation of the
number of cells cycling into S phase.
Figure 9.7. No difference in BrdU incorporation within the lesions types of
the ApcMl,t/+ mice. Percentage of live cells labelled with BrdU, two hours after
BrdU pulse. Each bar represents at least 3 mice and error bars represent SD. For
each mouse at least 50 normal /i crypts were scored, 10 single crypt lesions, 10
type II lesions and 5 adenomas.
Normal Type I Type II Adenoma
Despite very different levels of apoptosis in the different lesion types there were
no significant differences in Brdu incorporation (p=<0.20 for all groups, Mann
Whitney). Therefore the increases in the levels of apoptosis observed in type I
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lesions is not being counteracted by an increase in proliferation. This consolidates
the view that loss or reduction of apoptosis is important for tumour progression.
9.1.6 Apoptosis in tumours after temozolomide treatment
To investigate whether the gene depenedency of the apoptotic response is retained
in the adenomas, levels of apoptosis 6 hours following temozolomide exposure
were investigated in the lesions ofApcMm/+and (ApcMm/+, Msh2~/~) mice.
Figure 9.8 Apoptosis in lesions from ApcMin/+and (ApcMin/+, Msh2~/~) mice 6
hours following lOOmg/kg temozolomide treatment. Percentage of cells
undergoing apoptosis in temozolomide treated mice. Each bar represents at least 3
mice and error bars represent SD. For each mouse at least 50 normal V2 crypts
were scored, 10 type I (single crypt) lesions, 10 type II lesions and 5 adenomas.


























































In chapter 4, apoptosis post temozolomide treatment was shown to be Msh2-
dependent in normal mucosa. In both normal epithelium and adenomatous tissue
(type III lesion) a reduced apoptotic response was seen following temzolomide
treatment in the (ApcMin/+, Msh2~/~) mice compared to the ApcMm/+ mice (Mann
Whitney p=0.04). This highlights that gene dependency of the apoptotic response
is retained in tumours.
Interestingly, in the small lesions: type I and II, no significant Msh2 dependent
apoptosis was observed (p=<0.2, Mann Whitney). This argues that these small
lesions (which already have high levels of apoptosis) are primed to undergo
apoptosis and thus are exquisitely sensitive to DNA damage.
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9.2 Discussion
Using transgenic mice mutant for the tumour suppressor gene ApcMm/+ and the
DNA mismatch repair gene Msh2, the pattern of P-catenin expression in
neoplasms within the murine intestine has been characterised. It has been shown
that high levels of p-catenin are present in the majority of intestinal lesions, and
that dysregulation of p-catenin is associated with loss of the remaining wild type
copy of Ape, presumably as a direct consequence of perturbation of the Wnt
pathway. Areas showing high levels of P-catenin included those composed of
heterogeneous or single dysplastic crypts in the intestine. Histological atypia was
always observed within these foci in the intestine. Taken together, these findings
show that dysregulated P-catenin expression is an extremely efficient marker of
early neoplastic change in the murine intestine. In fact, it is relatively surprising
that in the intestine, there was no incidences of normal crypts showing over-
expression of P-catenin, especially as it is argued that the number of adenomas in
the ApcMm/+ mice is fixed in utero (Shoemaker et al., 1994, De Wind et al., 1998).
This argues that the time between P-catenin over expression in a 'normal cell' that
has lost Ape and the morphological appearance of a dysplatic cell is relatively
short.
Although p-catenin dysregulation is shown to be a common event here, it is not
absolutely associated with early neoplastic change. Thus, type II lesions were
identified arising in both Msh2~'~ and (ApcMnv+, Msh2~;~) mice which showed
normal levels and distribution of P-catenin. These findings show that dysregulated
p-catenin is not an obligate event in early lesion formation, and furthermore that
Msh2 deficiency predisposes to such apparent p-catenin-independent events. One
explanation for this is that Msh-2 deficiency may predispose to dysplasia through
mutations in other components of the Wnt signalling pathway which do not affect
P-catenin levels. In MMR deficient colorectal tumours mutations have been
found in axin and TCF4 (Duval et al., 1999,). However axin mutations would still
lead to upregulation of P-catenin. In MMR deficient tumours, frequent
frameshifts have been shown in TCF4 in a A(9) tract of the TCF4 gene. These
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produce truncated proteins that lack the c-terminal portion of TCF4 which has
been implicated to be important in repression of |3-catenin/TCF4 transcription.
Once again, this probably only becomes important once p-catenin is over-
expressed. This is highlighted by the synergy between mutations in ApcMm/+ and
Tcfl'1' null mice (mentioned in 1.3.1). Tcfl" mice very rarely develop intestinal
and mammary adenomas, however when they are crossed to Ape + mice, there
is both a much earlier onset and increased frequency of these tumours (Roose et
al, 1999).
Another possible explanation for the lack of upregulation of P-catenin in a subset
of Msh2~'~ and (ApcM,n+/~, Msh2~'~) lesions is that mutations in other pathways can
produce these dysplatic lesions. MMR deficiency increases the likelihood of
mutations occurring within other critical loci. One potential target is the TGFp
pathway, which is important for signalling cellular proliferation and apoptosis.
Loss of DPC4/Smad4, a central mediator of TGFp signalling, has been shown to
occur in a number of colorectal cancers (Vogelstein and Kinzler 1996, Miyaki et
al., 1999). More importantly in HNPCC, mutations in the TGFp RII are relatively
frequent (Akiyama et al., 1997). Indeed one HNPCC family had no obvious
MMR mutation yet had a germline TGFP RII mutation (Lu et al., 1998). This
indicates that dysregulation of this pathway could potentially lead to the dysplatic
crypts. However all small adenomas (type III) were characterised by increased p-
catenin, suggesting that adenoma formation is absolutely associated with changes
which modulate p-catenin levels. This concords with the hypothesis that Ape is
the key intestinal 'gatekeeper' in prevention of malignancy (Vogelstein and
Kinzler 1996)
Taken together, these results show that P-catenin dysregulation is associated with
the early steps in the development of neoplasia. These findings demonstrate that
altered expression of P-catenin is a key marker of Ape dysregulation. However, it
is also shown that P-catenin dysregulation is not an obligate step in the generation
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of intestinal lesions in a Msh2 deficient background, and therefore that other
mechanisms can underlie such early neoplastic change.
The increased levels of cyclin D1 observed in the lesions/adenomas in conjunction
with high expression of P-catenin suggests that the major reason for loss ofApe in
these adenomas is for inappropriate Wnt signalling. Two studies have previously
shown that cyclin D1 is a downstream target ofWnt signalling and one study has
shown that cyclin D1 is overexpressed in adenomas (Zhang et al., 1997). This is
the first in vivo confirmation that in murine intestinal neoplasia that expression of
both p-catenin and cyclin D1 are dysregulated. However this is purely correlative.
One argument against this direct mechanism is that the expression of cyclin D1
may merely be an indicator of the increased proliferation in the dysplatic tissue
rather than any true reflection ofWnt signalling. However as is shown here and
by Oshima et al., (1997), there is no difference in cellular proliferation (as
measured by BrdU incorparation) between normal intestinal epithelium and
adenomatous tissue in the ApcMm/+ mouse. This indicates that the cyclin D1 over-
expression observed in the lesions is not simply a reflection of increased
proliferation in the intestinal lesions and instead more likely represents
dysregulated Wnt signalling.
From other systems, other potential targets of Wnt signalling are C-myc, AP-1,
Tcf4 etc (see 1.4.1). Therefore one would predict that inappropriate Wnt
signalling would cause increased proliferation and/or death. The paradigm for
this is the activity of c-myc which has been shown to induce both proliferation and
apoptosis depending on the cellular context (Evan et al., 1992). Previously Bedi
et al., (1995) showed that there is a relative inhibition of apoptosis when normal
colorectal epithelium is compared to adenoma/adeno-carcinomas. The detailed
analysis of apoptosis performed here shows that this is in fact an over¬
simplification and there is a specific induction of apoptosis in the very small
dysplatic lesions compared to normal epithelium. As the tumour progresses to
adenoma, there is a reduction of apoptosis compared to both normal mucosa and
the dysplatic crypts (type I and II). This is highly indicative that loss of apoptosis
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is important for tumour progression. This also concurs with our understanding of
oncogenes such as c-myc and P-catenin and progression in murine intestinal
neoplasia. Therefore in the small lesions, high abberant expression of p-catenin,
cyclin D1 and possibly c-myc induce apoptosis rather than proliferation as the
cells may still have an intact apoptotic programme. However selection against
apoptosis would select for those cells that lose their apoptotic response and lead to
lesions with lower levels of apoptosis. Again this correlates with the molecular
changes seen in intestinal neoplasia. For example Oshima et al., (1997) showed
that the Tgfpl receptor and TgP receptor II were expressed in microadenomas
(equivalent to lesion I and II) and not in adenomas (type III). This is important as
loss of Tgfp signalling is thought to cause a reduction in apoptosis.
Following damage, p53 is widely acknowledged as a central mediator of the
apoptotic response. It seems unlikely that loss ofp53 plays any role in the loss of
these basal levels of apoptosis from the type I lesion to the type III lesions. The
reason for this is that P53 is generally lost post adenoma stage when apoptosis is
already reduced. Fazeli et al., (1997) showed that there were no differences in the
levels of apoptosis between adenoma and adeno-carcinomas. Similarly p53
dependent apoptosis in the tumours was retained between ApcMin/+ tumours and
(.ApcMm/+, p53'/') tumours following gamma irradiation. This indicates that in
these ApcMm/+ adenomas there is functional p53. Likewise apoptosis following
temozolomide at 6 hours is p53 dependent so if p53 was absent no apoptosis at
this timepoint would be seen. Furthermore, the lack of an obvious increase in
tumourigenesis in (ApcM'n/+, p53~/~) mice compared to the ApcMml+ mice argues that
it is unlikely the spontaneous high levels of apoptosis observed in type I lesions is
dependent on p53. Therefore it would be interesting to investigate whether there
are increased levels of apoptosis in (ApcM'"/~T,p53~/~) type I and II lesions.
When apoptosis was induced following temozolomide, in both the adenomatous
and the morphologically normal epithelium, there was Msh2-dependent apoptosis.
However, in the type I and type II lesions there was no significant Msh2-
dependent apoptosis. This is even more apparent if one takes into account that
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basal levels of apoptosis were lower in type 1 and II lesion arising in the (ApcM,n/+,
Msh2'/') mice. Thus, it could be argued that there would be selection for loss of
Msh2 in untreated type I and II lesions and in intestinal adenomas following
treatment with alkylating agents. In this instance (unlike chapter 4) this fits with
the Tomlinson and Bodmer (1999) argument that loss ofMMR delivers a selective
advantage through loss of apoptosis rather than a mutator phenotype.
This would also suggest that MMR deficient adenomas would not respond as well
to alkylating agents as MMR proficient tumours. However this is assuming that
this induced apoptosis is an important critea for chemotherapy to work. In chapter
5, it was shown that despite having a completely abrogated apoptotic response to
NMNU, p53~'~ mice unlike Msh2~/~ mice did not have an increased clonogenic
survival in the small intestinal epithelium. From the apoptotic data alone, one
would have predicted that Msh2 and p53 deficient tumours would not respond to
alkylating agents, though from the clonogenic data it would have been predicted
that Msh2 deficient tumours would not respond whilst p53 deficient tumours
would. Therefore further experiments are required to see which is the better
indicator of tumour prognosis, apoptosis or clonogenic survival.
Another interesting point raised from the induction of apoptosis in tumours is that
normal intestinal epithelium appeared more sensitive than the adenomatous tissue.
This raises questions on the widely held view that chemotherapy works through
the specific induction of apoptosis in the tumours. Clearly some apoptosis is
occurring in the tumours but this is much less than that occurring in the normal
intestinal epithelium. The level of apoptosis in normal tissue was 30% in normal
tissue compared to 8% in the adenomas. Given that in humans the majority of
colorectal tumours would have lost P53, one would predict that this situation
would be exacerbated. Fazeli et al., (1997) showed that basal levels of apoptosis
in ApcMin/+ adenomas were 2-3% apoptosis compared to approximately 17% after
6 hours after 8 GY gamma irradiation. However there was no induction of
apoptosis at this timepoint in the (ApcM"'/+, p53~/~) lesions following gamma
irradiation. Therefore as normal colorectal epithelium in humans would have
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retained P53, one would predict levels of apoptosis would be far greater in this
normal epithelium following chemotherapy than in colorectal tumours. This
makes it very hard to reconcile that chemotherapy is working via the specific
induction of apoptosis in the neoplastic tissue. In fact it almost appears to be
working in an opposite manner!
In this study temozolomide has been used which is not a treatment of colorectal
cancer and so could explain the lack of a specific induction of apoptosis in the
tumours. However the Fazeli et al., (1997) study used gamma irradiation which is
still one of the principle agents for treating colorectal cancer. Therefore, as was
stated in chapter 5, if treatment was being tailored to p53 status, no colorectal
cancer would be treated with gamma irradiation. These studies have only looked
at apoptosis at one timepoint, thus it possible at later timepoints there could be
elevated levels of apoptosis in the adenomas. Therefore it would be interesting to
score apoptosis at later timepoints following temozolomide treatment in lesions
from ApcMm/+ and (ApcMm+/~, Msh2~'~) mice
Some care should be always be exercised in interpreting the relevance of murine
small intestinal epithelium to human colorectal cancer. However these studies
highlight that apoptosis in intestinal neoplasia is complex and that assessing
whether chemotherapy will work based on whether it induces apoptosis is a gross
over-simplification. It also highlights that we are far from understanding the
mechanism of how many chemotherapeutics works. For example, cisplatin cures
approximately 90% testicular cancers though why it is so successful is still
unknown. Other drugs produce similar lesions, levels of apoptosis and arrest
profiles, yet they do not work as effectively. Therefore although there is now the
technology to genetically profile tumours for many different genes (e.g. by
microarray) as yet informed decisions on whether certain chemotherapeutics will
or will not work from the genetic background of the tumour alone cannot be
made.
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Instead as the ability to specifically inhibit pathways in tumours with less toxic
drugs/gene therapies grows, hopefully this may offer new treatments. Examples of
these include the inhibition of Cox-2 (cyclo-oxygenase 2) in colorectal tumours by
selective Cox-2 inhibitors (which I will discuss in the next chapter) and deletion of
P53 null cells using ONYX015 adenovirus which replicates in P53 deficient cells.
None of these rely on potentially false assumptions concerning apoptosis,
proliferation and resistance.
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Chapter 10: Suppression of intestinal and mammary neoplasia by




During the course of this thesis the difficulties of translating apoptosis to long term
measures of survival have been discussed. NSAIDS (Non-Steroidal Anti
Inflammatory Drugs) such as aspirin and sulindac have also been shown to induce
apoptosis (Chen et al., 1999, Stark et al., 2001). Unlike the cytotoxic agents
(temozolomide, cisplatin and nitrogen mustard) used, these NSAIDS do not elicit
DNA damage and thus are not as carcinogenic or toxic to patients. This allows
potential for chemoprevention with these agents in addition to chemotherapy.
Importantly, NSAIDS have been shown to down regulate pathways that are
dysregulated in colorectal cancer, thus raising the hope of treatment targeting
tumours specifically. These targets down regulated by NSAIDS include P-catenin
(shown to be upregulated in the last chapter), PPAR delta (a target of Wnt
signalling), and Cox2 (upregulated in adenomas in the ApcM'"/+ mouse). In addition
Ruschoff et al., (1999) showed that aspirin and sulindac may delete cells that exhibit
MSI, again which should preferentially kill tumour cells. Therefore given that there
was still confusion over the role for aspirin in suppression of intestinal
tumourigenesis in the mouse, it seemed an ideal agent to test whether it could
suppress intestinal neoplasia in ApcMm,+ and (ApcM'n/+, Msh2~'~) mice
Substantial epidemiological evidence shows that treatment with NSAIDS reduces the
risk of developing colorectal cancer. The most commonly used NSAID has been
aspirin, which has been reported to reduce the risk of colon cancer by up to 40%.
Clinical studies using the NSAID sulindac have also reported reduced polyp counts
in FAP patients (Thun et al., 1991, Giardiello et al., 1993). The precise mechanism
of NSAID action remains unclear, although the suppression of cyclooxygenase 2
(Cox2) is thought to be of pivotal importance. Significantly, Cox2 is over-expressed
in approximately 85% of human colorectal adeno-carcinomas and adenomas from
the ApcM'"/+ mouse (Eberhart et al., 1994, Williams et al., 1996, Williams et al.,
1999). The definitive study highlighting the relevance of Cox2 to tumourigenesis
showed that a Cox2 deficient background markedly suppressed intestinal neoplasia
£7 1 r
in mice carrying the Ape allele (Oshima et al., 1996).
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The biological activities of aspirin and sulindac are not restricted to suppression of
the Cox2 pathway. This is exemplified by the fact that both sulindac metabolites
(sulindac sulfide and sulindac sulfone) have been shown to inhibit animal models of
tumourigenesis, even though only sulindac sulphide inhibits COX2 (Piazza et al.,
1997). However it must be added that of the two sulindac metabolites sulindac
sulfide is the most effective at tumour suppression.
Aspirin, sulindac and even the selective Cox2-inhibitor celecoxib have been shown
to induce apoptosis in a Cox2 independent fashion (Williams et al., 2000). Both
aspirin and sulindac down regulate beta-catenin and beta-catenin/ TCF4 mediated
transcription (Mamhood et al., 1998a, 1998b, McEntee et al, 1998, Dihlmann et al.,
2001). They have also been shown to specifically reduce the survival of genetically
unstable (MSI+) MMR deficient colorectal cancer cell lines (Ruschoff et al., 1998),
raising the possibility that aspirin may also suppress malignancy in HNPCC families
characterised by mutations in the MMR genes.
Mice constitutively heterozygous for the ApcMm allele have been used to determine
the ability of the NSAIDs to suppress intestinal malignancy. However with respect to
aspirin, these studies have produced contrasting results. Virtually every study (e.g.
Beazer-Barclay et al., 1996, Mamhoud et al., 1998b) has shown that sulindac causes
a reduction in the number of the spontaneous malignancies (apart from Oshima et al,
1996) who used a relatively low levels of sulindac). However, of the studies that have
investigated spontaneous intestinal malignancy following aspirin treatment, only two
have shown suppression of malignancy in the ApcMm/+ mouse. Two further studies
failed to show suppression in either the ApcMm/+ mouse or the Apc,638N mouse
(Mamhoud et al, 1998a, Barnes and Lee 1998, Williamson et al., 1999, Chiu et al,
2000). The basis for these discrepancies may lie within differences in the aspirin
regime used. Shoemaker et al, (1995) and Reitmair et al, (1996) have argued that
the majority of adenomas are fixed either in utero or perinatally just after birth.
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Here to directly test this, the period of aspirin exposure was increased to include the
entire period from the point of conception onwards. Furthermore whether this regime
could modify the development of MMR associated neoplasia was also tested by




10.1.1 Aspirin does not suppress intestinal neoplasia when administered at
weaning
Wild type and ApcM,n/+ mice were placed on aspirin containing diets (either
200mg/kg and 400mg/kg) at weaning. Mice exposed to the aspirin diet gained weight
normally when compared to mice on the control diet and no ulceration or intestinal
pathology such as perforation of the intestine was observed in any of the wild type
mice treated with aspirin. Two independent analyses were performed.
First, cohorts of mice either wild type or heterozygous for the ApcM"' allele were
killed at 150 days of age and the adenoma burden assessed on whole mount
preparations of the entire small intestine. No adenomas were seen in wild type mice.
Adenoma burden was as follows: for mock treated ApcM,n/+ mice (n=5) 9.8 (+/- 6.3);
mice treated with 200mg/kg (n=7) 9.7 (+/- 5.88) ; for mice treated with 400mg/kg of
aspirin (n=5) 8.2 (+/- 6.05). There was no difference in tumour burden at either
200mg/kg (p=1.00) or at 400mg/kg (p=0.75 Mann Whitney) compared to mock
treated mice, indicating that aspirin exposure was not modifying the ApcMm/+
phenotype
Second, cohorts of mice were permitted to age until they developed obvious
symptoms of intestinal neoplasia, usually bleeding from the anus or anaemia scored
through whitening of the feet.
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Fig 10.1 Kaplan Meier plot of survival of ApcM,n/+ exposed to control or aspirin
containing diet. Black line, mock treated mice (n=15); red line, 200mg/kg diet (n=
12); blue line, 400mg/kg of diet (n=10). There was no significant difference in the
survival curves of either the mice treated with 200mg/kg (Log Rank p= 0.96) and
400mg/kg (Log rank p=0.30).
Green line, ApcMm/+ mice exposed to aspirin containing diet aspirin from point of
conception. These mice (n=16) showed a significant increase in survival (Log rank,
p= 0.0004) compared to mock treated and aspirin treated mice at weaning.
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Figure 10.1 shows a Kaplan Meier plot reflecting survival over a 400 day period.
Exposure to aspirin at either 200 mg/kg or 400 mg/kg did not alter the survival
profile, again indicating that exposure to aspirin did not modify the ApcMm
phenotype.
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10.1.2 Aspirin suppresses intestinal neoplasia when administered in utero
As Shoemaker et al., (1995) and Reitmair et al., (1996) have argued that the
majority of adenomas are fixed before 6 days of age, the effect of aspirin exposure
throughout embryogenesis and weaning was investigated. Cohorts of wild type and
ApcMm'+ heterozygotes were derived from parents placed on aspirin containing diet
prior to conception. Dietary exposure to aspirin was maintained throughout and
beyond weaning. First it was investigated whether in utero exposure resulted in
increased embryonic lethality ofApcM"'/+ heterozygotes, as has been reported for the
Cox 1 and Cox2 inhibitor piroxicam (Jacoby et al., 2000). Analysis of offspring
showed this not to be the case, as there was no reduction in the number of ApcMm +
heterozygotes in progeny from Aspirin exposed parents (p=0.2, Chi-squared test).
Figure 10.2: Numbers of mice from ApcMm/+ crosses to wild type mice.
Apcmn/+ Wild type
Untreated 99 100
In Utero exposure 50 63
The survival profiles of each cohort were then determined (figure 10.1), they showed
a significant increase in survival in ApcMm/+ heterozygotes exposed to aspirin from
conception onwards (p=0.0004, Log Rank test). This effect was sufficient to
completely prevent the development of symptoms associated with intestinal
neoplasia in 5/16 ApcMm at 500 days of age. Analysis of tumour burden and
distribution in those mice that developed intestinal tumours showed no obvious
differences (figure 10.3).
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Figure 10.3: Tumour burden ofApcMin/+ mice. Tumour burden at point of sacrifice
as determined by onset of overt symptoms of intestinal tumourigenesis. Black bars,
mock treated mice; open bars, mice treated with 200mg/kg; grey bars, mice treated
with 400mg/kg of aspirin at weaning; and blue bars, mice treated with 400mg/kg of
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There was no significant difference in the number of tumours at sacrifice between
mock exposed mice (n=15) and mice exposed to 400mg/kg from conception (Mann
Whitney p=0.613) (n=9). Tumour burden of mice aged over 500 days old were
excluded from this analysis as these mice were killed when symptomatic of
lymphoma and not intestinal neoplasia.
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10.1.3 Aspirin weakly suppresses neoplasia though not mutation in Msh2_/" mice
Having established an effective protocol for aspirin exposure in the murine model of
FAP, it was determined if this approach could modulate the phenotype of the murine
model of HNPCC. A significant subset of human intestinal tumours are characterised
by mutations in the MMR pathway, and all murine models ofMMR deficiency show
increased predisposition to neoplasia.
Cohorts of Msh2~/~ mice were either exposed to aspirin or were fed control diet from
conception and Kaplan Meier survival curves generated (figure 2A). All eighteen
animals on the control diet were killed following the development of lymphoma,
although two animals also had co-existent intestinal malignancy. All Msh2" mice
exposed to aspirin also developed lymphoma, however there was a small increase in
survival compared to controls (p=0.05, Log Rank). This slight shift in survival may
reflect weak suppression of either intestinal malignancy or lymphomagenesis. This
latter possibility is consistent with the one report that showed aspirin exposure can
result in the deletion ofMSI unstable cells in culture (Ruschoff et al., 1998).
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Figure 10.4 Kaplan Meier plot of survival of Msh2~/~ mice exposed to control or
aspirin containing diet from point of conception. Solid black line, mock treated
Msh2~/~ mice (n=18); red hatched line, 400mg/kg treated Msh2'/' mice (n=20).
Msh2~'~ mice treated with aspirin showed a weak increase in survival (Log rank
p=0.05).
0 100 200 300
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These results prompted the investigation whether aspirin exposure could suppress in
vivo mutation in a mismatch repair deficient background. Mutation frequency was
scored at the dolichos biflorus (Dlb-lb) locus in Msh2 mutant mice continually
exposed to either control or aspirin containing diets. Using this assay, we have
previously shown that Msh2 deficient mice have a mutator phenotype at the Dlb-lb
locus. Msh2 deficient mice were analysed at 4 months of age following exposure to
either control or aspirin containing diet. No difference in mutation frequency was
observed at this time point, demonstrating that this regime of aspirin exposure does
not modify the mutator phenotype ofMsh2 null epithelium (figure 10.5).
?.?.o
Figure 10.5: in vivo mutation frequency per 10000 villi at the Dlb-lb locus after
aspirin treatment. Mutation frequencies were determined from intestinal
wholemounts at 4 months of age. Columns represent mean mutation frequency at the
Dlb-lb locus. At least 3 mice were used per each column. Error bars represent SD.
Black bar, mock treated wild type mice; open bar, mock treated Msh2~/~ mice; grey
bar, Msh2~/~ mice exposed to 400mg/kg of dietary aspirin from point of conception.
There was not a significant reduction in mutation frequency after aspirin treatment
(p= 0.77, Mann Whitney)
10.1.4. Aspirin supresses intestinal and mammary neoplasia in ApcM,n/+ Msh2'/'
mice
In human colorectal cancer MMR deficient tumours differ in a number of respects to
MMR proficient tumours. For example, MMR deficient tumours express lower levels
of Cox2 (Karnes et al., 1998) as well as exhibiting very different patterns of mutation
and genomic instability. These differences invoke different mechanisms for MMR
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driven neoplasia, raising the possibility that aspirin exposure may have an additional
effect in a MMR deficient background, for example through the deletion of cells
showing MSI.
The development of lymphoma in Msh2~/~ mice largely precludes an analysis of the
effect of aspirin upon Msh2 dependent intestinal neoplasia (De Wind et al., 1995).
However, Msh2 deficiency has been shown to greatly accelerate intestinal neoplasia
in the ApcM'" mouse (Reitmair et al., 1996), so permitting an analysis of the effect of
aspirin in this context. In addition mammary akanthoma occur in ApcMm/+ mice
(Moser et al., 1993) and this is greatly accelerated in (ApcMin/+, Msh2~/') mice,
permitting a study of the effect of aspirin on the development of this lesion (see
below). Cohorts of (ApcMl +, Msh2") mice were generated and exposed to either
control diet or aspirin containing diet from conception onwards and Kaplan Meier
survival curves generated (figure 10.6). Survival was markedly enhanced following
aspirin exposure (Log Rank p=0.0001), although still reduced by comparison to
untreated ApcMm heterozygotes. Aspirin exposure did not alter either tumour
distribution or burden scored at the point of death.
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Figure 10.6. Kaplan Meier plot of survival of ApcMml+ MshTA mice exposed to
control or aspirin containing diet from point of conception. Solid black line,
mock treated mice (n=43); Red hatched line, mice treated with 400mg/kg from




In the cohorts maintained on control diet, a single mammary akanthoma was
observed in a total of 15 ApcM,n/+ mice, whilst none were detected in 18 Msh2''~ mice.
Development of this tumour type was enhanced in ApcMin/+ Msh2~/~ mice (11 tumours
in 41 mice). In the cohorts exposed to aspirin, no mammary akanthomas were
observed in 10 ApcMm/+ mice, whilst a single akanthoma was observed in 21 Msh2~/~
mice. In the (ApcM,n/+, Msh2~'~) cohort, 5 mammary akanthomas were observed in 20
mice. All of these mice also had intestinal neoplasia. Although this represents a
similar prevalence to that observed in the untreated (ApcMm/+ , Msh2~/~ ) cohort, the
onset of akanthoma was significantly retarded in the aspirin treated mice (figure
10.7)
Figure 10.7. Graph showing delayed incidence of mammary tumourigenesis in
the (ApcMin/+, Msh2~/~) mice. Blue line, mock treated mice, Grey line, mice treated
with 400mg/kg of aspirin treatment from conception. Inset picture of mammary
akanthoma with large keratin whorls.
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10.2 Discussion
Over the past 10 years there has been great excitement at the possibility of
chemoprevention by NSAIDS. However, contradictory results have been obtained
from 4 different analyses using aspirin in the ApcMm murine models of intestinal
neoplasia (Mamhoud et ah, 1998a, Barnes and Lee 1998, Williamson et ah, 1999,
Chiu et al., 2000), where aspirin was only observed to suppress tumorigenesis in 2
studies (Mamhoud et al., 1998a, Barnes and Lee 1998).
A number of different possibilities may underlie the discrepancies between the
published studies examining the effect of aspirin on ApcMm associated
tumourigenesis. First, as a consequence of differences in the level of aspirin
exposure, a possibility which seems unlikely given the similar levels used in each
experiment. Second, due to differences in the genetic background of the mice used,
either at known modifiers of the ApcM,n/+ phenotype such as Mom-1 or at as yet
unidentified modifiers (Cormier et ah, 2000). In this respect, it is notable that this
study differs from previous studies by using mice homozygous for the relatively
resistant C57/B16 Mom-1 allele. Third, as a consequence of different husbandry
regimes; for example, mice housed in a sterile facility may respond very differently
to those in a non-sterile facility.
Comparison of the data presented here with published experiments does not permit
which of these possibilities are true, but does serve to underline the relatively fragile
nature of aspirin mediated suppression within this model. Here it is shown that one of
the key modifiers of the effectiveness of aspirin is the timepoint of exposure. By
increasing the period of dietary exposure to include in utero and perinatal exposure
we have dramatically enhanced the ability of aspirin to modify the ApcMm/+
phenotype. Within our experimental design, this enhancement is particularly notable
given the failure to observe any effect in the ApcM,n/+ cohort treated post-weaning.
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These findings are consistent with the presence of a developmental 'window' for
adenoma formation either in utero or shortly after birth. In support of this,
Shoemaker et al., (1994) showed that perinatal exposure to chemical carcinogens
specifically enhances intestinal tumour development in the adult. One possible
explanation for this phenomenon is the huge expansion in the number of intestinal
crypts which occurs three weeks after birth. This process of crypt fission inevitably
expands the number of any mutation-bearing crypts present within the intestine and
may therefore clonally expand any crypts bearing mutations at the Ape locus.
The presence of a very early 'window' for neoplastic development raises serious
questions about our understanding of Hpc-mediated tumorigenesis. Loss of Ape
function is considered to be the key initiating event in intestinal neoplasia and is
strongly associated with both dysplasia and dysregulation of P-catenin (e.g.
Kongkanuntn et al., 1999). However these phenomena are simply not observed in
mice aged less than four weeks, indicating either that loss ofApe alone is insufficient
to lead to the upregulation of p-catenin and development of dysplasia, or that loss of
Ape (and thereby dysregulation of P-catenin) occurs as a secondary event. In this
regard it has previously been shown that a proportion of dysplasias occurring in a
mismatch repair deficient background are not characterised by increased beta-catenin
levels (Kongkanuntn et al., 1999).
Aspirin clearly acts to suppress these early events either by deleting or suppressing
the phenotype of those cells which carry an increased predisposition to adenoma
formation. This seems unlikely to be through modulation of /Tcatenin levels, as has
been suggested by Mahmood et al., (1998a, 1998b), because, as stated above,
elevated levels of /Tcatenin are not observed in young animals. A second possibility
is that aspirin may suppress neoplasia through a Cox2 mediated pathway. Cox2
upregulation is observed in 80-85% of human colorectal carcinomas, 50% of
colorectal adenomas and within tumours arising in the ApcMm model (Williams et al.,
1996). However, it seems unlikely that the primary effect of in utero aspirin exposure
is mediated through Cox2 suppression, as Cox2 overexpression is associated with the
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later stages of tumorigenesis by modulating angiogenesis and levels of apoptosis
within tumours (Tsujii and Dubois 1995, Tsujii et al., 1998).
Whatever the mechanism of action of aspirin, these studies demonstrate that
initiation of adenoma formation occurs very early in the ApcM"' mouse and that
aspirin exposure at this time point can efficiently suppresses this process.
Given aspirins reported ability to down regulate p-catenin in tumours, the effect of
single high dose aspirin is currently being investigated. In the last chapter it was
shown that P-catenin upregulation occurs at very early stages of intestinal neoplasia
in the ApcMinJ+ mice. Therefore in a similar study to the previous chapter, the effect
of aspirin upon apoptosis and cell cycle (via BrdU incorporation) in both normal
intestine and intestinal lesions is being performed. This could raise the possibility
that NSAIDs could work in chemotherapy as well as chemoprevention.
Aspirin also delayed tumourigenesis in Msh2~f~ background (albeit weakly), and in
the (ApcMin/+, Msh2~/') mice. Overall, the median lifespan of mock exposed ApcMm/+
mice was 175 days compared to 330 days of aspirin treated mice, an increase of 89%
or 155 days. The comparable figures for the (ApcM,n/+, Msh2~/~) cohort are 98 days
(mock treated) and 127 days (exposed), an increase of 29% or 29 days. This
comparison suggests that the effect of aspirin was no greater in the
(ApcMin/+, Msh2'/") background. Taken together with the weak effect of aspirin on
survival of Msh2~/~ mice and the failure to observe an influence of aspirin upon
mutation rate, these data argue that aspirin specifically suppresses tumourigenesis in
an Ape dependent manner. This conclusion contrasts the observation that in vitro
aspirin can delete cells characterised by MSI (Ruschoff et al., 1998). This
contradiction may be explained by the surprising fact that adenomas developing in
(.ApcMin/+, Msh2~/~) mice do not show microsatellite instability (Reitmair et al., 1996a,
1996b). This demonstrates that gross microsatellite instability is not required to drive
adenoma formation in this background, possibly because of the high selective
pressure for adenoma formation consequent upon the ApcMm mutation. Thus,
somewhat paradoxically, cells within the (.ApcMin/+, Msh2'/') mice do not exhibit gross
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levels of MSI and therefore are not available as targets for aspirin mediated deletion.
The weak suppression of lymphomagenesis on the Msh2~/~ background could also
reflect the fact that only 50% of Msh2~'~ lymphomas show MSI (see chapter 6). This
is in contrast to intestinal tumours from HNPCC patients, where all tumours show
MSI. Thus there is still the possibility that NSAIDS could work even more
effectively on these tumours with MSI.
In addition to suppressing intestinal neoplasia, aspirin exposure also significantly
delays the onset of mammary tumorigenesis in the {ApcM,n/+, Msh2~/~) mice. This is
consistent with several recent studies, which have shown that both mutation of Ape
and over-expression of Cox2 can lead to mammary neoplasia (Liu et al., 2001), and
furthermore that selective Cox2 inhibitors can suppress rodent mammary
tumourigenesis (Alshafie et al., 2000). At present pancreatic neoplasia is being
scored in these ApcMm/+ and (ApcKUn/+, Msh2~/~) mice to see whether this is also
delayed (Clarke et al., 1995). This raises the possibility that NSAIDS could be
effective on a range of different tumours with Ape mutations and upregulation of
Cox2.
In summary, it has been shown that dietary aspirin exposure can suppress
tumourigenesis in the murine intestine and the mammary gland. This effect appears
to be specifically associated with loss of function ofApe and appears to only weakly
modify the MMR phenotype. Critically, in the intestine suppression only becomes
apparent if exposure covers the period between conception and weaning. Obviously,
prophylactic treatment with aspirin of FAP patients during this window would be
inappropriate due to the well-known deleterious side effects of aspirin. This therefore
identifies a potential window of opportunity for the chemoprevention of intestinal
neoplasia. The challenge will now to establish whether NSAIDS (other than aspirin)
can be therapeutically effective within this window.
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Chapter 11: Summary
This section gives a brief overview of the main conclusions of this thesis.
First, that apoptosis following DNA damage is dependent on a number of genes. I
have shown that this gene dependent apoptosis is agent type specific and in some
circumstances dose dependent. The levels of the reduction in apoptosis in the
knockout mice are again gene dependent. For example, loss of p53 virtually
abrogates the immediate wave of apoptosis, whilst loss ofMsh2 can cause a much
smaller reduction. Similarly, the kinetics of the apoptotic response differ with a
delayed wave of apoptosis observed in the p53~' nulls, but not in the other singly
mutant mice.
Second, that the loss of a particular gene dependent apoptosic response does not
necessarily lead to increased long term survival nor increased mutation
accumulation. Again this appears agent type specific. I have shown that loss of
Msh2 in vivo causes reduced apoptosis, increased survival and mutation following
alkylation damage. This agrees with the simple hypothesis that loss of apoptosis
causes long term accumulation of mutant cells that can predispose to malignancy.
Flowever this is very much the exception to the general trend whereby failure to
engage apoptosis does not predict either survival or mutation accumulation. One
example of this is that loss of Mbd4'f' causes both a reduction in the apoptotic
response to cisplatin and enhanced long term survival, yet it does not increase
mutation accumulation. Therefore a central conclusion of this thesis is that failure
to engage apoptosis cannot be used as a direct predictor of long term cell fate.
Third, that a reduction in apoptosis correlates with progression of intestinal
neoplasia in the ApcM"'/+mouse. However this relationship is more complicated
than first reported by Bedi et al., (1995), with small single crypt (type I) lesions
showing increased levels of apoptosis compared to normal epithelium. This
therefore supports the widely believed hypothesis (which in fact has little direct
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evidence to support it) that loss of the apoptotic response is an important factor in
tumour progression.
Fourth, that gene dependency of the apoptotic response is retained within tumours.
This has clear ramifications for treatments that are thought to work by engaging
apoptosis, given the high frequency ofp53 mutations in colorectal cancer and poor
understanding of how precisely chemotherapy works. From the data presented
here it seems that we are still faced with a significant challenge in understanding
the response of a system (e.g. a tumour) in terms of individual cellular responses
(e.g. apoptosis). Thus, although the development of new therapies based on single
gene functions appear potentially very logical, the need to understand basic
tumour biology still persists.
Finally, the ApcMin/+ and the (ApcM",/+, Msh2~/~) murine models of intestinal
malignancy were used to test the efficacy of aspirin for chemoprevention. Aspirin
was shown to dramatically suppress intestinal malignancy when adminstered in
utero. Given aspirin's reported ability to down regulate [3-catenin and the findings
reported here linking high P-catenin expression with apoptosis, it will be of great
interest to determine whether aspirin mediates its effect through gene dependent
apoptosis (Mamhoud et al., 1998a).
230
12.0 References
Acharya S, Wilson T, Gradia S, Kane MF, Guerrette S, Marsischky GT, Kolodner R, Fishel R (1996).
HMSF12 forms specific mispair-binding complexes with F1MSH3 and HMSH6. Proc. Natl. Acad. Sci.
USA, Vol.93, No.24, pp. 13629-13634
Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, Howell SB., (1997). Resistance to cytotoxic
drugs in DNA mismatch repair-deficient cells. Clinical Cancer Research, 3 (10): 1763-1767
Agarwal ML, Agarwal A, Taylor WR, Stark GR (1995). p53 controls both the G(2)/M and the G(l)
cell-cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad.
Sci. USA, 92: 8493-8497
Alani E (1996). The Saccharomyces-cerevisiae MSH2 and MSH6 proteins form a complex that
specifically binds to duplex oligonucleotides containing mismatched DNA-base pairs. Molecular And
Cellular Biology, 16 (10): 5604-5615
Alani E, Chi NW, Kolodner R (1995). The saccharomyces-cerevisiae MSH2 protein specifically binds
to duplex oligonucleotides containing mismatched dna-base pairs and insertions. Genes &
Development, 9 (2): 234-247
Alani E, Sokolsky T, Studamire B, Miret JJ, Lahue RS (1997). Genetic and biochemical analysis of
Msh2p-Msh6p: Role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair
recognition. Molecular And Cellular Biology, 17 (5): 2436- 2447
Akiyama Y, Iwanaga R, Saitoh K, Shiba K, Ushio K, Ikeda E, Iwama T, Nomizu T, Yuasa Y (1997)
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary
nonpolyposis colorectal cancer. Gastroenterology 112: 33-39
Akiyama, Y., Nagasaki H, Yagi, KO, Nomizu T., Yuasa, Y (2000). |3-catenin and adenamatous
polyposis coli (APC) mutations in adenomas from heriditary non-polyposis colorectal cancers. Cancer
letters 157: 185-191
Allay E, Veigl M, Gerson SL (1999). Mice over-expressing human 0(6)alkylguanine-DNA
alkyltransferase selectively reduce 0(6)methylguanine mediated carcinogenic mutations to threshold
levels after N-methyl-N-nitrosourea. Oncogene. 18: 3783-3787
Alshafie GA, Abou-Issa HM, Seibert K, Harris RE (2000). Chemotherapeutic evaluation of Celecoxib,
a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncology reports. 7 (6): 1377-1381
231
Andrew SE, McKinnon M, Cheng BS, Francis A, Penny J, Reitmar AH, Jirik FR(1998). Tissues of
MSH2- deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proc.
Natl. Acad. Sci. USA, 95 : 1126-1130
Andrew SE, Xu XXS, Baross-Francis A, Narayanan L, Milhausen K, Liskay RM, Jirik FR, Glazer PM
(2000). Mutagenesis in PMS2-and MSH2-deficient mice indicates differential protection from
transversions and frameshifts. Carcinogenesis 21: (7) 1291-1295
Aquilina G, Ceccotti S, Martinelli S, Hampson R, Bignami M (1998). N-(2-chloroethyl)-N'-
cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Research, 58:
135-140
Arai N, Nomura D, Yokota K, Wolf D, Brill E, Shohat O, Rotter V (1986). Immunologically distinct
p53 molecules generated by alternative splicing. Mol. Cell. Biol. 6: 3232-3239.
Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995). High-frequency developmental
abnormalities in /?J3-deficient mice. Current. Biology, 5: 931-936
Attardi LD, Jacks T (1999). The role of p53 in tumour suppression: lessons from mouse models.
Cellular AndMolecular Life Sciences, Vol.55, No. 1: 48-63
Bader S, Walker M, Heindrich B, Bird A, Bird C, Hooper M, Wyllie A (1999). Somatic frameshift
mutations in the MBD4 gene of sporadic colon cancers with mismatch repair deficiency. Oncogene, 18:
8044-8047
Bader S, Walker M, Harrison D (2000) Most microsatellite unstable sporadic colorectal carcinomas
carry MBD4 mutations. British Journal ofCancer, 83: 1646-1649
Baker SM Bronner CE, Zhang L, Plug AW, Robatzek M, Warren G, Elliott EA, Yu JA, Ashley T,
Arnheim N, Flavell RA, Liskay RM (1995). Male-mice defective in the DNA mismatch repair gene
PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell, 82 (2): 309-317
Baker SM, Plug AW, Prolla TA, Bronner CE, Harris AC, Yao X, Christie DM, Monell C, Arnheim N,
Bradley A, Ashley T, Liskay RM (1996) Involvement of mouse MLH1 in DNA mismatch repair and
meiotic crossing-over, Nature Genetics, 13 (3): 336-342
Baker SM, Harris AC, Tsao JL, Flath TJ, Bronner CE, Gordon M, Shibata D, Liskay RM (1998).
Enhanced intestinal adenomatous polyp formation in Pms2(-/-); Min mice. Cancer Research, Vol.58:
1087-1089
232
Barnes CJ, Lee M (1998). Chemoprevention of spontaneous intestinal adenomas in the adenomatous
polyposis coli Min mouse model with aspirin. Gastroenterology 114 (5): 873-877
Bates S and Vousden KH (1996). p53 signalling in checkpoint arrest or apoptosis. Current opinion in
Genetics and Development 6: 12-19
Bawa S, Xiao W (1997). A mutation in the MSH5 gene results in alkylation tolerance. Cancer
Research, 57: 2715-2720
Baylin SB, Herman JG (2000). DNA hypermethylation in tumorigenesis - epigenetics joins genetics.
Trends in Genetics, 16 (4): 168-174
Bean CL, Bradt CI, Hill R, Johnson TE, Stallworth M, Galloway SM (1994). Chromosome aberrations;
persistence of alkylation damage and modulation by 06-alkylguanine-DNA-alkyltransferase, Mutation
Research, 307: 67-81.
Bearss, DJ, Subler, MA, Hundley, JE, Troyer, DA, Salinas, RA, Windle JJ (2000). Genetic
determinants of response to chemotherapy in transgenic mouse mammary and salivary tumours.
Oncogene 19: 1114-1122
BeazerBarclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, Kinzler KW (1996).
Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis. 17(8): 1757-1760
Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR,
Jones RJ (1995) Inhibition Of Apoptosis During Development Of Colorectal-Cancer. Cancer Research
55: (9) 1811-1816
Behrens J, von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, and Birchmeier W(1996).
Functional interaction of b-catenin with the transcription factor LEF-1. Nature 382:638-642
Behrens J, Jerchow BA, Wurtele M, Grimm J, Asbrand C, Wirtz R, Kuhl M, Wedlich D,Birchmeier W
(1998). Functional interaction of an axin homolog, conductin, withbeta-catenin, APC, and GSK3beta.
Science 280:596-599
Beinhauer JD, Hagan 1M, Hegemann JH, Fleig U (1997). Mal3, the fission yeast homologue of the
human APC-interacting protein EB-1 is required for microtubule integrity and the maintenance of cell
form. J Cell Biol 139:717-728.
233
Bellacosa A, Cicchillitti L, Schepis F, Riccio A, Yeung AT, Matsumoto Y, Golemis EA, Genuardi M,
Neri G (1999). MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA
mismatch repair protein MLH1. Proc. Natl. Acad. Sci. USA. 96: 3969-3975
Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC (1996). p53 mutations as a possible predictor
of response to chemotherapy in metastatic colorectal carcinomas. International Journal OfCancer 69:
190-192
Berardini M, Mazurek A, Fishel R (2000). The effect of O-6-methylguanine DNA adducts on the
adenosine nucleotide switch functions of hMSH2-hMSH6and hMSH2-hMSH3. Journal of Biological
Chemistry. 275: 27851-27857
Bertrand P, Tishkoff DX, Filosi N, Dasgupta R, Kolodner RD (1998) Physical interaction between
components of DNA mismatch repair and nucleotide excision repair. Proc. Natl. Acad. Sci. USA 95:
(24) 14278-14283
Bienz, M (1999). APC: The plot thickens. Current Opinions in Genetics and Development 9: 595-603
Bignami M, O'Driscoll M, Aquilina G, Karran P (2000). Unmasking a killer: DNA O-6-methylguanine
and the cytotoxicity of methylating agents. Mutation Research-Reviews In Mutation Research. 462: (2-
3)71-82
Bilger A, Shoemaker AR, Gould KA, Dove WF (1996). Manipulation of the mouse germline in the
study of A//«-induced neoplasia. Seminars in Cancer Biology. 7: 249-260
Bird AP (1986). CpG-Rich Islands And The Function Of DNA Methylation. Nature 321 209-213
Bird A (1992). The Essentials of DNA Methylation. Cell 70: (1) 5-8
Bosari S, Viale G (1995). The Clinical-Significance Of P53 Aberrations In Human Tumors. Virchows
Archiv-An International Journal OfPathology. 427. 229-241
Bouffler, SD, Kemp CJ, Balmain A, Cox R (1995). Spontaneous and ionizing radiation-induced
chromosomal abnormalities in/?53-deficient mice. Cancer Research. 55: 3883-3889.
Boyes J, Bird A (1992) Repression Of Genes By Dna Methylation Depends On CPG Density And
Promoter Strength - Evidence For Involvement Of A Methyl-CPG Binding-Protein. EMBO Journal,
11: 327-333
234
Boynton R, Blout P, Yin J, Brown V, Huang Y, Tong Y, McDaniel T, Newkirk C, Resau J, Raskind
W, Haggitt R, Ried B, Meltzer S (1992). Loss of heterozygosity involving the APC and MCC genetic
loci occurs in the majority of human esophageal cancers. Proc. Natl. Acad. Sci,. USA 89: 1-4.
Bradford MM (1976). A rapid and sensitive method for the quantification of micogram quantities of
protein using the principle of protein-dye binding. Analytical Biochemistry, 72: 248-254.
Branch P, Masson M, Aquilina G, Bignami M, Karran P (2000). Spontaneous development of drug
resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells .Oncogene.
19: 3138-3145
Brown JM, Wouters BG (1999). Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer
Research 59 :1391-1399
Brown R, Hirst GL, Gallagher WM, Mcllwrath AJ, Margison GP, vanderZee AGJ, Anthoney DA
(1997). hMLHl expression and cellular responses of ovarian tumour cells to treatment with cytotoxic
anticancer agents. Oncogene .15 45-52.
Bubb VJ, Curtis LJ, Cunningham C, Dunlop MG, Carothers AD, Morris RG, White S, Bird CC, and
Wyllie AH (1996). Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer.
Oncogene 12:2641-2649
Buermeyer, A.B., Deschennes, S.M., Baker, S.M., Liskay, R.M., (1999) Mammialian DNA mismatch
repair. Annual Review ofGenetics. 33 :533-564
Buermeyer AB, Wilson-Van Patten C, Baker SM, Liskay M (1998b). The human MLH1 cDNA
complements DNA mismatch repair defects in Mlhl-deficient mouse embryonic
fibroblasts. Cancer Research, 59: 538-541
Buettner VL, Hill KA, Nishino H, Schaid DJ, Frisk CS, Sommer SS (1996). Increased mutation
frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53 Big
Blue double transgenic mice, Oncogene, 13: 2407-2413
Buettner VL, Nishino H, Haavik J, Knoll A, Hill K, Sommer SS (1997). Spontaneous mutation
frequencies and spectra in p53 (+/+) and P53 (-/-) mice: A test of the 'guardian of the genome'
hypothesis in the Big Blue(R) transgenic mouse mutation detection system. Mutation Research-
Fundamental And Molecular Mechanisms Of Mutagenesis, 379: 13-20
235
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang YG, Dillehay L, Williams J, Lengauer C, Kinzler
KW, Vogelstein B (1999). Disruption of p53 in human cancer cells alters the responses to therapeutic
agents. Journal OfClinical Investigation. 104 : 263-269
Cai WB, Roberts SA, Bowley E, Hendry JH, Potten CS (1997). Differential survival of murine small
and large intestinal crypts following ionizing radiation. International Journal Of Radiation Biology,
Vol.71: 145-155
Carder PJ, Wyllie AH, Purdie CA, Morris RG, White S, Piris J, Bird CC (1993). Stabilised p53
facilitates aneuploid clonal divergence in colorectal cancer. Oncogene 8: 1397-1401.
Cascalho M, Wong J, Steinberg C, Wabl M (1998). Mismatch repair co-opted by hypermutation.
Science, 279: 1207-1210
Chan TL, Curtis LC, Leung SY, Farrington SM, Ho JWC, Chan ASY, Lam PWY, Tse CW, Dunlop
MG, Wyllie AH, Yuen ST (2001). Early-onset colorectal cancer with stable niicrosatellite DNA and
near-diploid chromosomes. Oncogene. 20 : 4871-4876
Chao C, Saito S, Kang J, Anderson CW, Appella E, Xu Y (2000). p53 transcriptional activity is
essential for/?J3-dependent apoptosis following DNA damage. EMBO JOURNAL 19: (18) 4967-4975
Chen H, Paradies N, Fedor-Chaiken M, Brackenbury R (1997). E-cadherin mediates adhesion and
suppresses cell motility via distinct mechanisms. J. Cell. Sci., 110: 345-356
Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R (1998). DNA hypomethylation leads
to elevated mutation rates. Nature 395: 89-93
Chen RZ, Akbarian S, Tudor M, Jaenisch R (2001). Deficiency of methyl-CpG binding protein-2 in
CNS neurons results in a Rett-like phenotype in mice. Nature Genetics, 27: 327-331
Chinnasamy N, Rafferty JA, Hickson I , Ashby J, Tinwell H, Margison GP, Dexter TM and Fairbairn
LJ (1997). BeG potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in the
mouse bone marrow. Blood, 89: 1566-1573.
Chiu CH, McEntee MF, Whelan J (2000). Discordant effect of aspirin and indomethacin on intestinal
tumor burden in Apc(Min/+) mice. Prostaglandins Leukotrienes And Essential Fatty Acids, 62 (5):
269-275
Christmann M, Kaina B (2000). Nuclear translocation ofmismatch repair proteins MSH2 and MSH6 as
a response of cells to alkylating agents. Journal OfBiological Chemistry, 275: 36256-36262
236
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993). Thymocyte
apoptosis induced by pii-dependent and independent pathways. Nature 362: 849-852.
Clarke AR, Gledhill S, Hooper ML, Bird CC, Wyllie AH (1994). p53 dependence of early apoptotic
and proliferative responses within the mouse intestinal epithelium following gamma-irradiation.
Oncogene 9: 1767-1773.
Clarke AR, Cummings MC, Harrison DJ (1995). Interaction between murine germline mutations in
p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene
11: 1913-1920.
Clarke AR., Howard LA, Harrison DJ, Winton DJ (1997). p53 mutation frequency and apoptosis in the
murine small intestine. Oncogene, 14: 2015-2018.
Corbet SW, Clarke AR, Gledhill S, Wyllie AH (1999). P53-dependent and -independent links between
DNA-damage, apoptosis and mutation frequency in ES cell. Oncogene, 18: 1537-1544
Cormier RT, Dove WF (2000). Dnmtl(N/+) reduces the net growth rate and multiplicity of intestinal
adenomas in C57BL/6-multiple intestinal neoplasia (Min)/plus mice independently of p53 but
demonstrates strong synergy with the modifier of Min l(AKR) resistance allele. Cancer Research. 60
(14): 3965-3970
Cormier RT, Bilger A, Lillich AJ, Halberg RB, Hong KH, Gould KA, Borenstein N, Lander ES, Dove
WF (2000). The Moml(AKR) intestinal tumor resistance region consists of Pla2g2a and a locus distal
to D4Mit64. Oncogene 19 (28): 3182-3192
Cosentino I, Heddle J A (1999). A comparison of the effects of diverse mutagens at the lacZ transgene
and Dlb-1 locus in vivo. Mutagenesis, 14: 113-119
Cottu PH, Muzeau F, Estreicher A, Flejou J-F, Iggo R, Thomas G, Hamelin R (1996). Inverse
correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene, 13: 2727-
2730.
Cranston A, Fishel R (1999.) Female embryonic lethality in Msh2-Trp53 nullizygous mice is strain
dependent. Mamm Genome. 10:1020-1022.
Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T, Fishel R (1997). Female embryonic
lethality in mice nullizygous for both Msh2 and p53. Nature Genetics, 17: 114-118.
237
Damjanov, I., and Linder, J. (1996) Andersons Pathology. 10th edition, Mosely.
Davis TW, WilsonVanPatten C, Meyers M, Kunugi KA, Cuthill S, Reznikoff C, Garces C, Poland
CR, Kinsella TJ, Fishel R, Boothman DA (1998). Defective expression of the DNA mismatch repair
protein, MLH1, alters G(2)-M cell cycle checkpoint arrest following ionizing radiation. Cancer
Research, 58: 767-778
Degtyareva N, Subramanian D, Griffith JD (2001). Analysis of the binding of p53 to DNAs containing
mismatched and bulged bases. Journal ofBiological Chemistry. 276: 8778-8784
Deka J, Herter P, Sprenger-Haussels M, Koosch S, Franz D, Muller KM, Kuhnen C, Hoffmann I,
Muller O (1999). The APC protein binds to A/T rich DNA sequences. Oncogene 18: 5654-5661
Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P (1995). Mice Lacking P21 (C/P1/Waf1)
Undergo Normal Development, But Are Defective In G1 Checkpoint Control. Cell 82(4):675-684
Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LLG, Slack JA (1994). NMR And Molecular
Modeling Investigation Of The Mechanism Of Activation Of The Antitumor Drug Temozolomide And
Its Interaction With DNA. Biochemistry 33(31): 9045-9051
DeWeese TL, Shipman JM, LarrierNA, Buckley NM, Kidd LR, Groopman JD, Cutler RG, te Tiele H,
Nelson WG (1998). Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond
abnormally to oxidative stress inflicted by low-level radiation. Proc. Natl. Acad. Sci. USA. 95:11915-
11920
de Wind, N., Dekker M, Berns A, Radman M, Riele HT(1995). Inactivation of the mouse Msh2 gene
results in mismatch repair deficiency, methylation tolerance, hyperrecombination and predisposition to
cancer. Cell 82: 321-330.
DeWind N, Dekker M, vanRossum A, vanderValk M, Riele HT (1998). Mouse models for hereditary
nonpolyposis colorectal cancer, Cancer Research, 58 (2): 248-255
Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove WF (1993).
Genetic identification of candidate genes for the Mom-1 locus modifier of intestinal neoplasia in the
mouse. Cell 75: 631-639
Dihlmann S, Siermann A, Doeberitz MV (2001). The nonsteroidal anti-inflammatory drugs aspirin and
indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 20 (5): 645-653
238
Dolan ME, Moschel RC, and Pegg AE (1990) Depletion of mammalian 06-alkylguanine-DNA-
alkyltransferase activity by BeG provides a means to evaluate the role of this protein in protection
against ca.rcinogenic and therapeutic alkylating agents. Proc. Natl. Acad. Sci. USA, 87: 5368-5372.
Dolan ME, Pegg AE, Moschel RC, and Grindey GB (1993). Effect of BeG on the sensitivity of human
colon tumour xenografts to l,3-bis(2-chIoroethyl)-l-nitrosourea (BCNU). Biochem. Pharmacol, 46,
285-290.
Donehower LA (1996). Effects of p53 mutation on tumor progression: Recent insights from mouse
tumor models. Biochimica Et Biophysica Acta-Reviews On Cancer, Vol.1242, No.3 :.171-176
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A (1992).
Mice deficient for p53 are developmental^ normal but susceptible to spontaneous tumours. Nature
356: 215-221.
Donehower LA, Harvey M, Vogel H, Mcarthur M, Montgomery CA, Park SH, Thompson T, Ford RJ,
Bradley A (1995). Effects Of Genetic Background on Tumorigenesis in P53-Deficient Mice. Molecular
Carcinogenesis, 14(1): 16-22
Dosch J, Christmann M, Kaina B (1998). Mismatch G-T binding activity and MSH2 expression is
quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis, 19:567-573
Drotschmann K, Clark AB, Tran HT, Resnick MA, Gordenin DA, Kunkel TA (1999) Mutator
phenotypes of yeast strains heterozygous for mutations in the MSH2 gene. Proc. Natl. Acad. Sci 96:
2970-2975
Drotschmann K, Shcherbakova PV, Kunkel TA (2000). Mutator phenotype due to loss of
heterozygosity in diploid yeast strains with mutations in MSH2 and MLH1. Toxicology Letters, 112:
239-244
Drummond JT, Bellacosa A (2001) Human DNA mismatch repair in vitro operates independently of
methylation status at CpG sites. Nucleic Acid Research, 29: 2234-2243
Duckett DR, Drummond JT, Murchie A1H, Reardon JT, Sancar A, Lilley DM, Modrich P (1996).
Human MutS alpha recognizes damaged DNA base pairs containing O-6-methylguanine, 0-4-
methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA.93. 6443-6447
239
Duckett DR, Bronstein SM, Taya Y, Modrich P (1999). hMutS alpha- and hMutL alpha-dependent
phosphorylation of p53 in response to DNA methylator damage. Proc. Natl. Acad. Sci. USA. 96:
12384-12388
Dudenhoffer C, Rohaly G, Will K, Deppert W, Wiesmuller L (1998). Specific Mismatch recognition in
heteroduplex Intermediates by p53 suggests a Role in fidelity Control of Homologous Recombination.
Molecular and Cellular Biology 18 (9): 5332-5342
Deubel W, Bassukas ID, Schlereth W, Lorenz R, Hempel K (1996). Age dependent selection against
HPRT deficient T lymphocytes in the HPRT+/- heterozygous mouse. Mutation Research-Fundamental
And Molecidar Mechanisms OfMutagenesis, 351: 61-11
Dumenco LL, Allay E, Norton K, Gerson SL (1993). The prevention of thymic lymphomas in
transgenic mice by human 06-Alkylguanine-DNA alkyltransferase. Science. 259: 219-222
Dunothing MG. (1996). Mutator genes and mosaicism in colorectal cancer. Current opinion in genetics
and development, 6 :75-80
Durant ST, Morris MM, Illand M, McKay HJ, McCormick C, Hirst GL, Borts RH, Brown R (1999).
Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch
repair genes. Current Biology. 9: (1) 51-54
Duval A, Gayet J, Zhou XP, lacopetta B, Thomas G, Hamelin R (1999). Frequent frameshift mutations
of the TCF-4 gene in colorectal cancers with microsatellite instability. Cancer Research, 59: 4213-
4215
Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN (1994). Up-Regulation
Of Cyclooxygenase-2 Gene-Expression In Human Colorectal Adenomas And Adenocarcinomas.
Gastroenterology 107 (4): 1183-1188
Edelmann W, Cohen PE, Kane M, Lau K, Morrow B, Bennett S, Umar A, Kunkel T, Cattoretti G,
Chaganti R, Pollard JW, Kolodner RD, Kucherlapati R (1996). Meiotic pachytene arrest in MLH1-
deficient mice. Cell, 85 (7): 1125-1134
Edelmann W, Yang K, Umar A, Heyer J, Lau K, Fan KH, Liedtke W, Cohen PE, Kane MF, Lipford
JR, Yu NJ, Crouse GF, Pollard JW, Kunkel T, Lipkin M, Kolodner R, Kucherlapati R (1997). Mutation
in the mismatch repair gene Msh6 causes cancer susceptibility. Cell, 91 (4): 467-477
Eisaleh H, Soontrapornchai P, Grieu F, Joseph D, lacopetta B (1999). P53 alterations have no
prognostic or predictive significance in Dukes' C rectal carcinomas. International Journal Of
Oncology. 15: 1239-1243
240
Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Gonzalez S, Tarafa G,
Sidransky D, Meltzer SJ, Baylin SB, Herman JG (2000). Analysis of Adenomatous Polyposis Coli
promoter hypermethylation in human cancer. Cancer Research. 60 4366-4371
Evan GI, Wyllie AH, Gilbert GS, Littlewood TD, Land H, Brooks M, Waters C, Penn LZ, Hancock
DC (1992). Induction of apoptosis by the c-myc protein. Cell 69: 119-128
Fan SJ, Chang JK, Smith ML, Duba D, Fornace AJ, O'Connor PM (1997). Cells lacking CIP1/WAF1
genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene. 14: 2127-2136
Fazeli A, Stern RG, Dickinson SL, Bautista B, Dietrich WF, Bronson RT, Bresalier RS, Lander ES,
Costa J, Weinberg, RA (1997). Effects of p53 mutations on apoptosis in mouse intestinal and human
colonic adenomas. Proc. Natl. Acad. Sci. USA , 94: 10199-10204
Fink D, Nebel S, Aebi S, Nehme A, Howell SB (1997a). Loss of DNA mismatch repair due to
knockout of MSH2 or PMS2 results in resistance to cisplatin and carboplatin. International Journal Of
Oncology, 11: 539-542
Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL,
Howell SB (1997b). In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch
repair. Cancer Research, 57 (10): 1841-1845
Fink D, Nebel S, Aebi S, Zheng H, Kim HK, Christen RD, Howell SB (1997c). Expression of the DNA
mismatch repair proteins hMLHl and hPMS2 in normal human tissues. British Journal OfCancer, 76:
890-893
Fink D, Aebi S and Howell SB (1998). The role of DNA mismatch repair in drug resistance. Clinical
Cancer Research, A, 1-6.
Fishel R (1999). Signaling mismatch repair in cancer. Nature Medicine 5 : 1239-1241
Fishel R, Wilson T (1997). MutS homologs in mammalian cells. Current Opinion In Genetics &
Development, 7: 105-113
Fishel R, Ewel A, Lescoe MK (1994). Purified human MSH2 protein binds to DNA containing
mismatched nucleotides. Cancer Research, 54: 5539-5542
Fishel R, Ewel A, Lee S, Lescoe MK, Griffith J (1994). Binding of mismatched microsatellite DNA-
sequences by the human MSH2 protein. Science, 266:1403-1405
241
Fleck O, Lehmann E, Schar P, Kohli J (1999). Involvement of nucleotide-excision repair in msh2
pmsl-independent mismatch repair. Nature Genetics . 21: (3) 314-317 MAR 1999
Fleischhacker M, Strohmeyer T, Imai Y, Slamon DJ, Koeffler HP (1994). Mutations Of The P53 Gene
Are Not Detectable In Human Testicular-Tumors. Modern Pathology. 7: 435-439
Flores-Rozas H, Clark D, Kolodner RD (2000). Proliferating cell nuclear antigen and Msh2p-Msh6p
interact to form an active mispair recognition complex. Nature Genetics 26: 375-378
Fodde R, Edelmann, Yang K, van Leeuwen C, Carlson C, Reanult B, Alt E, Lipkin M, Khan PM
(1994). A targeted chain termination mutation in the mouse Ape gene results in multiple intestinal
neoplasia. Proc. Natl. Acad. Sci. USA. 91: 8969-8973
Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Bruekel C, Wiegant J,
Giles RH, Clevers H (2001). Mutations in the APC tumour suppressor gene cause chromosomal
instability. Nature Cell Biology, 3: 433-438
Friedman HS, Kerby T, Calvert H (2000). Temozolomide and treatment of malignant glioma. Clinical
Cancer Research, 6 (7): 2585-2597
Fritzell JA, Narayanan L, Baker SM, Bronner CE, Andrew SE, Prolla TA, Bradley A, Jirik FR, Liskay
RM, Glazer PM (1997). Role of DNA mismatch repair in the cytotoxicity of ionizing radiation.
Cancer Research, 57: 5143-5147
Furuuchi K, Tada M, Yamada H, Kataoka A, Furuuchi N, Hamada J, Takahashi M, Todo S, Moriuchi
T (2000). Somatic mutations of the APC gene in primary breast cancers. American Journal Of
Pathology. 156: 1997-2005
Glaab WE, Tindell KR (1997). Mutation rate at the hprt locus in human cancer cell lines with specific
mismatch repair gene defects. Carcinogenesis, 18: 1-8
Genuardi M, Anti M, Capozzi E, Leonardi F, Fornasarig M, Novella E, Bellacosa A, Valenti A,
Gasbarrini GB, Roncucci L, Benatti P, Percesepe A, deLeon MP, Coco C, dePaoli A, Valentini M,
Boiocchi M, Neri G, Viel A (1998). MLH1 and MSH2 constitutional mutations in colorectal cancer
families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer. International
Journal OfCancer, 75: 835-839
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson
CR, Offerhaus GJA (1993). Treatment Of Colonic And Rectal Adenomas With Sulindac In Familial
Adenomatous Polyposis. N. Engl. J. Med. 328 (18): 1313-1316
242
Going JJ and Lamb RF (1996). Practical histological microdissection for PCR analysis. Journal of
Pathology. 179: 121-124
Goldmacher VS, Cuzick RA, Thilly WG (1986). Isolation and partial characterization of human cell
mutants differing in sensitivity to killing and mutation by Methylnitrosourea and N-Methyl-N'-Nitro-
N-Nitrosoguanidine. Journal OfBiological Chemistry 261 :12462-12471
Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, Wang JYJ (1999). The tyrosine
kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806-
809
Gossen JA, Molijn AC, Douglas GR, Vijg J (1992). Application Of Galactose-Sensitive Escherichia-
Coli Strains As Selective Hosts For Lacz- Plasmid. Nucleic Acids Research, 20: 3254-3260
Gould KA, Luongo C, Moser AR, McNeley MK, Borenstein N, Shedlovsky A, Dove WF, Hong K,
Dietrich WF, Lander ES (1996). Genetic evaluation of candidate genes for the Moml modifier of
intestinal neoplasia in mice. Genetics 144: 1777-1785
Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996). Hypoxia-
mediated selection of cells with diminished apoptotic potential in solid tumours, Nature. 379: 88-91
Gradia S, Acharya S, Fishel R (1997). The human mismatch recognition complex hMSH2-hMSH6
functions as a novel molecular switch. Cell, 7: 995-1005
Griffiths SD, Clarke AR, Healy LE, Ross G, Ford AM, Hooper ML, Wyllie AH, Greaves M (1997).
Absence of p53 permits propagation of mutant cells following genotoxic damage. Oncogene. 14 523-
531
Groden J, Thliversis A, Samowitz W, Carslon M, Gelbert L, Albertson H, Joslyn G, Stevens J, Spirio
L, Robertson M, Sargeant L, Krapcho K, Wolff E, Burt R, Hughes JP, Warrington J, McPherson J,
Wasmuth J, LePaslier D, Abderrahim H, Cohen D, Leppert M, White R (1991). Identification and
characterisation of the familial polyposis gene. Cell 66, 589-600
Gu LY, Hong Y, McCulloch S, Watanabe H, Li GM (1998). ATP-dependent interaction of human
mismatch repair proteins and dual role of PCNA in mismatch repair. Nucleic Acids Research, 26: 1173-
1178
Guy J, Hendrich B, Holmes M, Martin JE, Bird A (2001) A mouse Mecp2-null mutation causes
neurological symptoms that mimic Rett syndrome. Nature Genetics, 27 : 322-326
243
Habraken Y, Sung P, Prakash L, Prakash S (1996). Binding of insertion/deletion DNA mismatches by
the heterodimer of yeast mismatch repair proteins MSH2 and MSH3. Current Biology, 6: 1185-1187
Habraken Y, Sung P, Prakash L, Prakash S (1997). Enhancement of MSH2-MSH3-mediated mismatch
recognition by the yeast MLH1-PMS1 complex. Current Biology,7: 790-793
Habraken Y, Sung P, Prakash L, Prakash S (1998). ATP-dependent assembly of a ternary complex
consisting of a DNA mismatch and the yeast MSH2-MSH6 and MLH1-PMS1 protein complexes.
Journal OfBiological Chemistry, 273: 9837- 9841
Hall Cn, Badawi Af, Oconnor Pj, Saffhill R (19991). The detection of alkylation damage in the DNA
of human gastrointestinal tissues. British Journal ofCancer, 54: 59-63
Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka
N, Orita K (1996). The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in
gastric and colorectal cancers. Journal OfCancer Research And Clinical Oncology. 122 : 360-365
Hamelin R, Laurentpuig P, Olschwang S, Jego N, Asselain B, Remvikos Y, Girodet J, Salmon RJ,
Thomas G (1994). Association Of P53 Mutations With Short Survival In Colorectal-Cancer.
Gastroenterology. 106:42-48
Hansen RS, Wijmenga C, Luo P, Stanek AM, Canfield TK, Weemaes CMR, Gartler SM (1999). The
DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome. Proc.
Natl. Acad. Sci. USA, 96 (25): 14412-14417
Hardman RA, Afshari CA, Barrett JC (2001). Involvement of mammalian MLH1 in the apoptotic
response to peroxide-induced oxidative stress. Cancer Research. 61: 1392-1397
Harris CC (1996). Structure and function of the p53 tumor suppressor gene: Clues for rational cancer
therapeutic strategies, Journal of the National Cancer Institute, 88 (20): 442-1455
Harris CC, Hollstein M (1993) Clinical Implications Of The P53 Tumor-Suppressor Gene. New
England Journal OfMedicine, 329 (18): 1318-1327
Harrison DJ, Hooper ML, Armstrong JF, Clarke AR (1995). Effects Of Heterozygosity For The Rb-
l(T19neo) Allele In The Mouse, Oncogene, 10: 1615-1620
244
Hart MJ, Santos RD1, Albert IN, Rubinfield B, Polakis P (1998). Downregulation of p-catenin by
human axin and its association with the Ape tumour suppressor, P-catenin and GSK3p. Current
Biology. 8 : 573-581
Hartwell L (1992). Defects in a cell cycle checkpoint may be responsible for the genomic instability of
cancer cells. Cell 71: 543-546.
Haupt Y, Maya R, Kazaz A, Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature,
387:296-299
Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA,
Bradley A, Donehower LA (1993). In-vitro growth-characteristics of embryo fibroblasts isolated from
p53-deficient mice. Oncogene, 8:2457-2467.
Harvey M, Vogel H, Lee EYHP, Bradley A, Donehower LA. (1995). Mice Deficient in Both P53 And
Rb Develop Tumors Primarily Of Endocrine Origin. Cancer Research, Vol.55: 1146-1151
Hawkins NJ, Tomlinson I, Meagher A, Ward RL (2001). Microsatellite-stable diploid carcinoma: a
biologically distinct and aggressive subset of sporadic colorectal cancer. British Journal of Cancer.
84:232-236
Hawn MT, Umar A, Carethers JM, Marra G, Kunkel TA, Boland CR, Koi M (1995). Evidence for a
connection between the mismatch repair system and the G2 cell cycle checkpoint. Cancer Research.
55: 3721-3725.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler
KW (1998). Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512
Hendrich B, Bird A (1988). Identification and characterization of a family of mammalian methyl-CpG
binding proteins. Molecular and Cellular Biology. 18: 6538-6547
Hendrich B, Bird A (2000). Mammalian methyltransferases and methyl-CpG-binding domains:
Proteins involved in DNA methylation. CURR. TOP. MICROBIOL.: DNA Methylation And Cancer
249: 55-74
Hendrich B, Hardeland U, Ng HH, Jiricny J, Bird A (1999). The thymine glycosylase MBD4 can bind
to the product of deamination at methylated CpG sites. Nature, 401 : 301-304
245
Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A (2001) Closely related proteins MBD2 and
MBD3 play distinctive but interacting roles in mouse development. Genes and Development. 15: 710-
723
Hendry JH, Cai WB, Roberts SA, Potten CS (1997). p53 deficiency sensitizes clonogenic cells to
irradiation in the large but not the small intestine. Radiation Research. 148: 254-259
Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa J-P, Markowitz S, Willson JKV, Hamilton SR,
Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB (1998). Incidence and
functional consequence of hMLHl promoter hypermethylation in colorectal carcinona. Proc. Natl.
Acad. Sci. USA. 95 6870-6875
Hickman MJ, Samson LD (1999). Role of DNA mismatch repair and p53 in signaling induction of
apoptosis by alkylating agents. Proc. Natl. Acad. Sci USA. 96 : 10764-10769
Hoffmann J, Pillaire M, Lesca C, Burnour D, Fuchs RP, Defais M, Villani G (1996). Fork- like DNA
templates supports bypass replication of lesions that blocks DNA synthesis on single stranded
templates. Proc. Natl. Acad. Sci. USA.93: 13766-13769.
Hollander MC, Sheikh MS, Bulavin DV, Lundgren K, Augeri-Henmueller L, Shehee R, Molinaro TA,
Kim KE, Tolosa E, Ashwell JD, Rosenberg MP, Zhan QM, Fernandez-Salguero PM, Morgan WF,
Deng CX, Fornace AJ (1999). Genomic instability in Gadd45a-deficient mice. Nature Genetics 23 (2):
176-184
Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Ando H, Yanagisawa A, Tsuchiya E, Kato Y,
Nakamura Y (1992). Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer
Research. 52: 6696-6698.
Houldsworth J, Xiao H, Murty VVVS, Chen WY, Ray B, Reuter VE, Bosl GJ, Chaganti RSK (1998).
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16 :
2345-2349
Huber O, Korn R, McLaughlin J, Ohsugi M, Herrmann BG, Kemler R (1996). Nuclear localisation of
beta-catenin by interaction with transcription factor LEF-1. Mech. Dev. 59: 3-10
Hulsken J, Birchmeier W, Behrens J (1994) E-Cadherin and Ape compete for the interaction with Beta-
Catenin and the cytoskeleton. Journal OfCell Biology. 127 (6): 2061-2069
Hunter N, Borts RH (1997). Mlhl is unique among mismatch repair proteins in its ability to promote
crossing-over during meiosis. Genes & Development, 11: 1573-1582
246
Iaccarino I, Palombo F, Drummond J, Totty NF, Hsuan JJ, ModrichP, Jiricny J (1996). MSH6, a
saccharomyces-cerevisiae protein that binds to mismatches as a heterodimer with MSH2. Current
Biology, 6: 484-486
laccarino I, Marra G, Palombo F, Jiricny J (1998). hMSH2 and hMSH6 play distinct roles in mismatch
binding and contribute differently to the ATPase activity of hMutS alpha. EMBO Journal, 17(9): 2677-
2686
Ijiri K, Potten CS (1983). Response Of Intestinal-Cells Of Differing Topographical And Hierarchical
Status To 10 Cyto-Toxic Drugs And 5 Sources Of Radiation. British Journal OfCancer. 47: 175-185
Ijiri K, Potten CS (1987). Further-Studies On The Response Of Intestinal Crypt Cells Of Different
Hierarchical Status To 18 Different Cytotoxic Agents. British Journal OfCancer.SS\ \ 13-123
Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S and Kikuchi A (1998). Axin, a negative
regulator of the Wnt signaling pathway, forms a complex with GSK-3 beta and beta-catenin and
promotes GSK-3 beta-dependent phosphorylation of beta-catenin. EMBO. 17:1371-1384. (1998)
Ilyas, M., Tomlinson, I.P..M., Bodmer, W. F. (1999). Genetic Pathways in Colorectal and other
Cancers. European Journal ofCancer, 35 (3): 335-351
Inomata M, Ochiai A, Akimoto S, Kitano S, Hirohashi S (1996) Alteration of beta-catenin expression
in colonic epithelial cells of familial adenomatous polyposis patients. Cancer Research, 56: 2213-2217
Ishidate T, Matsumine A, Toyoshima K, Akiyama T (2000). The APC-hDLG complex negatively
regulates cell cycle progression from the G0/G1 to S phase. Oncogene. 19: (3) 365-372
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994).
Tumor Spectrum Analysis In P53-Mutant Mice. Current Biology, 4 (1): 1-7
Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, Dausman T, Lee
P, Wilson C, Lander E, Jaenisch R (2001). Loss of genomic methylation causes p53-dependent
apoptosis and epigenetic deregulation. Nature Genetics. 27: 31-39
Jacoby RF, Cole CE, Tutsch K, Newton MA, Kelloff G, Hawk ET, Lubet RA (2000).
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Ape
mutant Min mouse adenomas, and selective toxicity against Ape mutant embryos. Cancer Research 60
(7): 1864-1870
247
Janus F, Albrechtsen N, Dornreiter I, Wiesmuller L, Grosse F, Deppert W (1999). The dual role model
for p53 in maintaining genomic integrity. Cellular and Molecular Life Sciences, .55 (1): 12-27
Jasani B, Campbell F, Navabi N, Schmid KW, Williams GT (1999). Clonal overexpression of
metallothionein is induced by somatic mutation in morphologically normal colonic mucosa, Journal of
Pathology, 184: 144-147
Jimenez, GS, Nister M, Stommel JM, Beeche M, Barcase ER, Zhang X.-Q, O'Gorman S, Wahl G,
(2000). A transactivation-deficient mouse model provides insights into Trp53 regulation and function.
Nature Genetics. 26: 37-43
Jiricny J (1994). Colon cancer and DNA repair: have mismatches met their match. Trends in Genetics,
10(5): 164-168
Jordan P, Carmo-Fonseca M (2000). Molecular mechanisms involved in cisplatin cytotoxicity. Cellular
AndMolecular Life Sciences 57: (8-9) 1229-1235.
Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue Of Embryonic Lethality In Mdm2-
Deficient Mice By Absence of P53, Nature, 378:206-208
Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A (1998). Overexpression of Mdm2 in
mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA, 95:
15608-15612
Johnson RE, Kovvali GK, Prakash L, Prakash S (1996). Requirement of the yeast MSH3 and MSH6
genes for MSH2-dependent genomic stability, Journal OfBiological Chemistry, 271(13): 7285-7290
Kaina B, Ziouta A, Ochs K, Coquerelle T (1997). Chromosomal instability, reproductive cell death and
apoptosis induced by O-6-methylguanine in Mex(-), Mex(+) and methylation-tolerant mismatch repair
compromised cells: facts and models. Mutation Research-Fundamental And Molecular Mechanisms Of
Mutagenesis, 381(2): 227-241
Kallioniemi OP, Kallioniemi A, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D (1992)
Comparative genomic hybridization: a rapid new method for detecting and mapping DNA
amplification in tumours. Seminars in Cancer Biology 4: 41-46
Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, Nathke IS (2001). A role for the
Adenomatous Polyposis Coli protein in chromosome segregation. Nature Cell Biology, 3: 429-432
248
Karnes WE, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, Kim CY,
McDonnell SK, Schaid DJ, Thibodeau SN (1998). Reduced COX-2 protein in colorectal cancer with
defective mismatch repair. Cancer Research 58 (23): 5473-5478.
Karran P, Bignami M, (1992). Self-destruction and tolerance in resistance of mammalian cells to
alkylation damage. Nucleic Acid Research, 20 (12): 2933-2940
Karran M, Bignami, P (1994). DNA-Damage Tolerance, Mismatch Repair And Genome Instability,
Bioessays, 16 (1 1): 833-839
Kashiwaba, M., Tamura, G. and Ishida, M. (1994). Aberrations of the APC gene in primary breast
carcinoma. Journal ofCancer Research Clinical Oncology. 120: 727-731.
Kasparkova J, Pospisilova S, Brabec V (2001). Different recognition of DNA modified by antitumor
cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53. Journal Of
Biological Chemistry. 276: 16064-16069
Kawate H, Sakumi K, Tsuzuki T, Nakatsuru Y, Ishikawa T, Takahashi S, Takano H, Noda T,
Sekiguchi M (1998). Separation of killing and tumorigenic effects of an alkylating agent in mice
defective in two of the DNA repair genes. Proceedings Of The National Academy OfSciences Of The
United States OfAmerica, 95 (9): 5116-5120
Kawate H, Itoh R, Sakumi K, Nakabeppu Y, Tsuzuki T, Ide F, Ishikawa T, Noda T, Nawata H,
Sekiguchi M (2000) A defect in a single allele of the Mlhl gene causes dissociation of the killing and
tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice Carcinogenesis 21:
(2) 301-305
Kerr JF, Wyllie API, Currie AR (1972). Apoptosis: a basic biological phenomenon with wide ranging
implications in tissue kinetics. British Journal ofCancer, 26: 239-257
Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Rome! L, Gore M, Ironside J, MacDougall
RH, Heise C, Randlev B, Gillenwater AM, Bruso P, Kaye SB, Hong WK, Kirn DH (2000). Controlled
trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and
5-fluorouracil in patients with recurrent head and neck cancer. Nature Medicine. 6 : 879-885
Kinzler KW, Vogelstein B (1996). Lessons from Hereditary Colorectal Cancer. Cell 87: 159-170
Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton, SR,
Hedge P, Markham A, Carlson M, Joslyn G, Grogen J, White R, Miki Y, Miyoshi Y, Nishisho I,
Nakamura Y (1991). Identification of a gene located at chromosome 5q21 that is mutated in colorectal
cancer. Science, 251: 1366-1370
249
Kirkpatrick DT, Petes TD (1997). Repair of DNA loops involves DNA-mismatch and nucleotide-
excision repair proteins. Nature, 387: (6636) 929-931
Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, Kikuchi A (1998). Axin, a
negative regulator of the Wnt signaling pathway, directly interacts with adenomatous polyposis coli
and regulates the stabilization of beta-catenin. Journal OfBiological Chemistry 273: 10823-10826
Kolodner RD (1995) Mismatch repair: mechanisms and relationship to cancer susceptibility. Trends
Biochem. Sci. 20: 397-401.
Kongkanuntn R, Bubb VJ, Sansom OJ, Wyllie AH, Harrison DJ, Clarke AR (1999). Dysregulated
expression of beta-catenin marks early neoplastic change in Ape mutant mice, but not all lesions arising
in Msh2 deficient mice. Oncogene. 18 (51): 7219-7223
Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H
(1997) Constitutive transcriptional activation by a p-catenin-Tcf complex in APC-/- colon carcinoma.
Science 275:1784-1787
Kurpad SN, Dolan ME, McLendon RE, Archer GE, Moschel RC, Pegg AE, Bigner DD, Friedman HS
(1997) Intraarterial BeG enables the specific therapy of nitrosourea-resistant intracranial human glioma
xenografts in athymic rats with l,3-bis(2-chlororthyl)-l-nitrososurea. Cancer. Chemother. Pharmacol,
39: 307-316.
Lacal PM, D'Atri S, Orlando L, Bonmassar E, and Graziani G (1996) In vitro inactivation of human
06-alkyltransferase by antitumour triazene compounds. J. Pharmacol. Exp. Ther, 279: 416-422.
Lane DP (1992). P53: guardian of the genome. Nature, 358: 15-16
Lanzi C, Perego P, Supino R, Romanelli S, Pensa T, Carenini N, Viano I, Colangelo D, Leone R,
Apostoli P, Cassinelli G, Gambetta RA, Zunino F (1998). Decreased drug accumulation and increased
tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. Biochemical
Pharmacology, 55 (8): 1247-1254
Lauhe R, Au KG, Modrich P (1989). DNA mismatch correction im a defined system. Science, 245:
160-164
Leadon SA, Avrutskaya AV (1997). Differential involvement of the human mismatch repair proteins,
hMLHl and hMSH2, in transcription-coupled repair. Cancer Research. 57 (17): 3784-3791
250
Lee S, Elenbaas B, Levine A, Griffith J (1995). p53 and its 14 kDa C-terminal domain recognise
primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020.
Lengauer C, Kinzler KW, Vogelstein B (1997). Genetic instability in colorectal cancers. Nature 386:
623-627.
Lengauer C, Kinzler KW, Vogelstein B (1997b). DNA methylation and genetic instability in colorectal
cancer cells. Proc.Natl. Acad. Sci. USA. 94: 2545-2550
Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogelstein B, Kinzler KW (1994). Inactivation
of both APC alleles in human and mouse tumours. Cancer Research 54: 5953-5958
Lewis JD, Meehan RR, Henzel Wj, Maurerfogy I, Jeppesen P, Klein F, Bird A (1992) Purification,
sequence, and cellular-localization of a novel chromosomalprotein that binds to methylated DNA. Cell,
69: 905-914
Lin XJ, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB (2001). P53 modulates the
effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic
and mutagenic effects of cisplatin. Cancer Research 61: 1508-1516
Liu B, Nicolaides NC, Markowitz S, Willson JK, Parsons RE, Jen J, Papadopoulos N, Peltomaki P, de
la Chapelle A, Hamilton SR, Vogelstein B, Kinzler KW (1995). Mismatch repair gene defects in
sporadic colorectal cancers with microsatellite instability. Nature Genetics. 9: 48-55.
Liu,L., Lee,K., Markowitz,S., and Gerson,S.L. (1996) Differential sensitivity of human and mouse
alkyltransferase to BeG using a transgenic model. Cancer Research, 56, 1880-1885
Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001).
Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. Journal
OfBiological Chemistry. 276 (21): 18563-18569
Loazano G, Lui G (1998). Mouse models dissect the role of p53 in cancer and development. Seminars
in cancer biology, 8 337-344
Loeb LA (1998). Foundations in cancer research: cancer cells exhibit a mutator phenotype. Advances
in Cancer Research, 72: 25-26
Lowe SW, Schmitt EM, Smith SW, Osborne BA, and Jacks T (1993). p53 is required for radiation
induced apoptosis in mouse thymocytes. Nature 362: 847-849.
251
Lowe SW, Ruley HE, Jacks T, Housman DE (1993B). P53-Dependent Apoptosis Modulates The
Cytotoxicity Of Anticancer Agents. Cell 74: 957-967
Lowe SW, Bodis S, Mcclatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994).
P53 Status And The Efficacy Of Cancer-Therapy In-Vivo. Science. 266 : 807-810
Lu SL, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, Yuasa Y (1998). HNPCC
associated with germline mutation in the TGF-beta type 11 receptor gene. Nature Genetics 19:17-18
Luhr B, Scheller J, Meyer P, Kramer W (1998). Analysis of in vivo correction of defined mismatches
in the DNA mismatch repair mutants msh2, msh3 and msh6 of Saccharomyces cerevisiae. Molecular
& General Genetics, 257(3): 362-367
Lukash LL, Boldt J, Pegg AE, Dolan ME, Maher VM McCormick J J (1991). Effect of O6-
alkylguanine-DNA-alkyltransferase on the frequency and spectrum of mutations induced by N-methyl-
N'-nitro-N-nitrosoguanidine in the HPRT gene of diploid human fibroblasts. Mutation Research, 250:
397-409.
Luna RMD, Wagner DS, Lozano G. (1995). Rescue Of Early Embryonic Lethality In Mdm2-Deficient
Mice By Deletion of P53. Nature , Vol.378, No.6553 : 203-206
Luongo C, Moser AR, Gledhill S, Dove WF (1994). Loss of Apc+ in intestinal adenomas from Min
mice. Cancer Research 54: 5947-5952
Lutzker SG, Levine AJ (1996). A functionally inactive p53 protein in teratocarcinoma cells is activated
by either DNA damage or cellular differentiation. Nature Medicine. 2 : 804-810
Lynch, HT, Smyrk TC, Watson SJ, Lanspa SJ, Boman BM, Lynch PM, Lynch JF, Cavalieri RT
(1991) Hereditary colorectal cancer. Seminars in Oncology 18: 337-366
Lynch HT, Smyrk TC, Watson SJ, Lanspa SJ, Boman BM, Lynch PM, Cavalieri RT, Boland CR
(1993). Genetics, natural history, tumour spectrum, and pathology of heriditary non-polyposis
colorectal cancer: an updated review. Gastroenterology 104: 1535-1549
Mahmoud NN, Boolbol SK, Bilinski RT, Martucci C, Chadburn A, Bertagnolli MM (1997). Ape gene
mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Research,
57: 5045-5050
252
Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H,
Bertagnolli MM (1998). Aspirin prevents tumors in a murine model of familial adenomatous polyposis.
Surgery 124 (2): 225-231
Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Martucci C, Newmark HL,
Chadburn A, Bertagnolli MM (1998B). The sulfide metabolite of sulindac prevents tumors and restores
enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis. 19 (1):
87-91
Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ,
Tainsky MA, Friend SH (1990). Germ Line P53 Mutations In A Familial Syndrome Of Breast-Cancer,
Sarcomas, And Other Neoplasms, Science, Vol.250: 1233-1238
Mann B, Gelos M, Siedow A, Flanski ML, Gratchev A, Ilyas M, Bodmer WF, Moyer MP, Riecken EO,
Buhr HJ, Hanski C (1999) Target genes of beta-catenin-T cell-factor lymphoid-enhancer-factor
signaling in human colorectal carcinomas. Proc. Natl. Acad. Sci. USA 96: (4) 1603-1608.
Marsischky GT, Filosi N, Kane MF, Kolodner R (1996). Redundancy Of Saccharomyces-Cerevisiae
Msh3 And Msh6 In Msh2- Dependent Mismatch Repair, Genes & Development, 10(4): 407-420
Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M (2001). Tumor Susceptibility of
p21Wafl/Cipl-deficient Mice. Cancer Research 61 6234-6238.
Matsumine A, Ogai A, Senda T et al Binding of APC gene product to the human homolog of the
Drosophila Discs Large tumour suppressor protein. Science 1996 272:1020-1023.
McEntee MF, Chiu CH, Whelan J (1999). Relationship of beta-catenin and Bc!-2 expression to
sulindac-induced regression of intestinal tumors in Min mice. Carcinogenesis. 20 (4): 635-640
Meehan RR, Lewis JD, Mckay S, Kleiner El, Bird AP (1989). Identification of a mammalian protein
that binds specifically to dna containing methylated CPGs. Cell, 58: 499-507
Mello JA, Acharya S, Fishel R, Essigmann JM (1996) The mismatch-repair protein hmsh2 binds
selectively to DNA adducts of the anticancer drug cisplatin, Chemistry & Biology, 3(7): 579-589
Mellon I, Champe GN (1996).Products of DNA mismatch repair genes mutS and mutL are required for
transcription-coupled nucleotide-excision repair of the lactose operon in Escherichia coli. Proceedings
OfThe National Academy OfSciences OfThe United States OfUSA, 93: (3) 1292-1297
253
Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA (2001) Role of the hMLHl DNA
mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer
Research, 61 : 5193-5201
Miyaki M, Iijima T, Konishi M, Sakai K, Ishii A, Yasuno M, Hishima T, Koike M, Shitara N, Iwama
T, Utsunomiya J, Kuroki T, Mori T (1999) Higher frequency of Smad4 gene mutation in human
colorectal cancer with distant metastasis Oncogene 18 3098-3103
Miyoshi, Y., Nagase, H., Ando, H., Horii, A., Ichii, S., Nakatsuru, S., Aoki, T., Miki, Y., Mori, T. and
Nakamura, Y. (1992) Somatic mutations of the APC gene in colorectal tumours: mutation cluster
region in the APC gene. Human Molecular Genetics. 1:229-233.
Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, Hall PA (1994). The Role Of
P53 In Spontaneous And Radiation-Induced Apoptosis In The Gastrointestinal-Tract Of Normal And
P53-Deficient Mice, Cancer Research, 54: 614-617
Merritt AJ, Allen TD, Potten CS, Hickman JA (1997). Apoptosis in small intestinal epithelia from
p53-null mice: Evidence for a delayed, p53-independent G2/M-associated cell death after gamma-
irradiation, Oncogene, 1997, Vol.14, No.23,: 2759-2766
Meyers M, Theodosiou M, Acharya S, Odegaard E, Wilson T, Lewis JE, Davis TW, VanPatten CW,
Fishel R, Boothman DA (1997), Cell cycle regulation of the human DNA mismatch repair genes
hMSH2, hMLHl, and hPMS2. Cancer Research, 57(2): 206-208
Moreland, N.J., Illand, M., Kim, Y.T., Paul, J., Brown R. (1999) Modulation of drug resistance
mediated by loss of mismatch repair by the DNA polymerase inhibitor Aphidicolin. Cancer Research.
59 :2102-2106
Modrich P (1991) Mechanisms and biological effects of mismatch repair. Annual Review OfGenetics,
25: 229-253
Modrich P and Lauhe R (1996) Mismatch repair in replication fodelity. genetic recombination and
cancer biology. Annual Review OfBiochemistry ,65: 101-131
Mori Y, Shiwaku H, Fukushige S, Wakatsuki S, Sato M, Nukiwa T, Horii A (1997), Alternative
splicing of hMSH2 in normal human tissues, Human Genetics, 99 (5): 590-595
Morin, P.J., Sparks, A. B., Korinek, V., Barker, N., Vogelstein, B., Kinzler, K.W. (1997) Activation of
P-catenin-Tcf signalling in colon cancer by mutations in p-catenin or APC. Science 275: 1787-1790
254
Moser AR, Pitot HC, Dove WF(1990).A dominant mutation that predisposes to multiple intestinal
neoplasia. Science, 247:322-324
Moser AR, Dove WF, Roth KA, Gordon JI The Min (multiple intestinal neoplasia) mutation: its effect
on gut epithelial cell differentiation and interaction with a modifier system J Cell Biol 116:1517-1526
(1992)
Moser AR, Mattes EM, Dove WF, Lindstrom MJ, Haag JD, Gould MN (1993) Apc(Min), A Mutation
In The Murine Ape Gene, Predisposes To Mammary Carcinomas And Focal Alveolar Hyperplasias
Proc. Natl. Acad. Sci. USA. 90 (19): 8977-8991
Moser AR, Luongo C, Gould KA, McNeley MK, Shoemaker AR, Dove WF ApcM,n: a mouse model
for intestinal and mammary tumorigenesis. Eur J Cancer 31:1061-1064 (1995)
Moslein G, Tester DJ, Lindor NM, Honchel R, Cunningham JM, French AJ, Hailing KC, Schwab M,
Goretzki P, Thibodeau SN(1996) Microsatellite instability and mutation analysis of hMSH2 and
hMLHl in patients with sporadic, familial and hereditary colorectal-cancer, Human Molecular
Genetics, 5 (9): 1245-1252
Mu D, Tursun M, Duckett DR, Drummond JT, Modrich P, Sancar A (1997) Recognition and repair of
compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair
systems, Molecular And Cellular Biology, 17(2): 760-769
Muhua L, Adames NR, Murphy MD, Shields CR, Cooper JA (1998) A cytokinesis checkpoint
requiring the yeast homologue of an APC binding protein. Nature. 393: (6684) 487-491
Mummenbrauer T, Janus F, Muller B, Wiesmuller L, Deppert W, Grosse F. (1996). P53 protein
exhibits 3'-to-5' exonuclease activity. Cell 85:1089-1099
Munemitsu S, Souza B, Muller O, Albert I, Rubinfeld B, Polakis P (1994). The APC gene product
associates with microtubules in vivo and promotes their assembly in vitro. Cancer Research 54:3676-
3681.
Nakatsuru S, Yanagisawa A, Ichii S, Tahara E, Kato Y, Nakamura Y, Horii A (1992). Somatic
mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated
adenocarcinomas and signet-ring cell carcinoma. Human Molecular Genetics. 1:559-563.
Nathke IS, Adams CL, Polakis P, Sellin JH, Nelson WJ (1996). The adenomatous polyposis coli tumor
suppressor protein localizes to plasma membrane sites involved in active cell migration. Jounal of
Cellular Biology, 134: 165-179
255
Neddermann P, Gallinari P, Lettieri T, Schmid D, Truong O, Hsuan JJ, Wiebauer K, Jiricny J (1996).
Cloning and expression of human G/T mismatch-specific thymine-DNA glycosylase. Journal of
Biological Chemistry. 271: 12767-12774.
Nehme A, Baskaran R, Aebi S, Fink D, Nebel S, Cenni B, Wang JYJ, Howell SB, Christen RD (1997).
Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-
proficient and deficient cells exposed to cisplatin. Cancer Research, 57(15): 3253-3257
Neufeld KL, Nix DA, Bogerd H, Rang YB, Beckerle MC, Cullen BR, White RL (2000). Adenomatous
polyposis coli protein contains two nuclear export signals and shuttles between the nucleus and
cytoplasm. Proc. Natl. Acad. Sci. USA 92 (22): 12085-12090
Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C (1997). Temozolomide: A review
of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treatment
Reviews 23 (1): 35-61
Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter K.C, Ruben SM, Rosen CA, Haseltine WA,
Fleischmann RD, Fraser CM, Adams MD, Venter JC, Dunlop MG, Hamilton SR, Petersen GM,
Delachapelle A, Vogelstein B, Kinzler KW (1994). Mutations of 2 PMS homologs in Hereditary
Nonpolyposis Colon-Cancer. Nature, 371:75-79
Nishino H, Knoll A, Buettner VL, Frisk CS, Maruta Y, Haavik J, Sommer SS (1995). P53 Wild-Type
And P53 Nullizygous Big-Blue Transgenic Mice Have Similar Frequencies And Patterns Of Observed
Mutation In Liver, Spleen And Brain. Oncogene, 11: 263-270
Nishino H, Buettner VL, Haavik J, Schaid DJ, Sommer SS (1996). Spontaneous mutation in Big
Blue(R) transgenic mice: Analysis of age, gender, and tissue type, Environmental And Molecular
Mutagenesis, 28: 299-312
Nusse R (1997). A versatile transcriptional effector of Wingless signalling. Cell. 89: 321-323
Nusse R and Varmus HE (1982). Many tumours induced by the mouse mammary tumour virus
contains a provirus integrated in the same region of the host genome. Cell. 31:99-109
Ochs K, Kaina B (2000). Apoptosis induced by DNA damage O-6-methylguanine is Bcl-2 and
caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Research, 60. 5815-58241
256
Okano M, Bell DW, Haber DA, Li E (1999). DNA methyltransferases Dnmt3a and Dnmt3b are
essential for de novo methylation and mammalian development Cell, 99: (3) 247-257
Okano M, Xie SP, Li E (1998). Cloning and characterization of a family of novel mammalian DNA
(cytosine-5) methyltransferases. Nature Genetics, 19: 219-220
Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW (1997). Serine phosphorylation-regulated
ubiquitination and degradation of beta-catenin. Journal Of Biological Chemistry 272: (40) 24735-
24738
Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M (1995). Loss of Ape
heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated
Ape gene. Proc. Natl. Acad. Sci. USA 92:4482-4486
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF,
Taketo MM (1996). Suppression of intestinal polyposis in Apc(Delta 716) knockout mice by inhibition
of cyclooxygenase 2 (COX-2). Cell 87 (5): 803-809
Oshima H, Oshima M, Kobayashi M, Tsutsumi M, Taketo MM (1997) Morphological and molecular
processes of polyp formation in Apc(Delta 716) knockout mice. Cancer Research, 57: 1644-1649
Orsulic S., Peifer M (1996). An in vivo structure-function study of Armadillo, the beta-catenin
homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and
for wingless signaling. Journal ofCell Biology 134: (5) 1283-1300
Ozbun, MA, Jerry J, Kittrell FS, Medina D, Butel JS (1993). p53 mutations selected in vivo when
mouse mammary epithelial cells form hyperplastic outgrowths are not necessary for establishment of
mammary cell lines in vitro. Cancer Research. 53: 1646-1652.
Pao MM, Liang GN, Tsai YC, Xiong ZG, Laird PW, Jones PA (2000) DNA methylator and mismatch
repair phenotypes are not mutually exclusive in colorectal cancer cell lines. Oncogene. 19:943-952
Palombo F, Iaccarino I, Nakajima E, Ikejima M, Shimada T, Jiricny J (1996) HMUTS-BETA, a
heterodimer of HMSH2 and HMSH3, binds to insertion/deletion leaps in DNA, Current Biology, 6 (9):
1181-1184
Papkoff J, Rubinfeld B, Schryver B, Polakis P (1996). Wnt-1 regulates free pools of catenins and
stabilizesAPC-catenin complexes. Mol Cell Biol 16: 2128-2134
257
PaquisFlucklinger V, SantucciDarmanin S, Paul R, Saunieres A, TurcCarel C, Desnuelle C (1997).
Cloning and expression analysis of a meiosis-specific MutS homolog: The human MSH4 gene.
Genomics, 44 (2): 188-194
Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C,
Kolesnick R (2001). Endothelial apoptosis as the primary lesion initiating intestinal radiation damage
in mice. Science 293: 293-297
Pegg AE (1990). Mammalian 06 Alkylguanine-DNA alkyltransferase: Regulation and importance in
response to alkylating carcinogenic and therapeutic agents. Cancer Research, 50: 6119-6129
Pegg AE and Byers TL (1992). Repair of DNA containing 06-alkylguanine. FASEB J, 6, 2302-2310.
Pegg AE, Boosalis M, Samson L, Moschel RC, Byers TL, Sween K, and Dolan ME (1993) Mechanism
of inactivation of 06-alkylguanine-DNA alkyltransferase by BeG. Biochemistry, 32, 11998-12006.
Petronzelli F, Riccio A, Markham GD, Seeholzer SH, Genuardi M, Karbowski M, Yeung AT,
Matsumoto Y, Bellacosa A (2000) vestigation of the substrate spectrum of the human mismatch-
specific DNA N-glycosylase MED1 (MBD4): Fundamental role of the catalytic domain. Journal of
Biological Chemistry. 185: 473-480
Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G (1998). A causal role for E-cadherin in the
transition from adenoma to carcinoma. Nature 392: 190-193
Petersen S, Thames HD, Nieder C, Petersen C, Baumann M (2001). The results of colorectal cancer
treatment by p53 status - Treatment-specific overview. Diseases OfThe Colon & Rectum. 44: 322-333
Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross
PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R (1997). Sulindac sulfone inhibits
azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer
Research. 57 (14): 2909-2915
Pieper RO (1995) Cellular responses to methylation damage. FROM DNA Damage and Repair Vol 2.
DNA repair in Higher Eukaryotes. Edited by J.A. Nickoloff and M.F. Hoekstra: 33-49
Polakis P (2000). Wnt Signalling and Cancer. Genes and Development 14: 1837-1851
Poller DN, Baxter KJ, Shepherd NA (1997). p53 and Rbl protein expression: Are they prognostically
useful in colorectal cancer? British Journal ofCancer. 75 : 87-93.
258
Polyak K, Xia Y, Zweler JL, Kinzler KW, Vogelstein B (1997). Model for p53-induced apoptosis.
Nature. 389 300-305
Potten CS (1990). A Comprehensive Study Of The Radiobiological Response Of The Murine (Bdfl)
Small-Intestine, International Journal OfRadiation Biology. 58 : 925-973
Potten CS (1997). Regulation and significance of apoptosis in the stem cells of the gastrointestinal
epithelium, Stem Cells, 15: 82-93
Potten CS and Hendry JM (Eds) Cytotoxic Injury to Tissue, Edinburgh Churchill Livingstone 1983
105-152 : cytotoxic effects in gastrointestinal epithelium
Potten CS, Rezvani M, Hendry JH, Moore JV, Major D (1981) The correction of intestinal
microcolony counts for variation in size. International Journal OfRadiation Biology, 40 (3): 321-326
Potten CS, Booth C, Pritchard DM (1997) The intestinal epithelial stem cell: the mucosal governor.
International Journal ofExperimental Pathology, 78, No.4: 219-243
Pritchard DM, Potten CS, Hickman JA (1998). The relationships between p53-dependent apoptosis,
inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia.
Cancer Research, 58: 5453-5465
Pritchard DM, Potten CS, Korsmeyer SJ, Roberts S, Hickman JA (1999). Damage-induced apoptosis in
intestinal epithelia from bcl-2-null and bax-null mice: investigations of the mechanistic determinants of
epithelial apoptosis in vivo. Oncogene 18: 7287-7293
C. Prives, P.A. Hall (1999). The P53 pathway. Journal ofPathology, 187: 112-126
Prolla TA, Abuin A, Bradley A (1996). DNA mismatch repair deficient mice in cancer research.
Seminars In Cancer Biology, 7(5): 241-247
Prolla TA, Baker SM, Harris AC, Tsao EL, Yao X, Bronner CE, Zheng BH, Gordon M, Reneker J,
Arnheim N, Shibata D, Bradley A, Liskay RM (1998). Tumour susceptibility and spontaneous
mutation in mice deficient in Mlhl, Pmsl and Pms2 DNA mismatch repair. Nature Genetics, 18 (3):
276-279
Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SE, Salter DM, Bird CC, Wyllie AH,
Hooper ML (1994) Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53
gene. Oncogene 9: 603-609.
259
Rafferty JA, Clarke AR, Sellapan D, Koref MS, Frayling IM and Margison GP (1996). Induction of
Murine -alkylguanine-DNA-alkyltransferase in Response to Ionising Radiation is p53 Gene Dose
Dependent. Oncogene 12: 693-697.
Razin A (1998). CpG methylation, chromatin structure and gene silencing - a three-way connection.
EMBO Journal, 17: 4905-4908
Reed E (1998). Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer
chemotherapy. Cancer Treatment Reviews 24: (5) 331-344
Reichmann, Martin AP, Levin B (1981). Chromosome banding patterns in human large bowel cancer.
Int. J. Cancer 28: 431-440.
Reitmair AH, Schmits R, Ewel A, Bapat B, Redston M, Mitri A, Waterhouse P, Mittrucker HW,
Wakeham A, Liu B, Thomason A, Griesser H, Gallinger S, Ballhausen WG, Fishel R, and Mak TW.
(1995). MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nature Genetics, 11: 64-
70.
Reitmair AH, Cai JC, Bjerknes M, Redston M, Cheng H, Pind MTL, Hay K, Mitri A, Bapat BV, Mak
TW, Gallinger S (1996A) MSH2 deficiency contributes to accelerated APC-mediated intestinal
tumorigenesis, Cancer Research, 56: 2922-2926
Reitmair AH, Redston M, Cai JC, Chuang TCY, Bjerknes M, Cheng H, Hay K, Gallinger S, Bapat B,
Mak TW (1996B) Spontaneous intestinal carcinomas and skin neoplasms in MSH2-defkient mice
Cancer Research, 56 (16): 3842-3849
Reitmair AH, Risley R, Bristow RG, Wilson T, Ganesh A, Jang A, Peacock J, Benchimol S, Hill RP,
Mak TW, Fishel R, Meuth M (1997), Mutator phenotype in Msh2-deficient murine embryonic
fibroblasts, Cancer Research, 57(17): 3765-3771
Reynaud CA, Bertocci B, Frey S, Delbos F, Quint L, Weill JC (1999) Mismatch repair and
immunoglobulin gene hypermutation: did we learn something? Immunology today 20 522-527
Riccio A, Aaltonen LA, Godwin AK, Loukola A, Percesepe A, Salovaara R, Masciullo V, Genuardi M,
Paravatou-Petsotas M, Bassi DE, Ruggeri BA, Klein-Szanto AJP, Testa JR, Neri G, Bellacosa A
(2000). The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite
instability. Nature Genetics. 23: 266-268
260
Roberts SA, Potten CS (1994). Clonogen Content Of Intestinal Crypts - Its Deduction Using A
Microcolony Assay On Whole-Mount Preparations And Its Dependence On Radiation-Dose
International Journal OfRadiation Biology, 65: 477-481
Roberts SA, Hendry JH, Potten CS (1995). Deduction Of The Clonogen Content Of Intestinal Crypts -
A Direct Comparison Of2-Dose And Multiple-Dose Methodologies, Radiation Research, 141: SOS-
SOS
Roose J, Molenaar M, Peterson J, Hurenkamp J, Brantjes H, Moerer P, van de Wetering M, Destree O,
Clevers H (1998). The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional
repressors Nature 395: (6702) 608-612
Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R, Logtenberg T, Clevers H
(1999). Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcfl. Science, 285:
1923-1926.
Rowen AJ, Lamlum H, Ilyas M, Wheeler J, Papadopoulou A, Bicknell D, Bodmer WF, Tomlinson
IPM (2000). APC mutations in sporadic colorectal tumours: A mutational hotspot and interdependence
of the two hits. Proc. Natl. Acad. Sci. USA. 91 (4): 3352-3357
Rubinfeld B, Souza B, Albert I, Muller O, Chamberlain SH, Masiarz Fr, Munemitsu S, Polakis P
(1993). Association of the Ape gene-product with beta-catenin.. Science. 262:1731-1734
Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P (1996). Binding of GSK3b to the
APC-P-catenin complex and regulation of complex assembly. Science. 272:1023-1026
Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E and Polakis P (1997). Stabilization of P-
catenin by genetic defects in melanoma cell lines. Science, 275: 1790-1792
Ruschoff J, Wallinger S, Dietmaier W, Bocker T, Brockhoff G, Hofstadter F, Fishel R (1998). Aspirin
suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic
selection. Proc. Natl. Acad. Sci. USA. 95 (19) 11301-11306
Sands AT, Suraokar MB, Sanchez A, Marth JE, Donehower LA, Bradley A (1995). P53 Deficiency
Does Not Affect The Accumulation Of Point Mutations In A Transgene Target. Proc.Natl. Acad. Sci
USA 92: 8517-8521
261
Sanderson BJ, and Shield AJ (1996). Mutagenic damage to mammalian cells by therapeutic alkylating
agents. Mutat Research, 355: 41-57.
Sansom OJ, Clarke AR (2000). P53 null mice: damaging the hypothesis? Mutation Research-
Fundamental AndMolecular Mechanisms OfMutagenesis. 452 : 149-162
Sansom OJ, Toft NJ, Winton DJ, Clarke AR (2001). Msh-2 suppresses in vivo mutation in a gene dose
and lesion dependent manner. Oncogene. 20 : 3580-3584
Shcherbakova PV and Kunkel TA (1999). Mutator phenotypes conferred by MLH1 overexpression and
by heterozygosity for mlhl mutations. Molecular and Cellular Biology, 19: 3177-3183
Schmitt CA, Rosenthal, CT, Lowe, SE (2000). Genetic analysis of chemoresistance in primary murine
lymphomas. Nature Medicine. 6 (8): 1029-1035
Selva EM, New L, Crouse GF, Lahue RS (1995). Mismatch correction acts as a barrier to homeologous
recombination in saccharomyces-cerevisiae. Genetics, 139 (3): 1175-1 188
Shackney SE, Smith CA, Miller BW, Burholt DR, Murtha KR, Giles HR, Ketterer DM, Pollice AA
(1989). Model for the genetic evolution of human solid tumours. Cancer Research. 49: 3344-3354.
Sheng H, Shao J, Williams CS, Pereira MA, Taketo MM, Oshima M, Reynolds AB, Washington MK,
DuBois RN and Beauchamp RD (1998). Nuclear translocation of P-catenin in hereditary and
carcinogen induced intestinal adenomas. Carcinogenesis. 19:543-550
Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S, Matsumoto H, Takano H, Akiyama T,
Toyoshima K, Kanamaru R, Kanegae Y, Saito I, Nakamura Y, Shiba K and Noda T (1997). Rapid
colorectal adenoma formation initiated by conditional targeting of the Ape gene. Science, 278:120-
123.
Shoemaker AR, Moser AR, Dove WF (1995) N-ethyl-N-nitrosourea treatment of multiple intestinal
neoplasia (min) mice -age-related effects on the formation of intestinal adenomas, cystic crypts, and
epidermoid cysts. Cancer Research, 55(19): 4479-4485.
Shoemaker AR, Gould KA, Luongo C, Moser AR, Dove WF (1997) Studies of neoplasia in the Min
mouse. Biochim Biophys Acta, 1332: 25-48
Shoemaker AR, Moser AR, Midgely CA, Clipson L, Newton MA, Dove WF (1998) A resistant genetic
background leading to incomplete penetrance of intestinal neoplasia and reduced loss of heterozygosity
in ApcMlu /+ mice. Proc. Natl. Acad. Sci. USA , 95: 10826-10831
262
Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A (1999) The
cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA. 96 (10):
5522-5527
Smits R, van der Houven van Oordt W, Luz A, Zurcher C, Jagmohan-Changur S, Breukel C, Khan PM,
Fodde R Apcl638N (1998). A mouse model for familial adenomatous polyposis-associated desmoid
tumors and cutaneous cysts. Gastroenterology, 114: 275-283
Sonneveld E, Vrieling H, Mullenders LHF, van Hoffen A (2000). Mouse mismatch repair gene Msh2 is
not essential for transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers. Oncogene.
20 : 538-541
Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R, House A, Iacopetta B (1997). p53 alterations
are associated with improved prognosis in distal colonic carcinomas. Clinical Cancer Research, 3:
1405-1411
Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B (2000)
Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of
tumour site, stage, adjuvant chemotherapy and type of mutation. European Journal Of Cancer, 36:
2053-2060
Sparks AB, Morin PJ, Vogelstein B, Kinzler KW (1998) Mutational analysis of the APC/beta-
catenin/Tcf pathway in colorectal cancer. Cancer Research, 58 (6): 1130-1134
Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990). Germ-Line Transmission of A
Mutated P53 Gene In A Cancer-Prone Family With Li-Fraumeni Syndrome, Nature, 348: 747-749
Stark LA, Din FVN, Zwacka RM, Dunlop MG (2001). Aspirin-induced activation of the NF-kappa B
signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB
Journal. 15 (7) 1273-1275
Stevens LC, Little CC (1954). Spontaneous testicular teratomas in an inbred strain of mice. Proc..Natl
Acad. Sci USA, 40 : 1080-1087
Strand M, Earley MC, Crouse GF, Petes TD (1995). Mutations in the Msh3 gene preferentially lead to
deletions within tracts of simple repetitive DNA in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci.
USA, 92 (22): 10418-10421
263
Strathdee G, MacKean MJ, Illand M, Brown R (1999). A role for methylation of the hMLHl promoter
in loss of hMLHl expression and drug resistance in ovarian cancer. Oncogene, 18: 2335-2341
Strathdee G, Sansom OJ, Sim A, Clarke AR, Brown R (2001). A role for mismatch repair in control of
DNA ploidy following DNA damage. Oncogene, 20: 1923-1927
Su LK, Kinzler KW, Vogelstein B, Presinger AC, Moser AR, Luonga C, Gould KA, Dove WF (1992).
Multiple intestinal neoplasia caused by a mutation in the murine homologue of the APC gene. Science,
256: 668-670
Sugawara N, Paques F, Colaiacovo M, Haber JE (1997). Role of Saccharomyces cerevisiae Msh2 and
Msh3 repair proteins in double-strand break-induced recombination. Proc. Natl. Acad. Sci. USA, 94:
(17) 9214-9219
Symonds H, Krall L, Remington L, Saenzrobles M, Lowe S, Jacks T, Vandyke T (1994). P53-
Dependent Apoptosis Suppresses Tumor-Growth And Progression In-Vivo. Cell, 78: 703-71 1
Takayama T, Shiozaki H, Shibamoto S, Oka H, Kimura Y, Tamura S, Inoue M, Mondon T, Ito F,
Monden M (1996). Beta-catenin expression in human cancers. American Journal of Pathology, 148:
39-46
Tao KS, Heddle JA (1994). The Accumulation And Persistence Of Somatic Mutations In-Vivo.
Mutagenesis, 9: 187-191
Tentori L, Orlando L, Lacal PM, Benincasa E, Faraoni I, Bonmassar E, DAtri S, Graziani G (1997).
Inhibition of O-6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases
susceptibility of leukemic coils to apoptosis induced by temozolomide. Molecular Pharmacology. 52
(2): 249-258
Tetsu O, McCormick F (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells
Nature, 398: 422-426
Thompson AM, Morris RG, Wallace M, Wyllie AH, Steel CM and Carter DC (1993). Allele loss from
5q21 (APC/MCC) and 18q21(DCC) and DCC mRNA expression in breast cancer. British Journal of
Cancer, 68: 64-68.
Thun MJ, Namboodiri MM, Heath CW (1991). Aspirin Use And Reduced Risk Of Fatal Colon
Cancer. N. Engl. J. Med., 328 : 1593-1596
264
Toft NJ, Arends MJ, Wyllie AH, Clarke AR (1998). No female embryonic lethality in mice nullizygous
for Msh2 and p53. Nature Genetics, 18: 17.
Toft NJ, Winton DJ, Kelly J, Howard LA, Dekker M, Riele HT, Arends MJ, Wyllie AH, Margison GP,
Clarke AR (1999). Msh2 status modulates both apoptosis and mutation frequency in the murine small
intestine. Proc. Natl. Acad. USA. 96: 3911-3915
Toft NJ, Sansom OJ, Brookes RA, Arends MJ, Wood M, Margison GP, Winton DJ, Clarke AR (2000).
In vivo administration of O-6-benzylguanine does not influence apoptosis or mutation frequency
following DNA damage in the murine intestine, but does inhibit P450-dependent activation of
dacarbazine. Carcinogenesis. 21: 593-598
Tomlinson IPM, Ilyas M, Bodmer WF (1996). Allele loss occurs frequently at hmlhl, but rarely at
hmsh2, in sporadic colorectal cancers with microsatellite instability. British Journal Of Cancer, 74
(10): 1514-1517
Toyota M, Ohe-Toyota M, Ahuja N, Issa JPJ (2000). Distinct genetic profiles in colorectal tumors with
or without the CpG island methylator phenotype. Proc. Natl. Acad. Sci. USA, 97: (2) 710-715
Tsujii M, Dubois RN (1995). Alterations in cellular adhesion and apoptosis in epithelial-cells
overxpressing prostaglandin-endoperoxide-synthase-2. Cell, 83 (3): 493-501.
Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998). Cyclooxygenase regulates
angiogenesis induced by colon cancer cells. Cell, 93 (5): 705-713
Turkcr MS (1998). Estimation of mutation frequencies in normal mammalian cells and the
development of cancer. Seminars In Cancer Biology, 8: 407-419
Tweedie S, Charlton J, Clark V, Bird A(1997) Methylation of genomes and genes at the invertebrate-
vertebrate boundary. Molecular and Cellular Biology, 17:1469-1475
Umar A, Koi M, Risinger JI, Glaab WE, Tindall KR, Kolodner RD, Boland CR, Barrett JC, Kunkel TA
(1997), Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective
DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2
and MSH6, Cancer Research, 57 (18): 3949-3955
Umar A, Risinger JI, Glaab WE, Tindall KR, Barrett JC, Kunkel TA (1998). Functional overlap in
mismatch repair by human MSH3 and MSH6, Genetics, 148: 1637-1646
265
van der Houven, van Oordt CW, Smits R, Williamson SL, Luz A, Khan PM, Fodde R, van der Eb AJ,
Breuer ML (1997). Intestinal and extra-intestinal tumor multiplicities in the Apc1638N mouse model
after exposure to X-rays. Carcinogenesis, 18:2197-2203
VanMeyel DJ, SanchezSweatman OH, Kerkvliet N, Stitt L, Ramsay DA, Khokha R, Chambers AF,
Cairncross JG (1998). Genetic background influences timing, morphology and dissemination of
lymphomas in p53-deficient mice. International Journal OfOncology, Vol.13, No.5 : 917-922
Veigl ML, Kasturi L, Olechnowitz J, Ma A, Lutterbaugh JD, Periyasamy S, Li G-M, Drummond J,
Modrich PL, Sedwick WD, Markowitz SD (1998). Biallelic inactivation of hMLHl by epigenetic gene
silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. USA,. 95: 8698-8702
Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, Pinkel D and Donehower LA (1998).
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can
promote cancer formation. EMBO Journal, 17:4657-4667.
Vindelov LL, Christensen IJ, Nissen NI (1983). A detergent-trypsin method for the preparation of
nuclei for flow cytometric DNA analysis. Cytometry, 3: 323-327.
Vleminckx K, Vakaet L, Mareel M, Fiers W, Vanroy F (1991). Genetic Manipulation Of E-Cadherin
Expression By Epithelial Tumor-Cells Reveals An Invasion Suppressor Role. Cell, 66: (1) 107-119
Vogelstein B, Kinzler KW (1992). p53 function and dysfunction. Cell, 70: 523-526.
Vogelstein B, Kinzler KW(1993). The multistep nature of cancer. Trends in Genetics, 9: 138-141.
Vogelstein B, Lane D, Levine AJ (2000). Surfing the p53 network. Nature, 408 : 307-310.
von Hofe E, and Kennedy AR (1988). In vitro induction of 06-methylguanine-DNA methyltransferase
in C3H/10T1/2 cells by X-rays is inhibited by nitrogen. Carcinogenesis, 9: 679-681.
Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ (2000). WISP1 is a Wnt-1 and P-catenin
responsive oncogene. Genes and Development. 14: 585-595
Xu XXS, Narayanan L, Dunklee B, Liskay RM, Giazer PM (2001) Hypermutability to ionizing
radiation in mismatch repair-deficient, Pms2 knockout mice. Cancer Research, 61: 3775-3780
Wang XW, Zhan QM, Coursen JD, Khan MA, Kontny HU, Yu LJ, Hollander MC, O'Connor PM,
Fornace AJ, Harris CC (1999). GADD45 induction of a G(2)/M cell cycle checkpoint. Proc. Natl
.Acad. Sci. USA. 96: 3709-3711
266
Wang Y, Cortez D, Yazdi P, NeffN, Elledge SJ, Qin J (2000). BASC, a super complex of BRCA1-
associated proteins involved in the recognition and repair of aberrant DNA structures. Genes &
Development, 14: (8) 927-939
Waters TR, Swann PF (2000). Thymine-DNA glycosylase and G to A transition mutations at CpG
sites. Mutation Research-Reviews In Mutation Research. 462 :137-147
Wedge SR and Newlands ES (1996). BeG enhances the sensitivity of a glioma xenograft with low O6-
alkylguanine-DNA-alkyltransferase activity to temozolomide and BCNU. Br. J. Cancer, 73, 1049-
1052.
Welsh KM, Lu A-L, Clark S, Modrich P (1987). Isolation and characterisation of the Escherichia coli
mutH gene product. Journal OfBiological Chemistry, 262: 15624-15629
Wheeler JMD, Mortensen NJMcC, Bodmer WF (2000). DNA mismatch repair genes and colorectal
cancer. Gut. 47:148-153
Wieschaus E and Riggleman R (1987). Autonomous requirements for the segment polarity gene
armadillo during Drosophila embryogenesis. Cell, 49: 179-184
Wiltert K, Nusse, R (1998) p-catenin: a key mediator of Wnt signalling. Current opinion in Genetics
and Development. 8 :95-102
Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN
(1996). Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology. Ill (4) 1134-
1140
Williams CS, Mann M, DuBois RN (1999). The role of cyclooxygenases in inflammation, cancer, and
development. Oncogene. 18: 7908-7916
Williams CS, Watson AJM, Sheng HM, Helou R, Shao JY, DuBois RN (2000). Celecoxib prevents
tumor growth in vivo without toxicity to normal gut: Lack of correlation between in vitro and in vivo
models. Cancer Research. 60 (21): 6045-6041
Williamson SLH, Kartheuser A, Coaker J, Kooshkghazi MD, Fodde R, Burn J, Mathers JC (1999).
Intestinal tumorigenesis in the Apcl638N mouse treated with aspirin and resistant starch for up to 5
months. Carcinogenesis, 20 (15) 805-810
267
Winton DJ, Blount MA, Ponder BAJ (1988) A Clonal Marker Induced By Mutation In Mouse
Intestinal Epithelium, Nature, 333: 463-466
Wong MH, Hermiston ML, Syder AJ, Gordon JI (1996) Forced expression of the tumor suppressor
adenomatosis polyposis coli protein induces disordered cell migration in the intestinal epithelium.
Proc. Natl. Acad. Sci. USA, 93: 9588-9593
Wyllie AH (1980). Glucocortocoid- induced thymocyte apoptosis is associated with endonuclease
activation. Nature. 284 :555-556
Wyllie AH (1985). The biology of cell death in tumours. Anticancer Research, 5 : 131-135
Wyllie AH (1987) Apoptosis: cell death under homeostatic control. Arch. Toxicol, 11 3-10
Wyllie AH, Kerr JF, Currie AR (1980). Cell death: the significance of apoptosis. Int. Rev.Cytl. 68 :
251-3066
Wyllie AH, Carder PJ, Clarke AR, Cripps KJ, Gledhill S, Greaves MF, Griffiths S, Harrison DJ,
Hooper ML, Morris RG, Purdie CA, Bird CC (1994). Apoptosis in carcinogenesis - the role of p53.
Cold Spring Harbor Symposia on Quantitative Biology,\ol.59: 403-409
Yamada M, Oregan E, Brown R, Karran P (1997). Selective recognition of a cisplatin-DNA adduct by
human mismatch repair proteins. Nucleic Acids Research, 25 (23): 491-495
Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992). Wild-type p53 restores cell cycle
control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70: 937-948.
You YH, Halangoda A, Buettner VL, Hill K, Sommer SS, Pfeifer G (1998). Methylation of CpG
dinucleotides in the lacl gene of the Big Blue (R) transgenic mouse. Mutation Research-Genetic
Toxicology And Environmental Mutagenesis, 420: 55-65
Yuan ZM, Shioya H, Ishiko T, Sun XG, GuJ JJ, Huang YY, Lu H, Kharbanda S, Weichselbaum R,
Kufe D (1999). P73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage.
Nature, 399: 814-817
Zeng M, Narayanan L, Xu XXS, Prolla TA, Liskay RM, Glazer PM (2000). Ionizing radiation-induced
apoptosis via separate Pms2-and p53-dependent pathways. Cancer Research, 60: 4889-4893
Zhang T, Nanney LB, Luongo C, Lamps L, Heppner KJ, DuBois RN (1997). Concurrent
overexpression of cyclin D1 and cyclin-dependent kinase 4 (Cdk4) in intestinal adenomas from
268
multiple intestinal neoplasia (Min) mice and human familial adenomatous polyposis patients. Cancer
Research. 57: 169-175
269
13.0 Appendix: Cytotoxic agents and gene dependency
This final section gives a brief overview of the genotoxic drugs that will be used
in this thesis.
13.1 Methylating Agents : Temozolomide, MNNG, MNU
The cytotoxic lesion produced by all of these drugs is thought to be the 06meG. It
elicits both Msh2 and p53 dependent apoptosis (Toft et al. 1999). Both NMNU
and temozolomide have been used in chemotherapy. At present temozolomide is
being used to treat malignant glioma in the US (Friedman et al. 2000). However
for all three of these drugs the most predominant lesions are N7 methyl guanine
and N3 methyl adenine. These are thought to repaired very quickly by the base
excision repair genes : N7-methylguanine and N3 methyl adenine DNA
glycosylases (Newlands et al. 1997). The evidence that 06 methylguanine is the
cytotoxic lesion comes form studies using NMNU as a carcinogen. Mice treated
with NMNU can be protected from tumourigenesis by over expression of 06-
alkylguanine-DNA alkyltransferase (MGMT). MGMT is a suicide transferase
which removes the 06 meG and to a lesser extent 04 meT. Thus increases in the
level of this enzyme protects against tumourigenesis (Dumenco et al. 1993, Allay
et al. 1999). Likewise reduction of levels ofMGMT causes increased sensitivity
and apoptosis to these agents (Tentori et al. 1997, Bignami et al. 2000).
/
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Figure 13.1. Percentage lesion profile of the methylating agents: Adapted
from Pieper 1995, Eisenbrand et al. (1994), Goldmacher et al. (1986) and Denny
et al. (1994). In case where numbers of lesions do not add up to 100% (e.g.
temozlomide) this is due to the study only quantifying a certain lesion type
(Denny et al. 1994).
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Figure 13.2. Structure of 06 methyl Guanine (06meG). Although the 06
position of guanine is a weak nucleophile and reacts with the methylating agents
much less than the N7 lesion, it's the most important adduct for both mutagenesis
and carcinogenesis.
13.2 Cisplatin damage
Cisplatin (cis-diamminedichlorolplatinum II) is used very successsfully in the
treatment of testicular cancer. It is also used in the treatment of ovarian and
bladders cancers (Brown et al. 1997 ).
Figure 13.3: Structure of cisplatin and transplatin (adapted from Leng and
Brebec 1994)
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Insights into the cytotoxic adducts have come from comparison of the adducts
formed between cisplatin and transplatin. Unlike cisplatin, transplatin (an isomer
of cisplatin) does not appear to be cytotoxic (Zlatnova et al. 1998). The major
difference is that predominant lesion (approx 65%) cisplatin produces is an cis
GG intrastrand crosslink. This induces a large bend in the DNA, blocking
transcription. It is thought that the major pathway for cisplatin removal is through
nucleotide excision repair with mismatch repair playing a smaller role (Zlatanova
et al. 1998). Cisplatin has also been shown to induce apoptosis (probably through
the G-G lesion) which is p53 dependent (Toft et al. 1999). Recently Branch et al.
(2000) showed in ovarian cell lines that resistance to cisplatin predominantly
related to p53 status with mismatch repair playing a much smaller role.
13.3 Nitrogen Mustard
Nitrogen mustards are among the oldest chemotherapeutics still being used. They
can form large bulky adducts and crosslinks that block DNA replication
(Hemminiki 1994). In fact the nitrogen mustard melphalan produces a very
similar set of lesion to cisplatin. The nitrogen mustard used here is nitrogen
mustard (Mechlorethamine Hydrochloride). Fan et al. (1997) showed that both
p21 null MEFS and HCT116 colorectal cancer cells showed preferential
sensitivity to Nitrogen Mustard. Nitrogen Mustard has been shown to induce
apoptosis and kill small intestinal stem cells (Ijiri and Potten 1984, 1987). In this
thesis the p53 and the MMR dependency of this apoptosis will be investigated.
Figure 13.4. Structure of Nitrogen Mustard
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13.4 Additional Methods
The methods described in the following section were performed by Lucy Curtis
and Neil Toft. Data from these methods are included in chapter 6.
Immunophenotyping of thymic lymphomas
Fresh tumour tissue was dissagregated and frozen in 1ml freezing medium. Prior
to analysis samples were defrosted and lymphocytes isolated using Lympholyte M
(Cedarlane Laboratories) as per protocol. Lymphocytes were resuspended in Flow
Buffer [1% Bovine Serum Albumin, 1% Sodium Azide] and incubated with
primary antibody on ice for 1 hour, washed and incubated with 25pl of the
appropriate FITC secondary antibody for a further hour. Cells were resuspended
in 200pl of Flow Buffer before analysis on the EPICS XL Flow Cytometer using
XL2 Software (Coulter).
Analysis ofwild-type p53 allele in MSH2' ~ p53~ mice
DNA was extracted from small pieces (3mm x 3mm) of tumour using phenol /
chloroform extraction and resuspended in 500pl TE and p53 status determined by
PCR Total RNA was extracted using 1ml Trizol (GibcoBrl). lpl of RNA was
reverse transcribed into cDNA using oligo(dT)is primers. PCR primers 33A and
21B (Ozbun et al. 1993) were used to amplify a 686 bp fragment of p53 cDNA
which included exons 5-9. For each tumour cDNA three separate PCR reactions
were performed. Each PCR product was cloned and sequenced from both
directions using a Fluorescent Automated DNA Sequencer (Licor).
DNA flow cytometry
DNA content of tumours was analysed according to Vindelov et al. 1983. DNA
content was analysed on a EPICS XL Flow Cytometer using Multicycle Software
(Coulter).
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Comparative Genomic Hybridisation (CGH)
CGH was carried out on a series of 42 lymphomas according to the method of
Kallioniemi et al., (1992), slightly modified. Briefly, DNA was labelled by
incorporation of digoxygenin-11-dUTP (normal DNA) or biotin-16-dUTP (test
DNA) by nick translation. Metaphase spreads were prepared from karyotypically
normal E14 mouse embryonic stem cells. Slides were pretreated with lOpg/ml
RNase A at 37°C for one hour and lOOng/ml proteinase K solution at 37°C for 2.5
minutes, denatured in 70% formamide/2XSSC solution at 70°C for 3 minutes and
dehydrated through a ethanol series. 500ng of each labelled probe and 20pg
mouse Cot-1 DNA were denatured at 70°C for 5 minutes and allowed to reanneal
at 37°C for 1 hour before hybridisation onto slides for 2 days. Detection was
carried out with FITC-avidin and antidigoxygenin-rhodamine and chromosomes
counterstained with DAPI as described (Kallioniemi et al., 1992). Hybridisations
were analysed using Quantitative Image Processing System (QUIPS) software
(Vysis Ltd, Richmond, UK). For each tumour, four to eight metaphase spreads
were karyotyped manually and green/red ratio cut-off points of 1.2 and 0.8 were
chosen for scoring of chromosome copy number changes.
Microsatellite analysis ofmouse tumours
Four microsatellite loci were chosen for analysis: DlMit4, D7Mitl7, D10Mit2
and D14Mitl5. Primers sequences and reaction conditions were obtained from the
Whitehead Institute for Biomedical Research/Massachusetts Institute of
Technology Centre for Genome Research website at
http://www.genome.wi.mit.edu. MSI was assessed by comparison of normal and
tumour PCR products on a 6% denaturing polyacrylamide gel with silver staining,
as described elsewhere (Bubb et al. 1996).
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families characterized by mutations in the MMR genes. Mice consti-
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Abstract
Numerous studies have indicated that exposure to nonsteroidal anti¬
inflammatory drugs is associated with a lowered risk of colorectal
cancer. However, analyses of the effect of aspirin upon tumorigenesis
in ApcMin,+ mice have yielded contrasting results. We show that adult
dietary exposure to aspirin does not suppress intestinal tumorigenesis
in ApcMin/+ mice, but that continual exposure from the point of con¬
ception does. To test whether this regime could suppress the ohenotype
of murine models of hereditary nonpolyposis colorectal offiS
Msfc2-deficient mice were exposed to aspirin. This did not modify the
mutator phenotype of Msh2~'~ mice, but weakly extended survival.
Finally, we analyzed (ApcMiD,+, Msh2~'~) mice and found that lifetime
aspirin exposure significantly delayed the onset of both intestinal and
mammary neoplasia. Thus embryonic and perinatal exposure to aspi¬
rin suppresses neoplasia specifically associated with the loss of Ape
function, opening a potential window of opportunity for nonsteroidal
anti-inflammatory drug intervention.
Introduction
Substantial epidemiological evidence shows that treatment with
NSAIDS3 reduces the risk of developing colorectal cancer. The most
commonly used NSAID has been aspirin, which has been reported to
reduce the risk of colon cancer by up to 40%. Clinical studies using
the NSAID sulindac have also reported reduced polyp counts in FAP
patients (1, 2). The precise mechanism of NSAID action remains
unclear, although the suppression of Cox2 is thought to be of pivotal
importance. Significantly, Cox2 is overexpressed in ~85% of human
colorectal adenocarcinomas and adenomas from the ApcMm mouse
(3). The definitive study highlighting the relevance of Cox2 to tumor¬
igenesis showed that a Cox2-deficient background markedly sup¬
pressed intestinal neoplasia in mice carrying the Ape6716 allele (4).
The biological activities of aspirin and sulindac are not restricted to
suppression of the Cox2 pathway. Aspirin, sulindac, and even the
selective Cox2-inhibitor celecoxib (5) have been shown to induce
apoptosis in a Cox2-independent fashion. Both aspirin and sulindac
down-regulate /3-catenin- and /3-catenin/TCF4-mediated transcription
(6, 7). NSAIDS also act on the nuclear factor kB signaling pathway
(8), and recent data suggest this may be important for their antitumor
activities (8). They have also been shown to specifically reduce the
survival of genetically unstable (MSI+) MMR-deficient colorectal
cancer cell lines (9), raising the possibility that aspirin may also
suppress malignancy in hereditary nonpolyposis colorectal eaiutiuillU
tutively heterozygous for the ApcMm allele have been used to deter¬
mine the ability of the NSAIDs to suppress intestinal malignancy.
However with respect to aspirin, these studies have produced con¬
trasting results. Virtually every study [e.g., Beazer-Barclay etal., (10)
has shown that sulindac causes a reduction in the number of the
spontaneous malignancies, apart from Oshima et al. (4) who use AQ:K
relatively low levels of sulindac]. However, of the studies that have
investigated spontaneous intestinal malignancy after aspirin treatment, / ,
only two have shown suppression ofmalignancy in the ApcMm mouse.
Two other studies failed to show suppression in either the ApeMm
mouse or the ApcI638N mouse (6, 11-13). The basis for these discrep¬
ancies may lie within differences in the aspirin regime used. Shoe¬
maker et al. (14) and Reitmair et al. (15) have argued that the majority
of adenomas are fixed either in utero or perinatally just after birth.
Here we directly test the effect of increasing the period of aspirin
exposure to include the entire period from the point of conception
onwards. Furthermore, we have investigated whether this regime can
modify the development of MMR-associated neoplasia by investigat¬
ing the course of neoplasia in cohorts of Msh2~/~ and (ApcMln/+,
Msh2~/~) mice. We find that prolonged aspirin exposure dramatically
enhances the suppression of Apc-associated neoplasia both within the
intestine and the mammary gland but only weakly influences the
phenotype of MMR deficiency.
Materials and Methods
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Administration ofDietary Aspirin atWeaning. C57BL/6 mice wild-type
and heterozygous for the ApeM,n mutation were placed on diets containing
either 0, 200, or 400 mg/kg of aspirin (Harlan/Tekad). These levels of exposure
are comparable with the highest doses used in previous studies (6, 11-13).
Mice were monitored everyday for signs of disease, generally manifesting
itself as anemia, loss of weight, and a hunched appearance.
Two experiments were performed: one where mice were killed at 150 days
of age and one where mice were killed where they showed signs of disease.
Permanent Administration of Aspirin. Matings segregating for progeny
which were ApcM,n/+, Msh2~/~ or (ApcMM+, Msh2~/~) were placed on aspirin
diets containing either 0 or 400 mg/kg of aspirin before conception and
throughout pregnancy and lactation. Progeny were weaned onto appropriate
diets. Mice were killed when they showed signs of disease.
Histological Analysis. Tissues were removed, fixed in 10% neutral buff¬
ered formalin, embedded in paraffin, sectioned at 10 um, and stained with
H&E before microscopic analysis. Scoring of intestinal lesion was achieved by
. removing the entire intestine at necropsy, flushing with PBS, and mounting en
UUV) C£Sface. These preparations were then fixed in methacam (4:2:1, methanol:
chloroform:glacial acetic acid). Lesions were then scored macroscopically.
Intestine was then wound into a "swiss" roll, which was subsequently embed¬
ded in paraffin and then sectioned as above.
Mutation Frequency at the Dlb-lb Locus. The Dlb-1 assay was per¬
formed as described previously (16). For this assay, experimental cohorts were
derived by backcrossing the Msh2 mutants to two different C57B1/6 strains,
one of which was homozygous for the Dlb-1 a allele and one of which was
homozygous for the Dlb-1 b allele. Mice were subsequently intercrossed from
A9Z M t C roScvfeXL'tte. nTrxS-fobL1
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these two lines to generate mice heterozygous at the Dlb-1 locus and segre¬
gating for all possible Msh2 genotypes.
Results and Discussion
Aspirin Does Not Suppress Intestinal Neoplasia when Admin¬
istered at Weaning. Wild-type and ApcMm mice were placed on
aspirin-containing diets (either 200 mg/kg or 400 mg/kg) at weaning.
(Fig. 1). Mice exposed to the aspirin diet gained weight normally
when compared with mice on the control diet, and no ulceration or
intestinal pathology such as perforation of the intestine was observed
in any of the wild-type mice treated with aspirin. Two independent
analyses were performed.
First, cohorts of mice either wild-type or heterozygous for the
ApcMin allele were killed at 150 days of age, and the adenoma burden
was assessed on whole mount preparations of the entire small intes¬
tine. No adenomas were seen in wild-type mice. Adenoma burden was
as follows: for mock treated ApcMm mice (n = 5), 9.8 (±/6.3); for
mice treated with 200 mg/kg (n = 7), 9.7 (±5.88); and for mice
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Fig. 1. A, Kaplan-Meier plot of survival of ApcAfm/+ exposed to control or aspirin-
containing diet. Black line, mock treated mice (n = 15); red line, 200 mg/kg diet (n = 12);
blue line, 400 mg/kg of diet (n = 10). There was no significant difference in the survival
curves of either the mice treated with 200 mg/kg (log-rank test; P = 0.96) and 400 mg/kg
^log-rank test; P = 0.30). Green line, ApcMUl/+ mice exposed to aspirin-containing diet
from point of conception. These mice (n = 16) showed a significant increase in survival
(log-rank; P = 0.0004) compared with mock-treated and aspirin-treated mice at weaning.
B, tumor burden of mice at point of sacrifice as determined by onset of overt symptoms
of intestinal tumorigenesis. ■, mock-treated mice; □, mice treated with 200v mg/kg; d,
mice treated with 400 mg/kg of aspirin at weaning; 63, mice treated with 400 mg/kg of
aspirin from point of conception. There was no significant difference in the number of
tumors at sacrifice between mock-exposed mice (n = 15) and mice exposed to 400 mg/kg
from conception (Mann-Whitney; P = 0.613; n = 9). Tumor burden of mice >500 days
)f age were excluded from this analysis, because these mice were killed when sympto¬
matic of lymphoma and not intestinal neoplasia.
difference in tumor burden at either 200 mg/kg (P = 1.00) or at 400
mg/kg (P = 0.75; Mann Whitney) compared with mock-treated mice,
indicating that aspirin exposure was not modifying the ApcMln phe-
motype.
•e\ Second, cohorts of mice were permitted to age until they developed
obvious symptoms of intestinal neoplasia, usually bleeding from the
anus or anemia scored through whitening of the feet. Fig. 1A shows a
Kaplan-Meier plot reflecting survival over a 400-day period. Expo¬
sure to aspirin at either 200 mg/kg or 400 mg/kg did not alter the
survival profile, again indicating that exposure to aspirin did not
modify the ApeMin phenotype.
Aspirin Suppresses Intestinal Neoplasia when Administered in
Utero. Because Shoemaker et al. (14) and Reitmair et al. (15) have
argued that the majority of adenomas are fixed before 6 days of age,
we investigated the effect of aspirin exposure throughout embryogen-
esis and weaning. Cohorts of wild-type and ApcMin heterozygotes
were derived from parents placed on aspirin-containing diets before
conception. Dietary exposure to aspirin was maintained throughout
and beyond weaning. We first wished to establish whether in utero
exposure resulted in increased embryonic lethality of ApcMi" het¬
erozygotes, as has been reported for the Coxl- and Cox2-inhibitor
piroxicam (17). Analysis of offspring showed this not to be the case,
because there was no reduction in the number ofApeMm heterozygotes
in progeny from aspirin-exposed parents (P = 0.2; x2 test).
We next determined the survival profiles of each cohort (Fig. 1A),
which showed a significant increase in survival in ApcMln heterozy¬
gotes exposed to aspirin from conception onwards (P = 0.0004;
log-rank test). This effect was sufficient to completely prevent the
development of symptoms associated with intestinal neoplasia in 5 of
16 ApcMt" at 500 days of age. Analysis of tumor burden and distri¬
bution in those mice that developed intestinal tumors showed no
obvious differences in either small (Fig. IB) or large intestine (data
not shown).
A number of different possibilities may underlie the discrepancies
between the published studies examining the effect of aspirin on
ApcA/m-associated tumorigenesis. First, that it is a consequence of
differences in the level of aspirin exposure—a possibility which
seems unlikely given the similar levels used in each experiment.
Second, that it is attributable to differences in the genetic background
of the mice used, either at known modifiers of the ApeMm phenotype,
such as Mom-1, or at as-yet unidentified modifiers (18). In this
respect, it is notable that our study differs from previous studies by
using mice homozygous for the relatively resistant C57/B16 Mom-1
allele. Third, that it is a consequence of different husbandry regimes;
for example, mice housed in a sterile facility may respond very
differently to those in a nonsterile facility.
Comparison of the data presented here with published experiments
does not permit us to distinguish between these possibilities, but it
does serve to underline the relatively fragile nature of aspirin-medi¬
ated suppression within this model. We show here that one of the key
modifiers of the effectiveness of aspirin is the time point of exposure.
By increasing the period of dietary exposure to include in utero and
perinatal exposure, we have dramatically enhanced the ability of
aspirin to modify the Apc?lm phenotype. Within our experimental
design, this enhancement is particularly notable given the failure to
observe any effect in the ApeMm cohort treated postweaning.
These findings are consistent with the presence of a developmental
"window" for adenoma formation either in utero or shortly after birth.
In support of this, Shoemaker et al. (14) showed that perinatal expo¬
sure to chemical carcinogens specifically enhances intestinal tumor
development in the adult. One possible explanation for this phenom¬
enon is the huge expansion in the number of intestinal crypts which
occurs 3 weeks after birth. This process of crypt fission inevitably
AQrot^
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expands the number of any mutation-bearing crypts present within the
intestine and may therefore clonally expand any crypts bearing mu-
tations at the Ape locus.
The presence of a very early window for neoplastic development
raises serious questions about our understanding of Ape-mediated
tumorigenesis. Loss of Ape function is considered to be the key
initiating event in intestinal neoplasia and is strongly associated with
both dysplasia and dysregulation of /3-catenin [e.g., Kongkanuntn et
al. (19)]. However these phenomena simply are not observed in mice
aged <4 weeks, indicating either that loss ofApe alone is insufficient
to lead to the up-regulation of /3-catenin and development of dyspla¬
sia, or that loss ofApe (and thereby dysregulation of /3-catenin) occurs
as a secondary event. In this regard we have shown previously that a
proportion of dysplasias occurring in a mismatch repair-deficient
background are not characterized by increased /3-catenin levels (19).
Aspirin clearly acts to suppress these early events either by deleting
or suppressing the phenotype of those cells which carry an increased
predisposition to adenoma formation. This seems unlikely to be
through modulation of /3-catenin levels, as has been suggested by
Mahmood et al. (6), because, as stated above, elevated levels of
/3-catenin are not observed in young animals. A second possibility is
that aspirin may suppress neoplasia through a Cox2-mediated path¬
way. Cox2 up-regulation is observed in 80-85% of human colorectal
carcinomas, in 50% of colorectal adenomas, and within tumors arising
in the ApeM,n model (3). However, it seems unlikely that the primary
effect of in utero aspirin exposure is mediated through Cox2 suppres¬
sion,Tnasmticli-es Cox2 overexpression is associated with the later
stages of tumorigenesis by modulating angiogenesis and levels of
apoptosis within tumors (3).
Whatever the mechanism of action of aspirin, these studies dem¬
onstrate that the initiation of adenoma formation occurs very early in
the ApcMm mouse, and that aspirin exposure at this time point can
efficiently suppresses this process. Understanding the factors deter¬
mining the predisposition to adenoma formation during embryonic
development and perinatally might lead to greater insights into the
molecular mechanisms of cancer in humans.
Aspirin Weakly Suppresses Neoplasia though not Mutation in
Msh2_/_ Mice. Having established an effective protocol for aspirin
exposure in the murine model of FAP, we determined whether this
approach could modulate the phenot^jte^o^the murine model of
hereditary nonpolyposis colorectal carcinoma. A significant subset of
human intestinal tumors are characterized by mutations in the MMR
pathway, and all murine models of MMR deficiency show increased
predisposition to neoplasia.
Cohorts of Msh2~'~ mice were either exposed to aspirin or were
fed control diet from conception, and Kaplan-Meier survival curves
were generated (Fig. 2A). All 18 animals on the control diet were
killed after the development of lymphoma, although 2 animals also [\
had coexistent intestinal malignancy. All Msh2~'~ mice exposed to
aspirin also developed lymphoma; however, there was a small in¬
crease in survival compared with controls (P = 0.05; log-rank test).
This slight shift in survival may reflect weak suppression of either
intestinal malignancy or lymphomagenesis. This latter possibility is
consistent with the one report that showed that aspirin exposure can
result in the deletion of MSI-unstable cells in culture (9).
These results prompted us to determine directly whether aspirin
exposure can suppress in vivo mutation in a mismatch repair-deficient
background. Mutation frequency was scored at the Dlb-lb locus in
Msh2 mutant mice continually exposed to either control or aspirin-
containing diets. Using this assay, we have shown previously that
Ms/i2-deficient mice have a mutator phenotype at the Dlb-lb locus
(16, 20). Msh2-deficient mice were analyzed at 4 months of age after















Fig. 2. A, Kaplan-Meier plot of survival of Msh2 7 mice exposed to control or
aspirin-containing diet from point of conception. , mock-treated Msh2~/~ mice
(n = 18); —, 400 mg/kg-treated Msh2~/~ mice (n = 20). Msh2~y~ mice treated with
aspirin showed a weak increase in survival (log-rank test; P = 0.05). B, in vivo mutation
frequency/10,000 villi at the Dlb-lb locus after aspirin treatment. Mutation frequencies
were determined from intestinal wholemounts at 4 months of age. Columns, mean
mutation frequency at the Dlb-lb locus. At least three mice were used per each column.
Bars, SD. ■, mock-treated wild-type mice; □, mock-treated Msh2~/~ mice; H, Msh2~y~
mice exposed to 400 mg/kg of dietary aspirin from point of conception. There was not a
significant reduction in mutation frequency after aspirin treatment (P = 0.77; Mann-
Whitney).
mutation frequency was observed at this time point, demonstrating
that this regime of aspirin exposure does not modify the mutator
phenotype of Msh2-null epithelium (Fig. 2B).
Aspirin Suppresses Intestinal and Mammary Neoplasia in
ApcMin/+ Msh2~/_ Mice. In human colorectal cancer MMR-
deficient tumors differ in a number of respects to MMR-proficient
tumore. For example, MMR-deficient tumors express lower levels of .
Cox2rks well as exhibiting very different patterns of mutation andA'
genomic instability. These differences invoke different mechanisms 2
for MMR-driven neoplasia, raising the possibility that aspirin expo- '
sure may have an additional effect in a MMR-deficient background,
for example through the deletion of cells shewing MSI.
The development of lymphoma in Msh2~mice largely precludes an
analysis of the effect of aspirin uponMs/t2-dependent intestinal neoplasia
(22). However, Msh2 deficiency has been shown to greatly accelerate
intestinal neoplasia in the Apc^m mouse (15), so permitting an analysis of
the effect of aspirin in this context. In addition, mammary akanthoma
occur in ApcMin/^ mice (23), and this is greatly accelerated in (ApcMin/+,
Mr/t2~/_) mice, permitting a study of the effect of aspirin on the devel¬
opment of this lesion (see below). Cohorts of (ApcMi^+, Msh2~/~) mice
were generated and exposed to either control diet or aspirin-containing
diet from conception onwards, and Kaplan-Meier survival curves were
generated (Fig. 3A). Survival was markedly enhanced after aspirin expo- F






















Fig. 3. A, Kaplan-Meier plot of survival ofApcMlD/+ Msh2~/~ mice exposed to control
or aspirin-containing diet from point of conception. , mock-treated mice (n = 43);
—, mice treated with 400 mg/kg from conception (n = 17). Aspirin treatment signifi¬
cantly increased survival (log-rank test; P = 0.0001). B, graph showing delayed incidence
of mammary tumorigenesis in the Min Msh2 mice. , mock-treated mice; , mice
treated with 400 mg/kg of aspirin from conception.
sure (log-rank test; P = 0.0001), although it was still reduced by com¬
parison to untreated ApcMm heterozygotes. Aspirin exposure did not alter
either tumor distribution or burden scored at the point of death (data not
shown).
hi the cohorts maintained on the control diet, a single mammary
akanthoma was observed in a total of 15 ApcMln/+ mice, whereas none
were detected in 18 Msh2~'~ mice. Development of this tumor type was
enhanced in ApcMin/+ Msh2~'~ mice (11 tumors in 41 mice). In the
cohorts exposed to aspirin, no mammary akanthomas were observed in
10 ApcMin/+ mice, whereas a single akanthoma was observed in
21 Msh2~,~ mice. In the (Ap<?"^+' Msh2~/~) cohort, five mammary
akanthomas were observed in 20 mice. All of these mice also had
intestinal neoplasia Although this represents a similar prevalence to that
observed in the untreated {Apc*"n/+' Msh2~/~) cohort, the onset of
akanthoma was significantly retarded in the aspirin-treated mice
(Fig. 35). These results therefore show aspirin exposure significantly
delays the onset ofmammary tumorigenesis in the (ApcMin/+, Msh2~/~)
background, consistent with several recent studies which have shown that
both mutation ofApe and overexpression of Cox2 can lead to mammary
neoplasia (24), and, furthermore, that selective Cox2 inhibitors can sup¬
press rodent mammary tumorigenesis (25).
Overall, the median life span of mock-exposed ApeMm mice was
175 days compared with 330 days for aspirin-treated mice, an increase
of 89% or 155 days. The comparable figures for the (ApcM'"/+,
Msh2~/~) cohort are 98 days (mock-treated) and 127 days (exposed),
an increase of 29% or 29 days. This comparison suggests that the
effect of aspirin was no greater in the (ApcMln/+, MsW7'"back¬
ground. Taken together with the weak effect of aspirin on survival of
Msh2~'~ mice and the failure to observe an influence of aspirin upon
mutation rate, these data argue that aspirin specifically suppresses
tumorigenesis in an Ape-dependent manner. This conclusion contrasts
the observation that in vitro aspirin can delete cells characterized by
MSI (9). This contradiction may be explained by the surprising fact
that adenomas developing in (ApcM,n/+Msh2~/~) mice do not show
microsatellite instability (15), which was independently confirmed
here (data not shown). This demonstrates that gross microsatellite
instability is not required to drive adenoma formation in this back¬
ground, possibly because of the high selective pressure for adenoma
formation consequent upon the Apc?,m mutation. Thus, somewhat
paradoxically, cells within the (ApcM,n/+Msh2~/_) mice do not ex¬
hibit gross levels of MSI and therefore are not available as targets for
aspirin-mediated deletion.
In summary, we have shown that dietary aspirin exposure can
suppress tumorigenesis in the murine intestine and the mammary
gland. This effect seems to be specifically associated with a loss of /
function of Ape and seems to only weakly modify the MMR pheno- \~C,
type. Critically, in the intestine, suppression only becomes apparent if
exposure covers the period between conception and weaning. Obvi¬
ously prophylactic treatment with aspirin of FAP patients during this
window would be inappropriate because of the well-known deleteri¬
ous side effects of aspirin. This, therefore, identifies a potential
window of opportunity for the chemoprevention of intestinal neopla¬
sia. The challenge will now be to establish whether NSAIDS (other
than aspirin) can be therapeutically effective within this window.
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Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent
manner
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Mice deficient for the mismatch repair (MMR) gene
Msh2 show accelerated tumourigenesis and a reduced
apoptotic response to DNA damage of methylation type.
Here we examine the effect of mutation for Msh2 on in
vivo mutation frequencies in the intestine as determined
by loss of function at the Dolichos biflorus (Dlb-1) locus.
Spontaneous mutation frequencies were scored in cohorts
of ageing mice either wild type or mutant for Msh2. In
mice less than 1 year old, mutation frequencies were only
elevated in Msh2 null mice. However, beyond this age
heterozygous Msh2 mice showed significantly higher
mutation frequencies than controls. These findings
implicate a gene dose dependent requirement for Msh2
in mutation suppression and prompted an analysis of
young Msh2 mutants following exposure to DNA
damage. Following exposure to N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG), Msh2 deficient mice show a
reduced apoptotic response and an increase in mutation
frequency. Heterozygotes did not differ from controls.
Following exposure to cisplatin, no significant elevation
was seen in mutation frequencies, even within homo-
zygotes. This is particularly surprising given the
association between cisplatin resistance and MMR
deficiency. These findings therefore demonstrate a
complex reliance upon functional Msh2 in mutation
surveillance. We have identified three separate scenarios.
First, where retention of both Msh2 alleles over an
extended period of time appears critical to the
suppression of spontaneous mutation; second, 3 weeks
following exposure to MNNG, where only complete loss
of Msh2 results in elevated mutation; and finally
following cisplatin exposure, where induced levels of
mutation are independent of Msh2 status. Oncogene
(2001) 20, 3580-3584.
Keywords: mismatch repair; apoptosis; mutation; het¬
erozygosity; cisplatin; alkylation
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nucleotides are recognized by proteins encoded by the
mismatch repair genes. Several members of this family
of genes have been characterized within Saccharomyces
cerevisiae, which led to the identification of mammalian
homologues. Six human mismatch repair genes have
been cloned, MSH2, MLH1, PMS1, PMS2, MSH3 and
MSH6 (Kinzler and Vogelstein, 1996; Wheeler et al.,
2000). Constitutive inactivation of these genes has been
associated with the development of cancer, the best
characterized relationship being between the inherited
cancer-susceptibility syndrome of Hereditary Nonpoly-
posis Colorectal Cancer (HNPCC) and germline
mutations in MSH2, MLH1 and PMS2 (Nicolades et
al., 1994; Kinzler and Vogelstein, 1996). Mice have
been produced bearing targeted inactivations of the
Mlltl, Msh2, and Pms2 genes. Homozygous mice of
these mutant strains are viable but prone to the
development of different types of neoplasia. All of
these mutant strains develop lymphoma, however they
differ in their susceptibility to intestinal neoplasia,
which only develops in Mlhl and Msh2 deficient mice
(De Wind et a/., 1995; Reitmair et al., 1996; Prolla et
al., 1998). As such, Msh2 and Mlhl homozygotes can
be considered reasonably good models of HNPCC. By
contrast, mice heterozygous for Msh2 and Mlhl do not
show reduced survival compared to wild type controls,
nor are they predisposed increased intestinal neoplasia.
They are, however characterized by increased tumor-
igenesis. Surprisingly when these tumours were exam¬
ined for Loss of Heterozygosity (LOH) only one out of
71 had lost the remaining copy of Msh2 and this was
the only tumour to exhibit microsatellite instability
(MI), indicating that the majority of tumours retained
heterozygosity for Msh2 (De Wind et al., 1998). These
results are therefore consistent with a heterozygous
effect of Msh2.
There are currently two possible biological mechan¬
isms underlying the relationship between MMR
deficiency and neoplasia. The first of these arises out
of the MMR proteins defining role in mediating DNA
repair. MSH2 recognizes mismatched nucleotides as a
heterodimer with MSH6 and insertion/deletion loops
with MSH3 (Buermeyer et al., 1999). In what is
assumed to be a direct consequence of failure of these
processes, Msh2—/— cells exhibit a mutator phenotype
and microsatellite instability (De Wind et al., 1995;
Reitmair et al., 1997). These data support the concept
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that failed recognition and repair of mismatch lesions
leads directly to an increase in mutation frequency and
thereby to malignancy. A second possible mechanism
derives from recent studies which have shown that loss
of the mismatch repair gene Msh2 impairs the
apoptotic response to alkylating agents in a variety of
systems (Toft et al., 1999; Hickman and Samson,
1999). Consistent with this, cells deficient in MMR
have been shown to be resistant to a number of
clinically important drugs, such as cisplatin, temozolo-
mide and doxorubicin (Fink et al., 1998). This raises
the possibility that increased mutation frequencies may
partly arise from failed clearance of DNA damage
bearing cells. Currently, there is little direct evidence in
support of this hypothesis, although it is clear that
Msh2 deficiency does lead to an elevation in mutation
frequencies following exposure to DNA damage
(Andrew et al., 1998; Toft et al., 1999). Toft et al.
(1999) have demonstrated that (in a model system) a
component of this increase is attributable to increased
cell survival. Thus, although Msh2 clearly plays a role
in mediating cell death, the precise relationship
between the ability to engage apoptosis and mutation
surveillance remains relatively poorly defined.
To investigate the in vivo consequences of hetero¬
zygosity at the Msh2 locus and to further explore the
relationship between apoptosis and mutation surveil¬
lance, we have examined the gene dependency of these
two endpoints in the small intestine of mice wild type,
heterozygous and nullizygous for Msh2. These studies
were performed both at spontaneous levels of damage
and following exposure to the DNA damaging agents
MNNG and cisplatin.
We first scored mutation frequency at the Dlb-1
locus at spontaneous levels of DNA damage over a 13
month time course (Figure 1). The Dlb-1 assay was
performed as previously described (Winton et al.,
1988). For this assay, experimental cohorts were
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Figure 1 Spontaneous Dlb-1 mutation frequencies scored per
10 000 villi in mice wild type (crosses), heterozygous (circles) and
homozygous null (square points) for Msh2. Each point represents
at least three mice. At ages over 1 year, heterozygous mice (n= 12,
mean = 24) have a significantly higher mutation frequency than
wild type (n = 8. mean= 11) mice. /) = 0.04. Mann Whitney U test)
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different C57B1/6 strains, one of which was homo¬
zygous for the Dlb-la allele and one of which was
homozygous for the Dlb-lb allele. Mice were subse¬
quently intercrossed from these two lines to generate
mice heterozygous at the Dlb-1 locus and segregating
for all possible Msh2 genotypes. Loss of the Dlb-lb
allele was then scored per 10 000 villi.
Msh2 null mice exhibited a higher mutation
frequency than wild type controls and Msh2 hetero¬
zygous mice. Msh2 null mice showed a marked increase
in mutation frequency from 4 to 8 weeks: a period
where there is a significant increase in the number of
crypts (Shoemaker et al., 1995). Surprisingly, beyond
this time point there was no further increase in
mutation frequency. This may reflect selection for mice
with a reduced predisposition to neoplasia (and
potentially reduced mutation frequencies) at the later
time points as the peak incidence of neoplasia occurs at
3-4 months.
The most intriguing result is the increase in mutation
frequency in the heterozygotes aged over 12 months.
Similar results have been shown using very sensitive
mutation screens in Msh2 and Mlhl heterozygous
diploid yeast (Shcherbakova and Kunkel, 1999;
Drotschmann et al., 1999, 2000). The authors of these
studies argued that this increased mutation frequency
occurred due to loss of heterozygosity in a small
population of the heterozygote cells. However,
although LOH at the Msh2 locus cannot be formally
ruled out as the mechanism underlying the increase in
the aged hemizygotes, we believe this to be unlikely as
this requires two mutations (inactivation of the
remaining Msh2 allele and subsequent inactivation of
Dlb-lb) to occur sequentially within the same stem cell.
Wild type cells accumulate on average one additional
mutation per 10 000 crypts each month (Winton et al.,
1988). If we assume a null hypothesis and that
heterozygosity for Msh2 plays no direct role in
suppressing mutation, and furthermore that Msh2 is
inactivated at a similar rate to Dlbl, then after 13
months there would be approximately 13 Msh2 null
clones per 10 000 crypts. Our analysis shows Msh2
deficiency increases the mutation frequency to, at
maximum, less than 10 times that found in wild type
cells (the highest fold difference of 9.6 was observed at
1 month). This indicates that the additional mutation
burden from the Msh2 null clones would be less than 1
mutation per 10 000 villi. This increase is clearly
insufficient to account for the actual observed increase,
strongly implying that the elevation in mutation
frequency is occurring as a direct consequence of
Msh2 heterozygosity.
We interpret the effect of heterozygosity at the Msl:2
locus as leading to a constant but small increase in
mutability which only becomes evident over a long
period of elapsed time (in this instance 12 months of
age). However, it remains formally possible that
heterozygosity for Msh2 may result in the mice
becoming hypermutable at old age, a hypothesis which
we have not addressed in this study, but one which
could be addressed by future experiments.
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using Mlhl heterozygous mice following MNU (N-
methyl-N-nitrosourea) exposure have revealed in¬
creased rates of tumourigenesis compared to wild type
controls (Kawate et al., 2000). We therefore investi¬
gated mutation frequency at the Dlb-1 locus in young
(8-12 weeks old) Msh2 mutant mice following
treatment with either MNNG (Sigma) or cisplatin
(David Bull Laboratories) (Figure 3). Mutation was
scored 3 weeks post i.p. injection. Following exposure
to 50 mg/kg MNNG we observed a significant increase
in mutation frequency in Msli2 null mice compared to
controls (Mann Whitney U test, P = 0.0414), but not in
heterozygotes (Mann Whitney U test, P=0.17). These
results parallel those obtained following exposure to
the alkylating agent Temozolomide (Toft et al., 1999),
confirming that Msh2 normally suppresses mutation
following damage of alkylation type but also showing
that this response is not Msh2 gene-dose sensitive.
Following cisplatin exposure Msh2 nulls showed
increased mutation frequencies relative to controls
and heterozygous mice, however these increases could
entirely be accounted for by the increase in sponta¬
neous mutation frequency. These results therefore fail
to demonstrate a role for Msh2 in mutation surveil¬
lance following cisplatin treatment and question the
significance of mismatch repair in the clearance of
cisplatin-induced DNA damage in normal cells. Our
findings complement recent studies by Branch et al.
(2000), who demonstrated that loss of MMR was only
a minor contributor to cisplatin resistance in ovarian
tumour cell lines.
The studies reported here have been performed in
normal intestinal enterocytes. It remains possible that
the reliance upon functional MMR for mutation
surveillance markedly differs between normal and
neoplastic cells. Pertinently, Strathdee et al. (2001)
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have shown that mouse embryonic fibroblasts deficient
for Msh2 still undergo a G2 arrest following cisplatin
treatment in marked contrast to MMR deficient
tumour cell lines which lose this checkpoint (Brown
et al., 1997).
In conclusion, we demonstrate an extremely complex
reliance upon Msh2 in mutation surveillance. We show
that Msh2 is critical in monitoring spontaneous levels
of DNA damage, such that even a 50% reduction in
Msh2 gene dosage can elevate mutation frequency. We
show that this reliance upon Msh2 in response to
spontaneous levels of DNA damage is not directly
reflected by gene dependencies in either the apoptotic
response or mutation burden following acute DNA
damage. We show that Msh2 deficiency leads to an
increase in the in vivo mutation frequency following
MNNG treatment, but remarkably that this is not the
case following exposure to cisplatin. Taken in the
context of the recent proliferation of data relating to
MMR-dependent DNA damage responses, these ob¬
servations show that reliance upon functional MMR is
highly lesion type dependent. They also challenge our
understanding of MMR-dependent suppression of
mutation, perhaps partly because MMR dependent
responses are usually interpreted in an experimental
setting following high, non physiological levels of DNA
damage. Clearly, although such scenarios may directly
relate to the response to chemotherapeutics in a clinical
setting, they may not accurately reflect the reliance
upon MMR in normal tissues exposed to low levels of
spontaneous damage.
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Abstract
P53 is extremely well characterised as a tumour suppressor gene, and many activities have been attributed to it which are
consistent with this function. However, despite being the subject of intense study it still remains unclear precisely which of
these functions is crucial to its in vivo role as a tumour suppressor gene. This is particularly true of its role in the induction
of apoptosis. The original observation of p53-dependent apoptosis gave rise to the following hypothesis: namely, that p53
deficiency leads to a persistence ofDNA damaged cells which are the potential founders ofmalignancy. This review summarises
the data for and against this hypothesis, with specific emphasis on data obtained from studies of the murine intestine. What
emerges from these studies is a complex picture, where data can be obtained in support of this hypothesis, but there are many
circumstances which exist where it is not supported. Taken together this collection of data suggests that the abrogation of
p53-dependent apoptosis may indeed impact upon carcinogenesis and neoplastic progression, but that the simplistic notion
of p53 as the single gatekeeper of this pathway is untenable. © 2000 Elsevier Science B.V. All rights reserved.
Keywords: P53; Mice; Tumour suppressor gene
1. Introduction
Any search on p53 soon yields a staggering number
of publications (in 1998 alone there were 3744 pub¬
lications), highlighting that this is probably the most
studied protein in scientific world. This statistic re¬
flects the fact that p53 mutations are amongst the com¬
monest molecular events in neoplasia: it is mutated in
approximately 50% of human cancers and is possibly
inactivated in all tumours through loss or upregulation
of other genes in the p53 pathway, e.g. and
Mdm2 [1,2].
* Corresponding author.
E-mail address: clarkear@cardiff.ac.uk (A.R. Clarke).
For many years it has been known that p53 is a
critical cellular mediator of the response to genotoxic
damage in vivo and in vitro [3], P53 has been shown to
induce apoptosis (programmed cell death) in response
to a wide variety of insults and shown in vitro to also
induce G1 and G2 cell cycle arrest via transcriptional
activation of p21/WAF [4],
Recently, a series of significant advances have been
made in the in vitro characterisation of the p53 path¬
way. These include the identification of ever increas¬
ing types of cellular stress that upregulate p53; the
identification of post-translational modifications in re¬
sponse to such stress, and the characterisation of pro¬
teins that interact with or are transactivated by p53
(see Fig. 1) (for a recent review see [5]). One obvious
goal of these studies is to link stimuli, such as ionising
0027-5107/00/$ - see front matter © 2000 Elsevier Science B.V. All rights reserved.
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vivo phenomenon, and even that it may be an artefact
of the culturing procedure [8]. This represents an ex¬
treme interpretation of these difficulties, however, it
serves to highlight the inherent difficulties in the study
of a range of biological phenomena in vivo. Certainly
the scope of in vivo analysis is currently restricted by
the complexity of the in vivo setting and by the rela¬
tively limited availability of good in vivo tools.
This review will focus upon studies performed in
vivo using p53 null mice and specifically on those
experiments aimed at addressing the significance of
p53 in inducing apoptosis following DNA damage.
The observation that p53 deficiency abrogates the nor¬
mal apoptotic response to DNA damage gave rise to
the notion that the normal ability to engage apoptosis
may underlie the role of p53 as a tumour suppressor.
Hence, in the absence of functional p53 it was pro¬
posed that cells bearing DNA damage would persist,
and that these 'undead' cells would carry an increased
mutation burden, and therefore, be more likely to act
as the founders of neoplastic clones [3]. Results ad¬
dressing this hypothesis obtained from p53 null mice
will be discussed and compared to similar data ob¬
tained from mice deficient in the mismatch repair gene
Msh2 (MutS homologue 2).
2. The phenotype of the p53-deficient mice
Three different strategies were employed to gen¬
erate the first p53 knockout mice in the early 1990s
[9-11]. All gave similar phenotypes with the majority
of the p53 null mice dying from lymphoma at around
6 months. This gave definitive proof that p53 was a
tumour suppressor gene, which previous clinical data
and in vitro work had suggested [12],
Mice heterozygous for p53 can be viewed as a rel¬
atively accurate model of the Li-Fraumeni syndrome,
as they develop tumours of a similar spectrum as
those seen in Li-Fraumeni patients (oestosarcomas,
lymphomas and soft tissue sarcomas) [13,14], There
are, however, two notable exceptions to this, namely,
the high incidence of lymphoma in the mice and
the absence of breast tumours (for recent reviews of
mouse data see [15,16]). P53 heterozygotes develop
symptoms of disease later than their p53 null counter¬
parts, with approximately 50% of mice succumbing
to tumours by 18 months. As wild type mice live
for up to 36 months, this age of death of the het¬
erozygotes is often compared to Li-Fraumeni patients
where affected individual have a 50% chance of de¬
veloping cancer by the age of 30 [17]. However, great
care should be taken in making direct comparisons
between the consequences of p53 deficiency in man
and mouse as many species specific differences exist,
perhaps most notably in the strong predisposition to
lymphoma observed in the mouse.
Within the mouse, strain dependent differences in
phenotypes have readily been observed [18,19], For
example, pure bred 129SV p53 null mice die from tu¬
mours much earlier than those crossed onto a C57B16
background. Furthermore, 50% of p53 null males in
129SV develop testicular teratomas which are only
observed rarely in other backgrounds. This latter ob¬
servation probably reflects that p53 deficiency accen¬
tuates any natural tumour predisposition, as wild type
129SV mice show a spontaneous predisposition to
testicular teratomas compared to other strains [ 19-21 ].
3. P53 and development
Prior to the development of mice deficient for p53, a
number of different in vitro studies had suggested key
roles for p53 in initiating both apoptosis and cell cy¬
cle arrest. These predicted a severe phenotype for p53
deficiency, and it was therefore, of some surprise that
p53 deficiency did not result in embryonic lethality as
had been reported for other cell cycle genes, such as
Retinoblastoma (Rb) [22], This led to the suggestion
that p53's true role was as a 'guardian of the genome',
with a primary function of protecting against geno-
toxic damage [23]. Any role for p53 in development
was therefore initially discounted, however, several
lines of evidence have now made it clear that p53 does
indeed play a role in normal embryonic development.
A common misconception when trying to under¬
stand the function of tumour suppressor genes is to
presuppose that their sole function lies in the preven¬
tion of malignancy. However, if this were the case it
is difficult to understand the common inheritance of
tumour suppressor genes across many organisms that
are clearly not prone to malignancy. Moreover, it is
difficult to identify the selection pressure for retention
of such a class of genes if the phenotype of cancer is
only manifested post-reproduction [24], These points
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approach to overexpress a Mdm2 transgene and so
cause loss of p53 [36].
4. Measuring mutation frequency in vivo
The fact that the majority of p53 null mice (and
Msh2 null) are viable has allowed questions to be
posed addressing the importance of loss of gene func¬
tion for phenotypically normal cells in vivo, when pre¬
viously these questions had been restricted to (usually
immortalised) cell lines in vitro. Although studies on
such lines have produced invaluable data and will con¬
tinue to do so, nearly all of these lines carry multiple
genetic alterations. This makes the task of dissecting
out the effect of individual genes very difficult.
The advent of knockout technology has not only
produced a range of new in vivo systems, but it has
also permitted the production of a new series of in vitro
models. An obligatory step in the production of the
knockout mice is the generation of targeted embryonic
stem (ES) cells. If so desired, these can be rendered
homozygous by either a second round of targeting or
by the use of high levels of the appropriate antibiotic,
which can select for conversion of the wild type al¬
lele. The availability of mutant cell lines are not, how¬
ever, restricted to ES cells, as primary lines, such as
embryonic fibroblasts (MEFs) can relatively easily be
derived from mutant strains. Such primary lines carry
the considerable advantage that they will not have been
selected for additional genetic change in culture, and
so should parallel the genotype of the mutant strain.
In each of these systems attempts have been made to
determine the effect of genotype upon mutation rate.
In reality these assays measure mutation frequencies,
and broadly fit into two categories. First, those that
that focus on a phenotypic change due to inactivation
or overexpression of a somatic gene which is either au¬
tosomal or X-linked. These include changes resulting
in loss of function at the DIbl [37] and hypoxanthine
phosphoribostltransferase (HPRT) loci [38], overex¬
pression of metallothinein [39] and ouabain resistance
[40], The second category includes those approaches
which measure mutation frequency from exoge¬
nous transgenes, including lacl (Big Blue™, lacZ
(Muta™) and supF (tRNA suppressor gene) [40],
The most commonly used in vivo assays in the
mouse are the DIbl assay, and assays using the lacl
and lacZ transgenes [41,42], The HPRT is the most
commonly used assay for in vitro estimates [38]. All
of these techniques have drawbacks associated with
them, however, it is encouraging that many of the
in vivo tests yield relatively similar frequencies (see
[43]).
The Dlb-1 locus encodes for 2 lectin binding pro¬
teins. Dlb-la is constitutively expressed on vascular
endothelium. The Dlb-lb allele specifies binding of
the Dolichos biflorus agglutinin to intestinal epithe¬
lium. Thus, in mice heterozygous for these alleles a
single inactivating mutation at the Dlb-lb will ab¬
rogate the ability to bind this lectin in the intestinal
epithelium. After cell proliferation and clonal ex¬
pansion, mutations that occurred in the stem cell
population will form clones that fail to bind a peroxi¬
dase conjugate of Dolichos biflorus agglutinin. These
mutant clones can easily be visualised and scored to
give an estimate of the mutation frequency.
As with the other approaches, the Dlb-1 assay does
suffer from some shortcomings. One drawback of this
approach is that it is limited to the analysis of in¬
testinal mutation rates, as specific DIbl-lb expression
is restricted to the intestine, and thus, mutation fre¬
quency can only be estimated in this tissue. A further
difficulty is that the locus has not yet been cloned and
so questions relating to mutational spectra cannot be
addressed [44], The assay does, however, possess a
number of unique advantages over other approaches.
Key amongst these is its ability to specifically score
mutation within the stem cell population and to permit
visualisation of the mutant clones in situ [41], Further¬
more, because the Dlb-1 locus is an endogenous al¬
lele, there are few concerns over the in vivo relevance
of results, as have been raised following the use of an
exogenous transgene.
When mutation frequencies are compared between
the DIbl assay and the transgenic mice Big Blue™
and MutA™, the transgenic models generally appear
a little less sensitive [43]. You et al. [45] showed that
one of the reasons for this was the presence of a large
number ofCpG sites in the lacl gene which are methy¬
lated in vivo. The lacl transgene usually consists of
multiple concatemers (around 40) of the lacl gene
within a \-like shuttle vector. This can be harvested
from the mouse genome and packaged within the X.
phage. Bacteria are then infected on XGAL contain¬
ing plates. After lysis those phages which contained
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Second, the spectrum of mutations identified by these
assays may be inappropriate for the type of instability
produced by lack of p53. However, this possibil¬
ity seems extremely unlikely given the concordance
between the different types of assay.
A third possibility arises from the fact that a large
proportion of p53 mutations in human tumours are
dominant negative, implying that the nullizygous state
may be an inappropriate model for the study of p53 as
a tumour suppressor [12]. However, the vast majority
of studies strongly argue that loss of function of p53
is functionally equivalent, whether through the acqui¬
sition of a dominant negative mutation or through a
homozygous null genotype. Although this difference
is an important caveat to remember when consider¬
ing the p53 null mouse as a model for p53 mediated
tumourigenesis, it is extremely unlikely to bear any
significance on the role played by p53 in protecting
against mutation in normal cells.
A fourth possibility is that p53 is only relevant in
guarding against increased mutation within abnormal
or malignant cells. However, this also seems unlikely,
as when Buettner et al. [53] analysed thymic lym¬
phomas from p53 null mice only one out of four tu¬
mours had an increased mutation frequency compared
to normal thymus. In four tumours examined by Sands
et al. [52], none were found to have an increased mu¬
tation frequency. This in itself is a fascinating obser¬
vation, questioning the mutator hypothesis of cancer
which attempts to explain why tumours acquire so
many somatic mutations (far above the postulated mu¬
tation rate for somatic tissues) (see [54]).
Finally, it may be that p53 cannot be shown to play
a role because it is essentially redundant. Recently,
several p53 homologues have been identified that
could theoretically substitute for p53 in the p53 nulls.
For example, the homologue p73 has been implicated
in p53 independent apoptosis following both cisplatin
treatment and ionising radiation [55,56]. Obviously,
this cannot reflect complete redundancy, otherwise
no exclusively p53-dependent phenomena (such as
p53-dependent apoptosis) would be observed. How¬
ever, given that mutation frequency is almost cer¬
tainly determined by a number of interacting factors,
redundancy remains a tenable explanation.
Given the current state of the field, it is not yet pos¬
sible to discriminate between these possibilities. How¬
ever, the fundamental observation that deficiency of
p53 fails to influence spontaneous mutation rate has
challenged the view that p53 plays a direct role that in
DNA repair. It has also questioned the in vivo signifi¬
cance of p53 dependent apoptosis and cell cycle arrest.
6. Apoptosis, clonogenic survival and mutation
frequency in vivo
The preceding discussion has addressed the conse¬
quences of loss of gene function at spontaneous levels
of DNA damage. These studies are clearly limited to
the low levels of environmental insult that may exist
in a normal laboratory animal house setting, and will
therefore, not address the consequences of exposure to
defined types of DNA damage. Analysis using spon¬
taneous levels of DNA damage also precludes the de¬
termination of a series of endpoints. Thus, apoptotic
dependency can only be scored in circumstances that
induce apoptosis. Similarly, clonogenic survival can
only be scored when the majority of cells are lethally
damaged. This is a particularly crucial endpoint to
study as the emergence of malignant clones must be
absolutely dependent upon the long term survival of
the founder cell. For these reasons mice mutant for
p53 and Msh2 have been studied following exposure
to defined types of DNA damage.
Amongst the first studies performed using the p53
knockout mice were those investigating the p53-
dependency of apoptosis following genotoxic insult
(normally ionising radiation). Initially Clarke et al.
[57] and Lowe et al. [58] showed that unlike wild type
thymocytes, which rapidly undergo apoptosis follow¬
ing treatment with ionising radiation and etoposide,
p53 null thymocytes were resistant. Heterozygotes
were found to have an intermediate phenotype. How¬
ever, p53 null thymocytes were not resistant to the glu¬
cocorticoid methylprednisoline, nor to apoptosis
induced following treatment with a calcium ionophore.
These experiments showed that p53-dependence was
restricted to certain types of stress, usually clasto-
genic damage. These observations gave rise to the
notion that the failure to engage apoptosis may be
the critical predisposing factor to tumourigenesis in
a p53 null environment. Thus, cells exposed to DNA
damage would not be deleted in the absence of p53,
but would persist with a higher mutation burden, and
therefore, a greater predisposition to malignancy.
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difference between p53 nulls and wild types. How¬
ever, p53-dependent difference was observed at the
higher dose of 600rads. Notably, this increase was
not seen to be p53 gene-dose dependent, despite the
fact that heterozygotes have an intermediate apoptotic
phenotype.
One possible explanation for these results is that
p53-independent apoptosis may be sufficient to re¬
move cells harboring DNA damage cells following
exposure to low doses of ionising radiation, but that
this mechanism is incapable of dealing with the dam¬
age inflicted at high doses. Such an explanation does
not, however, rest easily with the failure to see a
p53-dependent difference in clonogenic survival, as
this predicts a difference at the high levels of DNA
damage used in the reported assays.
It is also quite possible that the nature of p53-
dependency will alter with other insults. For example,
we have obtained data indicating a clear p53-depen¬
dency on clonogenic survival following treatment with
cisplatin [64].
In summary, the available data examining the rela¬
tionship between apoptosis, clonogenic survival and
mutation frequency in vivo is at the least inconsis¬
tent with the simple hypothesis originally proposed.
Indeed, the clearest published demonstration of p53
dependency in clonogenic survival appears to disasso¬
ciate apoptosis and clonogenicity [70], Here, both low
(40mg/kg) and high (400mg/kg) doses of the drug
5 fluorauracil (FU) was used. Both induced similar
levels of apoptosis, which was p53 dependent at the
24 h peak (although in the wild types the levels of
apoptosis returned back to basal levels sooner in the
animals treated at 40mg/kg). However, it was only
the mice treated at the higher dose which showed in¬
creased p53-dependent clonogenic survival. Pritchard
et al. [70] suggested that this was due to changes in
cellular proliferation as mitotic cell indices and thymi¬
dine incoroparation fell to a much lower level in the
mice treated at the higher dose. Thus, the presence
or absence of a p53 dependent growth arrest is sug¬
gested as the crucial factor governing clonogenic sur¬
vival. These results again strongly suggest that simple
correlations cannot readily be drawn between loss of
apoptosis, increased clonogenic survival and mutation
frequency.
The situation as described for p53 contrasts some¬
what with studies performed on Msh2 deficient mice
treated with the alkylating agents temozolomide and
MNU (/i-methyl-n-nitrosourea) [50,51]. Both of these
drugs produce the cytotoxic O6 methylguanine le¬
sion. This lesion generally produces a G-T mispair
after replication which is recognised by the mismatch
repair machinery. Karran and Bignami [71] proposed
that as this is recognised as a mismatch, the MMR
machinery will remove the newly synthesised T.
However, there will be no base that will correctly pair
with the O6 methylguanine lesion so it is proposed
that this causes cycles of abortive repair which will
eventually lead to apoptosis [71]. Toft et al. [51],
showed that in the small intestine, Msh2 deficiency
reduces the apoptotic response to both temozolomide
and MNNG (5 methyl-A'-nitro-A-nitroguanidine).
Unlike the situation with p53 deficiency, there was no
delayed Mv/?2-independent death. When clonogenic
survival and mutation frequency was investigated in
vitro in Msh2 null ES cells, these showed both an
increase in survival and mutation frequency relative
to wild type controls. Significantly, an element of the
increase in mutation frequency could be attributed to
increased clonogenic survival. When mutation fre¬
quency was measured in vivo at the Dlb-1 locus, there
was a significant dose dependent increase in mutation
after temozolomide treatment. Andrew et al. [50] also
showed a significant increase (above basal levels) in
mutation using the Big Blue™ mouse after treat¬
ment with MNU (7V-methyl-nitrosourea). Thus, here
there seems to be a clear relationship between loss of
apoptosis and increase in survival and mutant cells,
indicating that loss of apoptosis could be important
in predisposing to malignancy. However, it is worth
noting that as with many studies of this type, the level
of DNA damage used was far from physiological.
This may be of particular relevance when studying
alkylating agents, as many O6 methylguanine lesions
are normally removed in vivo by the action of ATase
(O6 alkylguanine transferase). It may be that defects
in the mismatch repair machinery only become rele¬
vant when this pathway is saturated, for example as
might occur following high dose chemotherapy [72].
8. P53 and tumourigenesis
From the above it is possible to conclude that al¬
though p53 is clearly important in inducing apoptosis
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response to DNA damage, as predicted from in vitro
studies. However, experiments using the p53 null mice
have identified a number of surprising results. Perhaps
the first of these was that the null animals survived to
birth at all, given the widespread roles proposed for
p53. A partial role for p53 in embryogenesis has now
been established. Other results have directly contra¬
dicted predictions from experimental systems. After
genotoxic insult, despite the presence of a wave of
p53-dependent apoptosis, increases in clonogenic sur¬
vival and mutation are only seen in some systems and
in some circumstances. Thus, for both of these phe¬
nomena there are tissue and drug specific variations in
p53-dependency, and the significance to neoplasia of
p53-dependent in vivo apoptosis remains to be proven.
These findings contrast somewhat to those obtained
from mice deficient in the mismatch repair protein
Msh2, which show clear increases in mutation follow¬
ing exposure to alkylating agents. ES cells mutant for
Msh2 also show increased clonogenic capacity, at least
when scored in vitro. These increases are consistent
with the observed loss of an Ms7i2-dependent apop-
totic pathway, although the relative importance played
by Ms/i2-dependent repair and Msh2-dependent apop¬
tosis remains to be established in vivo [51],
It is also now clear that p53-independent pathways
exist which can mediate the delayed induction of apop¬
tosis in the absence of p53, and that these may be me¬
diated by p53 homologues. It may be that only when
these other pathways are fully characterised will we
be able to determine the true relevance of cell death
to neoplasia. For example, we have been able to show
that loss of both Msh2 and p53 causes complete loss of
the apoptotic response following treatment with temo-
zolomide [51]. This observation predicts a number of
phenomena that can be directly tested, for example
that treatment of an Msh2 null tumour with an alky¬
lating agent, such as temozolomide will select for loss
of p53 (and vice versa).
In summary, the generation of p53 knockout mice
has yielded a vast body of data on p53 function in
vivo, and yet it may have left us with many more
questions than answers. The original supposition that
tumour suppression would be simply mediated by the
apoptotic deletion of DNA damaged cells now seems
somewhat naive. We, therefore, remain faced with the
task of unravelling the in vivo relevance of each differ¬
ent aspect of tumour suppressor activity, both for p53
and its related genes. This process will be greatly fa¬
cilitated by the rapid advancement in our understand¬
ing of the molecular pathway of p53 in vitro and by
the generation of more advanced transgenic models.
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murine intestine, but does inhibit P450-dependent activation of
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Clinically relevant cancer chemotherapeutic alkylating
agents such as temozoloniide and dacarbazine induce
apoptosis and are mutagenic via the formation of
06-alkylguanine adducts in DNA. The DNA repair protein
06-alkylguanine-DNA alkyltransferase (AGT) functions by
dealkylating such adducts and can thus prevent apoptosis
and mutagenesis. In attempts to maximize the clinical
effectiveness of these alkylating agents, inhibitors of AGT
such as 06-benzylguanine (BeG) have been developed. We
show here that within murine small intestinal crypt cells,
BeG administration does not alter the apoptotic response to
the direct-acting methylating agents A-methyl-A-nitrosurea
(MNU), temozolomide and A-methyl-W-nitro-A-nitrosogu-
anidine. Furthermore, we show that BeG pretreatment fails
to elevate the mutation frequency at the murine Dlb-1 locus
following exposure to MNU. Consistent with these results,
we show that intestinal AGT activity is effectively abolished
by administration of 100 mg/kg temozolomide, even in
the absence of BeG. In contrast, pretreatment with BeG
transiently abolished the apoptotic response to the methyl¬
ating prodrug dacarbazine. Activation of dacarbazine to
its reactive intermediate has previously been shown to
be cytochrome P450 dependent and we show here that
pretreatment of mice with the cytochrome P450 inhibitor
metyrapone also inhibits dacarbazine-induced apoptosis.
Thus BeG increases neither the prevalence of apoptosis
nor mutation frequency in the murine small intestine, but
is capable of inhibiting P450-dependent prodrug activation.
The positive implication from this study is that BeG
treatment may not exacerbate the toxic and mutagenic
effects of methylating agents within normal cells, although
it may engender other adverse reactions through the sup¬
pression of cytochrome P450-dependent processes.
Introduction
The murine small intestine offers an ideal experimental system
to study both apoptosis and mutation frequency in response to
Abbreviations: AGT, CP-alkylguanine-DNA alkyltransferase; BeG, O6-
benzylguanine; DBA, Dolichos biflorus agglutinin; dacarbazine, 5-(3,3-
dimethyltriazen-1 -yl)imidazole-4-carboxamide; MITC, 5-(3-methyltriazen-1 -
yl)imidazole-4-carboxamide; MNNG, A-methyl-A'-nitro-A'-nitrosoguanidine;
MNU, /V-methyl-ZV-nitrosurea; PBS, phosphate-buffered saline.
DNA damaging agents such as y-irradiation and alkylating
agents (1-3). The DNA repair protein <96-alkylguanine-DNA
alkyltransferase (AGT) is expressed in the murine small
intestine and is up-regulated in a /?53-dependent manner in
response to DNA strand breaks following ionizing irradiation
(4). AGT functions by recognizing and removing specific
alkyl lesions from DNA (5). The principal substrate is O6-
methylguanine, which is the major toxic and premutagenic
lesion induced by methylating agents. AGT-mediated repair
occurs via transfer of the alkyl group to a cysteine residue in
the AGT protein, a process which is stoichiometric and
autoinactivating (6). AGT therefore confers protection against
the mutagenic and toxic effects of alkylating agents, which
include the clinically important antitumour agents temozolom¬
ide and 5-(3,3-dimethyltriazen-l-yl)imidazole-4-carboxamide
(dacarbazine) (7-10). Failure of AGT to repair D6-methylguan-
ine results in (96-methylguanine:thymine mispairs following
DNA replication and it is postulated that these mediate cell
death via mismatch repair (11). The DNA mismatch repair
enzyme MSH2 is known to bind to and recognize 06-methyl-
guanine:thymine mispairs and is also essential for a large
proportion of apoptosis observed in the murine small intestine
following exposure to alkylating agents (12,13). Mutations
arise if the (/'-methylguanineThymine mispairs undergo further
rounds of replication.
06-benzylguanine (BeG) is a competitive and irreversible
inhibitor of AGT which acts by binding to the -CH3 cysteine
acceptor site of AGT forming S-benzylcysteine (14,15). BeG-
bound AGT is inactive and is subsequently degraded. Cellular
AGT activity can be restored only by de novo protein synthesis
(5) and its depletion by BeG has been proposed as a useful
adjuvant to clinical methylating and chloroethylating agent treat¬
ment of tumours (16). Adjuvant therapy of BeG combined with '
such agents offers the potential to use lower, and hence less
toxic, doses of chemotherapeutic drug and may also be of benefit
in overcoming tumour resistance associated with high levels of
AGT (17). Dacarbazine is a DNA alkylating agent used in the
treatment of metastatic melanoma and Hodgkin's lymphoma
(18). It is a prodrug requiring cytochrome P450-dependent
(V-demethylation to produce the active compound 5-(3-methyl-
triazen-l-yl)imidazole-4-carboxamide (MITC) (19,20). MITC
is also generated when temozlomide reacts spontaneously with
H20 (21). MITC decomposes to a methylating intermediate
common to a variety of agents that result in the methylation of
DNA with subsequent consequences for cell death and mutation.
One approach to directly determine the somatic in vivo
mutation frequency relies upon detecting loss of function at
the polymorphic genetic locus Dlb-1 (22). This locus deter¬
mines the ability to bind the lectin from Dolichos biflorus in
mouse intestinal epithelium. Mutation frequency can be scored
by identifying clonal populations which are no longer capable
of binding the lectin. We have previously shown that in vivo
administration of BeG reversibly suppresses AGT function,
but does not modulate the apoptotic response to temozolomide
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Fig. 2. The effect of BeG upon apoptosis induced by varying doses of
temozolomide. Cohorts of wild-type mice treated with temozolomide (range
0.5-16 mg/kg) in the presence and absence of BeG. Data show the
prevalence of apoptosis 6 h after temozolomide administration and 7 h after
1.p. injection of BeG (60 mg/kg). Each point represents data from a
minimum of three mice. Closed circles. BeG treated; open circles, no BeG.








Fig. 3. The effect of BeG on mutation rates following exposure to MNU.
Dlb-1 mutation frequency in the murine small intestine following 100 mg/
kg MNU treatment in the presence and absence of BeG. BeG was
administered at a dose of 60 mg/kg prior to the administration of MNU.
Each point represents data from three mice. Filled bars, no BeG; open bars,
BeG treated. Error bars represent SEM.
and therefore rendering BeG treatment ineffective, very low
doses of temozolomide (range 0.5-16 mg/kg) were adminis¬
tered to mice with and without BeG administration. Apoptosis
was scored 6 h later (Figure 2). The rationale was that at low
doses of temozolomide not all functional AGT activity would
be abolished by the alkylating agent and thus, if AGT could
actually alter the level of apoptosis, a difference between BeG-
treated and non-treated mice may be revealed. No significant
differences in the incidence of apoptosis were observed
between BeG-treated and non-treated mice at any dose of
temozolomide (P > 0.07 for all doses, Mann-Whitney (/-test).
MNU-induced mutation frequency at the Dlb-1 locus is not
influenced by BeG
Mutation rate within the murine small intestine following
MNU was scored at the Dlb-1 locus using standard approaches
(1,22). The mutation frequency increased with increasing doses
of MNU (Figure 3), but prior treatment with BeG did not
result in a significant elevation in the mutation frequency at
the Dlb-1 locus (P > 0.05 for both doses, Mann-Whitney
U- test).
Temozolomide administration effectively ablates AGT activity
in the intestine
One explanation for the failure to observe BeG-dependent
differences in apoptosis and mutation frequency is that treat¬
ment with the methylating agent alone is sufficient to render
AGT functionally inactive and that, further, BeG-mediated
suppression is therefore largely irrelevant. To directly test this
we exposed mice to varying doses of temozolomide and scored
AGT activity in both the liver and intestine. As we have shown
before, pretreatment with BeG markedly reduces resting levels
of AGT activity at 6 h (13). In the liver this reduction is from
150 ± 40.8 to 13.3 ± 21 fmol/mg protein. In the intestine
AGT activity falls from a lower resting level (45.6 ± 12 fmol/
mg) to become undetectable 6 h after BeG treatment (13). The
effect of exposure to increasing doses of temozolomide was
indeed to reduce levels of AGT activity, as shown in Figure
4. Following exposure to 100 mg/kg temozolomide, AGT
activity was effectively depleted in both the liver and small
intestine.
BeG inhibits the P450-dependent metabolic activation of
dacarbazine
We have shown that exposure to BeG inhibits apoptosis
induced by dacarbazine (Figure 1). In order to study the
kinetics of this inhibition a single dose of BeG (60 mg/kg)
was administered to wild-type mice at time 0. Mice were then
subsequently injected with 150 mg/kg dacarbazine at 0, 1, 6,
12, 24. 48 and 72 h after BeG delivery. Six hours after each
dacarbazine injection, levels of apoptosis were scored in the
small intestine (Figure 5). Dacarbazine alone induced high
levels of apoptosis with a mean of >60 apoptotic bodies per
50 half-crypts. However, between 1 and 6 h following BeG
administration dacarbazine failed to induce apoptosis. This
suppression was reversible, such that a normal apoptotic
response was restored by 24 h. Thus, BeG administration
reversibly inhibited dacarbazine-dependent apoptosis. The act¬
ive DNA-damaging metabolite of dacarbazine is MITC, which
is generated from dacarbazine in a cytochrome P450-dependent
manner. In order to confirm that cytochrome P450 function
was essential in eliciting a dacarbazine-dependent apoptotic
response we used the P450 inhibitor metyrapone (25). Dacarba¬
zine was administered 1 h following treatment with metyrapone
(100 mg/kg i.p.). Metyrapone treatment significantly reduced
the apoptotic response to dacarbazine (Figure 6), confirming
that activation of the prodrug and the associated apoptotic
response were P450 dependent (P < 0.05, Mann-Whitney li¬
test). These findings indicate that BeG administration blocks
activation of the prodrug dacarbazine, possibly by comprom¬
ising host P450 activity.
Discussion
We have directly addressed the ability of BeG to alter rates of
apoptosis and mutation in the normal murine epithelium
following exposure to a range of different types of damage.
No induction of apoptosis was associated with BeG treatment.
This excluded the possibility that either BeG itself or the
depletion of AGT activity could result in the induction of
apoptosis in the murine small intestine. Following treatment
with BeG, and in the absence of detectable AGT activity,
exposure to MNU, cisplatin and y-irradiation all induced
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Fig. 7. Degradation pathways for dacarbazine and temozolomide.
Dacarbazine and temozolomide give rise to the active compound MITC.
which decomposes spontaneously to an active methylating agent which
produces, amongst 11 other base lesions, 06-methylguanine, the major
premutagenic lesion in DNA. Dacarbazine requires oxidative
/V-demethylation by cytochrome P450 to form MITC, unlike temozolomide,
which reacts spontaneously with water to give MITC.
to an active alkylating agent. Dacarbazine is known to undergo
oxidative /V-demethylation to its active compound MITC
(18,28,29). This metabolic activation is mediated through the
action of cytochrome P450 enzymes (20,30). Two observations
argue in favour of the possibility that BeG is blocking the
normal metabolism of dacarbazine. First, temozolomide is able
to induce apoptosis in the presence of AGT depletion (13).
Thus, the inhibitory action of BeG cannot be arising subsequent
to the generation of MITC since it is also the active compound
formed when temozolomide undergoes spontaneous chemical
transformation (19,21) (Figure 7). Second, one of the major
routes of metabolism of BeG in mice involves oxidation to
form 0fi-benzyl-8-oxoguanine (31), which occurs through the
actions of aldehyde oxidase and the cytochrome P450 isoforms
CYP1A2 and CYP3A4 (32,33). Dacarbazine is also metab¬
olized by a number of different isoforms of P450, including
CYP1A1, CYP1A2 and CYP2E1 (34). For both dacarbazine
and BeG, the primary isoform responsible for metabolism is
CYP1A2. The possibility therefore arises that BeG metabolism
may competitively deplete cytochrome P450 activity. Thus,
BeG appears capable of inhibiting at least some of the
demethylating ability of cytochrome P450 enzymes in the
mouse liver. The consequences of this novel finding are likely
to be significant in view of the central role of P450 enzymes
in the metabolism of drugs and carcinogens.
There is increasing interest in the use of BeG clinically as
an adjuvant to alkylating agent chemotherapy to overcome
tumour resistance mediated by AGT and to potentiate the
cytotoxic effects of chemotherapy (16,35). There are, however,
a number of uncertainties concerning the clinical benefits
of BeG. First, alkylating agents themselves are capable of
inactivating AGT activity by depleting cellular pools (5,27).
We show here that this can be an effective mechanism for
suppressing AGT activity both in the normal cells of the small
intestine and in the liver of mice. There are, however, several
lines of evidence to suggest that the use of alkylating agents to
suppress AGT activity can be ineffective or even inappropriate,
either because of failure to increase the therapeutic index or
because of dose-limiting toxicity (27). Thus, although alkylat¬
ing agents can reduce the activity of AGT, the available data
indicate BeG administration to be the most effective and least
toxic method to achieve this. Second. BeG has been reported
to increase mutation rates, chromosome aberrations and toxicity
in normal cells treated with methylating or chloroethylating
agents (36-38). In contradiction to these reports, we do not
observe any effect upon in vivo mutation rate in these studies.
Third, from the data presented here it is clear that in the
murine small intestine AGT depletion does not elevate in vivo
apoptotic levels following methylating DNA damage. This
result has clear positive implications for the therapeutic use
of BeG, in that BeG administration fails to augment cell death
within normal tissues. This result may directly follow from
the demonstrated ability of alkylating agents to partially
suppress AGT activity and may simply reflect the low resting
levels of AGT in the murine intestine. Finally, and perhaps
most significantly, these data show that BeG can alter the
metabolism of drugs or carcinogens, exemplified here by
activation of the prodrug dacarbazine, and may therefore be a
cause of unexpected adverse drug reactions if used clinically.
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A role for mismatch repair in control of DNA ploidy following DNA
damage
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Many reports have shown a link between mismatch
repair (MMR) deficiency and loss of normal cell cycle
control, particularly loss of G2 arrest. However almost
all of these studies utilized transformed cell lines, and
thus the involvement of other genes in this phenotype
cannot be excluded. We have examined the effects of
cisplatin treatment on primary embryo fibroblasts
(MEFs) derived from mice in which the MMR gene
Msh2 had been inactivated (Msh2"'-). This analysis
determined that both primary Msh2-'- and wild type
(WT) fibroblasts exhibited an essentially identical G2
arrest following cispiatin treatment. Similarly, we
observed a cisplatin-induced G2 arrest in immortalized
MMR deficient (Mlhl and Pms2"'") and WT MEFs.
p53 deficient primary MEFs {p53~'~) exhibited both a
clear G2 arrest and an increase in cells with a DMA
content of 8N in response to cisplatin. When the Msh2
and pS3 defects were combined (pS3~>-/MjM-'-) the
G2 arrest was essentially identical to the p53~'~
fibroblasts. However, the p53~'~/Msh2-'~ fibroblasts
demonstrated a further increase in cells with an 8N DNA
content, above that seen in the p53~r' fibroblasts. These
results suggest that loss of MMR on its own is not
enough to overcome G2 arrest following exposure to
cisplatin but does play a role in preventing polyploidiza-
tion, or aberrant DNA reduplication, in the absence of
functional p53. Oncogene (2001) 20, 1923-1927.
Keywords: mismatch repair; cell cycle; polyploidy; p53;
DNA damage
DNA mismatch repair is known to play an important
role in maintaining genomic stability, due to its
function in correcting DNA mismatches introduced
during replication, and cells deficient in MMR exhibit
an increased mutation rate (for review see Buermeyer
et at., 1999). However the proteins that make up the
MMR system have also been associated with a number
of other phenotypes. Cells deficient in MMR have been
shown to be resistant to a number of clinically
important drugs, such as cisplatin, temozolomide and
•Correspondence: R Brown
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doxorubicin (Fink et al., 1998). This resistance may be
mediated by an altered ability to engage apoptosis, us
the MMR proteins have been shown to be critical in
mediating the normal in v/vo apoptotic response to
alkylating agents (Toft el al., 1999). Restoration of
MMR activity in cell lines, cither by chromosome
transfer or by direct re-introduction of the gene, results
in drug resensitization, demonstrating that the drug
resistance is not secondary to an increase in mutation
rate but is due to the direct involvement of the MMR
system. In addition MMR deficiency has also been
associated with a loss of normal cell cycle controls in
response to agents such as MNNG (Koi et al., 1994),
6-thioguanine (6-TG) (Hawn ei al., 1995) cisplatin
(Brown et al., 1997) and ionizing radiation (IR) (Davis
el al., 1998), suggesting that the MMR system may
have a regulatory role, primarily at the G2/M
boundary. Indeed the activity of a number of key
regulators of the cell cycle, such as p53 (Duckctt et al.,
1999), p73 (Gong et al., 1999) and c-abl (Nehme et al.,
1997), are known to be modulated in a MMR
dependent fashion in response to certain types of
DNA damage.
Loss of MMR has also been shown to play an
important role in the development of cancer. Loss of at
least five of the MMR proteins (MLH1, MSH2,
MSH6, PMSl and PMS2) has been shown to be
associated with the hereditary cancer syndrome
HNPCC (Buermeyer et al., 1999). In addition loss of
mismatch repair, and the resulting microsatellite
instability phenotype, is seen in a significant fraction
of sporadic tumours of many different cancer types
(Arzimanoglou ef al.. 1998). It is generally assumed
that loss of MMR leads to cancer due to the resulting
increased mutation rate, although it has also been
suggested that defective cell cycle control may be the
primary oncogenic mechanism in MMR deficient cells
(Tomlinson and Bodmer, 1999).
Nearly all studies on the role of MMR in drug
resistance and cell cycle control have been performed
in tumour-derived or immortalized cell lines. Such cell
lines will inevitably have multiple alterations in cell
cycle control, which may well interact with a deficiency
in MMR and influence the apparent phenotype of
MMR defects. To more clearly define the role of
MMR in the cell cycle response to a commonly used
chemotherapeutic agent, cisplatin, we have assessed cell
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families characterized by mutations in the MMR genes. Mice consti-
tutively heterozygous for the ApeMm allele have been used to deter¬
mine the ability of the NSAIDs to suppress intestinal malignancy.
However with respect to aspirin, these studies have produced con¬
trasting results. Virtually every study [e.g., Beazer-Barclay etal., (10)
has shown that sulindac causes a reduction in the number of the
spontaneous malignancies, apart from Oshima et al. (4) who use AQ:K
relatively low levels of sulindac]. However, of the studies that have
investigated spontaneous intestinal malignancy after aspirin treatment, ,, *
Numerous studies have indicated that exposure to nonsteroidal anti¬
inflammatory drugs is associated with a lowered risk of colorectal
cancer. However, analyses of the effect of aspirin upon tumorigenesis
in ApcMin/+ mice have yielded contrasting results. We show that adult
dietary exposure to aspirin does not suppress intestinal tumorigenesis
in Ape mice, but that continual exposure from the point of con¬
ception does. To test whether this regime could suppress the
of murine models of hereditary nonpolyposis colorectal »
henot
Msh2-deficient mice were exposed to aspirin. This did not modify the
mutator phenotype of Msh2~'~ mice, but weakly extended survival.
Finally, we analyzed (ApcMln/+, Msh2~/~) mice and found that lifetime
aspirin exposure significantly delayed the onset of both intestinal and
mammary neoplasia. Thus embryonic and perinatal exposure to aspi¬
rin suppresses neoplasia specifically associated with the loss of Ape
function, opening a potential window of opportunity for nonsteroidal
anti-inflammatory drug intervention.
only two have shown suppression ofmalignancy in the Ape _ mouse.
Introduction
Substantial epidemiological evidence shows that treatment with
NSAIDS3 reduces the risk of developing colorectal cancer. The most
commonly used NSAID has been aspirin, which has been reported to
reduce the risk of colon cancer by up to 40%. Clinical studies using
the NSAID sulindac have also reported reduced polyp counts in FAP
patients (1, 2). The precise mechanism of NSAID action remains
unclear, although the suppression of Cox2 is thought to be of pivotal
importance. Significantly, Cox2 is overexpressed in —85% of human
colorectal adenocarcinomas and adenomas from the ApeMm mouse
(3). The definitive study highlighting the relevance of Cox2 to tumor¬
igenesis showed that a Cox2-deficient background markedly sup¬
pressed intestinal neoplasia in mice carrying the Ape57'6 allele (4).
The biological activities of aspirin and sulindac are not restricted to
suppression of the Cox2 pathway. Aspirin, sulindac, and even the
selective Cox2-inhibitor celecoxib (5) have been shown to induce
apoptosis in a Cox2-independent fashion. Both aspirin and sulindac
down-regulate /3-catenin- and /3-catenin/TCF4-mediated transcription
(6, 7). NSAIDS also act on the nuclear factor kB signaling pathway
(8), and recent data suggest this may be important for their antitumor
activities (8). They have also been shown to specifically reduce the
survival of genetically unstable (MSI+) MMR-deficient colorectal
cancer cell lines (9), raising the possibility that aspirin may also
suppress malignancy in hereditary nonpolyposis colorectal •cdiuiiuiiia
Two other studies failed to show suppression in either the ApeMm
mouse or the ApcI638N mouse (6, 11-13). The basis for these discrep¬
ancies may lie within differences in the aspirin regime used. Shoe¬
maker et al. (14) and Reitmair et al. (15) have argued that the majority
of adenomas are fixed either in utero or perinatally just after birth.
Here we directly test the effect of increasing the period of aspirin
exposure to include the entire period from the point of conception
onwards. Furthermore, we have investigated whether this regime can
modify the development of MMR-associated neoplasia by investigat¬
ing the course of neoplasia in cohorts of Msh2~/~ and (ApcM°^+,
Msh2~'~) mice. We find that prolonged aspirin exposure dramatically
enhances the suppression of Apc-associated neoplasia both within the
intestine and the mammary gland but only weakly influences the
phenotype of MMR deficiency.
Materials and Methods
Administration ofDietary Aspirin atWeaning. C57BL/6 mice wild-type
and heterozygous for the ApeMm mutation were placed on diets containing
either 0,200, or 400 mg/kg of aspirin (Harlan/Tekad). These levels of exposure
are comparable with the highest doses used in previous studies (6, 11-13).
Mice were monitored everyday for signs of disease, generally manifesting
itself as anemia, loss of weight, and a hunched appearance.
Two experiments were performed: one where mice were killed at 150 days
of age and one where mice were killed where they showed signs of disease.
Permanent Administration of Aspirin. Matings segregating for progeny
which were Apc",n/+,Msh2or (ApcMM+, Msh2~/~) were placed on aspirin
diets containing either 0 or 400 mg/kg of aspirin before conception and
throughout pregnancy and lactation. Progeny were weaned onto appropriate
diets. Mice were killed when they showed signs of disease.
Histological Analysis. Tissues were removed, fixed in 10% neutral buff¬
ered formalin, embedded in paraffin, sectioned at 10 um, and stained with
H&E before microscopic analysis. Scoring of intestinal lesion was achieved by
removing the entire intestine at necropsy, flushing with PBS, and mounting en
Received 7/23/01; accepted 8/13/01.
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face. These preparations were then fixed in methacam (4:2:1, methanol:
chloroform:glacial acetic acid). Lesions were then scored macroscopically.
Intestine was then wound into" a "swiss" roll, which was subsequently embed¬
ded in paraffin and then sectioned as above.
Mutation Frequency at the Dlb-lb Locus. The Dlb-1 assay was per¬
formed as described previously (16). For this assay, experimental cohorts were
derived by backcrossing the Msh.2 mutants to two different C57B1/6 strains,
one of which was homozygous for the Dlb-1 a allele and one of which was
homozygous for the Dlb-1 b allele. Mice were subsequently intercrossed from
MK roscvfelt'tife. Xr\sM7i1U-^
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these two lines to generate mice heterozygous at the Dlb-1 locus and segre¬
gating for all possible Msh2 genotypes.
Results and Discussion
Aspirin Does Not Suppress Intestinal Neoplasia when Admin¬
istered at Weaning. Wild-type and ApeMm mice were placed on
aspirin-containing diets (either 200 mg/kg or 400 mg/kg) at weaning.
(Fig. 1). Mice exposed to the aspirin diet gained weight normally
when compared with mice on the control diet, and no ulceration or
intestinal pathology such as perforation of the intestine was observed
in any of the wild-type mice treated with aspirin. Two independent
analyses were performed.
First, cohorts of mice either wild-type or heterozygous for the
ApcMin allele were killed at 150 days of age, and the adenoma burden
was assessed on whole mount preparations of the entire small intes¬
tine. No adenomas were seen in wild-type mice. Adenoma burden was
as follows: for mock treated ApcM,n mice (n = 5), 9.8 (±/6.3); for
mice treated with 200 mg/kg (n = 7), 9.7 (±5.88); and for mice
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Fig. 1. A, Kaplan-Meier plot of survival of ApcM,n/+ exposed to control or aspirin-
containing diet. Black line, mock treated mice (n = 15); red line, 200 mg/kg diet (n = 12);
blue line, 400 mg/kg of diet (n = 10). There was no significant difference in the survival
curves of either the mice treated with 200 mg/kg (log-rank test; P = 0.96) and 400 mg/kg
(log-rank test; P = 0.30). Green line, ApcMin/+ mice exposed to aspirin-containing diet
from point of conception. These mice (n - 16) showed a significant increase in survival
(log-rank; P = 0.0004) compared with mock-treated and aspirin-treated mice at weaning.
B, tumor burden of mice at point of sacrifice as determined by onset of overt symptoms
of intestinal tumorigenesis. ■, mock-treated mice; □, mice treated with 200v mg/kg; H,
mice treated with 400 mg/kg of aspirin at weaning; E3, mice treated with 400 mg/kg of
aspirin from point of conception. There was no significant difference in the number of
tumors at sacrifice between mock-exposed mice (n = 15) and mice exposed to 400 mg/kg
from conception (Mann-Whitney; P = 0.613; n = 9). Tumor burden of mice >500 days
)f age were excluded from this analysis, because these mice were killed when sympto¬
matic of lymphoma and not intestinal neoplasia.
difference in tumor burden at either 200 mg/kg (P = 1.00) or at 400
mg/kg (P = 0.75; Mann Whitney) compared with mock-treated mice,
indicating that aspirin exposure was not modifying the ApeMi" phe-
_notype.
\ Second, cohorts of mice were permitted to age until they developed
obvious symptoms of intestinal neoplasia, usually bleeding from the
anus or anemia scored through whitening of the feet. Fig. 1A shows a
Kaplan-Meier plot reflecting survival over a 400-day period. Expo¬
sure to aspirin at either 200 mg/kg or 400 mg/kg did not alter the
survival profile, again indicating that exposure to aspirin did not
modify the ApcM,n phenotype.
Aspirin Suppresses Intestinal Neoplasia when Administered in
Utero. Because Shoemaker et al. (14) and Reitmair et al. (15) have
argued that the majority of adenomas are fixed before 6 days of age,
we investigated the effect of aspirin exposure throughout embryogen-
esis and weaning. Cohorts of wild-type and ApcMm heterozygotes
were derived from parents placed on aspirin-containing diets before
conception. Dietary exposure to aspirin was maintained throughout
and beyond weaning. We first wished to establish whether in utero
exposure resulted in increased embryonic lethality of ApeMin het¬
erozygotes, as has been reported for the Coxl- and Cox2-inhibitor
piroxicam (17). Analysis of offspring showed this not to be the case,
because there was no reduction in the number ofApcMln heterozygotes
in progeny from aspirin-exposed parents (P = 0.2; x1 test).
We next determined the survival profiles of each cohort (Fig. 1A),
which showed a significant increase in survival in ApcMm heterozy¬
gotes exposed to aspirin from conception onwards (P — 0.0004;
log-rank test). This effect was sufficient to completely prevent the
development of symptoms associated with intestinal neoplasia in 5 of
16 ApcMm at 500 days of age. Analysis of tumor burden and distri¬
bution in those mice that developed intestinal tumors showed no
obvious differences in either small (Fig. IB) or large intestine (data
not shown).
A number of different possibilities may underlie the discrepancies
between the published studies examining the effect of aspirin on
ApcAfm-associated tumorigenesis. First, that it is a consequence of
differences in the level of aspirin exposure—a possibility which
seems unlikely given the similar levels used in each experiment.
Second, that it is attributable to differences in the genetic background
of the mice used, either at known modifiers of the ApcMin phenotype,
such as Mom-1, or at as-yet unidentified modifiers (18). In this
respect, it is notable that our study differs from previous studies by
using mice homozygous for the relatively resistant C57/B16 Mom-1
allele. Third, that it is a consequence of different husbandry regimes;
for example, mice housed in a sterile facility may respond very
differently to those in a nonsterile facility.
Comparison of the data presented here with published experiments
does not permit us to distinguish between these possibilities, but it
does serve to underline the relatively fragile nature of aspirin-medi¬
ated suppression within this model. We show here that one of the key
modifiers of the effectiveness of aspirin is the time point of exposure.
By increasing the period of dietary exposure to include in utero and
perinatal exposure, we have dramatically enhanced the ability of
aspirin to modify the ApeM,n phenotype. Within our experimental
design, this enhancement is particularly notable given the failure to
observe any effect in the ApeMm cohort treated postweaning.
These findings are consistent with the presence of a developmental
"window" for adenoma formation either in utero or shortly after birth.
In support of this, Shoemaker et al. (14) showed that perinatal expo¬
sure to chemical carcinogens specifically enhances intestinal tumor
development in the adult. One possible explanation for this phenom¬
enon is the huge expansion in the number of intestinal crypts which
occurs 3 weeks after birth. This process of crypt fission inevitably
AQ:
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expands the number of any mutation-bearing crypts present within the
intestine and may therefore clonally expand any crypts bearing mu-
tations at the Ape locus.
The presence of a very early window for neoplastic development
raises serious questions about our understanding of Ape-mediated
tumorigenesis. Loss of Ape function is considered to be the key
initiating event in intestinal neoplasia and is strongly associated with
both dysplasia and dysregulation of /3-catenin [e.g., Kongkanuntn et
al. (19)]. However these phenomena simply are not observed in mice
aged <4 weeks, indicating either that loss of Ape alone is insufficient
to lead to the up-regulation of /3-catenin and development of dyspla¬
sia, or that loss ofApe (and thereby dysregulation of /3-catenin) occurs
as a secondary event. In this regard we have shown previously that a
proportion of dysplasias occurring in a mismatch repair-deficient
background are not characterized by increased /3-catenin levels (19).
Aspirin clearly acts to suppress these early events either by deleting
or suppressing the phenotype of those cells which carry an increased
predisposition to adenoma formation. This seems unlikely to be
through modulation of /3-catenin levels, as has been suggested by
Mahmood et al. (6), because, as stated above, elevated levels of
/3-catenin are not observed in young animals. A second possibility is
that aspirin may suppress neoplasia through a Cox2-mediated path¬
way. Cox2 up-regulation is observed in 80-85% of human colorectal
carcinomas, in 50% of colorectal adenomas, and within tumors arising
in the ApcMm model (3). However, it seems unlikely that the primary
effect of in utero aspirin exposure is mediated through Cox2 suppres¬
sion, "TTra«nucii--as Cox2 overexpression is associated with the later
stages of tumorigenesis by modulating angiogenesis and levels of
apoptosis within tumors (3).
Whatever the mechanism of action of aspirin, these studies dem¬
onstrate that the initiation of adenoma formation occurs very early in
the ApeMin mouse, and that aspirin exposure at this time point can
efficiently suppresses this process. Understanding the factors deter¬
mining the predisposition to adenoma formation during embryonic
development and perinatally might lead to greater insights into the
molecular mechanisms of cancer in humans.
Aspirin Weakly Suppresses Neoplasia though not Mutation in
Msh2~/_ Mice. Having established an effective protocol for aspirin
exposure in the murine model of FAP, we determined whether this
approach could modulate the pheno^ge^o^tfie murine model of
hereditary nonpolyposis colorectal ciB-cinoma. A significant subset of
human intestinal tumors are characterized by mutations in the MMR
pathway, and all murine models of MMR deficiency show increased
predisposition to neoplasia.
Cohorts of Msh2~/~ mice were either exposed to aspirin or were
fed control diet from conception, and Kaplan-Meier survival curves
were generated (Fig. 24). All 18 animals on the control diet were
killed after the development of lymphoma, although 2 animals also f\
had coexistent intestinal malignancy. All Msh2~'~ mice exposed to
aspirin also developed lymphoma; however, there was a small in¬
crease in survival compared with controls (P = 0.05; log-rank test).
This slight shift in survival may reflect weak suppression of either
intestinal malignancy or lymphomagenesis. This latter possibility is
consistent with the one report that showed that aspirin exposure can
result in the deletion of MSI-unstable cells in culture (9).
These results prompted us to determine directly whether aspirin
exposure can suppress in vivo mutation in a mismatch repair-deficient
background. Mutation frequency was scored at the Dlb-lb locus in
Msh2 mutant mice continually exposed to either control or aspirin-
containing diets. Using this assay, we have shown previously that
Mr/i2-deficient mice have a mutator phenotype at the Dlb-lb locus
(16, 20). Ms/i2-deficient mice were analyzed at 4 months of age after














Fig. 2. A, Kaplan-Meier plot of survival of Msh2~/~ mice exposed to control or
aspirin-containing diet from point of conception. , mock-treated Msh2~/~ mice
(/i = 18); —, 400 mg/kg-treated Msh2~/~ mice (n = 20). Msh2~/~ mice treated with
aspirin showed a weak increase in survival (log-rank test; P = 0.05). B, in vivo mutation
frequency/10,000 villi at the Dlb-lb locus after aspirin treatment. Mutation frequencies
were determined from intestinal wholemounts at 4 months of age. Columns, mean
mutation frequency at the Dlb-lb locus. At least three mice were used per each column.
Bars, SD. ■, mock-treated wild-type mice; □, mock-treated Msh2~/~ mice; H, Msh2~/~
mice exposed to 400 mg/kg of dietary aspirin from point of conception. There was not a
significant reduction in mutation frequency after aspirin treatment (P = 0.77; Mann-
Whitney).
mutation frequency was observed at this time point, demonstrating
that this regime of aspirin exposure does not modify the mutator
phenotype of Msh2-null epithelium (Fig. 2B).
Aspirin Suppresses Intestinal and Mammary Neoplasia in
ApcMin/+ Msh2_/_ Mice. In human colorectal cancer MMR-
deficient tumors differ in a number of respects to MMR-proficient
tumore. For example, MMR-deficient tumors express lower levels of .
Cox2r>as well as exhibiting very different patterns of mutation andA'
genomic instability. These differences invoke different mechanisms
for MMR-driven neoplasia, raising the possibility that aspirin expo- '
sure may have an additional effect in a MMR-deficient background,
for example through the deletion of cells shewing MSI.
The development of lymphoma in Msh2~mice largely precludes an
analysis of the effect of aspirin uponMsh2-dependent intestinal neoplasia
(22). However, Msh2 deficiency has been shown to greatly accelerate
intestinal neoplasia in theApc™'" mouse (15), so permitting an analysis of
the effect of aspirin in this context. In addition, mammary akanthoma
occur in ApcMi^+ mice (23), and this is greatly accelerated in (ApcMln/+,
Msh2~/~) mice, permitting a study of the effect of aspirin on the devel¬
opment of this lesion (see below). Cohorts of (ApcMin'+, Msh2~/~) mice
were generated and exposed to either control diet or aspirin-containing
diet from conception onwards, and Kaplan-Meier survival curves were
generated (Fig. 3A). Survival was markedly enhanced after aspirin expo- F









Fig. 3. A, Kaplan-Meier plot of survival ofApcMia/+ Msh2~y~ mice exposed to control
or aspirin-containing diet from point of conception. , mock-treated mice (n = 43);
—, mice treated with 400 mg/kg from conception (n = 17). Aspirin treatment signifi¬
cantly increased survival (log-rank test; P = 0.0001). B, graph showing delayed incidence
of mammary tumorigenesis in the Min Msh2 mice. , mock-treated mice; , mice
treated with 400 mg/kg of aspirin from conception.
sure (log-rank test; P = 0.0001), although it was still reduced by com¬
parison to untreated ApcMm heterozygotes. Aspirin exposure did not alter
either tumor distribution or burden scored at the point of death (data not
shown).
In the cohorts maintained on the control diet, a single mammary
akanthoma was observed in a total of 15 ApcM"^+ mice, whereas none
were detected in 18 Msh2~'~ mice. Development of this tumor type was
enhanced in ApcMinr+ Msh2~/~ mice (11 tumors in 41 mice). In the
cohorts exposed to aspirin, no mammary akanthomas were observed in
10 ApcMin/+ mice, whereas a single akanthoma was observed in
21 Msh2~/~ mice. In the (ApcMin/+' Msh2~/~) cohort, five mammary
akanthomas were observed in 20 mice. All of these mice also had
intestinal neoplasia. Although this represents a similar prevalence to that
observed in the untreated (ApcM"u,+' Msh2~/~) cohort, the onset of
akanthoma was significantly retarded in the aspirin-treated mice
(Fig. 3B). These results therefore show aspirin exposure significantly
delays the onset ofmammary tumorigenesis in the {ApcMM+, Msh2~'~)
background, consistent with several recent studies which have shown that
both mutation ofApe and overexpression of Cox2 can lead to mammary
neoplasia (24), and, furthermore, that selective Cox2 inhibitors can sup¬
press rodent mammary tumorigenesis (25).
Overall, the median fife span of mock-exposed ApeMm mice was
175 days compared with 330 days for aspirin-treated mice, an increase
of 89% or 155 days. The comparable figures for the (ApcMin/+,
Msh2~/~) cohort are 98 days (mock-treated) and 127 days (exposed),
an increase of 29% or 29 days. This comparison suggests that the
effect of aspirin was no greater in the (Apc>'"1/+, Msh2~/-)back-
ground. Taken together with the weak effect of aspirin on survival of
Msh2~/~ mice and the failure to observe an influence of aspirin upon
mutation rate, these data argue that aspirin specifically suppresses
tumorigenesis in an Ape-dependent manner. This conclusion contrasts
the observation that in vitro aspirin can delete cells characterized by
MSI (9). This contradiction may be explained by the surprising fact
that adenomas developing in (Apc™"^*Msh2~/~) mice do not show
microsatellite instability (15), which was independently confirmed
here (data not shown). This demonstrates that gross microsatellite
instability is not required to drive adenoma formation in this back¬
ground, possibly because of the high selective pressure for adenoma
formation consequent upon the ApcMm mutation. Thus, somewhat
paradoxically, cells within the (ApcM,n/+Msh2~/~) mice do not ex¬
hibit gross levels of MSI and therefore are not available as targets for
aspirin-mediated deletion.
In summary, we have shown that dietary aspirin exposure can
suppress tumorigenesis in the murine intestine and the mammary
gland. This effect seems to be specifically associated with a loss of /
function of Ape and seems to only weakly modify the MMR pheno- \\^
type. Critically, in the intestine, suppression only becomes apparent if
exposure covers the period between conception and weaning. Obvi¬
ously prophylactic treatment with aspirin of FAP patients during this
window would be inappropriate because of the well-known deleteri¬
ous side effects of aspirin. This, therefore, identifies a potential
window of opportunity for the chemoprevention of intestinal neopla¬
sia. The challenge will now be to establish whether NSAIDS (other
than aspirin) can be therapeutically effective within this window.
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Mice deficient for the mismatch repair (MMR) gene
Msh2 show accelerated tumourigenesis and a reduced
apoptotic response to DNA damage of methylation type.
Here we examine the effect of mutation for Msh2 on in
vivo mutation frequencies in the intestine as determined
by loss of function at the Dolichos biflorus (Dlh-1) locus.
Spontaneous mutation frequencies were scored in cohorts
of ageing mice either wild type or mutant for Msh2. In
mice less than 1 year old, mutation frequencies were only
elevated in Msh2 null mice. However, beyond this age
heterozygous Msh2 mice showed significantly higher
mutation frequencies than controls. These findings
implicate a gene dose dependent requirement for Msh2
in mutation suppression and prompted an analysis of
young Msh2 mutants following exposure to DNA
damage. Following exposure to N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG), Msh2 deficient mice show a
reduced apoptotic response and an increase in mutation
frequency. Heterozygotes did not differ from controls.
Following exposure to cisplatin, no significant elevation
was seen in mutation frequencies, even within homo-
zygotes. This is particularly surprising given the
association between cisplatin resistance and MMR
deficiency. These findings therefore demonstrate a
complex reliance upon functional Msh2 in mutation
surveillance. We have identified three separate scenarios.
First, where retention of both Msh2 alleles over an
extended period of time appears critical to the
suppression of spontaneous mutation; second, 3 weeks
following exposure to MNNG, where only complete loss
of Msh2 results in elevated mutation; and finally
following cisplatin exposure, where induced levels of
mutation are independent of Msh2 status. Oncogene
(2001) 20, 3580-3584.
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erozygosity; cisplatin; alkylation
Structural distortions produced by nucleotides which
are either unpaired or paired with non-complementary
*Correspondence: AR Clarke
Received 18 January 2001; revised 1 March 2001; accepted 7
March 2001
nucleotides are recognized by proteins encoded by the
mismatch repair genes. Several members of this family
of genes have been characterized within Saccharomyces
cerevisiae, which led to the identification of mammalian
homologues. Six human mismatch repair genes have
been cloned, MSH2, MLH1, PMS1, PMS2, MSH3 and
MSH6 (Kinzler and Vogelstein, 1996; Wheeler et al.,
2000). Constitutive inactivation of these genes has been
associated with the development of cancer, the best
characterized relationship being between the inherited
cancer-susceptibility syndrome of Hereditary Nonpoly-
posis Colorectal Cancer (HNPCC) and germline
mutations in MSH2, MLH1 and PMS2 (Nicolades et
al., 1994; Kinzler and Vogelstein, 1996). Mice have
been produced bearing targeted inactivations of the
Mlhl, Msh2, and Pms2 genes. Homozygous mice of
these mutant strains are viable but prone to the
development of different types of neoplasia. All of
these mutant strains develop lymphoma, however they
differ in their susceptibility to intestinal neoplasia,
which only develops in Mlhl and Msh2 deficient mice
(De Wind et al., 1995; Reitmair et al., 1996; Prolla et
al., 1998). As such, Msh2 and Mlhl homozygotes can
be considered reasonably good models of HNPCC. By
contrast, mice heterozygous for Msh2 and Mlhl do not
show reduced survival compared to wild type controls,
nor are they predisposed increased intestinal neoplasia.
They are, however characterized by increased tumor-
igenesis. Surprisingly when these tumours were exam¬
ined for Loss of Heterozygosity (LOH) only one out of
71 had lost the remaining copy of Msh2 and this was
the only tumour to exhibit microsatellite instability
(MI), indicating that the majority of tumours retained
heterozygosity for Msh2 (De Wind et al., 1998). These
results are therefore consistent with a heterozygous
effect of Msh2.
There are currently two possible biological mechan¬
isms underlying the relationship between MMR
deficiency and neoplasia. The first of these arises out
of the MMR proteins defining role in mediating DNA
repair. MSH2 recognizes mismatched nucleotides as a
heterodimer with MSH6 and insertion/deletion loops
with MSH3 (Buermeyer et al., 1999). In what is
assumed to be a direct consequence of failure of these
processes, Msh2—/— cells exhibit a mutator phenotype
and microsatellite instability (De Wind et al., 1995;
Reitmair et al., 1997). These data support the concept
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that failed recognition and repair of mismatch lesions
leads directly to an increase in mutation frequency and
thereby to malignancy. A second possible mechanism
derives from recent studies which have shown that loss
of the mismatch repair gene Msh2 impairs the
apoptotic response to alkylating agents in a variety of
systems (Toft et al., 1999; Hickman and Samson,
1999). Consistent with this, cells deficient in MMR
have been shown to be resistant to a number of
clinically important drugs, such as cisplatin, temozolo-
mide and doxorubicin (Fink et al., 1998). This raises
the possibility that increased mutation frequencies may
partly arise from failed clearance of DNA damage
bearing cells. Currently, there is little direct evidence in
support of this hypothesis, although it is clear that
Msh2 deficiency does lead to an elevation in mutation
frequencies following exposure to DNA damage
(Andrew et al., 1998; Toft et al., 1999). Toft et al.
(1999) have demonstrated that (in a model system) a
component of this increase is attributable to increased
cell survival. Thus, although Msh2 clearly plays a role
in mediating cell death, the precise relationship
between the ability to engage apoptosis and mutation
surveillance remains relatively poorly defined.
To investigate the in vivo consequences of hetero¬
zygosity at the Msh2 locus and to further explore the
relationship between apoptosis and mutation surveil¬
lance, we have examined the gene dependency of these
two endpoints in the small intestine of mice wild type,
heterozygous and nullizygous for Msh2. These studies
were performed both at spontaneous levels of damage
and following exposure to the DNA damaging agents
MNNG and cisplatin.
We first scored mutation frequency at the D!b-1
locus at spontaneous levels of DNA damage over a 13
month time course (Figure 1). The Dlb-1 assay was
performed as previously described (Winton et al.,
1988). For this assay, experimental cohorts were
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Figure 1 Spontaneous Dlb-1 mutation frequencies scored per
10 000 villi in mice wild type (crosses), heterozygous (circles) and
homozygous null (square points) for Msh2. Each point represents
at least three mice. At ages over 1 year, heterozygous mice (n = 12,
mean = 24) have a significantly higher mutation frequency than
wild type (n = 8, mean= 11) mice. />= 0.04, Mann Whitney U test)
different C57B1/6 strains, one of which was homo¬
zygous for the Dlb-1a allele and one of which was
homozygous for the D!b-lb allele. Mice were subse¬
quently intercrossed from these two lines to generate
mice heterozygous at the Dlb-1 locus and segregating
for all possible Msh2 genotypes. Loss of the Dlb-lb
allele was then scored per 10 000 villi.
Mslt2 null mice exhibited a higher mutation
frequency than wild type controls and Msh2 hetero¬
zygous mice. Msh2 null mice showed a marked increase
in mutation frequency from 4 to 8 weeks: a period
where there is a significant increase in the number of
crypts (Shoemaker et al., 1995). Surprisingly, beyond
this time point there was no further increase in
mutation frequency. This may reflect selection for mice
with a reduced predisposition to neoplasia (and
potentially reduced mutation frequencies) at the later
time points as the peak incidence of neoplasia occurs at
3-4 months.
The most intriguing result is the increase in mutation
frequency in the heterozygotes aged over 12 months.
Similar results have been shown using very sensitive
mutation screens in Msh2 and Mlhl heterozygous
diploid yeast (Shcherbakova and Kunkel, 1999;
Drotschmann et al., 1999, 2000). The authors of these
studies argued that this increased mutation frequency
occurred due to loss of heterozygosity in a small
population of the heterozygote cells. However,
although LOH at the Msh2 locus cannot be formally
ruled out as the mechanism underlying the increase in
the aged hemizygotes, we believe this to be unlikely as
this requires two mutations (inactivation of the
remaining Msh2 allele and subsequent inactivation of
Dlb-lb) to occur sequentially within the same stem cell.
Wild type cells accumulate on average one additional
mutation per 10 000 crypts each month (Winton et al.,
1988). If we assume a null hypothesis and that
heterozygosity for Msh2 plays no direct role in
suppressing mutation, and furthermore that Msh2 is
inactivated at a similar rate to Dlbl, then after 13
months there would be approximately 13 Msh2 null
clones per 10 000 crypts. Our analysis shows Msh2
deficiency increases the mutation frequency to, at
maximum, less than 10 times that found in wild type
cells (the highest fold difference of 9.6 was observed at
1 month). This indicates that the additional mutation
burden from the Msh2 null clones would be less than 1
mutation per 10 000 villi. This increase is clearly
insufficient to account for the actual observed increase,
strongly implying that the elevation in mutation
frequency is occurring as a direct consequence of
Msh2 heterozygosity.
We interpret the effect of heterozygosity at the Msh2
locus as leading to a constant but small increase in
mutability which only becomes evident over a long
period of elapsed time (in this instance 12 months of
age). However, it remains formally possible that
heterozygosity for Msh2 may result in the mice
becoming hypermutable at old age, a hypothesis which
we have not addressed in this study, but one which
could be addressed by future experiments.
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The data presented here parallels other studies which
have suggested gene dose sensitivity for Msh2
dependent responses. These include analyses of the
level of DNA lesions and the apoptotic response
following exposure to low level radiation treatment
(DeWeese et al., 1998), and also by studies which have
shown very low rates of LOH at the Msh2 locus in
tumours arising in Msh2 hemizygotes (De Wind et al.,
1998).
The above observations prompted analysis of the
apoptotic response, to determine if this response was
also Msh2 gene dose sensitive. Apoptosis of enterocytes
within the crypts of Lieberkuhn was examined at 6 h
after drug exposure (Figure 2). This analysis was
performed on mice aged 8-1.2 weeks. We have
previously established that this time point coincides
with the peak induction of apoptosis within this
structure (see Toft et al., 1999; Sansom and Clarke,
2000). Consistent with previous results Msh2 deficient
mice showed a reduced apoptotic response following
exposure to MNNG whilst there was normal apoptotic
response in wild type and Msh2 heterozygous mice
(P = 0.38). Following exposure to cisplatin. no differ¬
ence was observed between hemizygotes and wild type






Figure 2 The in vivo apoptotic response at 6 h following drug
exposure. For each animal 50 half crypts were analysed; the total
number of apoptotic bodies scored in all crypts analysed is
plotted on the vertical axis, (a) Following 50 mg/kg of MNNG.
(b) following 10 mg/kg of cisplatin. Closed bars, wild type mice;
grey bars, heterozygous mice and open bars, Msli2 null mice.
Columns represent mean, errors bar represents s.d. At least three
mice were used for each point
perhaps not unexpected as Msh2 null mice show only a
marginal reduction in the apoptotic response compared
to wild type controls (Toft et al., 1999). The failure to
observe high levels of MMR-dependent cell death
following cisplatin exposure contradicts the scenario
reported for ovarian cancer cells, where resistance to
cisplatin is associated with loss of MMR function and
restoration of MMR causes re-sensitization. This must
either be a reflection of the rather subtle changes in the
ability to engage apoptosis, or must implicate non-
apoptotic MMR-dependent mechanisms in long term
cell survival.
Despite the presence of a normal, intact apoptotic
response in Msh2 heterozygotes it remained possible
that there could be a gene dosage effect in mutation
induction following these agents. Previously Shcherba-
kova and Kunkel (1999) have demonstrated significant
increases in mutation frequency in yeast heterozygous
for Mlhl following exposure to either bleomycin or UV
irradiation. These phenomena were assumed to arise





Figure 3 Induced in vivo mutation frequency at the Dth-lh
locus. Mutation frequencies were determined from intestinal
wholemounts 21 days after ip drug injection: Columns represent
mean mutation frequency at the Dth-lh locus at the drug dosage
shown. At least three mice were used per each column. Error bars
represent s.d. (a) Mutation frequency following MNNG. Open
bars, mock treatment; light grey bars, 10 mg/kg; dark grey bars,
25 mg/kg; closed bars, 50 mg/kg. At 50 mg/kg Msh2 nulls have a
significantly higher mutation frequency than wild type and
heterozygous mice (P = 0.04. Mann Whitney U test), (b) Mutation
frequency following cisplatin. Open bars, mock treatment, light
grey hars. 0.5 mg/kg; dark grey bars, 1 mg/kg; closed bars,
5 mg/kg
Oncogene
using Mlltl heterozygous mice following MNU (N-
methyl-N-nitrosourea) exposure have revealed in¬
creased rates of tumourigenesis compared to wild type
controls (Kawate et al., 2000). We therefore investi¬
gated mutation frequency at the D!b-1 locus in young
(8-12 weeks old) Msh2 mutant mice following
treatment with either MNNG (Sigma) or cisplatin
(David Bull Laboratories) (Figure 3). Mutation was
scored 3 weeks post i.p. injection. Following exposure
to 50 mg/kg MNNG we observed a significant increase
5 in mutation frequency in Msh2 null mice compared to
controls (Mann Whitney U test, P = 0.0414), but not in
heterozygotes (Mann Whitney U test, /-* = 0.17). These
results parallel those obtained following exposure to
the alkylating agent Temozolomide (Toft et aL, 1999),
confirming that Msh2 normally suppresses mutation
following damage of alkylation type but also showing
that this response is not Msh2 gene-dose sensitive.
Following cisplatin exposure Msh2 nulls showed
increased mutation frequencies relative to controls
and heterozygous mice, however these increases could
entirely be accounted for by the increase in sponta¬
neous mutation frequency. These results therefore fail
to demonstrate a role for Msh2 in mutation surveil¬
lance following cisplatin treatment and question the
significance of mismatch repair in the clearance of
cisplatin-induced DNA damage in normal cells. Our
findings complement recent studies by Branch et al.
(2000), who demonstrated that loss of MMR was only
a minor contributor to cisplatin resistance in ovarian
tumour cell lines.
The studies reported here have been performed in
normal intestinal enterocytes. It remains possible that
the reliance upon functional MMR for mutation
surveillance markedly differs between normal and
neoplastic cells. Pertinently, Strathdee et al. (2001)
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have shown that mouse embryonic fibroblasts deficient
for Msh2 still undergo a G2 arrest following cisplatin
treatment in marked contrast to MMR deficient
tumour cell lines which lose this checkpoint (Brown
et al., 1997).
In conclusion, we demonstrate an extremely complex
reliance upon Msh2 in mutation surveillance. We show
that Msh2 is critical in monitoring spontaneous levels
of DNA damage, such that even a 50% reduction in
Msh2 gene dosage can elevate mutation frequency. We
show that this reliance upon Msh2 in response to
spontaneous levels of DNA damage is not directly
reflected by gene dependencies in either the apoptotic
response or mutation burden following acute DNA
damage. We show that Msh2 deficiency leads to an
increase in the in vivo mutation frequency following
MNNG treatment, but remarkably that this is not the
case following exposure to cisplatin. Taken in the
context of the recent proliferation of data relating to
MMR-dependent DNA damage responses, these ob¬
servations show that reliance upon functional MMR is
highly lesion type dependent. They also challenge our
understanding of MMR-dependent suppression of
mutation, perhaps partly because MMR dependent
responses are usually interpreted in an experimental
setting following high, non physiological levels of DNA
damage. Clearly, although such scenarios may directly
relate to the response to chemotherapeutics in a clinical
setting, they may not accurately reflect the reliance
upon MMR in normal tissues exposed to low levels of
spontaneous damage.
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Abstract
P53 is extremely well characterised as a tumour suppressor gene, and many activities have been attributed to it which are
consistent with this function. However, despite being the subject of intense study it still remains unclear precisely which of
these functions is crucial to its in vivo role as a tumour suppressor gene. This is particularly true of its role in the induction
of apoptosis. The original observation of p53-dependent apoptosis gave rise to the following hypothesis: namely, that p53
deficiency leads to a persistence ofDNA damaged cells which are the potential founders ofmalignancy. This review summarises
the data for and against this hypothesis, with specific emphasis on data obtained from studies of the murine intestine. What
emerges from these studies is a complex picture, where data can be obtained in support of this hypothesis, but there are many
circumstances which exist where it is not supported. Taken together this collection of data suggests that the abrogation of
p53-dependent apoptosis may indeed impact upon carcinogenesis and neoplastic progression, but that the simplistic notion
of p53 as the single gatekeeper of this pathway is untenable. © 2000 Elsevier Science B.V. All rights reserved.
Keywords: P53; Mice; Tumour suppressor gene
1. Introduction
Any search on p53 soon yields a staggering number
of publications (in 1998 alone there were 3744 pub¬
lications), highlighting that this is probably the most
studied protein in scientific world. This statistic re¬
flects the fact that p53 mutations are amongst the com¬
monest molecular events in neoplasia: it is mutated in
approximately 50% of human cancers and is possibly
inactivated in all tumours through loss or upregulation
of other genes in the p53 pathway, e.g. and
Mdm2 [1,2].
* Corresponding author.
E-mail address: clarkear@cardiff.ac.uk (A.R. Clarke).
For many years it has been known that p53 is a
critical cellular mediator of the response to genotoxic
damage in vivo and in vitro [3], P53 has been shown to
induce apoptosis (programmed cell death) in response
to a wide variety of insults and shown in vitro to also
induce G1 and G2 cell cycle arrest via transcriptional
activation of p21/WAF [4],
Recently, a series of significant advances have been
made in the in vitro characterisation of the p53 path¬
way. These include the identification of ever increas¬
ing types of cellular stress that upregulate p53; the
identification of post-translational modifications in re¬
sponse to such stress, and the characterisation of pro¬
teins that interact with or are transactivated by p53
(see Fig. 1) (for a recent review see [5]). One obvious
goal of these studies is to link stimuli, such as ionising
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Fig. I. Postulated p53 pathway, see [51. Following a range of stresses, the p53 protein is modified. Thus far the proteins identified to
modify p53 are mainly kinases: DNA-PK, ATM and ATR. Although as yet unproven, such modifications are postulated to render Mdm2
unable to bind p53, thus, causing accumulation of p53. Depending on the specific cellular context, this could lead to apoptosis, cell cycle
arrest or even senescence (see [5] and references therein).
radiation to a particular set of events which determine
biological fate, such as the engagement of apoptosis
or cell cycle arrest. However, whether the system will
be as straightforward as this remains to be seen. It has
also been demonstrated in vitro that p53 may have
a direct role in maintaining genome integrity by pre¬
venting homeologous recombination, recognising and
removing mismatches and participating in Nucleotide
Excision Repair [6,7],
As the number of different roles that p53 plays in
vitro continues to proliferate, the question of in vivo
relevance comes to the fore. For example, embryonic
fibroblasts (MEFS) derived from p53 null mice do not
senesce in vitro unlike their wild type (WT) coun¬
terparts, indicating that p53 plays an essential role
in senescence. This implies that the ability to engage
senescence may play a crucial role in tumour suppres¬
sion. However, translating such a finding into a true in
vivo setting can prove difficult. As yet, irrefutable evi¬
dence has not yet been provided that senescence plays
a significant role in vivo. Indeed, an extreme viewpoint
would be that senescence may not be an important in
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vivo phenomenon, and even that it may be an artefact
of the culturing procedure [8]. This represents an ex¬
treme interpretation of these difficulties, however, it
serves to highlight the inherent difficulties in the study
of a range of biological phenomena in vivo. Certainly
the scope of in vivo analysis is currently restricted by
the complexity of the in vivo setting and by the rela¬
tively limited availability of good in vivo tools.
This review will focus upon studies performed in
vivo using p53 null mice and specifically on those
experiments aimed at addressing the significance of
p53 in inducing apoptosis following DNA damage.
The observation that p53 deficiency abrogates the nor¬
mal apoptotic response to DNA damage gave rise to
the notion that the normal ability to engage apoptosis
may underlie the role of p53 as a tumour suppressor.
Hence, in the absence of functional p53 it was pro¬
posed that cells bearing DNA damage would persist,
and that these 'undead' cells would carry an increased
mutation burden, and therefore, be more likely to act
as the founders of neoplastic clones [3], Results ad¬
dressing this hypothesis obtained from p53 null mice
will be discussed and compared to similar data ob¬
tained from mice deficient in the mismatch repair gene
Msh2 (MutS homologue 2).
2. The phenotype of the p53-deficient mice
Three different strategies were employed to gen¬
erate the first p53 knockout mice in the early 1990s
[9-11], All gave similar phenotypes with the majority
of the p53 null mice dying from lymphoma at around
6 months. This gave definitive proof that p53 was a
tumour suppressor gene, which previous clinical data
and in vitro work had suggested [12],
Mice heterozygous for p53 can be viewed as a rel¬
atively accurate model of the Li-Fraumeni syndrome,
as they develop tumours of a similar spectrum as
those seen in Li-Fraumeni patients (oestosarcomas,
lymphomas and soft tissue sarcomas) [13,14], There
are, however, two notable exceptions to this, namely,
the high incidence of lymphoma in the mice and
the absence of breast tumours (for recent reviews of
mouse data see [15,16]). P53 heterozygotes develop
symptoms of disease later than their p53 null counter¬
parts, with approximately 50% of mice succumbing
to tumours by 18 months. As wild type mice live
for up to 36 months, this age of death of the het¬
erozygotes is often compared to Li-Fraumeni patients
where affected individual have a 50% chance of de¬
veloping cancer by the age of 30 [17]. However, great
care should be taken in making direct comparisons
between the consequences of p53 deficiency in man
and mouse as many species specific differences exist,
perhaps most notably in the strong predisposition to
lymphoma observed in the mouse.
Within the mouse, strain dependent differences in
phenotypes have readily been observed [18,19], For
example, pure bred 129SV p53 null mice die from tu¬
mours much earlier than those crossed onto a C57B16
background. Furthermore, 50% of p53 null males in
129SV develop testicular teratomas which are only
observed rarely in other backgrounds. This latter ob¬
servation probably reflects that p53 deficiency accen¬
tuates any natural tumour predisposition, as wild type
129SV mice show a spontaneous predisposition to
testicular teratomas compared to other strains [ 19-21 ].
3. P53 and development
Prior to the development of mice deficient for p53, a
number of different in vitro studies had suggested key
roles for p53 in initiating both apoptosis and cell cy¬
cle arrest. These predicted a severe phenotype for p53
deficiency, and it was therefore, of some surprise that
p53 deficiency did not result in embryonic lethality as
had been reported for other cell cycle genes, such as
Retinoblastoma (Rb) [22]. This led to the suggestion
that p53's true role was as a 'guardian of the genome',
with a primary function of protecting against geno-
toxic damage [23]. Any role for p53 in development
was therefore initially discounted, however, several
lines of evidence have now made it clear that p53 does
indeed play a role in normal embryonic development.
A common misconception when trying to under¬
stand the function of tumour suppressor genes is to
presuppose that their sole function lies in the preven¬
tion of malignancy. However, if this were the case it
is difficult to understand the common inheritance of
tumour suppressor genes across many organisms that
are clearly not prone to malignancy. Moreover, it is
difficult to identify the selection pressure for retention
of such a class of genes if the phenotype of cancer is
only manifested post-reproduction [24], These points
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argue for other primary roles for tumour suppressor
genes, presumably based around their function in sup¬
pressing mutation and genomic instability. This can be
most easily rationalised in terms of a role in suppress¬
ing mutation within the germ line, as accumulation
of mutations in the germ line would clearly compro¬
mise the organism. By comparison, the accumulation
of mutations in the somatic cells (especially post re¬
production) are unlikely to effect the fitness of the or¬
ganism (Disposable Soma theory of ageing see [25]).
Taken together, these considerations argue in favour
of a general role for tumour suppressor genes either
in the germline or during embryogenesis.
This argument may be applied to tumour suppres¬
sor genes other than p53, such as the mismatch repair
genes Msh2 or Mlhl. Loss of function of these genes
leads predominantly to colorectal or ovarian cancer,
however, the primary function of these genes is to
maintain genome integrity by removing mismatches
and insertion/deletion loops [26]. If this were to occur
in the germ line, mutations would gradually accumu¬
late leading to a decline in fitness (e.g. smaller litters
due to lethal mutations). In this respect it will be inter¬
esting to determine if the phenotype of mice mutant
for given tumour suppressor genes is modified as the
number of generations increase.
These considerations suggest that if p53 is truly a
guardian of the genome, it is likely to play an impor¬
tant role in the germ line and in the developing em¬
bryo. Such a role is supported by the reported strain
dependent sub-fertility seen in the p53 mutant mice
[27,28], This led Kondo [24] to propose that the major
role for p53 was in 'apoptotic repair' (the deletion of
cells bearing DNA damage through apoptosis) princi¬
pally within the germ line. Data has been obtained in
support of a role in embryogenesis from the careful
analysis of p53 breeding data. This indicated an ap¬
parent deficiency in the number of live born p53 null
female mice [29,30]. When embryos were examined
in utero and at the point of parturition, 23% of female
null embryos were found to have neural tube defects,
which presented as exencephaly from approximately
day 12 of development, ultimately resulting in an
encephaly at birth. Further support of the concept
that p53 might suppress germline mutations comes
from the observation that a significant increase (60%)
in exencephaly is seen in p53 null female progeny
derived from males irradiated prior to mating. Again
this suggests that p53 plays an important role in pro¬
tection of the embryo against genotoxic stress. The
reason why this manifests itself predominantly within
females remains unclear, but this does reflect a similar
sex bias seen in some human neural tube defects.
The actual levels of p53-dependent exencephaly
have been found to be dependent on genetic back¬
ground. One apparently extreme example of this is
the background dependent variation in lethality seen
in mice null for both p53 and Msh2 using a C57B16
background Cranston et al. [31], showed that no dou¬
bly mutant females survived to birth. We have per¬
formed similar experiments using an outbred strain,
and although we did observe a relative deficiency of
doubly null females this was no greater than the de¬
ficiency due to loss of p53 [32]. Recently, we have
crossed the p53 null strain onto a C57B16J background
and find that the levels of exencephaly in females
increases dramatically, such that <5% of surviving
p53 nulls are female. This level of defect has been
sufficiently high to preclude any confirmation of the
results obtained by Cranston et al. [31 ] within our own
stocks.
Further support for a role for p53 in protecting the
embryo against genotoxic stress comes from Normiura
et al. [33], who demonstrated that if p53 +/+ fetuses
were irradiated at day 9.5 with 2Gy of irradiation,
many would die in utero and that those born would be
subject to a low frequency of malformation. However,
similarly treated p53 —I— fetuses showed a higher
proportion of surviving embryos, but these were sub¬
ject to a greater number of deformities. This in itself
does not prove Kondo's speculative claims but it does
highlight that p53 is important in development after
genotoxic insult.
These studies have demonstrated at least partial
dependency upon p53 for normal development. Our
understanding of this role has now been extended by
experiments using mice null for Mdm2 which have
shown that abnormal regulation of p53 is also incom¬
patible with normal development [34,35]. On its own,
Mdm2 deficiency results in lethality, yet this is res¬
cued in the absence of p53. The basis of this rescue
is assumed to lie in the ability of Mdm2 to target p53
for degradation. Thus, in the absence of functional
Mdm2, p53 is overexpressed resulting in lethality
(see Fig. 1). Similar evidence for interaction between
these two genes has been obtained using a transgenic
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approach to overexpress a Mdm2 transgene and so
cause loss of p53 [36].
4. Measuring mutation frequency in vivo
The fact that the majority of p53 null mice (and
Msh2 null) are viable has allowed questions to be
posed addressing the importance of loss of gene func¬
tion for phenotypically normal cells in vivo, when pre¬
viously these questions had been restricted to (usually
immortalised) cell lines in vitro. Although studies on
such lines have produced invaluable data and will con¬
tinue to do so, nearly all of these lines carry multiple
genetic alterations. This makes the task of dissecting
out the effect of individual genes very difficult.
The advent of knockout technology has not only
produced a range of new in vivo systems, but it has
also permitted the production of a new series of in vitro
models. An obligatory step in the production of the
knockout mice is the generation of targeted embryonic
stem (ES) cells. If so desired, these can be rendered
homozygous by either a second round of targeting or
by the use of high levels of the appropriate antibiotic,
which can select for conversion of the wild type al¬
lele. The availability ofmutant cell lines are not, how¬
ever, restricted to ES cells, as primary lines, such as
embryonic fibroblasts (MEFs) can relatively easily be
derived from mutant strains. Such primary lines carry
the considerable advantage that they will not have been
selected for additional genetic change in culture, and
so should parallel the genotype of the mutant strain.
In each of these systems attempts have been made to
determine the effect of genotype upon mutation rate.
In reality these assays measure mutation frequencies,
and broadly fit into two categories. First, those that
that focus on a phenotypic change due to inactivation
or overexpression of a somatic gene which is either au¬
tosomal or X-l inked. These include changes resulting
in loss of function at the Dlbl [37] and hypoxanthine
phosphoribostltransferase (HPRT) loci [38], overex¬
pression of metallothinein [39] and ouabain resistance
[40]. The second category includes those approaches
which measure mutation frequency from exoge¬
nous transgenes, including lacl (Big Blue™, lacZ
(Muta™) and supF (tRNA suppressor gene) [40],
The most commonly used in vivo assays in the
mouse are the Dlbl assay, and assays using the lacl
and lacZ transgenes [41,42], The HPRT is the most
commonly used assay for in vitro estimates [38]. All
of these techniques have drawbacks associated with
them, however, it is encouraging that many of the
in vivo tests yield relatively similar frequencies (see
[43]).
The Dlb-1 locus encodes for 2 lectin binding pro¬
teins. Dlb-la is constitutively expressed on vascular
endothelium. The Dlb-lb allele specifies binding of
the Dolichos biflorus agglutinin to intestinal epithe¬
lium. Thus, in mice heterozygous for these alleles a
single inactivating mutation at the Dlb-lb will ab¬
rogate the ability to bind this lectin in the intestinal
epithelium. After cell proliferation and clonal ex¬
pansion, mutations that occurred in the stem cell
population will form clones that fail to bind a peroxi¬
dase conjugate of Dolichos biflorus agglutinin. These
mutant clones can easily be visualised and scored to
give an estimate of the mutation frequency.
As with the other approaches, the Dlb-1 assay does
suffer from some shortcomings. One drawback of this
approach is that it is limited to the analysis of in¬
testinal mutation rates, as specific Dlbl-lb expression
is restricted to the intestine, and thus, mutation fre¬
quency can only be estimated in this tissue. A further
difficulty is that the locus has not yet been cloned and
so questions relating to mutational spectra cannot be
addressed [44], The assay does, however, possess a
number of unique advantages over other approaches.
Key amongst these is its ability to specifically score
mutation within the stem cell population and to permit
visualisation of the mutant clones in situ [41], Further¬
more, because the D!b-1 locus is an endogenous al¬
lele, there are few concerns over the in vivo relevance
of results, as have been raised following the use of an
exogenous transgene.
When mutation frequencies are compared between
the Dlbl assay and the transgenic mice Big BlueIN1
and MutA™, the transgenic models generally appear
a little less sensitive [43]. You et al. [45] showed that
one of the reasons for this was the presence of a large
number ofCpG sites in the lacl gene which are methy¬
lated in vivo. The lacl transgene usually consists of
multiple concatemers (around 40) of the lacl gene
within a X-like shuttle vector. This can be harvested
from the mouse genome and packaged within the A.
phage. Bacteria are then infected on XGAL contain¬
ing plates. After lysis those phages which contained
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a mutated copy of the lacl will produce clear plaques
whilst those with a functional copy will produce blue
plaques. The number of blue plaques, therefore, pro¬
vides an estimate of mutation frequency [42,44,45].
Likewise the transgene used in the MutA1M system is
lacZ, which encodes the (3-galactosidase gene. Here
the numbers of mutants are counted by growing the
phages on PGAL (Sigma) containing substrate, which
prevents wild type lacZ plaques from growing [46].
One feature of the transgenic assays is that they
allow the precise nature of the mutation to be de¬
termined. This can, therefore, be used to generate
mutation spectra, the detail of which can often be
used to rationalise apparently contradictory results.
For example, one unexpected finding was that muta¬
tion frequency in the lacl transgene did not increase
significantly following treatment with X-rays, whilst
a marked increase was observed at the Dlb-1 locus
[47], The probable explanation for this is that X-rays
predominantly cause gross deletions, which may re¬
sult in deletion of the entire shuttle vector. In such
circumstances these events will be under-represented
in the lacl assay but not the Dlb-1 assay.
One potential difficulty with assays using endoge¬
nous loci is that there may be in vivo selection against
mutants. For example, it has been shown that there is
selection against HPRT deficient T-lymphocytes cells
in mice. Also, large deletions encompassing the HPRT
locus can be selected against as a result of the dele¬
tion of flanking loci [48], Notably, these difficulties
have not been reported for the Dlb-1 assay. Some of
these considerations may also hold true for the trans¬
gene based assays, as the site of transgene integration
is thought to influence assay readout [49],
5. Spontaneous mutation frequency in p53
deficient and Msh2 deficient mice
Despite the individual limitations of each approach,
the assays described above have been shown to yield
broadly consistent results, and to be capable of iden¬
tifying increases in mutation following most types of
DNA damage. These assays have now been applied to
murine strains mutant for genes implicated in DNA re¬
pair. Such analyses have proven particularly powerful
where use has been made of both the transgenic and
endogenous gene-based assays. For example, an in¬
crease in mutation frequency in vivo in the Msh2 null
mouse has been reported using both the Big Blue™
mouse and Dlbl assay [50,51], The Big Blue mouse
showed an increase in all the three tissues studied:
small intestine, thymus and heart. Comparison of the
data generated by the two assays shows remarkable
similarity: an approximate 10-fold increase was scored
in the Big Blue mouse (3.1 x lO-"1 in wild type intes¬
tine rising to 34xl0~5 in the Msh2 null intestine). A
similar seven-fold increase was scored at the Dlb-1 lo¬
cus (four mutants per 10,000 villi for wild type intes¬
tine rising to 28 mutants per 10,000 villi in the Msh2
nulls intestine). Furthermore, both assays concurred
in that heterozygosity for Msh2 did not impact upon
mutation frequency.
The proposed role for p53 as a 'guardian of the
genome' predicts that p53 deficiency should lead to an
increase in mutation frequency. Surprisingly, this has
not been substantiated experimentally [37,42,44,52],
The initial report [42] showed no increase in the spon¬
taneous mutation frequency in the liver, spleen or brain
of the Big Blue™ mouse when bred onto a p53 null
background. Subsequent sequencing of the entire lacl
gene confirmed that there was no increase in either mu¬
tation frequency or spectra [44]. One possibility was
that p53 deficiency only influenced the mutation rate
in some tissue types. The most likely candidate tissue
for such an effect was the thymus, as this is heavily
predisposed to malignancy in the p53 null background.
However, a similar study to those above extended the
essentially negative finding to this tissue [53]. When
spontaneous mutation frequency in the small intestine
was examined at the Dlbl locus, again this yielded
no significant p53-dependent increase. Likewise when
Corbet et al. [38], examined mutation frequency at the
HPRT locus in ES cells, p53 null ES cells again failed
to show a significant elevation in mutation frequency.
Five potential explanations may be advanced to
explain the observed lack of p53-dependency. First,
these experiments were performed with 6-10 week
old mice and it could be argued that insufficient
time had elapsed for mutations to accumulate [42].
Certainly this is possible, if p53 is considered to be
responding to DNA damage which will accumulate
with age. However, since the majority of cells will
have undergone many rounds of replication by 6-10
weeks of age, it seems unlikely that they will not
have been exposed to substantial DNA damage [42].
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Second, the spectrum of mutations identified by these
assays may be inappropriate for the type of instability
produced by lack of p53. However, this possibil¬
ity seems extremely unlikely given the concordance
between the different types of assay.
A third possibility arises from the fact that a large
proportion of p53 mutations in human tumours are
dominant negative, implying that the nullizygous state
may be an inappropriate model for the study of p53 as
a tumour suppressor [12]. However, the vast majority
of studies strongly argue that loss of function of p53
is functionally equivalent, whether through the acqui¬
sition of a dominant negative mutation or through a
homozygous null genotype. Although this difference
is an important caveat to remember when consider¬
ing the p53 null mouse as a model for p53 mediated
tumourigenesis, it is extremely unlikely to bear any
significance on the role played by p53 in protecting
against mutation in normal cells.
A fourth possibility is that p53 is only relevant in
guarding against increased mutation within abnormal
or malignant cells. However, this also seems unlikely,
as when Buettner et al. [53] analysed thymic lym¬
phomas from p53 null mice only one out of four tu¬
mours had an increased mutation frequency compared
to normal thymus. In four tumours examined by Sands
et al. [52], none were found to have an increased mu¬
tation frequency. This in itself is a fascinating obser¬
vation, questioning the mutator hypothesis of cancer
which attempts to explain why tumours acquire so
many somatic mutations (far above the postulated mu¬
tation rate for somatic tissues) (see [54]).
Finally, it may be that p53 cannot be shown to play
a role because it is essentially redundant. Recently,
several p53 homologues have been identified that
could theoretically substitute for p53 in the p53 nulls.
For example, the homologue p73 has been implicated
in p53 independent apoptosis following both cisplatin
treatment and ionising radiation [55,56]. Obviously,
this cannot reflect complete redundancy, otherwise
no exclusively p53-dependent phenomena (such as
p53-dependent apoptosis) would be observed. How¬
ever, given that mutation frequency is almost cer¬
tainly determined by a number of interacting factors,
redundancy remains a tenable explanation.
Given the current state of the field, it is not yet pos¬
sible to discriminate between these possibilities. How¬
ever, the fundamental observation that deficiency of
p53 fails to influence spontaneous mutation rate has
challenged the view that p53 plays a direct role that in
DNA repair. It has also questioned the in vivo signifi¬
cance of p53 dependent apoptosis and cell cycle arrest.
6. Apoptosis, clonogenic survival and mutation
frequency in vivo
The preceding discussion has addressed the conse¬
quences of loss of gene function at spontaneous levels
of DNA damage. These studies are clearly limited to
the low levels of environmental insult that may exist
in a normal laboratory animal house setting, and will
therefore, not address the consequences of exposure to
defined types of DNA damage. Analysis using spon¬
taneous levels of DNA damage also precludes the de¬
termination of a series of endpoints. Thus, apoptotic
dependency can only be scored in circumstances that
induce apoptosis. Similarly, clonogenic survival can
only be scored when the majority of cells are lethally
damaged. This is a particularly crucial endpoint to
study as the emergence of malignant clones must be
absolutely dependent upon the long term survival of
the founder cell. For these reasons mice mutant for
p53 and Msh2 have been studied following exposure
to defined types of DNA damage.
Amongst the first studies performed using the p53
knockout mice were those investigating the p53-
dependency of apoptosis following genotoxic insult
(normally ionising radiation). Initially Clarke et al.
[57] and Lowe et al. [58] showed that unlike wild type
thymocytes, which rapidly undergo apoptosis follow¬
ing treatment with ionising radiation and etoposide,
p53 null thymocytes were resistant. Heterozygotes
were found to have an intermediate phenotype. How¬
ever, p53 null thymocytes were not resistant to the glu¬
cocorticoid methylprednisoline, nor to apoptosis
induced following treatment with a calcium ionophore.
These experiments showed that p53-dependence was
restricted to certain types of stress, usually clasto-
genic damage. These observations gave rise to the
notion that the failure to engage apoptosis may be
the critical predisposing factor to tumourigenesis in
a p53 null environment. Thus, cells exposed to DNA
damage would not be deleted in the absence of p53,
but would persist with a higher mutation burden, and
therefore, a greater predisposition to malignancy.
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Many different groups have attempted to directly
test this hypothesis in vivo. As discussed above, p53
deficiency apparently failed to influence the sponta¬
neous mutation frequency. In order to analyse the ef¬
fects of p53 deficiency post DNA damage, Griffiths
et al. [59] analysed short term primary cultures of
IL7-dependent B cell precursors following exposure to
X-rays. Here, they showed that p53 nulls were resis¬
tant to apoptosis and that there was no gross difference
in DNA repair as scored by the COMET assay. Clono-
genic survival was measured and the p53 null cells
were found to have significantly enhanced survival.
Mutation frequency was scored amongst the surviv¬
ing cells, yielding an intriguing result. The frequency
of mutants arising in the p53 null cells was found to
be equivalent to that previously scored for wild type
cells. However, the total mutation burden (number of
mutant clones) was considerably higher than predicted
for wild type cells as a direct consequence of the dif¬
ference in clonogenic survival. Taken together, these
findings strongly argue for a p53-dependent increase
in mutation burden occurring through increased clon-
ality. These results are therefore essentially supportive
of the central hypothesis [3,59].
The in vivo p53-dependency of apoptosis has also
been investigated in the small intestine and in spleno-
cytes. Analysis of both these tissue types again iden¬
tified a wave of p53-dependent apoptosis peaking at
4-6 h. However, a delayed p53-independent wave of
cell death was also identified which was specific to the
intestine and occurred at 48-72 h [37,60-62]. These
results highlight clear tissue specific differences in the
dependence upon p53 for the induction of apoptosis.
When this p53 independent wave was examined fur¬
ther, it was noted that the apoptotic bodies were much
larger, suggesting that cells had entered apoptosis from
a G2 block (see [62,63]).
More recently, we have noted a p53 independent
wave of apoptosis for two other cytotoxic drugs: temo-
zolomide (an alkylating agent) and cisplatin [51,64].
The precise significance of p53-independent death re¬
mains to be established, however, it seems likely that
it is effective in removing many of those cells survive
by virtue of p53 deficiency. This may well reflect p73
activity, as has been reported in other systems [55,56].
The tissue specific differences in p53-independent
death may also explain two basic observations made
in the p53 null mice. First, the failure to see a p53-
dependent difference in spontaneous mutation fre¬
quency in the intestine, as here there is an efficient
alternative to p53-mediated death. Second, the strong
predisposition to T-cell lymphoma in p53 null mice,
as this tissue relies exclusively on p53 to mediate cell
death.
7. Mutation and clonogenic survival following
DNA damage in the intestine
The small intestine provides an extremely well char¬
acterised system in which to study cellular prolifer¬
ation, apoptosis and differentiation (for a review see
[65,66]). It is proposed that at the base of the crypt,
there are approximately four to six stem cells. These
are thought to be exquisitely sensitive to damage and
undergo apoptosis under low levels of radiation (1 Gy).
However once these are destroyed other clonogenic
cells can then substitute for the original stem cells.
Following exposures of up to 9 Gy, there are thought
to be an additional six clonogenic cells. Beyond this
level of damage it is thought that up to 16-24 cells
can then act as clonogenic cells (approximately 1/3 of
the crypt) [67],
The significance of the above is that clonogenicity
can be investigated in vivo via an analysis of crypt sur¬
vival (the micro-colony assay [68]) and this data can
subsequently be related to the ability to engage apop¬
tosis. One problem with this assay is that relatively
high levels of DNA damage must be used to deliver
scorable crypt death. However, this assay circumvents
one of the major problems of in vitro assays in that it
scores clonogenicity in a normal cellular setting.
Mutation frequency has also been investigated
following exposure to DNA damage using those ap¬
proaches discussed above. Again, the prediction from
the central hypothesis is that p53 deficiency will re¬
sult in a significant increase in mutation frequency
following treatment. Both clonogenicity and mutation
frequency experiments have generated similar data.
Hendry et al. [69] showed that there was essentially no
increase in survival in p53 null mice in the small in¬
testine after gamma irradiation. In the large intestine,
this study even indicated that p53 nulls were more
sensitive than wild type counterparts. We have exam¬
ined mutation frequency at the DIbl locus Clarke et al.
[37]. At 200 and 400rads, there was no significant
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difference between p53 nulls and wild types. How¬
ever, p53-dependent difference was observed at the
higher dose of 600rads. Notably, this increase was
not seen to be p53 gene-dose dependent, despite the
fact that heterozygotes have an intermediate apoptotic
phenotype.
One possible explanation for these results is that
p53-independent apoptosis may be sufficient to re¬
move cells harboring DNA damage cells following
exposure to low doses of ionising radiation, but that
this mechanism is incapable of dealing with the dam¬
age inflicted at high doses. Such an explanation does
not, however, rest easily with the failure to see a
p53-dependent difference in clonogenic survival, as
this predicts a difference at the high levels of DNA
damage used in the reported assays.
It is also quite possible that the nature of p53-
dependency will alter with other insults. For example,
we have obtained data indicating a clear p53-depen-
dency on clonogenic survival following treatment with
cisplatin [64],
In summary, the available data examining the rela¬
tionship between apoptosis, clonogenic survival and
mutation frequency in vivo is at the least inconsis¬
tent with the simple hypothesis originally proposed.
Indeed, the clearest published demonstration of p53
dependency in clonogenic survival appears to disasso¬
ciate apoptosis and clonogenicity [70]. Here, both low
(40mg/kg) and high (400mg/kg) doses of the drug
5 fluorauracil (FU) was used. Both induced similar
levels of apoptosis, which was p53 dependent at the
24 h peak (although in the wild types the levels of
apoplosis returned back to basal levels sooner in the
animals treated at 40mg/kg). However, it was only
the mice treated at the higher dose which showed in¬
creased p53-dependent clonogenic survival. Pritchard
et al. [70] suggested that this was due to changes in
cellular proliferation as mitotic cell indices and thymi¬
dine incoroparation fell to a much lower level in the
mice treated at the higher dose. Thus, the presence
or absence of a p53 dependent growth arrest is sug¬
gested as the crucial factor governing clonogenic sur¬
vival. These results again strongly suggest that simple
correlations cannot readily be drawn between loss of
apoptosis, increased clonogenic survival and mutation
frequency.
The situation as described for p53 contrasts some¬
what with studies performed on Msh2 deficient mice
treated with the alkylating agents temozolomide and
MNU (n-methyl-n-nitrosourea) [50,51]. Both of these
drugs produce the cytotoxic O6 methylguanine le¬
sion. This lesion generally produces a G-T mispair
after replication which is recognised by the mismatch
repair machinery. Karran and Bignami [71] proposed
that as this is recognised as a mismatch, the MMR
machinery will remove the newly synthesised T.
However, there will be no base that will correctly pair
with the O6 methylguanine lesion so it is proposed
that this causes cycles of abortive repair which will
eventually lead to apoptosis [71]. Toft et al. [51],
showed that in the small intestine, Msh2 deficiency
reduces the apoptotic response to both temozolomide
and MNNG (5 methyl-N'-nitro-A-nitroguanidine).
Unlike the situation with p53 deficiency, there was no
delayed Ms/z2-independent death. When clonogenic
survival and mutation frequency was investigated in
vitro in Msh2 null ES cells, these showed both an
increase in survival and mutation frequency relative
to wild type controls. Significantly, an element of the
increase in mutation frequency could be attributed to
increased clonogenic survival. When mutation fre¬
quency was measured in vivo at the Dlb-1 locus, there
was a significant dose dependent increase in mutation
after temozolomide treatment. Andrew et al. [50] also
showed a significant increase (above basal levels) in
mutation using the Big Blue™ mouse after treat¬
ment with MNU (A-methyl-nitrosourea). Thus, here
there seems to be a clear relationship between loss of
apoptosis and increase in survival and mutant cells,
indicating that loss of apoptosis could be important
in predisposing to malignancy. However, it is worth
noting that as with many studies of this type, the level
of DNA damage used was far from physiological.
This may be of particular relevance when studying
alkylating agents, as many O'1 methylguanine lesions
are normally removed in vivo by the action of ATase
(O6 alkylguanine transferase). It may be that defects
in the mismatch repair machinery only become rele¬
vant when this pathway is saturated, for example as
might occur following high dose chemotherapy [72].
8. P53 and tumourigenesis
From the above it is possible to conclude that al¬
though p53 is clearly important in inducing apoptosis
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in normal cells, the significance of this upon long term
survival and mutation rate remains unclear. It may be
that there is indeed a simple relationship, but that it
has been obscured because the assays for clonogenic-
ity and mutation frequency are insufficiently rigorous.
It however seems more likely that a relationship does
exist, but that it is highly damage and cell type de¬
pendent. This raises the question of relevance of these
pathways in morphologically abnormal and neoplastic
cells.
Relatively little data has been produced to approach
this question. Fazeli et al. [73] investigated the induc¬
tion of apoptosis within intestinal adenomas arising
in either a wild type or p53 null background. They
reported that the p53-dependent apoptotic response
remained intact within adenomas following gamma
irradiation. However, a failure to observe similar p53
dependency has been reported in neoplasia arising in
p53(—/—)/MMTVras and p53null/Wntl mice [74],
In contrast, a number of other studies have associ¬
ated the loss of an apoptosis programme with tumour
progression. For example, use of an SV40 T antigen
mutant capable of binding Rb but not p53 resulted
in tumour development that was slower than mice
expressing wild type T antigen. This difference dis¬
appeared when these mice were subsequently crossed
onto a p53 null background [75]. Significantly in
p53 heterozygotes, loss of heterozygosity correlated
with a reduction in apoptosis and increased tumouri-
genesis. In further support of a role for apoptosis in
mediating tumour suppression, similar results were
obtained when the mutant T antigen was crossed onto
a Bax mutant background (a downstream apoptosis
inducing protein transactivated by p53) [76].
A role has also been demonstrated for p53 in me¬
diating apoptosis in response to hypoxia [77], This
is of particular relevance to tumour development,
as regions of low oxygen and necrosis are common
features of solid tumours. Loss of this apoptotic path¬
way has therefore been proposed as a key feature
in tumour development and in the selection within
tumours of more aggressive clones.
Co-operativity between different mutations has
been studied using mice bearing multiple germline
mutations (for review see [16]). For example, p53
knockouts crossed onto Msh2 Rb+/~, APC+/~,
ATM~\~ mutant backgrounds all show enhanced tu-
mourigenesis. In the case of p53_^/APC~^~ mice
this caused an increase in pancreatic neoplasia but
had no effect on intestinal neoplasia [77], This find¬
ing is consistent with a role for p53 deficiency late
in intestinal tumourigenesis, but clearly does not sup¬
port the notion that loss of a p53-dependent apoptotic
pathway predisposes to neoplasia. Furthermore, these
results challenge the significance of apoptotic path¬
ways in tumour prevention within the pancreas, as
normal pancreatic acinar cells have very low levels of
apoptosis compared to the intestine [78].
The observation that p53 deficiency predisposes to
a tissue specific pattern of tumourigenesis underlines
a cell-type specific role for this protein, which may be
interpreted in the light of the multiple roles attributed
to p53. Thus, in some tissues loss of an apoptotic
pathway may be crucial, whilst in other tissues loss of
a cell cycle checkpoint or altered differentiation status
may be the key predisposing factors [79].
Although we can, therefore, associate loss of p53
function with neoplasia, the relationship is clearly
complex and imperfectly understood. One reason for
this may be that studying mice characterised by com¬
plete loss of p53 function is simply too complex. To
this end, a significant effort is now being is focussed
on specific p53 mutants that are seen in neoplasia
[80], For example when p53l72H was expressed in the
epidermis of mice no increase in neoplasia was seen
[81].
However, an increased susceptibility to chemical
carcinogenesis was observed. The development of
these models and animals with engineered tissue spe¬
cific knockouts of p53 (for example to avoid early
onset lymphomagenesis) will undoubtedly provide
better insights into the functional roles played by p53
in tumour suppression.
9. Conclusions: are we any closer to
understanding the in vivo significance of p53?
The generation of p53 null mice has provided an ex¬
cellent in vivo model to test hypotheses formed from
clinical data and cell culture experiments. A number
of these have been borne out. As predicted, p53 defi¬
ciency was found to predispose strongly to neoplasia,
although the tumour spectrum did not accurately mir¬
ror tumourigenesis in humans. P53 deficiency has
also been demonstrated to lead to loss of the apoptotic
O.J. Sansom, A.R. Clarke/Mutation Research 452 (2000) 149-162 159
response to DNA damage, as predicted from in vitro
studies. However, experiments using the p53 null mice
have identified a number of surprising results. Perhaps
the first of these was that the null animals survived to
birth at all, given the widespread roles proposed for
p53. A partial role for p53 in embryogenesis has now
been established. Other results have directly contra¬
dicted predictions from experimental systems. After
genotoxic insult, despite the presence of a wave of
p53-dependent apoptosis, increases in clonogenic sur¬
vival and mutation are only seen in some systems and
in some circumstances. Thus, for both of these phe¬
nomena there are tissue and drug specific variations in
p53-dependency, and the significance to neoplasia of
p53-dependent in vivo apoptosis remains to be proven.
These findings contrast somewhat to those obtained
from mice deficient in the mismatch repair protein
Msh2, which show clear increases in mutation follow¬
ing exposure to alkylating agents. ES cells mutant for
Msh2 also show increased clonogenic capacity, at least
when scored in vitro. These increases are consistent
with the observed loss of an Msh2-dependent apop-
totic pathway, although the relative importance played
by Msh2-dependent repair and A/^/z2-dependent apop¬
tosis remains to be established in vivo [51].
It is also now clear that p53-independent pathways
exist which can mediate the delayed induction of apop¬
tosis in the absence of p53, and that these may be me¬
diated by p53 homologues. It may be that only when
these other pathways are fully characterised will we
be able to determine the true relevance of cell death
to neoplasia. For example, we have been able to show
that loss of both Msh2 and p53 causes complete loss of
the apoptotic response following treatment with temo-
zolomide [51]. This observation predicts a number of
phenomena that can be directly tested, for example
that treatment of an Msh2 null tumour with an alky¬
lating agent, such as temozolomide will select for loss
of p53 (and vice versa).
In summary, the generation of p53 knockout mice
has yielded a vast body of data on p53 function in
vivo, and yet it may have left us with many more
questions than answers. The original supposition that
tumour suppression would be simply mediated by the
apoptotic deletion of DNA damaged cells now seems
somewhat naive. We, therefore, remain faced with the
task of unravelling the in vivo relevance of each differ¬
ent aspect of tumour suppressor activity, both for p53
and its related genes. This process will be greatly fa¬
cilitated by the rapid advancement in our understand¬
ing of the molecular pathway of p53 in vitro and by
the generation of more advanced transgenic models.
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Clinically relevant cancer chemotherapeutic alkylating
agents such as temozolomide and dacarbazine induce
apoptosis and are mutagenic via the formation of
06-alkylguanine adducts in DNA. The DNA repair protein
f/'-alkylguanine-DNA alkyltransferase (AGT) functions by
dealkylating such adducts and can thus prevent apoptosis
and mutagenesis. In attempts to maximize the clinical
effectiveness of these alkylating agents, inhibitors of AGT
such as O^-benzylguanine (BeG) have been developed. We
show here that within murine small intestinal crypt cells,
BeG administration does not alter the apoptotic response to
the direct-acting methylating agents A-methyl-A-nitrosurea
(MNU), temozolomide and A-methyl-A'-nitro-A-nitrosogu-
anidine. Furthermore, we show that BeG pretreatment fails
to elevate the mutation frequency at the murine Dlb-1 locus
following exposure to MNU. Consistent with these results,
we show that intestinal AGT activity is effectively abolished
by administration of 100 mg/kg temozolomide, even in
the absence of BeG. In contrast, pretreatment with BeG
transiently abolished the apoptotic response to the methyl¬
ating prodrug dacarbazine. Activation of dacarbazine to
its reactive intermediate has previously been shown to
be cytochrome P450 dependent and we show here that
pretreatment of mice with the cytochrome P450 inhibitor
metyrapone also inhibits dacarbazine-induced apoptosis.
Thus BeG increases neither the prevalence of apoptosis
nor mutation frequency in the murine small intestine, but
is capable of inhibiting P450-dependent prodrug activation.
The positive implication from this study is that BeG
treatment may not exacerbate the toxic and mutagenic
effects of methylating agents within normal cells, although
it may engender other adverse reactions through the sup¬
pression of cytochrome P450-dependent processes.
Introduction
The murine small intestine offers an ideal experimental system
to study both apoptosis and mutation frequency in response to
Abbreviations: AGT, 06-alkylguanine-DNA alkyltransferase; BeG, Ob-
benzylguanine; DBA, Dolichos biflorus agglutinin; dacarbazine, 5-(3,3-
dimethyltriazen-1 -yl)imidazole-4-carboxamide; MITC, 5-(3-methyltriazen-1 -
yl)imidazole-4-carboxamide; MNNG, /V-methyl-A'-nitro-iV-nitrosoguanidine;
MNU, /V-methyl-/V-nitrosurea; PBS, phosphate-buffered saline.
DNA damaging agents such as y-irradiation and alkylating
agents (1-3). The DNA repair protein 06-alkylguanine-DNA
alkyltransferase (AGT) is expressed in the murine small
intestine and is up-regulated in a p53-dependent manner in
response to DNA strand breaks following ionizing irradiation
(4). AGT functions by recognizing and removing specific
alkyl lesions from DNA (5). The principal substrate is O6-
methylguanine, which is the major toxic and premutagenic
lesion induced by methylating agents. AGT-mediated repair
occurs via transfer of the alkyl group to a cysteine residue in
the AGT protein, a process which is stoichiometric and
autoinactivating (6). AGT therefore confers protection against
the mutagenic and toxic effects of alkylating agents, which
include the clinically important antitumour agents temozolom¬
ide and 5-(3,3-dimethyltriazen-l-yl)imidazole-4-carboxamide
(dacarbazine) (7-10). Failure of AGT to repair 06-methylguan-
ine results in C6-methylguanine:thymine mispairs following
DNA replication and it is postulated that these mediate cell
death via mismatch repair (11). The DNA mismatch repair
enzyme MSH2 is known to bind to and recognize 06-methyl-
guanine:thymine mispairs and is also essential for a large
proportion of apoptosis observed in the murine small intestine
following exposure to alkylating agents (12,13). Mutations
arise if the C6-methylguanine: thymine mispairs undergo further
rounds of replication.
06-benzylguanine (BeG) is a competitive and irreversible
inhibitor of AGT which acts by binding to the -CH3 cysteine
acceptor site of AGT forming S-benzylcysteine (14,15). BeG-
bound AGT is inactive and is subsequently degraded. Cellular
AGT activity can be restored only by de novo protein synthesis
(5) and its depletion by BeG has been proposed as a useful
adjuvant to clinical methylating and chloroethylating agent treat¬
ment of tumours (16). Adjuvant therapy of BeG combined with 1
such agents offers the potential to use lower, and hence less
toxic, doses of chemotherapeutic drug and may also be ofbenefit
in overcoming tumour resistance associated with high levels of
AGT (17). Dacarbazine is a DNA alkylating agent used in the
treatment of metastatic melanoma and Hodgkin's lymphoma
(18). It is a prodrug requiring cytochrome P450-dependent
(V-demethylation to produce the active compound 5-(3-methyl-
triazen-l-yl)imidazole-4-carboxamide (MITC) (19,20). MITC
is also generated when temozlomide reacts spontaneously with
H20 (21). MITC decomposes to a methylating intermediate
common to a variety of agents that result in the methylation of
DNA with subsequent consequences for cell death and mutation.
One approach to directly determine the somatic in vivo
mutation frequency relies upon detecting loss of function at
the polymorphic genetic locus Dlb-1 (22). This locus deter¬
mines the ability to bind the lectin from Dolichos biflorus in
mouse intestinal epithelium. Mutation frequency can be scored
by identifying clonal populations which are no longer capable
of binding the lectin. We have previously shown that in vivo
administration of BeG reversibly suppresses AGT function,
but does not modulate the apoptotic response to temozolomide
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or another methylating agent, /V-methyl-/V'-nitro-A-nitrosogu-
anidine (MNNG), in the small intestine. Furthermore, we have
shown that BeG treatment did not enhance the apoptotic
response in a mismatch repair-deficient background (13). We
show here that AGT plays no role in modulating the apoptotic
response or mutation rate in the normal epithelium of the
murine intestine following exposure to the methylating agent
/V-methyl-/V-nitrosurea (MNU) or the apoptotic response to




All mice were maintained under non-barrier conditions and given a standard
diet and water ad libitum.
AGT assay
Mice were killed and tissues of interest removed, snap frozen in liquid
nitrogen and stored at -70°C until assayed as described previously (4). Briefly,
tissue samples were defrosted and disrupted by sonication (10 s at 10 pm
peak-to-peak, followed by 10 s at 16 |im peak-to-peak) in 1 ml of 50 mM
Tris-HCl (pH 8.3), 1 mM EDTA, 3 mM dithiothreitol containing 5 pg/ml
leupeptin, after which 10 pi of phenylmethylsulphonyl fluoride (87 pg/ml in
ethanol) was added. Insoluble cellular debris was removed by centrifugation
for 10 min at 13 000 r.p.m. at 4°C. Aliquots of the supernatants were incubated
for 2 h at 37°C with a calf thymus DNA substrate that had been methylated
by reaction with ['HJMNU (14.5 Ci/mM; Amersham). Specific activities were
calculated from the amount (fmol) of ['Hjmethyl groups transferred per unit
amount of total protein in the extract under conditions where activity was
proportional to the amount of total protein assayed. The protein concentrations
of the extracts were determined using bovine serum albumin as a calibration
standard.
Treatment protocol
Eight to 10 week old mice were given i.p. injections of temozolomide (100
mg/kg), cisplatin (10 mg/kg; David Bull Laboratories), dacarbazine (150 mg/
kg; Sigma). MNNG (50 mg/kg) or MNU (100 mg/kg). BeG was administered
at a dose of 60 mg/kg i.p. Metyrapone was used at a concentration of 100
mg/kg i.p. The delivery volume for all reagents was 0.25 ml. All drugs, except
cisplatin. were prepared fresh and first dissolved in dimethylsulphoxide (10%
v/v) and made to a final concentration with phosphate-buffered saline
(PBS) (temozolomide, dacarbazine and benzylguanine) or corn oil (MNNG).
Metyrapone was dissolved in PBS alone. Mice were exposed to y-irradiation
using a ,37Cs source at 0.27 Gy/min for 15 min, so that each animal received
a dose of 4 Gy.
Apoptosis quantitation
I At a specified time point following reagent injection or irradiation, a minimum
of three animals were killed, the small intestine removed, flushed with water
and fixed overnight in methocarn (4 parts methanol, 2 parts chloroform, 1
part acetic acid). Haematoxylin and eosin stained sections were made and
apoptosis scored through the use of the Highly Optimised Microscope
Environment (HOME) as previously described (23,24). A minimum of fifty
half-crypts were scored per animal.
Dlb-I mutation assay
A cohort of 8-10 week old Dlb-I b/a heterozygote mice were treated with
BeG (60 mg/kg i.p.). A second identical cohort received no BeG. One hour
after BeG administration mice were injected i.p. with a single dose of MNU.
Twenty-one days later the mice were killed, their small intestines removed
and flushed with water. Whole mount preparations of 15 cm of the intestine
were stained with Dolichos biflorus agglutinin (DBA)-peroxidase as described
by Winton et al. (22). Villus ribbons not staining with the DBA-peroxidase
conjugate were scored using a Wild stereo microscope and the results presented
as number of mutations per 104 villi.
Results
BeG does not induce apoptosis within the murine small intestine
As previously shown, administration of 60 mg/kg BeG func¬
tionally depletes AGT activity in the small intestine for a
period between 1 and 12 h post-drug administration (13). AGT
inhibition may result in increased cell death as a consequence
</)
Fig. 1. The effect of BeG upon the induction of apoptosis in the murine
intestine. Cohorts of wild-type mice were treated with 100 mg/kg
temozolomide, 50 mg/kg MNNG, 100 mg/kg MNU, 10 mg/kg cisplatin, 4
Gy y-irradiation and 150 mg/kg dacarbazine in the presence and absence of
BeG. Data show the prevalence of apoptosis 6 h after reagent administration
and 7 h after i.p. BeG (60 mg/kg). Each bar represents data from six mice.
Closed boxes, no BeG; open boxes, BeG treated. Error bars represent SEM.
of failure to repair endogenous alkylated DNA damage. To
test this hypothesis, apoptosis was scored over a time course
following BeG administration. Cohorts of mice were injected
with 60 mg/kg BeG at time 0. Apoptosis was scored at 0, 3,
6, 12, 24, 48 and 72 h after injection. No increase in the
incidence of apoptosis was observed up to 72 h following
BeG injection (data not shown). During this time period
we also assessed the levels of necrosis within the sample
histologically, as it remained possible that BeG was eliciting
cell death through mechanisms other than apoptosis. We saw
no increase in the levels of necrosis.
MNU-, cisplatin- and y-irradiation-induced apoptosis in mur¬
ine small intestine is unaffected by functional AGT depletion
We have previously shown that BeG administration did not
modify enterocyte apoptosis following treatment with temozol¬
omide or MNNG (13). We report here the effect of BeG
administration on the apoptotic response to MNU, dacarbazine,
cisplatin and y-irradiation. These agents were chosen either to
determine the effect of exposure to alkylating agents (MNU
and dacarbazine) or to act as negative controls (cisplatin and
y-irradiation). Wild-type mice were pretreated with BeG (60
mg/kg) and 1 h later either 100 mg/kg MNU, 10 mg/kg
cisplatin, 150 mg/kg dacarbazine or 4 Gy of y-irradiation
were administered. Comparative data on temozolomide- and
MNNG-treated mice is reproduced here from Toft et al. (13).
Apoptosis was scored in the small intestine 6 h later (Figure
1). No significant differences in the prevalence of apoptosis
were observed between BeG- and non-BeG-treated animals
following MNU, temozolomide, cisplatin or ionizing irradiation
(P > 0.4 in all cases, Mann-Whitney (/-test). However,
dacarbazine-induced apoptosis was almost completely inhibited
following BeG treatment (P < 0.01, Mann-Whitney (/-test).
Once again, we did not observe an increase in necrosis in any
of the treatment protocols, indicating that these agents were
not killing cells through mechanisms other than apoptosis, at
least within the time frame studied.
The apoptotic response following low doses of temozolomide
is not altered by BeG administration
To investigate the possibility that the doses of alkylating agents
used in Figure 1 were depleting cellular pools of active AGT
594
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Fig. 2. The effect of BeG upon apoptosis induced by varying doses of
temozolomide. Cohorts of wild-type mice treated with temozolomide (range
0.5-16 mg/kg) in the presence and absence of BeG. Data show the
prevalence of apoptosis 6 h after temozolomide administration and 7 h after
1.p. injection of BeG (60 mg/kg). Each point represents data from a
minimum of three mice. Closed circles, BeG treated; open circles, no BeG.





Fig. 3. The effect of BeG on mutation rates following exposure to MNU.
Dlb-1 mutation frequency in the murine small intestine following 100 mg/
kg MNU treatment in the presence and absence of BeG. BeG was
administered at a dose of 60 mg/kg prior to the administration of MNU.
Each point represents data from three mice. Filled bars, no BeG; open bars,
BeG treated. Error bars represent SEM.
and therefore rendering BeG treatment ineffective, very low
doses of temozolomide (range 0.5-16 mg/kg) were adminis¬
tered to mice with and without BeG administration. Apoptosis
was scored 6 h later (Figure 2). The rationale was that at low
doses of temozolomide not all functional AGT activity would
be abolished by the alkylating agent and thus, if AGT could
actually alter the level of apoptosis, a difference between BeG-
treated and non-treated mice may be revealed. No significant
differences in the incidence of apoptosis were observed
between BeG-treated and non-treated mice at any dose of
temozolomide (P > 0.07 for all doses, Mann-Whitney U-test).
MNU-induced mutation frequency at the Dlb-1 locus is not
influenced by BeG
Mutation rate within the murine small intestine following
MNU was scored at the Dlb-1 locus using standard approaches
(1,22). The mutation frequency increased with increasing doses
of MNU (Figure 3), but prior treatment with BeG did not
result in a significant elevation in the mutation frequency at
//'-benzylguanine inhibits dacarbazine activation
the Dlb-1 locus (P > 0.05 for both doses, Mann-Whitney
(/-test).
Temozolomide administration effectively ablates AGT activity
in the intestine
One explanation for the failure to observe BeG-dependent
differences in apoptosis and mutation frequency is that treat¬
ment with the methylating agent alone is sufficient to render
AGT functionally inactive and that, further. BeG-mediated
suppression is therefore largely irrelevant. To directly test this
we exposed mice to varying doses of temozolomide and scored
AGT activity in both the liver and intestine. As we have shown
before, pretreatment with BeG markedly reduces resting levels
of AGT activity at 6 h (13). In the liver this reduction is from
150 ± 40.8 to 13.3 ± 21 fmol/mg protein. In the intestine
AGT activity falls from a lower resting level (45.6 ± 12 fmol/
mg) to become undetectable 6 h after BeG treatment (13). The
effect of exposure to increasing doses of temozolomide was
indeed to reduce levels of AGT activity, as shown in Figure
4. Following exposure to 100 mg/kg temozolomide, AGT
activity was effectively depleted in both the liver and small
intestine.
BeG inhibits the P450-dependent metabolic activation of
dacarbazine
We have shown that exposure to BeG inhibits apoptosis
induced by dacarbazine (Figure 1). In order to study the
kinetics of this inhibition a single dose of BeG (60 mg/kg)
was administered to wild-type mice at time 0. Mice were then
subsequently injected with 150 mg/kg dacarbazine at 0, 1, 6,
12, 24, 48 and 72 h after BeG delivery. Six hours after each
dacarbazine injection, levels of apoptosis were scored in the
small intestine (Figure 5). Dacarbazine alone induced high
levels of apoptosis with a mean of >60 apoptotic bodies per
50 half-crypts. However, between 1 and 6 h following BeG
administration dacarbazine failed to induce apoptosis. This
suppression was reversible, such that a normal apoptotic
response was restored by 24 h. Thus, BeG administration
reversibly inhibited dacarbazine-dependent apoptosis. The act¬
ive DNA-damaging metabolite of dacarbazine is M1TC, which
is generated from dacarbazine in a cytochrome P450-dependent
manner. In order to confirm that cytochrome P450 function
was essential in eliciting a dacarbazine-dependent apoptotic
response we used the P450 inhibitor metyrapone (25). Dacarba¬
zine was administered 1 h following treatment with metyrapone
(100 mg/kg i.p.). Metyrapone treatment significantly reduced
the apoptotic response to dacarbazine (Figure 6), confirming
that activation of the prodrug and the associated apoptotic
response were P450 dependent (P < 0.05, Mann-Whitney La¬
test). These findings indicate that BeG administration blocks
activation of the prodrug dacarbazine, possibly by comprom¬
ising host P450 activity.
Discussion
We have directly addressed the ability of BeG to alter rates of
apoptosis and mutation in the normal murine epithelium
following exposure to a range of different types of damage.
No induction of apoptosis was associated with BeG treatment.
This excluded the possibility that either BeG itself or the
depletion of AGT activity could result in the induction of
apoptosis in the murine small intestine. Following treatment
with BeG, and in the absence of detectable AGT activity,
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Fig. 4. The effect of temozolomide on AGT activity. AGT activity measured in fmol/mg protein scored in the liver (A) and in the small intestine (B) 6 h
following a single i.p. injection of temozolomide. Resting values for intestine are reproduced from Toft et al. (13). Error bars represent SEM.
Time after benzyiguanine administration (hours)
Fig. 5. The effect of BeG on dacarbazine-induced apoptosis. Following a
single dose of BeG (60 mg/kg) at time 0, mice were injected with
dacarbazine (150 mg/kg) at 0, 1, 6, 12, 24, 48 and 72 h after BeG. Six
hours after each dacarbazine injection levels of apoptosis were scored in the
small intestine. Each point represents data from three mice. Error bars
represent SEM.
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Fig. 6. The effect of metyrapone on dacarbazine-induced apoptosis. Bar
chart of the prevalence of apoptotic bodies in the murine small intestine 6 h
following 150 mg/kg dacarbazine or 100 mg/kg metyrapone. The prevalence
of apoptotic bodies at 6 h in dacarbazine-treated mice which were preheated
with 100 mg/kg metyrapone 1 h prior to injection with dacarbazine is also
shown (Met & Dae). Error bars represent SEM.
apoptosis. However, the levels of apoptosis were similar to
those observed in BeG-untreated controls. Thus. BeG treatment
neither reduced nor augmented the prevalence of apoptosis in
the intestine following application of a variety of DNA-
damaging agents.
Such a failure to modify the phenotype may have occurred
because in vivo exposure to alkylating agents reduces AGT
activity by depleting cellular pools of unmethylated AGT, so
limiting the impact of BeG pretreatment (5,26,27). To address
this possibility, temozolomide was administered at decreasing
doses in the presence and absence of BeG. Similar levels of
apoptosis were scored in both BeG-treated and BeG-untreated
mice, suggesting that either ablation of AGT was occurring
following exposure to very low levels of temozolomide or that
BeG-mediated inactivation of AGT is irrelevant to the induction
of apoptosis following alkylation damage. We further probed
this question by analysing the effect of temozolomide adminis¬
tration upon AGT activity and established that low levels of
temozolomide were effective in depleting AGT activity in the
intestine. This is perhaps not surprising as resting levels within
this tissue are relatively low. We also demonstrated a similar
phenomenon for the liver, which is characterized by much
higher basal AGT activity, although effective depletion was
only seen at the highest temozolomide dose used, 100 mg/kg.
Increasing doses of MNU increased the mutation frequency
scored at the Dlb-I locus. Since the principal mutagenic lesion
generated by MNU is 06-methylguanine, ablation of AGT
activity might be predicted to lead to an increase in Dlb-1
mutations. However, pretreatment of mice with BeG failed to
elevate the mutation rate following MNU treatment. As with
the effect of BeG treatment upon the induction of apoptosis,
the observed failure to modify the mutation rate in the murine
small intestine may be interpreted in several ways. First, AGT
activity may not be relevant to protection against mutation in
this tissue: other DNA lesions such as 3-methyladenosine
could be responsible for these mutations. Second, exposure to
the methylating agent alone may be sufficient to inactivate
AGT, as suggested by our results following exposure to
temozolomide. Third, it might be that in those cells in which
Dlb-1 mutations normally arise, recovery of AGT activity
occurs prior to fixation of the mutation by DNA replication.
It seems likely that the second of these explanations is correct,
although it should be remembered that we have only established
effective AGT depletion at a single time point for temozolom¬
ide. Taken together, these results show that BeG pretreatment
does not alter either the apoptotic response or mutation
frequency in the normal epithelium of the murine small
intestine.
A somewhat unexpected finding in the present study was
that BeG administration blocks dacarbazine-induced apoptosis.
It is reasonable to suggest that this occurs either because AGT
activity is required by dacarbazine to induce apoptosis or
because BeG is blocking the normal metabolism of dacarbazine
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Fig. 7. Degradation pathways for dacarbazine and temozolomide.
Dacarbazine and temozolomide give rise to the active compound MITC,
which decomposes spontaneously to an active methylating agent which
produces, amongst 11 other base lesions, 06-methylguanine, the major
premutagenic lesion in DNA. Dacarbazine requires oxidative
/V-demethylation by cytochrome P450 to form MITC, unlike temozolomide,
which reacts spontaneously with water to give MITC.
to an active alkylating agent. Dacarbazine is known to undergo
oxidative /V-demethylation to its active compound MITC
(18,28,29). This metabolic activation is mediated through the
action of cytochrome P450 enzymes (20,30). Two observations
argue in favour of the possibility that BeG is blocking the
normal metabolism of dacarbazine. First, temozolomide is able
to induce apoptosis in the presence of AGT depletion (13).
Thus, the inhibitory action of BeG cannot be arising subsequent
to the generation of MITC since it is also the active compound
formed when temozolomide undergoes spontaneous chemical
transformation (19,21) (Figure 7). Second, one of the major
routes of metabolism of BeG in mice involves oxidation to
form D6-benzyl-8-oxoguanine (31), which occurs through the
actions of aldehyde oxidase and the cytochrome P450 isoforms
CYP1A2 and CYP3A4 (32,33). Dacarbazine is also metab¬
olized by a number of different isoforms of P450, including
CYP1A1, CYP1A2 and CYP2E1 (34). For both dacarbazine
and BeG, the primary isoform responsible for metabolism is
CYP1A2. The possibility therefore arises that BeG metabolism
may competitively deplete cytochrome P450 activity. Thus,
BeG appears capable of inhibiting at least some of the
demethylating ability of cytochrome P450 enzymes in the
mouse liver. The consequences of this novel finding are likely
to be significant in view of the central role of P450 enzymes
in the metabolism of drugs and carcinogens.
There is increasing interest in the use of BeG clinically as
an adjuvant to alkylating agent chemotherapy to overcome
tumour resistance mediated by AGT and to potentiate the
cytotoxic effects of chemotherapy (16,35). There are, however,
a number of uncertainties concerning the clinical benefits
of BeG. First, alkylating agents themselves are capable of
inactivating AGT activity by depleting cellular pools (5,27).
We show here that this can be an effective mechanism for
suppressing AGT activity both in the normal cells of the small
intestine and in the liver of mice. There are, however, several
lines of evidence to suggest that the use of alkylating agents to
suppress AGT activity can be ineffective or even inappropriate,
either because of failure to increase the therapeutic index or
because of dose-limiting toxicity (27). Thus, although alkylat¬
ing agents can reduce the activity of AGT, the available data
indicate BeG administration to be the most effective and least
toxic method to achieve this. Second, BeG has been reported
to increase mutation rates, chromosome aberrations and toxicity
in normal cells treated with methylating or chloroethylating
agents (36-38). In contradiction to these reports, we do not
observe any effect upon in vivo mutation rate in these studies.
Third, from the data presented here it is clear that in the
murine small intestine AGT depletion does not elevate in vivo
apoptotic levels following methylating DNA damage. This
result has clear positive implications for the therapeutic use
of BeG, in that BeG administration fails to augment cell death
within normal tissues. This result may directly follow from
the demonstrated ability of alkylating agents to partially
suppress AGT activity and may simply reflect the low resting
levels of AGT in the murine intestine. Finally, and perhaps
most significantly, these data show that BeG can alter the
metabolism of drugs or carcinogens, exemplified here by
activation of the prodrug dacarbazine, and may therefore be a
cause of unexpected adverse drug reactions if used clinically.
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A role for mismatch repair in control of DNA ploidy following DNA
damage
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Many reports have shown a link between mismatch
repair (MMR) deficiency and loss of normal cell cycle
control, particularly loss of G2 arrest. However almost
all of these studies utilized transformed cell lines, and
thus the involvement of other genes in this phenotype
cannot be excluded. We have examined the effects of
cisplatin treatment on primary embryo fibroblasts
(MEFs) derived from mice in which the MMR gene
Msh2 had been inactivated (Msh2-'"). This analysis
determined that both primary Msh2~'~ and wild type
(WT) fibroblasts exhibited an essentially identical G2
arrest following cisplatin treatment. Similarly, we
observed a cisplatin-induced G2 arrest in immortalized
MMR deficient (Mlhl"'" and Pms2~'~) and WT MEfs.
p53 deficient primary MEFs (p53~'') exhibited both a
clear G2 arrest and an increase in cells with a DMA
content of 8N in response to cisplatin. When the Msh2
and pS3 defects were combined {p53~<-IMshl-'-) the
G2 arrest was essentially identical to the p53~'~
fibroblasts. However, the p53-'~j\3sk2-'~ fibroblasts
demonstrated a further increase in cells with an 8N ONA
content, above that seen in the p53-'~ fibroblasts. These
results suggest that loss of MMR on its own is not
enough to overcome G2 arrest following exposure to
cisplatin but does play a role in preventing polyploidiza-
tion, or aberrant DNA reduplication, in the absence of
functional p53. Oncogene (2001) 20, 1923-1927.
Keywords: mismatch repair; cell cycle; polyploidy; p53;
DNA damage
DNA mismatch repair is known to play an important
role in maintaining genomic stability, due to its
function in correcting DNA mismatches introduced
during replication, and cells deficient in MMR exhibit
an increased mutation rate (for review see Buermeycr
et al., 1999). However the proteins that make up the
MMR system have also been associated with a number
of other phenotypes. Cells deficient in MMR have been
shown to be resistant to a number of clinically
important drugs, such as cisplatin, temozolomide and
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doxorubicin (Fink et al., 1998). This resistance may be
mediated by an altered ability to engage apoptosis, as
the MMR proteins have been shown to be critical in
mediating the normal in vivo apoptotic response to
alkylating agents (Toft el al., 1999). Restoration of
MMR activity in cell lines, cither by chromosome
transfer or by direct re-introduction of the gene, results
in drug resensitizalion, demonstrating that the drug
resistance js not secondary to an increase in mutation
rate but is due to the direct involvement of the MMR
system. In addition MMR deficiency has also been
associated with a loss of normal cell cycle controls in
response to agents such as MNNG (Koi el al., 1994),
6-thioguanine (6-TG) (Hawn ei al., 1995) cisplatin
(Brown el al., 1997) and ionizing radiation (IR) (Davis
el al., 1998), suggesting that the MMR system may
have a regulatory role, primarily at the G2/M
boundary. Indeed the activity of a number of key
regulators of the cell cycle, such as p53 (Duckctt et al.,
1999), p73 (Gong et al., 1999) and c-abl (Nehme et al.,
1997), are known to be modulated in a MMR
dependent fashion in response to certain types of
DNA damage.
Loss of MMR has also been shown to play an
important role in the development of cancer. Loss of at
least five of the MMR proteins (MLHl, MSH2,
MSH6, PMSl and PMS2) has been shown to be
associated with the hereditary cancer syndrome
HNPCC (Buermeyer el al., 1999). In addition loss of
mismatch repair, and the resulting microsatellite
instability phenotype, is seen in a significant fraction
of sporadic tumours of many different cancer types
(Arzimanoglou et al.. 1998). It is generally assumed
that loss of MMR leads to cancer due to the resulting
increased mutation rate, although it has also been
suggested that defective cell cycle control may be the
primary oncogenic mechanism in MMR deficient cells
(Tomlinson and Bodmer, 1999).
Nearly all studies on the role of MMR in drug
resistance and cell cycle control have been performed
in tumour-derived or immortalized cell lines. Such cell
lines will inevitably have multiple alterations in cell
cycle control, which may well interact with a deficiency
in MMR and influence the apparent phenotype of
MMR defects. To more clearly define the role of
MMR in the cell cycle response to a commonly used
chemothcrapeutic agent, cisplatin, we have assessed cell
D
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cycle responses in both primary and spontaneously
immortalized mouse embryonic fibroblasts (MEFs) in
which one of the mismatch repair proteins. Msh2,
Mlhl or Pms2, had been genetically inactivated. In
addition we have also determined the response to
cisplatin in p53 proficient and deficient backgrounds.
MEFs were isolated from Msh2''' and WT embryos
taken from 13-day pregnant females. After 3 days in
culture the MEFs were split into 10 cm dishes to allow
cell cycle analysis using BrdU/propidium iodide
staining and FACS analysis. For each embryo,
separate plates were treated with 0, 5 or 10 pm
cisplatin tor 1 h. Cells were then harvested at 24 or
48 h post-treatment for cell cycle analysis (example
histograms in Figure 1). As expected the WT MEFs
















Figure 1 Effect of Msh2 and p53 status on G2 arrest and DNA
ploidy. Representative FACS profiles are shown 48 h after
treatment with 0, 5 or 10 pm cisplatin, as indicated, for MEFs
of each of the four genotypes. The percentage of cells with a
DNA content of 8N is shown on each profile. Primary MEFs
were derived from 13-day-old embryos and maintained in
Dulbecco's modified Eagle's medium (DMEM) (Gibco) supple¬
mented with 10% foetal calf serum. After 3 or 4 days ceils were
trypsinized and approximately I x 10* cells were plated out for
each dose/time point to be tested. The following day the cells were
exposed to 0, 5 or 10 pm cisplaiin (David Bull Laboratories) for
1 h at 37"C, then washed with PBS and fresh media added. Four
hours before the cells were due to be harvested the media was
removed and replaced with media containing 10 pm BrdU
(Sigma) and incubated ai 37°C for a further 4 h. The cells were
then trypsinized. centrifuged and fixed in 70% cthanol. The fixed
cells were stored at — 20"C and flow cytometric analysis was
performed us described before (Brown el «/., 1993) using a
FACScun (Beeton Dickinson). Statistical analysis was performed
using a two-tailed Student's f-tesi
5 or 10 pm cisplatin at both 24 and 48 h (Figures 1
and 2). The Msh2~'- MEFs also show a clear G2
arrest in response to cisplatin (Figures 1 and 2).
Indeed, the G2 arrest seen in the Msh2-'~ MEFs is
essentially identical to that of the WT MEFs. This
suggests that in these cells an intact MMR response is
not required to initiate or maintain a G2 arrest
following cisplatin damage. These results are in
contrast to previous studies showing loss of G2 arrest
following cisplatin treatment in MMR-defective cancer
cell lines (Brown et al., 1997), and loss of G2 arrest
after 6-TG or IR in MMR-defective MEFs (Davis et
al., 1998). Taken together these results suggest that in
primary MEFs a MMR defect is not sufficient to
overcome G2 arrest in response to cisplatin, and that a
MMR independent mechanism causes G2 arrest in
response to cisplatin. but not 6-TG or IR. Further
investigation will be required to determine the nature
of the MMR-independent mechanism, however a ■
number of other pathways leading to G2 arrest in
response to DNA damage have previously been
identified (Dasika et al., 1999). i
Three spontaneously immortalized MEF cell lines,
WT or deficient in either Mlhl (Mlhl'1') or Pms2
(Pms2~'-) (Prolla et at., 1998). were also used for cell
cycle analysis. As for the primary MEFs the
immortalized cell lines all exhibit a clear G2 arrest
in response to treatment with 5 or 10 pm cisplatin
(Figure 3). The G2 arrest observed in the Mlhl'1 and
Pms2immortalized MEFs is similar to lhat seen in
the immortalized WT MEFs, although the results
suggests that there is a more rapid exit from G2 arrest
in the Pms2~'~ MEFs (Figure 3; 10 pm/48 h time
point). Therefore, as in the primary MEFs, a
functional MMR system is not essential for the G2
arrest in response to cisplatin treatment.
The FACS analysis presented above does not
differentiate between G2 cells and cells in mitosis.
Therefore it is possible that the MMR deficient cells
have indeed lost G2 arrest but then subsequently arrest
in mitosis through a MMR independent mechanism.
To address this, the mitotic index of the three
immortalized MEF cell lines was determined in
untreated and cisplatin treated cells. Experiments in
which the mitotic spindle is disrupted by nocodozoie
treatment report a peak in the mitotic index at 8 h post
treatment (Notterman et al., 1998). We therefore
analysed cells at either 8 or 24 h after a 1 h exposure
to 10 pm cisplatin. Ceils were fixed in methanol: acetic
acid (3:1) and dropped onto microscope slides. Mitotic
cells were identified based on the presence of
condensed chromatin. As can be seen from Table 1,
there is no evidence of an increase in mitotic index in
any of the three cell lines (indeed mitotic indices are
reduced, presumably due to the arrest induced by
cisplatin in other phases of the cell cycle) showing that
arrest does not occur during mitosis. Our findings are
therefore consistent with a G2 arrest both in the
presence and absence of functional MMR.
The p53 protein is known to be a key regulator of
cell cycle checkpoints and its function is frequently lost
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Flguit 2 Effect or cisplatin treatment on cell cycle distribution of primary MEFs. The percentage of cells with a 2N, 4N or 8N
DNA content was assessed by FACS analysis. Cells were treated with 0, 5 or 10 pm cisplatin for 1 h and their cell cycle distribution
analysed either 24 or 48 h after drug treatment, as indicated. 2N cells are indicated by the open column, 4N cells by the filled
column and 8N cells by the striped column. Each dose/time point is an average of 3-8 replicates. The standard deviation is
represented by error bars
in human tumours (Bates and Vousden, 1996). In
addition the absence of p53 has been shown to be
associated with genomic instability and increasing
anneuploidy (Donehower el al., 1995). To further
investigate the effect of loss of MMR on cisplatin
induced cell cycle arrest we analysed primary MEFs
deficient for both Msh2 and p53 and compared them
with MEFs deficient for p53 alone using the same
analysis as described above. As can be seen from
Figure 2 the p53 deficient MEFs exhibit an even
stronger G2 arrest than the WT MEFs. This is likely to
be due to the loss of the p53 dependent Gl/S
checkpoint (El-Deiry el al., 1993; Keurbitz et al.,
1992) resulting in more cells entering and then arresting
in G2. As was seen in the WT background, the loss of
Msh2 function in a p53 deficient background does not
result in any loss of G2 arrest (Figure 2). A previous
study of MMR deficient, cancer-derived cell lines,
which did exhibit loss of G2 arrest in response to
cisplatin (Brown el al., 1997), also detected deficiencies
in p53 function (Anthoney et al., 1996). However, in
this study we detected no loss of G2 arrest even when
Msh2 was genetically inactivated in a p53 deficient
background. Thus the MMR independent pathway
that results in G2 arrest in response to cisplatin in
primary MEFs is also able to function in the absence
of p53 activity.
p53 is also thought to play a role in a second cell
cycle checkpoint at the G2/M boundary to prevent
aberrant reduplication of DNA (Cross et al., 1995).
Consistent with this observation our analysis detected
an increase in cells with an 8N DNA content in the
p53MEFs compared with the WT MEFs (Figures 1
and 2), in both the cisplatin treated and untreated cells
(/» = 0.028, 0.0028, 0.0032 for 0, 5, 10 pm treated cells
at 48 h post-treatment, respectively). The Msh2-'-
MEFs showed no increase in the 8N population
compared with WT MEFs. In contrast the p53~' /
Msh2'~ MEFs showed a clear increase in cells with an
8N DNA content, over and above that seen in the
MEFs deficient in p53 alone (Figures 1 and 2). This
increase in 8N cells was observed in untreated cells
(P- 0.023), as well as following treatment with cither 5
(P- 0.025) or 10 pm (/>=0.0075) cisplatin at 48 h post-
treatment. The results for the p53~'- MEFs are not
unexpected, but the increased rate of polyploidy
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Fleurc 3 Effect of cisplutin treatment on cell cycle dUlribuuon of immortalized MEFs. The percentage of cells with a 2N or 4N
DNA content was assessed by FACS analysis. 2N cells are indicated by the open column and 4N ceils by the filled column. Each
dose/lime point is an average of four replicates The standard deviation is represented by error bars
Table 1 Percentage of cells in mitosis
Genotype 0 ft" 8 h 24 h
WT 2. lOb 1.26 1.2#
Mlhl 1.48 O.SS 0.30
Pm52 1.67 0.90 1.22
"Time in hours a for exposure to 10 jim cisplatin at which cells were
harvested. 0 h indicates untreated. •'Percentage of mitotic cells
observed in the p53'l~/Msh2~l- MEFs suggests a novel
role for Msh2, and therefore possibly for MMR, in the
prevention of aberrant reduplication of DNA, particu¬
larly in response to cisplatin induced DNA damage.
Further investigation will be required to determine if
Msh2 also plays a role in preventing aberrant
reduplication of DNA in response to other DNA
damaging agents, such as 6-TG and IR. There are a
number of potential mechanisms by which Msh2 could
function 10 prevent aberrant reduplication. Msh2 and
its heterodimeric binding partner Msh3 are known to
be required for removal of non-homologous tails
during recombination (Sugawara et al., 1997). It is
therefore possible that MMR proteins could be
involved in signalling from unresolved or aberrant
recombination structures, to allow the resolution of
such structures and the appropriate completion of
mitosis. In the absence of MMR and p53 such cells
may not be able to complete mitosis due to the MMR
defect and may then aberrantly re-enter S phase due to
the defect in p53 function. Interestingly, cisplatin
treatment is known to increase mitotic recombination,
as judged by an increase in sister chromatid exchange,
a process regulated in part by MMR proteins (Durant
et al., 1999), and the Msh2 dependent increase in the
8N population is exaggerated following cisplatin
treatment. Alternatively, Msh2 could act to induce
apoptosis in polyploid cells, thus eliminating them
from the population. A role for MMR proteins in
signalling apoptosis in response to DNA damage is
already well established (Hickman and Samson, 1999;
Gong et al., 1999).
In summary, our results highlight an interdepen¬
dence between the MMR and the p53 pathways. Such
an interaction is supported by a number of other
studies, Lec et al. (1995) showed that p53 can recognize
insertion deletion loops, forming stable complexes at
these lesions where it can physically interact with
Msh2. p53 has also been shown to suppress non¬
homologous recombination by specific mismatch
Onco|«n«
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recognition (DudcnhofTer et al., 1998), and MMR-
depcndent phosphorylation of p53 has been reported
after mcthylation damage (Duckctt el al., 1999).
Finally, combined loss of Msh2 and p53 has been
shown to lead to embryonic lethality of female mice on
a C57BL6J background and to synergisticaUy increased
tumorigenesis in males (Cranston el al.. 1997),
Previous studies obtained from tumour cell lines
have implicated the MMR proteins in G2 arrest.
However we show here that primary cell lines (and
indeed immortalized lines derived from primary cell
lines) do not show an MMR dependent G2 arrest
following cisplatin treatment. These results demon¬
strate that MMR dependent responses are highly
context dependent and that the processes controlled
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Dysregulated expression of /?-catenin marks early neoplastic change in Ape
mutant mice, but not all lesions arising in Msh2 deficient mice
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&
We have analysed the pattern of /(-catenin expression by
immunohistochemistry in mice singly or multiply mutant
for Ape, p53 and Msh2. We observed increased
expression of /(-catenin in all intestinal lesions arising
on an ApcMi" + / — background. In all categories of lesion
studied mosaic patterns of /J-eatenin expression were
observed, with the proportion of cells showing enhanced
expression decreasing with increasing lesion size. p53
status did not alter these patterns. We also show that /(-
catenin dysregulation marks pancreatic abnormalities
occurring in ApcMi" + / — and (ApcMi" + / — , p53 —/—)
mice. In these mice both adenomas and adenocarcinomas
of the pancreas arose and were characterized by
increased expression of /(-catenin. We have extended
these analyses to intestinal lesions arising in mice mutant
for the mismatch repair gene Msh2. In these mice,
increased expression of /(-catenin was again observed.
However, in contrast with ApcM'" + /— mice, a subset of
lesions retained normal expression. Taken together, these
findings show that increased expression of /(-catenin is an
efficient marker of early neoplastic change in both
murine intestine and pancreas in Ape mutant mice.
However, we also show that dysregulation of /(-catenin is
not an obligate step in the development of intestinal
lesions, and therefore that genetic events other than the
loss of Ape function may initiate the transition from
normal to neoplastic epithelium.
Keywords: /(-catenin; Ape; p53; Msh2; intestine;
pancreas
Introduction
Germline mutations in the adenomatous polyposis coli
gene (APC) gene at 5q21 characterize an inherited
disorder known as familial adenomatous polyposis coli
(FAP) (Kinzler et al., 1991). FAP patients develop
numerous adenomas throughout both the small and
large intestine, some of which ultimately progress to
carcinoma. However, a more general role for APC
mutations in neoplasia is suggested by the fact that
FAP patients have an increased predisposition to
tumours of the brain, thyroid and bone and also to
focal proliferative lesions ('desmoid tumours') of the
connective tissue. Mutated APC has also been reported
in a range of sporadic tumours, including pancreatic
"Correspondence: AR Clarke
Received 16 March 1999; revised 20 August 1999; accepted
23 August 1999
and gastric tumours and the majority of adenomas and
carcinomas of the colorectum (Miyoshi et al., 1992;
Horii et al., 1992; Nakatsuru et al., 1992). Further¬
more, loss of heterozygosity at 5q21 has been observed
in sporadic tumours of the breast and oesophagus
(Boynton et al., 1992; Thompson et al., 1993;
Kashiwaba et al., 1994).
Several different murine models of FAP have been
generated by random chemical carcinogenesis (Moser
et al., 1992), conventional gene targeting (Fodde et al.,
1994; Oshima et al., 1995) and by the use of Cre-Lox
technology (Shibata et al., 1997). All of these models
are characterized by high levels of spontaneous
intestinal neoplasia, confirming a role for Ape in the
development of these lesions. Several observations
using these models support the notion that Ape has
more widespread tumour suppressor activity. First,
desmoid tumours have been reported to occur
spontaneously in Ape mutant mice (Shoemaker et al.,
1997; Smits et al., 1998). Second, Ape""' heterozygotes
show an increased susceptibility to mammary carcino¬
ma both spontaneously and following genotoxic stress
such as carcinogen treatment or X irradiation (Moser
et al., 1993, 1995; van der Houven et al., 1997). Finally,
Ape heterozygosity on a p53 null background has been
shown to strongly predispose to pancreatic neoplasia
(Clarke et al., 1995).
How loss of function of Ape predisposes to
malignancy remains unclear, however disruption of
the normal function of /(-eatenin has been implicated in
this process (Rubinfeld, 1993; Su et al., 1993). Levels of
/(-eatenin are modulated by Ape through the mamma¬
lian Wnt signalling pathway, where Ape interacts with
both glycogen synthase kinase 3/( (GSK3/() and /(-
catenin. The central portion of Ape contains sites at
which it can be phosphorylated by GSK3/( and also
through which it complexes with /(-catenin. Phosphor¬
ylation by GSK3/( increases the stability of the Apc//J-
catenin complex and is thereby thought to increase the
rate of /(-catenin degradation (Rubinfeld et al., 1996).
From the above it is clear that disruption of Ape
function can lead to an increase in the cellular levels of
/(-catenin. However, this is not the only potential
mechanism for such an increase. Wnt-1 has been
shown to regulate free pools of catenin (Papkoff et al.,
1996) and both axin and the axin homologue conductin
have been reported to alter /(-catenin activity through
interaction with Ape, /(-catenin and GSK3/( (Behrens
et al., 1998; Ikeda et al., 1998; Kishida et al., 1998).
The potential relevance of increased levels of /(-catenin
becomes clear in the light of findings which show that
/(-catenin functionally interacts with and activates
members of the Tcf family of DNA binding
p-catenin expression in Msh2 and Ape mutant mice
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transcription factors, including both Lef-1 and Tcf 4
(Behrens et al., 1998; Korinek et al., 1997). Activation
of transcriptional signalling by /?-catenin-Tcf complexes
has been shown to occur as a consequence of
mutations in both Ape and /1-catenin (Morin et al.,
1997; Rubinfeld et al., 1997) and mutations of [5-
catenin have been reported in human colorectal cancers
(Sparks et al., 1998). Dysregulated transcription has
therefore been proposed as the basis for early
neoplastic change, although the target genes through
which this may be mediated remain as yet undeter¬
mined (Nusse, 1997).
/1-catenin also regulates E-cadherin in conjunction
with a-catenin, and loss of function of any of these
proteins abrogates E-cadherin activities, including
maintenance of the adherens junction complex.
Amongst other activities this complex mediates cell-
to-cell adhesion and thereby the control of cell motility
(Chen et al., 1997). Modulation of cell adhesion
appears to be a common mechanism in neoplastic
change, and altered E-cadherin activity has been found
in a number of cancers of epithelial origin including
lobular breast carcinoma, colorectal carcinoma and
gastric adenocarcinoma (Birchmeier and Behrens,
1994). In a transgenic murine model of pancreatic /?-
cell carcinogenesis, loss of function of E-cadherin has
been shown to be a critical step in the transition from
adenoma to carcinoma (Perl et al., 1998).
Immunohistochemical analysis of both human and
murine intestinal tumours has shown that both
adenomas and well differentiated carcinomas are
characterized by high levels of /i-catenin (Inomata et
al., 1996; Takayama et al., 1996). However, both /?-
catenin and E-cadherin are reported to be expressed at
significantly lower levels in more aggressive malignan¬
cies, strongly suggesting that over-expression of /)-
catenin is only crucial in early tumour development
(Takayama et al., 1996).
Figure 1 The pattern of ft-catenin staining in the intestine of ApcMln + /— and (ApcMln + /—, p53 — /—) animals. Mice mutant for
Msh2 (De Wind et al., 1995), p53 (Clarke et al., 1993) and ApcMm (Moser et al., 1992) were maintained as outbred colonies
segregating for Ola/129, Balb C, SWR and C57B1/6 genomes. Mice were monitored on a daily basis for signs of ill health and were
killed when they showed signs of disease. All tissues were paraffin embedded using standard methods after overnight fixation in
either buffered formalin or methacarn (four parts methanol, two parts chloroform, one part acetic acid v/v). High temperature
antigen retrieval was performed (Alman et al., 1997). sections were cooled to room temperature and immersed in 1.5%H202
solution to block endogenous peroxidase for 15 min. Sections were then incubated with 1: 50 mouse monoclonal /5-catenin antibody
(IgGi. clone 14. Transduction Laboratories, USA) for 60 min. and subsequently with 1:400 Rabbit Anti-Mouse Biotinylated
secondary antibody (DAKO) for 30 min. The sections were incubated in StrepABComplex/HRP (DAKO) for 30 min. The labelled
complex was developed with diaminobenzidine (DAB, 0.5 mg/ml) for 5-8 min. at room temperature, (a g) Photographs
demonstrating the various features observed in animals with these genotypes. All the features illustrated here were observed
irrespective of p53 status. All scale bars represent 10 pm (a) (3-catenin staining in morphologically normal crypts of the small
intestine. /3-catenin was detected throughout the cytoplasm of epithelial cells but was strongly localized to the lateral borders. Strong
nuclear localization was observed in cells at the crypt base (arrows), (b) Heterogeneous expression in a type 1 lesion. The majority of
cells show the normal pattern of staining, with localization to the lateral borders. A subset of cells show increased cytoplasmic and
nuclear staining, (c) Uniformly increased /1-catenin staining within a type 1 lesion, (d) Increased /J-catenin staining in a type II
lesion, (e) Heterogeneous expression in a type II lesion. Cells showing increased /1-catenin showed localized to the cytoplasm and in
some instances localization to the nucleus, (f) Heterogeneous expression of /1-catenin within a type III lesion, (g) Reduced expression
within a type IV lesion. Where expression of /1-catenin was retained this was often localized to the nucleus
In order to further characterize the association
between tumourigenesis and dysregulation of /(-catenin
we have analysed the pattern of /(-catenin expression
in normal and neoplastic tissue derived from mice
mutant for the tumour suppressor genes p53 and Ape.
This analysis is performed on mice which carry a
mutant Ape allele. Loss of the remaining wild type
Ape allele results in dysregulated expression of /(-
catenin. Because we also wished to address the
possibility that dysregulation of /(-catenin is not an
obligate step in intestinal neoplasia, we also analysed
mice deficient for the DNA mismatch repair gene
Msh2 (De Wind et al., 1998), a murine model of
hereditary non-polyposis colorectal cancer (HNPCC).
Msh2— /— mice develop lymphomas with a peak
incidence at 2-3 months of age (De Wind et al., 1995;
Reitmair et al., 1996). Of the 50% of Msh2— j— mice
which survive beyond 6 months of age, 70% develop
intestinal neoplasms (Reitmair et al., 1996). We report
here the pattern of /(-catenin expression in lesions
arising in mice mutant for Msh2 — j— and (Msh2— /
ApcMi" + /— ).
We first investigated the pattern of expression of /(-
catenin in intestinal lesions arising in ApcMin and p53/
ApcMin mutants. In morphologically normal epithelium,
/(-catenin was localized at the cell membrane. Nuclear
localization was observed in some cells: these were
A
41 96 36 20 52 63 20 27 187 120 30 5 5 6 9 8









I II III IV
type of lesion
Figure 2 /i-catenin expression patterns within each class of
intestinal lesion, (a) Percentage of each lesion type showing either
upregulation of /f-catenin in all cells (black bars); a mosaic or
heterogeneous pattern of upregulation as defined in the text (grey
bars); or no upregulation (open bars). The number of lesions
scored is shown over each column. Insufficient numbers of
category V lesions were identified to permit scoring, (b)
Histogram showing the percentage of cells expressing high levels
of /3-catenin within lesions characterized by mosaic expression of
/i-Catenin. Black bars, ApcMm + /—; Grey bars (ApcMm + /—.
p53—/—); Hatched bars (ApcM"' + /—, Msh2—/— ). Mean values
are given for each lesion category, as defined in the text. Error
bars represent SEM. Insufficient numbers of mosaic lesions were
identified in mice to permit analysis
ll-catenin expression in Msh2 and Ape mutant mice
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always located at the crypt base (Figure la). This
observation suggests a role for /(-catenin in the base of
the crypt as /(-catenin is thought to mediate transcrip¬
tional regulation within the nucleus, and indeed
interaction with the transcription factor Lef-1 is
known to promote nuclear localization of /(-catenin
(Huber et al., 1996).
In both ApcM'" + /— and (ApcMin +/— , p53— /— )
mice, expression of /(-catenin is more intense in
dysplastic crypts and small adenomas. To control for
staining variability between sections, changes in the
intensity of expression were always scored relative to
normal epithelium within the same section. The lesions
were subclassified as in Clarke et al. (1995): (i) single
dysplastic crypts, showing nuclear pleomorphism and
stratification; (ii) complex lesions, comprising several
architecturally distorted crypts in the lamina propria
with virtually normal overlying surface epithelium; (iii)
small adenomas, identified by the overall disturbance
of architecture including the surface and distinguished
from the previous category on the basis of increased
size and surface involvement; (iv) large adenomas, and
(v) adenocarcinoma. The pattern of /(-catenin staining,
summarised in Figure 2, was essentially identical in
ApcM"' + /— and (ApcM"' + /— , p53 — /—) mice, with all
features described below noted in both groups. A
substantial proportion of all lesion types showed
heterogeneous expression of /(-catenin expression, even
where only single crypts were involved (type I lesions,
Figure lb,e and 2). The term 'heterogeneous' is used
here to describe lesions in which only a proportion of
cells were characterized by increased expression.
Although heterogeneous /(-catenin was observed in all
lesions types, the proportion of cells overexpressing /(-
catenin were at their highest in type I-III lesions
(Figure lc-d and 2). Mosaic type IV lesions showed
the lowest proportion of cells staining positive for /(-
catenin (Figure If). Large areas of reduced staining
were observed in some late stage lesions, including
those categorized both as type IV and V (Figure lg). In
all categories of lesion the predominant pattern was of
increased /(-catenin staining within the nucleus, within
the cytoplasm and also at the cell membrane. However
a pattern of strong nuclear localization without
concomitant cytoplasmic staining was also observed
within some lesions as has been previously reported
(Sheng et al., 1998).
These results show that high levels of /(-catenin are
present in the majority of intestinal lesions, presumably
as a direct consequence of perturbation of the Wnt
pathway. Furthermore, areas showing high levels of /(-
catenin included those composed of heterogeneous or
single dysplastic crypts in the intestine, supporting the
notion that dysregulated /(-catenin expression is an
extremely efficient marker of early neoplastic change in
the murine intestine. Lower levels of expression were
seen in focal areas within some larger adenomas and
adenocarcinomas, suggesting that genotypic changes
which lead to elevated /(-catenin are only relevant to
the early stages of neoplasia. This concept is supported
by observations of localized areas of reduced or absent
/(-catenin expression within some adenomas; and also
by studies of human tumorigenesis, where down-
regulation of both /(-catenin and E-cadherin has been
reported in a range of carcinomas (Takayama et al.,
1996).
p-catenin expression in Msh2 and Ape mutant mice
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We next investigated the pattern of expression of [J-
catenin in intestinal lesions arising in Msh2 mutant
animals and Msh2/ApcM,n mutants (summarized in
Figure 2). Previous studies have shown that the Msh2
mutation predisposes to intestinal tumorigenesis and
also accelerates neoplasia in ApcMin + / — mice (De Wind
et al., 1995, 1998; Reitmair et al., 1996). In Msh2 — /—
animals we identified type I , II and III lesions which
showed normal /(-catenin expression (Figure 3b), a
phenomenon we did not observe in ApcMin + / —mice
(Figure 3a). However, all type IV adenomas were
characterized by increased levels of /Fcatenin expres¬
sion. No type V lesions were identified. In (Msh2—/—,
ApcM'" + /—) mice there was a significant increase in the
frequency of adenomas, as has been previously reported
(Reitmair et al., 1996). The majority of these lesions
stained strongly for /I-catenin (Figure 3c), however we
again identified a small number of type I,II and III
lesions ( x 10%) with the pattern of /I-catenin expression
characteristic of normal cells (Figure 3d). All type IV
lesions analysed showed altered /1-catenin expression,
with an almost identical pattern to that observed in
ApcM'n + /—mice. No type V lesions were identified.
We therefore successfully identified small lesions in
both Msh2 and Msh2/ApcMi" mice which showed
normal levels and distribution of /(-catenin. These
findings show that dysregulated /Tcatenin is not an
obligate event in early lesion formation, and
furthermore that Msh2 deficiency predisposes to
such apparent /(-catenin-independent events. Thus,
Msh-2 deficiency may predispose to dysplasia
through mutations in other components of the Wnt
signalling pathway which do not affect /f-catenin
levels or indeed through mutations in other path-
Figure 3 The pattern of /5-catenin expression in the intestine of Msh2—/— mice (a.b) and (Msh2—/—, ApcMln + / —) mice (c.d).
Immunohistochemical analysis was performed as described in the legend to Figure 1. All scale bars represent 10 /<m. (a) Increased ft-
catenin staining in a type I lesion, (b) Normal pattern of /5-catenin expression in a type II lesion, with /3-catenin strongly localized to
the lateral borders, (c) Increased /i-catenin expression in a type II lesion, (d) Normal /J-catenin expression in a type II lesion, with
retained localization to the lateral borders. A type I lesion showing /I-catenin dysregulation is indicated for comparison (arrow)
(3-catenin expression in Msh2 and Ape mutant mice
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ways. All large adenomas (type IV) were character¬
ized by increased /i-catenin, showing that this degree
of morphological change is absolutely associated with
events which dysregulate /3-catenin levels.
We have previously described the phenotype of mice
mutant for both p53 and Ape (Clarke et al., 1995). In
addition to intestinal lesions these mice develop
pancreatic neoplasia, either adenoma or acinar
adenocarcinoma, with almost 100% penetrance. The
cell type observed in these lesions was predominantly
acinar, although some foci showed ductal transdiffer-
entiation. The involvement of Ape in the development
of pancreatic lesions was confirmed by loss of the
remaining wild type allele in adenocarcinomas (Clarke
et al., 1995). We therefore next wished to assess the
extent of dysregulation of /I-catenin in these lesions.
Within morphologically normal pancreatic cells, /?-
catenin was observed at the cell membrane, with no
obvious nuclear localization. In (ApcMi"+ /— p53—/—)
mice all foci showing histological change were
characterized by high levels of /i-catenin. Increased
7223
staining was also seen in foci which were virtually
histologically normal. Such increased staining was
never observed in pancreas samples derived from wild
type mice. Foci varied in size, with some containing
only single or a few cells in the plane of section (Figure
4a,b). The observation of few or single cell lesions
strongly suggests that dysregulated expression occurs
very early in neoplasia.
In lesions identified in formalin fixed tissues,
increased /(-catenin expression was seen within both
the nucleus and cytoplasm (Figure 4c). However,
cytoplasmic staining was rarely observed in Methacarn
fixed sections, suggesting that the observed cytoplasmic
localisation was an artefact of tissue fixation. Using
either fixation protocol we observed rare (<1%)
lesions which did not show increased nuclear staining
(Figure 4d). Nuclear atypia was seen in the majority of
lesions, although the extent of nuclear pleomorphism
varied considerably from mild to severe within each
lesion (Figure 4b,e). Acinar cell lesions classified as
adenoma were also characterized by increased /(-
Figure 4 The pattern of /Tcatenin staining in the pancreas of ApcMln + /— and (ApcMln + /—, p53 — / —) mice.
Immunohistochemical analysis was performed as described in the legend to Figure 1. (a-e) are representative of the patterns of
p-catenin staining and histological atypia observed in the pancreas of both Ape —mice and (ApcMm + /—, p53 — /—) mice, (f-
h) are representative of these patterns in pancreatic adenomas and adenocarcinomas arising in (Ape p53 — f—) mice. All
scale bars represent 10 pm. (a) Methacarn fixed. A single pancreatic acinar cell characterised by increased nuclear and cytoplasmic
expression. The surrounding acinar cells are representative of the normal pattern of f}-catenin staining, with localization to the cell
borders, (b) Methacarn fixed. Small focus of acinar cells with increased expression. These foci were often composed of cells with
increased nuclear size, prominent examples of which are indicated by arrows. This focus also contains a cell (short arrow) with no
increase in nuclear levels of /Tcatenin. (c) This picture demonstrates the pattern of staining observed in formalin fixed tissues. Cells
(arrowed or restricted to the upper right hand portion of this photograph) showing increased nuclear and cytoplasmic levels of P-
catenin staining, (d) Methacarn fixed. A dysplastic adenoma showing increased /?-catenin expression, but with no apparent nuclear
localization, (e) Methacarn fixed. Increased /I-catenin staining in a pancreatic focus, showing strong nuclear localization. Again,
these foci were often composed of cells with increased nuclear size, (f) Methacarn fixed. Heterogeneous /i-catenin expression in an
adenoma containing areas of acinar-ductal transdifferentiation (arrowhead). No increase in /?-catenin staining was detectable in
normal ducts (arrow), (g) Low levels of /I-catenin within an acinar adenocarcinoma, (h) Methacarn fixed. Areas of ductal
differentiation within an acinar adenocarcinoma which have retained high levels of /J-catenin expression
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Figure 5 PCR amplification of Ape alleles from microdissected lesions. PCR analysis. Histological microdissection was performed
as previously described (Going and Lamb, 1996). Samples were digested in proteinase K (1 mg/ml) and 1% Tween 20. The
proteinase K was subsequently heat-inactivated at 95°C, for 10 min. PCR amplification was then performed essentially as previously
described (Luongo et al 1994) using the primers (5'TCTCTT CTGAGAG CAGAAGTT) and (5'ATAGCCAA AGTTATGGAA
GAAGTATCA). Representative results from PCR analysis of microdissected lesions. Determination of Min status was by PCR and
Hindlll digest of PCR product as previously described (Luongo et al., 1994). WT. the amplification product from the wild type Ape
allele. Ape m. the amplification product from the mutant allele. Samples were all derived form lesions arising within Ape m mutant
mice and were as follows: lanes 1 and 2, pancreatic foci showing /J-catenin dysregulation; lane 3 normal pancreas; lanes 4 and 5,
small intestinal lesions; lanes 6 and 7 normal intestinal epithelium. All results were obtained using microdissected areas containing a'
minimum of 50 cells
catenin staining. Some of these lesions contained areas
of acinar-ductal transdifferentiation which were also
strongly stained (Figure 4f). Adenocarcinomas con¬
tained areas in which /3-catenin intensity was reduced
(Figure 4g), however areas of ductal differentiation
within these tumours retained high levels of /1-catenin
(Figure 4h).
These results prompted us to analyse ApcMin mice.
When these animals are maintained on a wild type
background they do not develop pancreatic adenomas
(Clarke et al., 1995). Surprisingly, although we
confirmed absolute absence of neoplasms of the
pancreas, we did find multiple foci of /1-catenin
dysregulation identical to those observed in (ApcMi"
+ / —p53—/ —) mice. Our previous analysis (Clarke et
al., 1995) had identified focal mild dysplasia in one out
of seven ApcMin heterozygotes. Subsequent re-exam¬
ination of these sections showed multiple ill-defined
areas containing cells characterized by nuclear size
variation. These areas overexpressed /Tcatenin. Thus,
/Tcatenin immunohistochemistry efficiently highlighted
focal areas of early histological change in the pancreas
of both (ApcMi" + /— p53 —/—) and ApcM"' + /—mice.
We also analysed pancreatic tissue derived from
Msh2—/—mice and (Msh2— /—, ApcM'" + /—) mice,
neither of which develop spontaneous pancreatic
neoplasms. No abnormal expression of /f-catenin or
histological atypia was observed in Msh2— /—mice.
Flowever, in (Msh2— /—, ApeM'"+ /—) mice we again
identified foci of /Tcatenin overexpression, and these
did not differ in morphological appearance from those
seen in ApcM'" + / — animals.
In the pancreas, dysregulated /)-catenin expression
was seen in 100% of lesions which appeared
morphologically abnormal. Previously, we had noted
the presence of these lesions at high frequency only in
(p53—/—, ApeM1" + / — ) mice and rarely in wild type
mice. The occurrence of high /Tcatenin expression in
areas of minimal histological abnormality in ApcMi"
heterozygotes allows an order of genetic events to be
proposed for this model of pancreatic neoplasia. In the
presence of wild type p53 such dysregulated expression
does not lead to neoplasia, but it is associated with
nuclear size variation, raising the possibility that loss of
Ape function may promote chromosomal instability.
We are currently characterizing this phenomenon in
greater detail. By contrast, a p53 null environment
allows progression to adenoma and then adenocarci¬
noma. Loss of p53 is therefore essential for adenoma
formation in the time frame analysed here. Notably,
the requirement for genetic change differs between
pancreas and intestine, as within the murine intestine
p53 loss does not increase either adenoma burden or
neoplastic progression (Clarke et al., 1995).
To characterize the status of the remaining Ape
allele in both the intestinal and pancreatic lesions
arising in ApeMi" + / — mice we performed PCR analysis
on microdissected foci. Serial sections were generated
and areas of increased /Tcatenin staining identified.
These areas were microdissected and DNA isolated.
Loss of the remaining Ape'" allele was assessed
following PCR amplification. This approach allowed
us to analyse intestinal and pancreatic lesions of, at the
lowest limit, approximately 50 cells per cross section.
Using this method we demonstrate loss of the
remaining wild type Ape allele in both the intestinal
and pancreatic lesions analysed from ApcMi" + /— and
ApcMi" + / — , p53 — /— mice (Figure 5). This finding is
consistent with the concept that /Lcatenin dysregula¬
tion occurs as a consequence of loss of Ape function.
Taken together, these results show that /f-catenin
dysregulation occurs in both the intestine and
pancreas, and that where present it is associated with
the very first steps in the development of neoplasia.
These findings demonstrate that altered expression of
/1-catenin is a key marker of Ape dysregulation in both
these tissues, and suggest that altered /Lcatenin
expression may be a useful diagnostic marker of early
*
neoplastic change in human disease. However, we also
show that /J-catenin dysregulation is not an obligate
step in the generation of intestinal lesions in an Msh2
deficient background, and therefore that other
mechanisms may underlie such early neoplastic change.
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